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Abstract 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the 
central nervous system (CNS) characterised by the formation of chronically 
demyelinated plaques of gliotic scar tissue associated with varying degrees of 
axonal injury and loss. The aetiology of MS remains inexplicit but it is now 
generally thought of as a ‘complex trait’ in which environmental factors disrupt 
immunological self-tolerance to myelin antigens in genetically susceptible 
individuals. The most obvious immunological abnormality associated with MS is a 
sustained intrathecal synthesis of immunoglobulins within the CNS, manifested 
by presence of oligoclonal bands of immunoglobulins when cerebrospinal fluid is 
analysed by isoelectric focusing. These immunoglobulins are derived from 
clonally expanded B cell populations sequestered in the CNS, but their 
pathophysiological significance remains obscure.   
 
The specificity profile of this intrathecal antibody repertoire is complex; 
however, an increasing body of evidence indicates a significant component of 
this repertoire to be specific for lipids, in particular sulphatide. We therefore 
used a sulphatide-specific mouse monoclonal antibody (mAb) that mimics the 
specificity profile of components of the intrathecal response in patients to 
investigate its effects in myelinating cultures derived from embryonic rat spinal 
cord in vitro. These experiments focused on exploring the effects of mAb O4 in 
the absence of serum, a model situation which reproduces that seen in the CNS 
of patients with progressive forms of MS in which blood brain barrier damage is 
minimal.  
 
We observed mAb O4 had no immediate effect on myelin integrity, but after 10 
days inhibited myelination completely, an effect associated with a 50 % increase 
in the number of Iba-1+ microglia. To explore the underlying mechanism we 
performed a gene microarray on cultures treated with mAb O4 in the presence 
and absence of serum as a source of complement. In the absence of serum mAb 
O4 induced an unexpected pattern of transcriptional responses characterised by 
induction of many chemokines (including Cxcl13, Cxcl11, Cxcl10, Cxcl9 and Ccl2) 
and a large number of interferon sensitive genes (ISGs) more commonly 
associated in the development of innate and adaptive immunity to pathogens in 
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the CNS. These responses were not seen when cultures were treated with mAbs 
with no known CNS-specificity, and were abolished when serum was added as a 
source of complement.  
 
These observations identify a novel antibody-dependent mechanism by which 
components of the intrathecal antibody repertoire may maintain a pro-
inflammatory signalling environment in the CNS in the absence of input from the 
peripheral immune system. If validated in patients, these findings identify the 
intrathecal B cell repertoire as an important therapeutic target in MS. 
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1 Introduction 
1.1 Mammalian central nervous system 
The mammalian nervous system is a complex highly vascularized organ that is 
generally discussed in terms of two anatomically distinct parts, the peripheral 
nervous system (PNS) and the central nervous system (CNS). The CNS consists of 
the brain and spinal cord, which are enclosed by the meninges and protected 
from physical trauma by the skull and vertebrae of the spinal column, 
respectively. The PNS comprises the remainder of the nervous system i.e. that 
located outside of the brain and spinal cord. The primary function of the CNS is 
to integrate, coordinate and respond to information received from the PNS via a 
diverse array of sensory inputs. This is dependent on a complex network of 
cellular interactions involving neurons, macroglia (astrocytes and 
oligodendrocytes) and microglia. These interactions can be disrupted by toxins, 
infection, hypoxia and trauma, effects that are responsible for the functional 
deficits seen in neurological and psychiatric disease. 
 
 
1.1.1 Neurons 
Neurons are specialised cells that use chemical and electrical signals to transmit 
information. The human brain contains approximately 1011 neurons each of 
which comprises a cell body (the perikaryon) and a network of processes 
(neurites) that relay information to and from other cells. Neurons receive 
information via electrical impulses from dendrites, while information is 
transmitted onto other targets via the axon. The speed at which information is 
transmitted down an axon is dependent on three factors, its diameter, whether 
or not it is myelinated (see Section 1.1.2.1) and length of the internodes (Brill et 
al., 1977; Young et al., 2013); nerve conduction velocities in small un-
myelinated fibres may be in the range of 0.5-2.0 m/s, whereas it may exceed 
120 m/s in large myelinated fibres (Siegel and Sapru, 2011).  
 
Metabolic and structural homeostasis along the length of the axon is maintained 
by axonal transport, a bidirectional mechanism that transports organelles, 
vesicles and proteins from the neuronal cell body. These cargos are transported 
via microtubules and include neurofilament proteins that polymerize to form 
17 
 
neurofilaments the major component of the axonal cytoskeleton (Griffin et al. 
1995; Silber et al., 2002).  
 
 
1.1.2 Glial cells of central nervous system 
1.1.2.1 Oligodendrocytes 
Oligodendrocytes derive from a variety of sites in the CNS during development. 
In the spinal cord 80 to 90 percent of oligodendrocytes derive from the ventral 
ventricular zone as oligodendrocyte precursor cells (OPC) which migrate and 
differentiate into myelin-forming oligodendrocytes (Bradl and Lassmann, 2010; 
Lu et al., 2002; Takebayashi et al., 2002; Zhou and Anderson, 2002). In addition, 
a small fraction of spinal cord oligodendrocytes are derived from OPC that 
migrate from the dorsal spinal cord (Bradl and Lassmann, 2010; Cai et al., 2005; 
Fogarty, Richardson and Kessaris, 2005; Vallstedt, Klos and Ericson, 2005). 
Migration patterns are thought to be influenced ventrally via sonic hedgehog and 
dorsally via bone morphogenetic protein gradients (Tekki-Kessaris et al., 2001; 
McTigue and Tripathi, 2008). In the forebrain, OPC populating the embryonic 
telencephalon derive from the medial ganglionic eminence and anterior 
entopeduncular area of the ventral forebrain (Bradl and Lassmann, 2010). These 
are joined by OPC originating in the lateral and/or caudal ganglionic eminences 
and postnatal cortex (Kessaris et al., 2006; Bradl and Lassmann, 2010). The 
different waves of cells compete against each other to populate the brain before 
differentiating into myelinating oligodendrocytes (Bradl and Lassmann, 2010). 
This is regulated by multiple positive and negative signalling mechanisms that 
include contributions from the extracellular matrix (Colognato and Tzvetanova, 
2011), growth factors (Redwine et al., 1997; Spassky et al., 2001), chemotropic 
molecules (Jarjour et al., 2003; Tsai et al., 2002), and chemokines (de Castro 
and Bribian, 2005; Dziembowska et al., 2005). 
 
Oligodendrocyte development involves multiple stages that can be followed 
using stage specific combinations of molecular markers which define the lineage 
development (Fig. 1.1.2.1a). This starts with a neural progenitor that 
differentiates into an OPC after which these cells lose their migratory and 
proliferative potential and differentiate into myelin protein expressing 
oligodendrocytes (Pfeiffer, Warrington and Bansal, 1993; He and Lu, 2013; 
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Stangel and Hartlung, 2002). This involves spatial-temporal regulation and 
integration of multiple, in some case redundant signalling pathways that include 
among others, Notch1 interactions with Jagged1 ligand on the axonal surface 
(Wang et al., 1998; Genoud et al., 2002; Radtke and Raj, 2003; Watkins et al., 
2008; Bradl and Lassmann, 2010). This transition from OPC to a differentiated 
oligodendrocyte is a critical step in the development of myelinating lineage 
(Miller, 2002); however, survival of these pre-myelinating oligodendrocytes is 
ultimately dependent on their ability to make productive contacts with axons 
(Simons and Trajkovic, 2006). This interaction occurs within 5 to 12 hours as 
demonstrated by experiments on zebra fish in vivo and rodent cultures in vitro, 
respectively (Watkins et al., 2008; Czopka et al., 2013). 
 
 
 
Figure 1.1.2.1a: Oligodendrocyte lineage indicated by their stage-specific markers. 
OPC development into mature myelin forming oligodendrocytes can be visualised by the 
use of different markers. (Adapted from Stangel and Hartung, 2002). 
 
 
Information on human oligodendrocyte development and myelination is 
relatively sparse due to ethical issues, but studies on aborted embryos indicate 
oligodendrocyte development begins during the second trimester (Back et al., 
2001; Jakovcevski et al., 2009). Similar to the situation in rodents, 
oligodendrogenesis in man exhibits ventral to dorsal progression (Pringle and 
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Richardson, 1993; Timsit et al., 1995; Jakovcevski et al., 2009) and there is a 
clear dissociation between the timing of oligodendrocyte differentiation and 
myelination in the forebrain (Back et al., 2001; Jakovcevski and Zecevic et al., 
2005). Myelination is first observed in basal ganglia during the third trimester 
and somewhat later in the corpus callosum (Back et al., 2001; Jakovcevski, Mo, 
Zecevic, 2007). Myelination in human peaks during the first year of life but 
continues into adulthood (Stangel and Hartung, 2002). However, the adult CNS 
retains a large pool of mitotic neural/glial antigen 2 (NG2) positive OPCs (Miller, 
2002), thus allowing myelination to continue at a low levels throughout life 
(Young et al., 2013). Under normal conditions turnover of adult OPC is slow 
(Young et al., 2013), but experimental studies demonstrate they can rapidly 
proliferate in response to tissue damage and differentiate to oligodendrocytes 
that will remyelinate axons (Levine, Reynolds and Fawcett, 2001; Reynolds et al., 
2001; Miller, 2002; Wilson, Scolding and Raine, 2006; Nishiyama et al., 2009; 
Tripathi et al., 2010). 
 
Mechanisms in myelination  
The mechanisms that determine the timing of myelination are regulated at many 
levels. One factor is axonal diameter, as only axons with a diameter of > 0.2 µm 
are myelinated in the CNS (Simons and Trajkovic, 2006; Piaton et al., 2010; 
Bradl and Lassmann, 2010; Tripathi et al., 2010). Axonal calibre also determines 
the thickness of the myelin sheath (Friede, 1972; Piaton et al., 2010). Moreover, 
the axo-glial interaction has also been shown to increase axon diameter (Colello 
and Schwab, 1994; Mason et al., 2001; McTigue and Tripathi, 2008). These 
observations demonstrate axonal signals play a major role in regulating 
functional myelination in vivo, but in vitro synthesis of myelin-like structures is 
actually a default response of mature oligodendrocytes that can occur in the 
absence of axons (Lee et al., 2012). However, this uncoordinated myelin 
production may lead to detrimental consequences (Simons and Trajkovic, 2006), 
thus further indicating the importance of the control mechanisms in vivo. The 
molecular and spatial constraints that control myelination in vivo are still poorly 
understood but these clearly involve multiple, often redundant, mechanisms. 
Successful myelination is dependent on the interplay of an array of permissive 
and inhibitory axonal factors that include neural electrical activity which 
provides a positive signal for myelination (Gyllensten and Malmfors, 1963; 
20 
 
Demerens et al., 1996; Pianton et al., 2010) and down regulation of 
polysialylated neural cell adhesion molecule (PSA-NCAM), an inhibitor of 
myelination expressed at the axonal surface (Charles et al., 2000; Miller, 2002; 
Coleman et al. 2005). Other factors shown to modulate myelination include 
signal transduction involving components of the extracellular matrix, growth 
factors and metabolites such as adenosine and adenosine triphosphate (ATP) 
(Kuperman, Volpert and Okamoto, 1964; Maire, Medilanski and Straub, 1984; 
Stevens et al., 2002; Ishibashi et al., 2006; Colognato et al., 2007; Furusho et al., 
2012; Bradl and Lassmann, 2010).  
 
Oligodendrocyte function 
For many years the function of the oligodendrocyte was considered to promote 
rapid saltatory conduction by ensheathing axons with myelin (Nave, 2010).  
This view was refined as studies demonstrated that formation of specific axo-
glial domains was required for saltatory conduction (Vabnick and Shager, 1998; 
Tait et al., 2000). Differential clustering of sodium channels (Nav1.2 channels 
that prior to myelination are replaced by Nav1.6 channels) and potassium 
channels (K+) are arranged in nodes of Ranvier and juxtaparanodal domains of 
myelinated axons, respectively (Fig. 1.1.2.1b; Boiko et al., 2001; Bhat et al., 
2001). However it is now recognised these interactions also maintain a structural 
relationship between the axon and myelin sheath that facilitates the ability of 
oligodendrocytes to provide metabolic support to axon segments and somas 
through several growth and trophic factors (McTigue and Tripathi, 2008; Edgar 
and Nave, 2009; Nave, 2010; Fünfschilling et al., 2011). Demyelination not only 
disrupts this trophic support, but also renders axons more susceptible to damage 
by inflammatory mediators (McTigue and Tripathi, 2008); a combination of 
effects predicted to compromise axonal survival in chronic inflammatory 
demyelinating diseases such as multiple sclerosis (Franklin et al., 2012). Unlike 
the situation in the PNS where myelinating Schwann cells maintain a one to one 
relationship with axons, oligodendrocytes in the CNS interact with multiple 
axons and can assemble and maintain > 40 individual myelin sheaths (Pfeiffer, 
Warrington and Bansal, 1993; Podblieska et al., 2013). As a consequence, the 
loss of a single oligodendrocyte has the potential to compromise the functional 
and structural integrity of multiple axons.   
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Figure 1.1.2.1b: Myelin protein composition in the CNS. Myelin wraps around the 
axons at internodes, leaving small gaps, nodes of Ranvier, between each segment. 
Adjacent to them are the paranode and the juxtaparanode. Each of the intervals has a 
distinctive myelin protein composition. PLP and MBP are found embedded within the 
internodal myelin, when MOG is expressed on the surface of the sheath. MAG is 
expressed in the periaxonal space. Saltatory conduction by the nerve is enabled by 
separation of the sodium and potassium channels into nodes of Ranvier and 
juxtaparanode, respectively (Mayer and Mein, 2012). 
 
 
Structure and composition of CNS myelin 
The molecular architecture of the myelin sheath requires the co-ordinated 
synthesis and assembly of myelin proteins and lipids into specific membrane 
domains (Fig. 1.1.2.1b). Initial biochemical analysis of compact internodal 
myelin revealed it was enriched in compacted lipids that constitute > 70 % of the 
dry weight (Dupree et al., 1998) and had a relatively simple protein composition; 
myelin basic protein (MBP) and proteolipid protein (PLP) accounting for > 80 % of 
its protein content (Table 1.1.2.1; Baumann and Pham-Dinh, 2001). However, it 
is now recognised CNS myelin also contains a several hundred quantitatively 
minor proteins (Ishii et al., 2009). Their functional significance is in general 
poorly understood but an increasing number are implicated as candidate 
autoantigens in MS  including 2',3'-Cyclic-nucleotide 3'-phosphodiesterase, 
myelin-associated glycoprotein (MAG), myelin oligodendrocyte protein (MOG), 
neurofascin-155 (Nfasc155) and many others (Brunner et al., 1989; Burgoon, 
22 
 
Gilden and Owens, 2004; Nave and Trapp, 2008; Nave, 2010; Dutta and Trapp, 
2011).  
 
The function of MBP and PLP is to maintain the structural integrity of compact 
internodal myelin (Simons and Trajkovic, 2006). MBP associates with the 
cytoplasmic face of the membrane where it acts as ‘glue’ holding opposing 
membrane surfaces in close apposition (Readhead et al., 1987; Fitzner et al., 
2006). To avoid this occurring within the oligodendrocyte cell body or its 
processes, mRNA transcripts encoding MBP are only translated after they are 
transported to sites of myelin assembly (Colman et al., 1982; Ainger et al., 1993; 
de Vries et al., 1997; Müller et al., 2013). In contrast, PLP is translated in the 
oligodendrocyte cell body and then transported to the myelin sheath via 
vesicular transport (de Vries et al., 1997; Bradl and Lassmann, 2010). mRNA 
transcripts of minor protein MOG (Quarles, 1997; Kuhle et al., 2007; Lee and 
Linker, 2012) are restricted to oligodendrocytes (Pham-Dinh et al., 1993; Iglesias 
et al., 2001). MOG N-terminal domain, the immunoglobulin-like domain, is 
expressed on the outermost lamellae of myelin sheath, therefore making the 
antigen accessible for antibodies (Brunner et al., 1989; Brehm et al., 1999). 
Although compact internodal membranes make up the bulk of the myelin sheath, 
its primary functions (supporting saltatory conduction and providing metabolic 
support to the axon) are dependent on specialised axo-glial junctional 
complexes that anchor the ends of the myelin sheath to the axonal surface (Fig. 
1.1.2.1b). Formation of these junctional complexes is dependent on expression 
of Nfasc155 by oligodendrocytes which then interacts with Caspr/contactin 
complexes on the axonal surface (Tait et al., 2000; Bhat et al., 2001; Boyle et 
al., 2001; Charles et al., 2002; Sherman et al., 2005; Bonnon et al., 2007). In the 
absence of Nfasc155 protein mice fail to form electron dense paranodal 
junctions and develop a paranodal pathology characterised by frequent 
paranodal loop eversion (Sherman et al., 2005). Intriguingly a similar pathology 
is developed in mice lacking either ceramide galactosyl transferase (CGT) or 
ceramide sulfotransferase (CST) (Jarjour et al., 2008), enzymes that are 
required for the synthesis of galactosylceramide and sulphatide, respectively.  
These glycosphingolipids are highly enriched in CNS myelin and together account 
for approximately 25% of the membranes lipid content (Table 1.1.2.1; Markus 
and Popko, 2002; Quarles et al., 2006). They clearly play a major role in 
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stabilizing the paranodal domain of myelin sheaths, but how this is achieved is 
unclear. This may involve lipid protein interactions that facilitate segregation of 
proteins such as Nfasc155 into discreet membrane rafts or domains, an effect 
that may also impact on signal transduction in oligodendrocytes (Jackman et al., 
2009). This is suggested by studies demonstrating antibodies that cross link 
myelin glycolipids in the plane of the membrane can trigger an influx of calcium 
leading to microtubule depolymerisation (Dyer and Benjamins, 1991; Ilyas et al., 
2003); an effect that may contribute to the ability of sulphatide –specific 
antibodies to inhibit oligodendrocyte differentiation in vitro (Bansal et al., 1989; 
Kirschning et al., 1995; Ilyas et al., 2003). 
 
Table 1.1.2.1: Composition of central nervous system myelin. (*percent total lipid 
adapted from Quarles et al., 2006; ** percent of total protein by weight adapted from 
Baumann and Pham-Dinh, 2001). 
 
 
 
1.1.2.2 Astrocytes 
The astrocyte is the most numerous of mammalian glial cells and may outnumber 
neurons ten to one (Benvenieste, 1992). They exhibit a range of morphologies 
but are typically stellate and are identified using antibodies specific for glial 
fibrillary acidic protein (GFAP) or excitatory amino acid transporter 1 (EAAT1 or 
 
Human  Rat 
*Lipid  70 70.5 
Cholesterol 27.7 27.3 
Galactolipids 27.5 31.5 
Minor galactolipids    
Cerebrosides  22.7 23.7 
Sulphatides 3.8 7.1 
Phospholipids 43.1 44.0 
Ethanolamine phosphatides  15.6 16.7 
Serine phosphatides  4.8 7.0 
Phosphatidylinositol  0.6 1.2 
Lecithin  11.2 11.3 
Sphingomyelin 7.9 3.2 
Plasmalogens 12.3 14.1 
 
**Proteins 
  Myelin basic protein (MBP)            30  
Proteolipid protein (PLP)            50  
Myelin associated glycoprotein (MAG)                                               1  
Myelin oligodendrocyte protein (MOG)                           > 0.1  
2’-3’-cyclic nucleotide 3’- phosphohydrolase (CNP)                       4  
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GLAST) (Barnett and Linington, 2012). Astrocytes are functionally heterogeneous 
(Oberheim, Goldman and Nedergaard, ‎2012) and in the normal CNS contribute to 
the maintenance of CNS homeostasis by providing metabolic support to 
oligodendrocytes and neurons, removing glutamate from the extracellular milieu 
and maintaining blood brain barrier (BBB) function (Barnett and Linington, 2012; 
Barros, 2013; Lundgaard et al., 2013). Astrocytes respond rapidly to CNS injury 
or infection, undergoing astrocytosis and shifting their phenotype to become 
more ‘reactive’ (Sofroniew, 2005; Zamanian et al., 2012). Astrocyte reactivity is 
a broad definition and recent studies emphasise this represents a spectrum of 
phenotypes rather than a single entity; the astrocyte response to injury is 
dependent on the nature of the insult and in addition, it will change over time 
(Zamanian et al., 2012). Nonetheless, this is generally equated with proliferation, 
secretion of pro-inflammatory cytokines and ultimately formation of glial scar 
tissue. The latter plays an important role in wound healing as it forms a barrier 
that prevents inflammatory cells invading the CNS from the periphery. However, 
this scar formation also provides an obstacle for axonal regeneration and 
myelination (Fawcett and Asher, 1999; Sofroniew, 2005). Another damaging 
effect by reactive astrocytes on neural cells can be caused by their cytotoxic 
potential to generate nitric oxide radicals (Sofroniew, 2005). It has also been 
suggested the spectrum of astrocyte reactivity includes an intermediate 
phenotype that secrete factors which support remyelination and promote 
neurite survival (Liberto et al., 2004; Nash et al., 2011; 2013).  
 
 
1.1.2.3 Microglia 
Ten to twenty percent of cells in the brain and spinal cord are microglia (Lawson 
et al., 1990; Langmann, 2007), a resident population of mononuclear phagocytes 
derived from primitive myeloid progenitors that populate the CNS before 
embryonic day 8 (Ginhoux et al., 2010). During CNS development microglia are 
involved in clearance of apoptotic cells and prune inappropriate neural 
connections (David and Kroner, 2011). However, in the adult they not only 
support CNS homeostasis, but respond rapidly to molecular signals associated 
with infections, hypoxia, and neurodegeneration (Kulkarni et al., 2004; 
Nimmerjahn et al., 2005; Mirshafiey and Kianiaslani, 2013; David and Kroner, 
2011). Microglia sense the micro-environmental changes via various surface 
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receptors, thus leading to severity-dependent increase in microglial numbers 
(Nimmerjahn, Kirchhoff and Helmchen, 2005). 
 
These responses are similar to those seen in tissue specific macrophages, but it 
is now apparent microglia are a specialised population of cells with a distinct 
transcriptional profile (Hickman et al., 2013). This recent transcriptional study 
also revealed that even ‘quiescent’ microglia express high levels of anti-
microbial peptides indicating they are primed to initiate innate host defence 
programs (Hickman et al., 2013). In advanced stages of neuronal diseases, 
microglia have been shown to function in a neurotoxic manner (Muzio et al., 
2007), thus causing induced functional and structural damage to the neurons.   
 
 
1.2 Demyelinating diseases 
Demyelinating diseases of the CNS compromise a broad spectrum of disorders in 
which major functional deficits are caused by loss of myelin, an effect that 
compromises the function and structural integrity of myelinated axons. The most 
prevalent are acquired inflammatory demyelinating diseases such as multiple 
sclerosis (MS), acute disseminated encephalomyelitis (ADEM) and neuromyelitis 
optica (NMO) (Reindl et al., 2013). Myelin is also a prominent target in the 
leukodystrophies, a group of genetic disorders that result in varying degrees of 
de- and dysmyelination (Poser, 1961; Chu et al., 1983; Patay, 2005), and is 
implicated in several important psychiatric disorders including schizophrenia 
(Davies et al., 2003; Takahashi et al., 2011).  
 
The aetiology of inflammatory demyelinating diseases remains poorly understood 
but in general they are considered complex traits in which an environmental 
factor triggers disease in genetically susceptible individuals, subsequent disease 
activity being driven by the development of autoimmune responses to CNS 
antigens. This is believed to be the case in ADEM, a monophasic disorder that is 
seen primarily in children (Van Haren et al., 2013). However although ADEM is 
often preceded by some prior, often apparently trivial infection, no specific 
pathogen has been unambiguously associated with disease induction (Lee and 
Linker, 2012). Nonetheless ADEM is associated with autoimmune response as 
demonstrated by the presence of antibodies to CNS antigens (Van Haren et al., 
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2013), in particular autoantibodies to MOG that can recognise epitopes exposed 
at the membrane surface and may be present in up to 40 % of cases (McLaughlin 
et al., 2009; Di Pauli et al., 2011; Probstel et al., 2011). Similar autoimmune 
responses have been recognised in the other acquired CNS inflammatory 
demyelinating diseases of the spectrum, however, differences appear in age of 
the onset, clinical course, disease severity, treatment, and radiological, 
pathological and cerebrospinal features (Reindl et al., 2013). 
 
 
1.2.1 Neuromyelitis optica 
Neuromyelitis optica (NMO), previously known as Devic’s disease, is a severe 
recurrent or progressive CNS inflammatory disease characterised by the 
preferential involvement of the optic tract and spinal cord (Lucchinetti et al., 
2002; Lalive, 2008; Jarius et al, 2014). NMO was previously considered a variant 
of MS, but it is now known to be a distinct disease entity characterised by the 
presence of autoantibodies that target aquaporin-4 (AQP4) expressed 
preferentially at astrocyte foot processes at the blood brain barrier (Lennon et 
al., 2005; Reindl et al., 2013). However, the reason why patients develop a 
pathogenic autoanibody response to AQP4, the precise role of the antigen in 
lesion formation, and the mechanisms leading to demyelination and loss of 
function remain unknown (Howe et al., 2014). The frequency of anti-AQP4 
antibodies is comparable between children and adults with NMO (Rostasy and 
Reindl, 2013); however adults with NMO develop severe disabilities more rapidly 
(Rostasy et al., 2013). The prognosis for adult patients with NMO is abominable 
as over 30 % die within 5 years (Huppke et al., 2010). Race and ethnicity have 
also indicated predisposal for the disease phenotype; NMO being most frequent 
in black, Asian and Indian population, whereas white population is rarely 
affected (Huppke et al., 2010). Clinical disease is associated with a range of 
pathologies but the primary insult is astrocyte injury and loss mediated by AQP4-
specific autoantibodies. However, a significant number of patients with NMO as 
defined by clinical and magnetic resonance imaging (MRI) criteria are 
seronegative for AQP4 specific autoantibodies (Lennon et al., 2004; Lalive et al., 
2006). The numbers reported are dependent on the assay used to detect the 
AQP4-specific response and estimates of the frequency of seronegative patients 
range from 5 to 40 % (Mader et al., 2011). These observations have led to 
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speculation of additional autoantigenic targets being involved in NMO, possibly 
as a consequence of epitope/antigen spreading (Lalive et al., 2006). MOG is one 
possible target as potentially demyelinating MOG-specific IgG1 autoantibodies 
are present in some AQP4-IgG negative patients (Mader et al., 2011; Rostasy et 
al., 2013). However, while MOG-specific antibodies may well exacerbate 
demyelination, they cannot account for the astrocyte pathologies that are 
characteristic of NMO. Indeed it remains unclear whether NMO is a purely 
antibody-mediated disease, as several studies demonstrate circulating AQP4-
specific antibodies have to cross the BBB in order to induce a pathological effect 
within the CNS (Bradl and Lassmann, 2013). This has raised speculation that T 
cell responses to AQP4 play a central role in the pathogenesis of NMO by 
providing T cell help for the AQP4-specific B cell response, while at the same 
time inducing an inflammatory response in the CNS; the latter leading to BBB 
disruption, penetration of AQP4-specific antibodies into the CNS, tissue damage 
and ultimately clinical disease (Saadoun et al., 2011). Evidence in support of this 
‘two hit’ model for NMO is provided by reports that AQP4-specific CD4+ T cells 
are encephalitogenic in mice (Nelson et al., 2010) and a similar, potentially 
encephalitogenic T cell response is present in patients (Varrin-Doyer et al., 
2012).  
 
 
1.2.2 Multiple sclerosis 
Multiple sclerosis (MS) is the most common inflammatory demyelinating disease 
of the CNS. It affects more than two million people worldwide (National MS 
Society, 2014; WHO, 2014) and is the major cause of acquired, non-traumatic 
chronic neurological disability among young adults in Western Europe and North 
America (WHO, 2014). MS is commonly diagnosed between the ages of 20 and 40, 
but may occur in all age groups. Some 5 % of cases develop their first clinical 
signs of disease before the age of 16 (paediatric MS; McLaughlin et al., 2009), 
whilst approximately 10 % of cases are diagnosed at ages > 50 (late onset MS; 
Martinelli et al., 2004).  
 
MS is clinically heterogeneous (Lucchinetti et al., 2000; Barnett and Prineas, 
2004) and at present no prognostic markers are available to either the 
subsequent course of disease, or to stratify patients for treatment. The most 
28 
 
common presentation is relapsing-remitting MS (RRMS) which is seen in 
approximately 80 % of cases (WHO, 2014) and is characterized by repeated, 
unpredictable episodes of disability followed by periods of complete or partial 
recovery. However, within five to fifteen years a majority of these patients will 
develop secondary progressive MS (SPMS; Steinman, 2001; Trapp et al., 1998; 
Lalive, 2008; Hafler, 2004) in which accumulation of disability continues in the 
absence of obvious clinical relapses or remissions; a disease course seen from 
onset in the 10 – 20 % of MS patients who present with primary progressive MS 
(PPMS; WHO, 2014). 
 
This distinction between RRMS and progressive forms of the disease is important 
as it is associated with marked differences in the clinical efficacy of current 
treatments for MS. Disease activity in RRMS is due to repeated episodes of 
inflammatory demyelination associated with varying amounts of axonal injury 
and loss (Hafler, 2004; Pender et al., 2004). Symptoms often present sub-acutely, 
developing over a period of several days and then persist for varying lengths of 
time after which they dissipate resulting in partial or complete clinical recovery 
(Hafler, 2004).  Historically RRMS was considered a white matter disease, but 
improvements in immunopathological and MRI techniques show that grey matter 
lesions do frequently occur in RRMS (Trapp et al., 1998; Kuhlmann et al., 2002; 
Frischer et al., 2009; Lassmann, 2013). Moreover in both cases demyelination 
and axonal injury are associated with perivascular infiltrates of macrophages, T 
cells and B cells (Lee and Linker, 2012; Bar-Or, 2005; Mirshafiey and Kianiaslani 
et al., 2013) that disperse and migrate into the surrounding parenchyma 
(Lucchineti et al., 2011; Lassmann, 2013). These focal inflammatory lesions are 
visualized as discrete areas of Gadolinium enhancement in magnetic resonance 
imaging (MRI) scans, a technique now used extensively to monitor disease 
activity in the CNS during clinical trials. The clinical importance of these 
gadolinium enhancing lesions in RRMS is apparent from the outcome of clinical 
trials of ‘anti-inflammatory’ disease modifying treatments (DMT) such as the 
beta interferons, Glatiramer acetate (Copaxone®),  Natalizumab (Tysabri), 
Fingolimod (FTY720/Gilenya®) and Alemtuzumab (Lemtrada®) (Jacobs et al., 
1996; Johnson et al., 2000; Polman et al., 2006; Hauser et al., 2008; Kappos et 
al., 2010; Cohen et al., 2010; Derwenskus, 2011). These treatments delay 
disability formation and suppress the development of gadolinium enhancing 
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lesions in the CNS of patients with RRMS, an effect associated with significant 
reductions in relapse frequency. However, they fail to halt accumulation of 
disability in patients with progressive MS (PMS).  
 
In hindsight this is perhaps not unexpected as the inflammatory foci seen in the 
CNS of patients with RRMS are generally absent in PPMS and SPMS (Confareux et 
al., 2000; Gold, Linington and Lassmann, 2006; Zwemmer et al., 2008). This 
observation provides a rational explanation why patients with PMS fail to benefit 
from current disease modifying therapies (SPECTRIMS Study Group, 2001; Cohen 
et al., 2002), and supports an emerging consensus that accumulation of disease 
in PMS is driven by effector mechanism(s) sequestered within the CNS that are 
largely independent of input from the immune system (Fischer et al., 2009). This 
concept is supported by data derived from clinical trials, pathological 
investigations and clinical imaging studies that demonstrate accumulation of 
disability in PMS is due to axonal loss (Confareux et al., 2000; Bjartmar and 
Trapp, 2001; Trapp et al., 1998) associated with widespread microglial 
activation and an inflammatory response sequestered within the meninges. 
These meningeal infiltrates are often enriched in B cells and are associated with 
demyelination, axonal loss and microglial activation in the underlying 
parenchyma (Magliozzi et al., 2007; Magliozzi et al., 2010; Lassmann, 2013). 
Meningeal inflammation is clearly clinically significant as it correlates with a 
more rapid accumulation of disability (Serafini et al., 2004; Magliozzi et al., 
2007; Choi et al., 2012), but the causal relationship between this sequestered 
inflammatory response and tissue damage in the parenchyma remains unclear. In 
addition to meningeal inflammation small numbers of infiltrating T and B cells 
are also found in the parenchyma where they are often associated with the 
active rim of slowly expanding white matter lesions in patients with progressive 
disease (Kutzelnigg et al., 2005; Lassmann, 2013). Remyelination is also less 
frequent in PMS (Kuhlmann et al., 2008; Podbielska et al., 2013) partly due to a 
deficit in oligodendrocyte recruitment, an effect predicted to exacerbate the 
development of chronically demyelinated plaques of glial scar tissue, the end 
stage of MS lesion development (Prineas et al., 2001; Lassmann, 2013).  
 
The ultimate cause of chronic disability in MS is due to axonal injury and loss 
(Trapp et al., 1998; Mirshafiey and Kianiaslani, 2013). Axonal injury is most 
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prominent in acute inflammatory demyelinating lesions in patients with RRMS, 
but this continues after the acute inflammatory response resolves and may 
ultimately result in the loss > 80 % of axons in individual lesions (Kuhlmann et al., 
2002). This axonal pathology is attributed to an axonal energy deficit caused by 
the effects of oxidative damage on mitochondrial metabolism (Lu et al., 2000; 
Dutta et al., 2006; van Horssen et al., 2008; Handel et al., 2011; Lee and Linker, 
2012; Davies et al., 2013) in a hypoxic environment. Energy deficiency impairs 
the functional activity of axonal Na+/K+-ATPase resulting in increased intra-
cellular sodium concentrations that reverse the axonal Na+/Ca2+ exchanger. This 
leads to increased axonal calcium concentrations, an effect that is amplified by 
the simultaneous failure of energy-dependent axonal Ca2+ efflux pumps, 
therefore resulting in membrane depolarisation and conduction block of the 
axons (Smith, 2007). Ultimately this compromises the functional and structural 
integrity of the axon (Stys, 2004; Kurnellas et al., 2005; Nave and Trapp, 2008). 
This axonal pathology, however, does not occur in isolation, but is associated 
intimately with the demyelinating component of the disease. Not only are 
myelinating oligodendrocytes themselves highly susceptible to oxidative damage 
(Benarroch, 2009; McTigue and Tripathi, 2008), but demyelination itself also 
increases axonal susceptibility to oxidative stress due to their increased 
energetic demand. In response, conduction properties are partially repaired by 
increasing expression of Nav1.2 channels along demyelinated axonal segments 
(Craner et al., 2003; Smith, 2007). However, in addition to oxidative effects 
mediated by free radicals (Smith et al., 2001), axonal survival is compromised by 
a variety of other mechanisms including proteolytic enzymes, cytokines, 
autoantibodies and Wallerian degeneration (Hohlfeld, 1997; Trapp et al., 1998; 
Bjartmar and Trapp, 2001; Mathey et al., 2007; Huizinga et al., 2008; Bradl and 
Lassmann, 2010; Haider et al., 2011; Elliot et al., 2012; Davies et al., 2013). 
Convincing arguments can be made about each of these mechanisms in disease 
pathogenesis, but their relative importance in patients with progressive disease 
is unknown. This highlights the major challenge faced in the field of MS research 
at present. Namely, there is an urgent need to understand how these 
pathological responses are maintained in the CNS of patients with progressive 
forms of MS. Thus, allowing development of effective treatments for the 
devastating disease. 
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1.2.2.1 Mechanisms associated with tissue damage in multiple sclerosis 
MS is a human-specific disease that does not occur in any other species. 
Therefore, researchers have been forced to use pathological investigations that 
are largely based on autopsy tissue from patients with longstanding disease, and 
animal models that replicate some but not all aspects of the disease. These 
models include viral diseases; however, the majority of studies are based on 
experimental autoimmune encephalomyelitis (EAE). It is a T cell mediated 
autoimmune disease induced in susceptible species by sensitisation with CNS 
tissue homogenates, CNS myelin or purified myelin antigens such as MBP, PLP 
and MOG, or adoptive transfer of myelin antigen-specific T cells (Gold et al., 
2006). EAE has had a major impact on our understanding of neuroinflammatory 
disease processes and was instrumental in the development of Glatiramer 
acetate (Copaxone) (Arnon et al., 1996) and Natalizumab (Tysabri) (Yednock et 
al., 1992) as a treatment for RRMS. Moreover, the model led to recognitions that 
formation of large ‘MS-like’ lesions in experimental animals requires 
contributions from both T- and B-cell dependent effector mechanisms. In this 
‘two-hit’ model of lesion formation, BBB dysfunction and inflammation are 
initiated by reactivation of MHC class II restricted Th1 and Th17 T cells within 
the CNS (Minager and Alexander, 2003; Frohman et al., 2006; Kebir et al., 2007; 
Bettelli et al., 2007; Nelson et al., 2010). This inflammatory response is alone 
sufficient to induce severe neurological deficits, but in rodents and primates 
does not induce widespread demyelination (Lucchinetti et al., 1996; Raine et al., 
1999; Lee and Linker, 2012). In these species extensive loss of myelin is only 
observed if autoantibodies that can bind to the myelin surface are also available 
to initiate antibody-dependent complement and/or cell mediated demyelination 
(Piddlesden et al., 1993; Elliot et al., 2012). These pathogenic autoimmune 
responses can target a variety of CNS autoantigens, but the demyelinating 
autoantibody response is restricted to a limited number of protein and lipid 
antigens (MOG, PLP, galactosyl ceramide and sulphatide) exposed at the 
myelin/oligodendrocyte surface (Linington et al., 1988; Fierz et al., 1988; Menon, 
Piddlesden, Bernard, 1997; Brehm et al., 1999; Rosenbluth et al., 1999; 2003; 
Morris-Downes et al, 2002; Kanter et al., 2006). However, this myelin damage 
may expose epitopes that provide further targets for antibody and/or T cell 
autoaggression (Matsuo et al., 1997) and ultimately extend to target myelin (e.g. 
MBP, PLP, MOG, MOBP) and non-myelin neural antigens (Fontana, Fierz and 
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Wekerle, 1984; Fierz et al., 1985; Sun and Wekerle, 1986), perpetuating disease 
activity in the CNS. 
 
These observations lead to a consensus developing that views MS as an 
(auto)immune disease (Steinman, 1996; Lalive et al., 2006; Hundgeburth et al., 
2013); a concept now supported by the clinical efficacy of anti-inflammatory 
disease modifying therapies (DMT) such as Natalizumab, Fingolimod 
(FTY720/Gilenya®) and Alemtuzumab (Lemtrada®), as well as the outcome of 
recent genome-wide association studies (GWAS) that implicate a primary role for 
T cell-mediated immunity in MS (Sawcer et al., 2011). However, there is still 
considerable debate as to the relative importance of different T and B cell 
subsets, their antigen-specificity and crucially whether or not autoimmunity 
plays a direct role in driving accumulation of disability in progressive forms of 
the disease (Bourquin et al., 2000). Until recently these questions focused solely 
on the role of the T cell division of the immune response, but it is now 
recognised that B cell dependent mechanisms also play an important if not 
crucial role in disease pathogenesis. 
 
 
1.2.2.2 B-cell involvement in multiple sclerosis 
A role for B-cells in MS was first discussed some 50 years ago following the 
demonstration MS was associated with intrathecal synthesis of immunoglobulin 
(Ig) (Kabat, Moore and Landow, 1942). The most obvious manifestation of this 
response is the presence of oligoclonal bands (OCB) of Ig in cerebrospinal fluid 
(CSF) which can be visualised by isoelectric focussing gels (Obermeier et al., 
2008). This further enforced the implication of B cell dependent mechanism in 
MS, however, it was not until the last decade when clinical trials of B cell 
depletion in MS patients provided formal evidence of B cell activity in the 
disease development (Hauser et al., 2008; Kappos et al., 2011; Table 1.2.2.2). 
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Table 1.2.2.2: Evidence for B cell dependent mechanisms in multiple sclerosis. 
(Adapted from Mein et al., 2006) 
Evidence Reference 
 
Intrathecal immunoglobulin (Ig) production associated with a 
poly-specific antibody response and oligoclonal bands  
Gilden, 2005; 
Walsh and Tourtellotte, 1986; 
Thompson, Kaufmann and Rudge, 1983; 
Sindic, Monteyne and Laterre, 1994; 
Derfuss et al., 2001; 
Derfuss et al., 2005; 
Reiber et al., 1998; 
Puccioni-Sohler et al., 1995; 
Bednarova, Stourac and Adam, 2005; 
 
Clonal expansion and hypersomatic mutation of B cells 
sequestered within the CNS indicative of local antigen-driven 
affinity maturation 
Qin et al., 1998; 
Owens et al., 1998; 
Baranzini et al., 1999; 
Smith-Jensen et al., 2000; 
Colombo et al., 2000; 
Colombo et al., 2003; 
Owens et al., 2003;  
Ritchie et al., 2004;  
Haubold et al., 2004; 
Corcione et al., 2004 
Disease activity/progression correlate with B cell/plasmablast 
numbers in CSF and intrathecal IgM synthesis 
Cepok et al., 2001;  
Cepok et al., 2005; 
 
Decoration of myelin sheaths by antibodies and complement 
activation products 
Warren, Catz and Steinman, 1995; 
O’Connor et al., 2005; 
Genain et al., 1999; 
Storch et al., 1998 
A subset of patients benefit from plasma exchange  Keegan et al., 2005; 
Clinical benefit of plasma exchange correlates with C9neo 
immune reactivity in lesions   
Storch et al., 1998; 
Demyelinating and axopathic autoantibodies identified in patient 
sera 
Villar et al., 2003; 
Villar et al., 2005; 
B-cell depletion by CD20-specific antibodies dramatically 
reduces disease activity 
Stüve et al., 2005; 
 
 
B cells develop from a common lymphoid progenitor in bone marrow after which 
immature B cells migrate to secondary lymphoid organs where they can 
differentiate into antibody secreting cells (Fig. 1.2.2.2). Members of the B-cell 
lineage normally comprise 10-25 % of circulating lymphoid cells (Corcione et al., 
2005; Vyshika and Kalman, 2008) and can perform a wide variety of immune 
functions, any of which may contribute to their pathogenic activity in MS. This is 
not restricted to their ability to differentiate into antibody-secreting cells (ASC; 
plasma cells and/or plasmablasts) that may secrete demyelinating or axopathic 
autoantibodies (Elliott et al., 2012), but also includes their function as highly 
efficient antigen-presenting cells (APCs) (Lanzavecchia, 1985; Bar-Or et al., 2001; 
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Harp et al., 2010) and their immune regulatory properties (Mauri and Bosma, 
2012; Yang et al., 2013). This diversity of B cell effector functions suggests 
involvement of different disease developmental mechanisms, which each may 
provide a novel therapeutic target.  
 
 
Figure 1.2.2.2: Possible pathways in immunoglobulin production in the CNS. B cell 
development starts in the bone marrow after which they travel to secondary lymphatic 
organs where antigen-driven germinal centre differentiation into memory B-cells and 
plasmablasts occurs. 1) Plasmablasts can either enter back into the bone marrow or the 
inflamed CNS. 2) Memory B cells after their entry to the CNS can differentiate into 
antibody-secreting cells in response to antigen outside of follicles, or 3) in response to 
follicle-like aggregates in the meninges. 4) Bystander reaction can cause the memory B 
cells to differentiate into plasmablasts (Meinl et al., 2006). 
 
 
1.2.2.3 Intrathecal antibody synthesis 
Intrathecal Ig synthesis occurs in at least 90 % of patients with MS (Stangel et al., 
2013), which is recognised with OCBs identification in CSF. This method is no 
longer mandatory for a diagnosis of MS if MRI criteria are fulfilled; however it is 
still widely used as it eliminates possibility of other inflammatory diseases. 
Synthesis of Ig within the CNS compartment in MS is substantial and may exceed 
200 mg/day, although the average is nearer to 30 mg/day (Tourtellotte and Ma, 
1978). The OCB patterns identified by isoelectric focusing patterns are patient-
specific and persist for many years, although some variations will occur over 
time (Walsh and Tourtellotte, 1986; Colombo e al., 2003; Di Pauli et al., 2011; 
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Probstel et al., 2011; Kitley et al., 2012). As each OCB represents the product of 
a clonally expanded B cell population formed in the CNS (Obermeier et al., 2008) 
these observations indicate the CNS provides a long term survival niche for 
differentiating B cells and/or terminally differentiated plasma cells. These 
exhibit patterns of hypersomatic mutation indicative of antigen-specific 
maturation, presumably within the CNS compartment itself (Qin et al. 1998; 
Owens et al. 1998; Baranzini et al. 1999; Colombo et al. 2000; Owens et al. 2003; 
Monson et al., 2005). Mapping the specificity profile of this intrathecal antibody 
response with the help of antigen arrays has revealed it can recognise a large 
number of different lipid and protein autoantigens (Sellebjerg, Christiansen and 
Garred, 1998; Brennan et al., 2011; Quintana et al., 2012), as well as antigens 
derived from microbial pathogens (Yao et al., 2001; Derfuss et al., 2001). The 
latter includes a poly-specific immunoglobulin response that recognises measles, 
rubella and varicella-zoster viruses (MRZ reaction). This is generally found in 
patients diagnosed with MS but is absent in other neurological diseases (Luxton 
et al., 1995; Reiber et al. 1998; Jarius et al., 2006; Jarius et al., 2008). 
Altogether these studies demonstrate that a significant proportion of the 
intrathecal antibody responses associated with MS is directed against myelin-
derived lipids, in particular sulphatide and its precursor galactosylceramide 
(Ryberg, 1978; 1980; Kasai et al., 1986; Ichioka et al. 1988; Kirschning et al., 
1995; Kolodny et al., 1995; Ilyas et al., 2003; Kanter et al., 2006; Brennan et al., 
2011). These glycosphingolipids are both exposed at the outermost surface of 
the myelin sheath and oligodendrocyte plasma membrane where they can 
provide targets for antibody-mediated demyelination in vivo (Fierz et al., 1988; 
Rosenbluth et al., 1999; 2003; Morris-Downes et al, 2002; Kanter et al., 2006).  
 
Researchers may not have been able to the confirm antigen specificity of 
individual OCB, but clinical studies have established intrathecal antibody 
synthesis is associated with a poorer prognosis in MS. Specifically, OCB and/or 
elevated intrathecal Ig synthesis in patients with clinically isolated syndromes 
such as optic neuritis correlate with more rapid conversion to clinically definite 
MS, or in patients with relapsing remitting disease more rapid progression to 
SPMS (Villar et al., 2002; Nilsson et al., 2005; Tintore et al. 2008). 
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1.2.2.4 Evidence from MS lesions 
Involvement of antibody-dependent mechanisms in the pathogenesis of 
demyelination has been suggested by reports identifying deposition of 
immunoglobulins and complement activation products in MS lesions (Compston et 
al., 1989; Genain etal., 1999; Lucchinetti et al. 2000; Storch et al., 1998). 
Lucchinetti et al., (2000) described four different patterns of demyelination in 
cortical MS lesion biopsies defined on the basis of immunopathological criteria. 
The most common (>50% of cases) were Type II lesions in which demyelination 
was associated a pattern of complement activation, immunoglobulin deposition 
and macrophage responses virtually identical to those induced by demyelinating 
antibodies in animals with EAE. Observations that lead the authors to speculate 
development of these lesions involved an autoantibody-response directed against 
the myelin surface. This concept is supported by demonstration of myelin 
sheaths being decorated at the leading edges of the lesion with immunoglobulin 
and c9neo depositions (Storch et al., 1998), myelin-specific autoantibodies 
associated with vesicular myelin debris (Raine et al., 1999; Genain et al., 1999), 
phagocytosis of these opsonized debris by activated macrophages (Prineas, 1985; 
Storch et al., 1998), and more recently the identification of demyelinating IgG 
autoantibodies in patient serum (Haase et al., 2001; Elliott et al., 2012). 
Nonetheless other groups have questioned the significance of these observations 
as similar patterns of complement deposition are seen in other, unrelated 
neurological disorders (Barnett and Prineas, 2004).  
 
It is generally assumed that if autoantibodies are involved in the pathogenesis of 
MS these will recognise a small number of myelin-associated antigens, but the 
specificity of this pathogenic autoantibody response remains elusive. A large 
number of potential candidates have been identified over the years, but with 
the exception of MOG, none were validated as relevant targets for MS. The most 
recent was the Kir4.1 potassium channel, which despite exciting initial studies 
could not be proven to provide a relevant target from pathogenic autoantibodies 
in MS (Brickshawana et al., 2014). Interest in MOG developed from studies 
demonstrating it as an important target for demyelinating autoantibodies in EAE 
(Lebar et al., 1986, Lebar, Baudrimont and Vincent, 1989; Linington et al., 1986, 
1988; Schluessner et al., 1987; Genain et al., 1995). Subsequently, detection of 
MOG-specific antibodies in patient sera (Kerlero et al., 1993; Diaz-Villoslada et 
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al., 1999; Lindert et al., 1999) and MS lesions (Raine et al., 1999; O’Connor et al., 
2005) indicated their role in pathogenesis of MS. The claim that presence of 
MOG-specific autoantibodies correlated with a poor clinical prognosis (Berger et 
al., 2003) generated considerable controversy largely because at the time 
current immunoassay techniques were unable to distinguish between 
pathologically relevant and irrelevant antibodies (Kuhle et al., 2007). This, 
however, was resolved following development of cell based assays that 
specifically identify antibodies recognising the native extracellular domain of 
MOG expressed at the membrane surface; a pre-requisite if these antibodies are 
to mediate demyelination in vivo (Brehm et al., 1999; Lalive et al., 2006). 
Following the introduction of this methodology, potentially pathogenic MOG-
specific antibodies were detected in less than 5 % of patients with classical adult 
onset disease, but were noted to occur at much higher frequencies in paediatric 
MS (approximately 20 %) and ADEM (approximately 40 %) (McLaughlin et al., 2009; 
Brilot et al., 2009; Selter et al., 2010; Probstel et al., 2011). These MOG-specific 
autoantibodies are predominantly of the complement fixing IgG1 subclass and 
recognise surface epitopes of the native extracellular domain of MOG (O’Connor 
et al., 2010); characteristics that support the view they will exacerbate 
demyelination in seropositive patients. However, clinical significance of the 
antibody response remains unproven and its correlation with disease severity is 
still debated (Probstel et al., 2011).   
 
 
1.2.2.5 Clinical evidence for antibody-dependent mechanisms in MS 
Therapeutic plasma exchange is used to treat a variety of autoantibody 
mediated diseases including myasthenia gravis, systemic lupus erythematosus 
and Guillain-Barre syndrome, and is now recommended for patients with MS who 
develop acute relapses that fail to respond to steroids (Valbonesi et al., 1981; 
Weiner et al., 1989; Rodriquez et al., 1993; Bennetto et al., 2004; AAN 
Guideline, 2014). This was prompted by a review of previous studies suggesting 
plasma exchange may promote functional recovery in some patients (Weiner et 
al., 1989; Weinshenker et al., 1999; Keegan et al., 2002; Keegan et al., 2005; 
Schilling et al., 2006). These clinical observations are generally interpreted as an 
indication of autoantibody involvement in disease development. A retrospective 
analysis of patients who underwent a diagnostic brain biopsy revealed a 
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beneficial treatment to plasma exchange response correlated with lesional 
C9neo immunoreactivity (Keegan et al., 2005); a defining feature associated 
with antibody mediated tissue damage in the CNS (Lucchinetti et al., 2000). 
Subsequently, it was demonstrated that in patients with severe steroid non-
responsive relapses, demyelinating IgG responses were significantly reduced 
following a plasma exchange treatment (Elliot et al., 2012). These observations 
provide persuasive evidence that autoantibody dependent mechanisms can be 
involved in MS; however, there is still considerable debate as to their clinical 
significance in the majority of patients. These concerns stem from two 
observations. First, plasma exchange is ineffective in most patients with MS; 
efficacy has only been noted in small number of patients with RRMS course 
(Keegan et al., 2002; 2005). Second, B cell depletion in RRMS reduces disease 
activity in the CNS, before any global effect on circulating Ig levels, which was 
first demonstrated in a clinical trial of Rituximab in RRMS (Hauser et al., 2008).  
 
Rituximab is a monoclonal chimeric antibody that selectively depletes CD20+ B 
cells from the immune system and which was already licensed to treat 
lymphoma and rheumatoid arthritis (Coiffier et al., 1998; McLaughlin et al., 1998; 
Edwards et al., 2004). Hauser and his colleague’s (2008) demonstrated a single 
course of Rituximab not only resulted in a rapid reduction in lesion activity in 
the brain, as demonstrated by MRI, but also reduced the relapse rate. However, 
this rapid response occurs before any significant reduction of serum Ig 
concentrations. In hindsight, this is not unexpected as CD20 is not expressed by 
antibody secreting plasma blasts or plasma cells (Fig 1.2.2.2; Cross et al., 2006). 
It also appears B cell depletion in the periphery has a minimal effect on 
intrathecal IgG synthesis or OCB patterns (Cross et al., 2006). These observations 
lead into an important dichotomy; immunopathological studies suggest 
involvement of antibody-mediated mechanisms in most MS cases when clinical 
studies provide significance only in a subset of MS patients.  
 
 
1.3 Aim  
To investigate this further we readdressed the prospect that complement 
independent antibodies targeting the myelin surface may mediate other 
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responses than demyelination. This is suggested by studies that indicate some 
naturally occurring IgM antibodies, one of them being sulphatide specific 
monoclonal O4, enhance oligodendrocyte survival and myelination in Theiler’s 
murine encephalomyelitis virus (TMEV) mediated demyelination (Rodriguez and 
Lennon, 1990; Miller and Rodriquez, 1995; Asakura et al., 1996; Asakura et al., 
1998; Asakura and Rodriguez, 1998; Warrington et al., 2000; Wright et al., 2009). 
Therefore, the aim of this thesis is to use the in vitro model of myelination to 
investigate the transcriptional changes occurring within the cultures in response 
to addition of mAb O4 in the cultures.  
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2 Methods 
2.1 Animals  
Sprague Dawley (Harlan Laboratories, UK) rats were used in the experiments. 
Animals were killed using a Schedule 1 method by a trained technician.  
 
2.2 Myelinating culture system 
Myelinating culture system was generated by producing a confluent monolayer of 
astrocytes and plating dissociated embryonic spinal cord directly on top (see 
below). The myelination was assessed after 18 days by use of 
immunocytochemistry and fluorescence microscopy. All culture preparation and 
maintenance was performed in an aseptic fashion, using laminar flow hoods. 
Only exception was the tissue dissection stage, which was performed on a bench 
using a microscope.  
 
Myelinating cultures contain all cellular elements present in the CNS, including 
OPCs, astrocytes, neurons, and microglia. Myelination in these cultures results in 
large numbers of myelin sheaths associated with Caspr+ paranodes and nodes of 
Ranvier (Elliot et al., 2012; Sorensen et al., 2008; Thomson et al., 2008). They 
therefore provide a simple model system in which effects on neuronal survival, 
neurite outgrowth, OPC proliferation and differentiation, and myelination can all 
be quantified by immunofluorescence microscopy. We quantify myelination 
determining the percentage of SMI31+ axons ensheathed with proteolipid protein 
or myelin–oligodendrocyte glycoprotein positive myelin sheaths using pattern 
recognition based algorithms to differentiate myelin sheaths from 
immunoreactive oligodendrocyte cell bodies and processes. 
  
 
2.2.1 Isolation and culturing of neurospheres 
Neonatal P1 rats were decapitated, their brains were excised and transferred to 
Leibovitz’s-15 medium (L-15; Invitrogen, Paisley, UK) on ice. Sterilised surgical 
instruments were used to cut the brains mid-sagitally, after which striatum was 
removed from each hemisphere and placed in 1 ml of L-15 on ice. Tissue was 
mechanically dissociated and titruated through a glass Pasteur pipette to 
produce single cell suspension.  
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The suspension was centrifuged at 800 rpm for 5 min at 4°C, the supernatant 
was disregarded and the cell pellet was resuspended into 20 ml of neurosphere 
medium [DMEM/F12 (1:1, DMEM containing 4,500 mg/L glucose), supplemented 
with 0.105 % NaHCO3, 2 mM glutamine, 5,000 IU/ml penicillin, 5 µg/ml 
streptomycin, 5.0 mM HEPES, 0.0001 % bovine serum albumin, (all from 
Invitrogen), 25 µg/ml insulin, 100 µg/ml apotransferrin, 60 µM putrescine, 20 nM 
progesterone, and 30 nM sodium selenite (all from Sigma)]. The culture was 
supplemented with 20ng/ml (4µl) mouse submaxillary gland epidermal growth 
factor (EGF; R&D Systems). After which the cell suspension was placed into a 
non-coated 75 cm3 tissue culture flask (Greiner, Gloucestershire, UK) and 
incubated at 37°C, in humidified atmosphere of 7 % CO2/93 % air. The cultures 
were treated every two to three days with addition of 5 ml neurosphere medium 
and 4µl of 20 ng/ml EGF.  
 
 
2.2.2 Astrocytes derived from neurospheres 
After five to ten days in vitro, when the neurospheres had reached a critical size, 
they were titruated with a Pauster pipette to produce small spheres. The cell 
clusters were centrifuged at 800 rpm for 5 min at 4°C, and the supernatant was 
removed. The pellet was resuspended in low glucose (1.0 g/ml glucose) DMEM 
astrocyte media [supplemented with 10 % foetal bovine serum (FBS) and 2 mM L-
glutamine]. Neurospheres were differentiated into astrocytes by plating them 
onto poly-lysine (PLL; 13 µg/ml, Sigma) -coated coverslips (13 mm diameter, 
VWR International, Leicestershire, UK) that were prepared by two hour 
incubation at 37°C, distilled sterile water wash, and overnight dry. 0.5 ml of 
neurosphere suspension was plated on the coverslips that was then topped up 
with 0.5 of astrocyte media. The cultures were incubated at 37°C and fed twice 
a week, until confluent astrocyte monolayer formed after 6-10 days.  
 
 
2.2.3 Plating of dissociated embryonic spinal cord 
Dissociated myelinating cultures were generated as previously described by Elliot 
et al., (2012). Myelinating cultures were produced from embryonic day (–E)15.5 
rats. At E15.5, the pregnant female was euthanized in a carbon dioxide chamber. 
The abdomen was sterilised by 70 % ethanol. Sterilised scissors were used to 
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open the abdomen, and the gravid uterus was placed in sterile plastic Petri dish 
containing Hanks balanced salt solution (HBSS; Gibco, Invitrogen, Paisley) on ice. 
The foetuses were removed from the individual amniotic sacs and placed in fresh 
HBSS. They were decapitated just caudal to the attachment of cerebellum, 
rostral to the cervical flexure. Curved forceps were used to remove the skin and 
tissue covering the spinal cord, after which the meninges were stripped off to 
avoid peripheral nerve contamination, and the spinal cord was placed in 1ml of 
HBSS.  
 
The spinal cords were broken down into smaller pieces using a Pasteur pipette. 
Enzymatic dissociation of tissue was produced by trypsin (100 µl of 2.5 % trypsin) 
and collagenase (100 µl of 1.33 % collagenase) in 1 ml HBSS, incubation of 15min. 
Enzymatic digestion was stopped by adding 2 ml of trypsin inhibitor (SD; 0.52 
mg/ml soyabean trypsin inhibitor, 3.0 mg/ml bovine serum albumin and 0.04 
mg/ml DNase). Cell mixture was spun down at 800 rpm for 5 min and the cell 
pellet was titruated with glass Pauster pipette into single cell solution and 
diluted with plating media (PM; 50 % Dulbecco’s modified Eagle medium, 25 % 
heat inactivated horse serum, 25 % HBSS with Ca2+ and Mg2+, and 2mM L-
glutamine; Invitrogen) to make up 10 ml. Trypan Blue was used estimate cell 
number. Optimal density of 3 million cells/ml was generated.  
 
The dissociated spinal cord cell mixture at cell density of 150,000cells/100µl was 
plated onto three coverslips containing an astrocyte monolayer. The coverslips 
were placed in a 35 mm Petri dish and the cells left to attach for two hours in 
the incubator. After which additional 350 µl of PM and 600 µl of insulin 
containing differentiation medium [DM+; DMEM containing 4,500 mg/L glucose, 
10 ng/ml biotin and 0.5 % N1 hormone mixture [1 mg/ml apotransferrin, 20 mM 
putrescine, 4 mM progesterone, 6 µM selenium], 50 nM hydrocortisone and 0.5 
mg/ml insulin (Sigma)] was added. Cultures were maintained for up to 28 days in 
a humidified atmosphere of 7 % CO2/93 % air, at 37°C. Cultures were fed by 
removing 500 µl of the media and replacing it with 600 µl of fresh DM+ three 
times a week. At 12 days in vitro (DIV), insulin was excluded from the DM.  
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2.3 Hybridoma production 
Frozen hybridomas (Z2 and O4) were thawed quickly under lukewarm water and 
washed in 20 ml RPMI-1640 media by centrifugation after which the media was 
removed. The cells were resuspended, placed in fresh media in capped 75 cm3 
tissue culture flask, and incubated at 37°C and 5 % CO2/95 % air.  
 
 
2.3.1 Antibody production 
Antibodies were produced using Cell mAb Medium in a CELLine Device (BD 
Biosciences). The nutrient compartment was pre-wet with 25 ml of 100 % BD cell 
mAb medium. Cells were counted and resuspended in 15ml of the basal medium. 
The suspension was inoculated into the cell compartment. The nutrient 
compartment was filled with ~250 ml of mAb medium. Cells were incubated in 5 % 
CO2/95 % air incubator at 37°C. Every seven days, 13ml of cells in Ab medium 
were harvested from the cell compartment and centrifuged at 400g for 5min. 
The antibody-containing supernatant was collected and stored in -20°C. The 
remaining cell mixture was topped up with Ab medium, and the nutrient 
compartment was exchanged with fresh medium.  
 
2.3.2 IgG2a antibody purification  
The IgG2a supernatant was filtered with 0.45 µm filter to remove any particles. 
Hi-Trap Protein G Column HP (GE Healthcare Life Sciences) was washed with five 
bed volumes of 20 mM sodium phosphate buffer. The filtered antibody sample 
was applied to the column, after which the column was washed again. Then the 
antibody was eluted with one to three times of the column volume of 0.1 M 
Glycine into 100 µl of 1M Tris base measured in Eppendorf tubes. The sample 
concentrations were measured using NanoDrop 1000 Specrtophotometer and 
antibody containing samples were pooled and dialyzed against PBS. The column 
was regenerated with 20 % ethanol and stored at 4°C.  
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2.3.3 IgM antibody purification 
The IgM supernatant was normalised to the binding buffer by addition of 0.8 M 
ammonium sulphate and filtered through 0.45 µm to remove any impurities. 
HiTrap IgM Purification HP (GE Healthcare Life Sciences) unit was equilibrated 
with 20 mM sodium phosphate, 0.8 M ammonium sulphate binding buffer. The 
sample was run through the column, after which the column was washed with 
binding buffer. The antibody was eluted with 20 mM sodium phosphate. The 
sample was nanodropped, and filtered through a filter unit (Merck Millipore). 
The purification column was regenerated by washing step involving regeneration 
buffer followed by binding buffer, then stored at 4°C.  
 
In both cases (IgG and IgM), the proteins were appropriately concentrated. They 
were purity tested by SDS-PAGE non-reducing polyacrylamide gel, then stored at 
-20°C. 
 
 
2.4 Antibody treatments of myelinating cultures 
Treatments were completed in the presence or absence of rabbit serum as a 
source of complement. Cultures were treated with different antibody containing 
media at days 18 or 24. Antibodies were diluted into DM- medium at 20 µg/ml 
and filtered with 20 µm filter to remove any impurities. Cultures were treated 
by removing 500 µl and adding 600 µl antibody-containing medium. Controls 
were fed with DM-. Complement dependent experiments were additionally 
treated with 2 % rabbit serum (Sigma). Treatments were carried on either for 24 
hours or ten days, in longer treatments feeding was done every two to three 
days.  
 
 
2.5 Immunocytochemistry 
To confirm these cultures reproduce the molecular organization and accessibility 
of auto-antigens present on myelinated axons in vivo, they were incubated with 
antibodies specific for myelin and axoglial antigens. 
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Staining was performed on various differently treated cultures after sterile 
incubations at 37°C for 24 hours or 10 days. Cultures were fixed in 50 µl 4 % PFA 
for 20 min, after which wash with 1xPBS was performed three times and excess 
was tapped off. The myelinating cultures were permeablised in 40 µl 0.5 % 
Triton X for 10 min. Coverslips were washed with PBS. Cultures were blocked for 
minimum of 30 minutes in 50 µl of blocking buffer [BB; 1 x phosphate buffered 
salin (PBS) containing 1 % bovine serum albumin and 10 % horse serum]. Next, 
myelinating cultures were blocked in primary antibodies diluted in 40 µl of BB. 
Wash with PBS was performed, after which blocking in secondary antibody 
diluted at 1:400 ratio into 40 µl of BB was executed. The myelinating cultures 
were washed in PBS and distilled water to remove salt traces, and mounted on 
labelled glass slides with 10 µl of Mowiol with DAPI. Cultures were dried out at 
4°C overnight. In all cases where immunostaining was performed for surface 
exposed antigens live cells were incubated at 4°C with the primary antibody for 
30 minutes. Cells were then washed extensively with PBS after which they were 
fixed and permeabilised as described above.  
 
Images were captured using an Olympus BX51 fluorescent microscope and Image-
Pro software. Quantitative analysis of neurite density and myelination was 
performed on 10 random images from each three coverslips that were taken at 
10x magnification. Migroglia images were taken at 20x magnification. Neurite 
density, myelination and cell counts were quantified using analytical pipelines 
developed from CellProfiler cell image analysis software (Carpenter et al., 2006). 
These are available at https://qithub.com/muecs/cp.   
 
Table 2.5: Immunocytochemistry primary and secondary antibodies 
Primary 
antibody 
Specificity Host Isotype Dilution Company 
Secondary 
antibody 
O4  Sulphatide Mouse IgM 1:500 
From supernatant 
R & D 
Milteneyi 
ms IgM 488 
Z2 
Myelin 
oligodendrocyte 
glycoprotein 
Mouse IgG2a 1:500 Our laboratory ms IgG2a 488 
AA3 
Proteolipid 
Protein 
Rat IgG2a 1:100 Chemicon rt IgG2a 488 
SMI31 
Phosphorylated 
neurofilament 
Mouse IgG1 1:1500 Abcam ms IgG1 568 
Iba1 Microglia Rabbit IgG 1:1000 Wako rb IgG 568 
Fab  Fab fragment Mouse IgG 1:150 Sigma FITC 
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2.6 Generation of the Fab fragment of mAb Z2 
The antibody was purified in the same manner as previously described (Andrew 
and Titus, 2000) and concentrated into 2 mg/ml stock. The protein was digested 
with papain (0.1mg/ml) dissolved in digestion buffer at equal volume to 
antibody solution at papain-to-antibody ratio of 1:20. Incubation was performed 
at 37°C and samples analysed after 4, 6, 8, 16, and 24 hours. The reaction was 
inactivated by addition of 0.3 M iodoacetamide to a final concentration of 0.03 
M. To determine the optimum digestion time samples were analysed by SDS-
PAGE under non-reducing conditions. Samples digested for 16 and 24 hours were 
pooled and dialysed against PBS overnight at 4°C. The Fab was then purified 
using Protein G column to remove undigested IgG and any Fc containing 
fragments (Section 2.3.2), unbound Fab was collected in the flow through. Fab 
was concentrated using a 10 K filter unit (Merck Millipore) and purity determined 
by SDS-PAGE under non-reducing conditions. Fab preparations were adjusted to 
1 mg/ml in PBS and stored at -20oC.  
 
 
2.7 Gene expression analysis 
2.7.1 RNA extraction and purification  
RNA was extracted following the RNeasy Micro Kit protocol (Qiagen). One dish 
containing three cover slips of treated and control myelinating cultures were 
used to produce RNA samples. The culture supernatant was removed, 
centrifuged at 800 rpm for 5 min, after which the supernatant without the 
precipitate was stored at -20°C for further use. The cultures were gently washed 
with 1ml of filtered PBS. The cells were lysed with 350 µl of RLT buffer and 
sterile scraper was used to scrape the cells. The mixture was transferred into 
Qiashredder and centrifuged at 8000 g for 1 min. The samples were frozen at     
-80°C to aid the homogenisation.  
 
Next the lysates were transferred into gDNA Eliminator spin columns (Qiagen) to 
remove contaminating gDNA and centrifuged at 8000 g for 30 sec. The flow 
through was mixed thoroughly with 350 µl 70 % ethanol, transferred into RNeasy 
MinElute spin column, and centrifuged at 8000g for 30 sec. The flow through was 
discarded and 700 µl RW1 was added, followed by 500 µl of RPE, and 500 µl 80 % 
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ethanol, each separated by centrifugation step at 8000 g for 30 sec and flow 
through removal. 14 µl of RNase free water was added directly on the filter 
centre and the extracted RNA was eluted to a new collection tube. The RNA 
concentration was Nanodropped and RNA was stored at -80°C. 
 
 
2.7.2  Microarray 
The RNA quality and integrity was assessed using Agilent Bioanalyser 6000 Nano 
LabChip platform system at Edinburgh Genomics at the University of Edinburgh 
Roslin Institute. The total RNAs were processed and labelled with biotin using 
Ambion WT Expression Kit following the Affymetrix GeneChip WT Terminal 
Labeling and Hybridization protocol. The processed RNAs were hybridized to 
Affymetrix GeneChip® Rat Gene 2.1 ST Arrays using manufacturer's protocols for 
using the Fluidics Station 450. The hybridized arrays were scanned on the Gene 
Array Scanner 3000-7G.  
 
2.7.2.1  Partek Genomic Suite and Pathway analysis 
Raw data from the microarray study were provided by the Roslin Intitute 
Polyomics Facility. The data analysis was carried out in Partek Genomics Suite 
and PathwayTM (version 6.6, Partek Inc., St. Louis, MO, USA) software. Probeset 
level data were normalized using GCRMA normalisation and summarised to 
transcript cluster level using One-Step Tukey's Biweight method. Details of the 
analyses are described in detail in the text (Chapter 4).  
 
2.7.2.2 Panther gene list analysis 
The PANTHER (protein analysis through evolutionary relationships) Classification 
System (http://www.pantherdb.org/) was used to cluster proteins and their 
genes according to their biological functions. Statistical enrichment was defined 
by Mann-Whitney test. Gene expression was considered significant if it satisfied 
a p-value cut-off of 0.05.  
 
2.7.2.3 Interferon signature analysis 
The interferome v2.0 (http://interferome.its.monash.edu.au/interferome/ 
home.jspx), online database, allows experimental evidence on different 
interferon (IFN) subtypes to regulate IFN sensitive genes (ISGs).  
48 
 
2.8 Real time-polymerase chain reaction array 
2.8.1 Total RNA extraction from myelinating cultures 
RNA was extracted using RNEasy Micro Kit (Qiagen) as previously described.Cells 
were lysed in RLT buffer, homogenised using Qiashredder and stored at -80°C 
until RNA purification. Next the genomic DNA was removed and RNA was 
precipitated by addition of 70 % ethanol. This was followed by washing and 
elution of RNA from the RNeasy MinElute spin columns with 14 µl of RNeasy 
water. The resultant RNA was quantified using a NanoDrop and stored at -80°C 
to maintain RNA integrity until the assessment. 
 
 
2.8.2 cDNA preparation 
Sample cDNA was prepared from 500ng RNA using RT2 First Strand Kits (Qiagen), 
as described by the manufactures. Genomic DNA elimination mix was prepared 
as follows: 
Template RNA   ≤ 8 µl 
RNase free water    *  
gDNA eliminator buffer  2 µl 
Total volume    10 µl 
* Reaction made up to total of 10 µl in H2O 
 
The mixture was incubated at 42°C for 5min, then immediately lifted on ice to 
stop the reaction. 
 
To perform the reverse transcription, total volume of 10µl of master mixture per 
reaction sample was prepared as followed: 
5xbuffer BC3    4 µl 
Control P2    1 µl 
RE3 reverse transcription mix  2 µl 
RNase free water    3 µl  
Total volume           10 µl 
 
Each sample tube was vortexed and centrifuged. The thermocycler was set as 
the following for the reverse transcription reaction to be carried out: 
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1. 42°C    15 minutes 
2. 95°C    5 minutes 
3. 4°C    Infinity 
  
Volume of 91µl of RNase free water was added in each of the reaction samples, 
they were mixed, and placed in -20°C or continued to real-time PCR. 
 
 
2.8.3 RT-PCR array 
Master mix was prepared: 
2xRT2 SYBR Green master mix   1350 µl  
RNase free water     1248 µl  
cDNA                  102 µl 
Total volume    2700 µl 
 
Multichannel pipette was used to insert 25 µl of master mix in each of the 96-
well RT2 PCR Array plate (Qiagen) wells. The plate was centrifuged at 1000 g for 
1 min. 
 
The RT-PCR Array was performed on Applied Biosystems® 7500 Real-Time PCR 
Systems. The instrument was set as following:  
1. 50°C  1 second 
2. 95°C  10 minutes 
3. 95°C  15 seconds 
4. 60°C  1 minute 
 
Steps three and four alternated for forty cycles after which data collection was 
performed. 
 
 
2.8.4 Data analysis 
Statistical analysis of the data was performed on free PCR array data analysis 
web portal (http://sabiosciences.com/pcrarraydataanalysis.php) using ΔΔCT 
method. This software allows automatic quantification of the CT data provided 
by the array and calculation of the fold changes.  
 
 
50 
 
2.9 Quantitative real-time PCR 
Change in the expression of selected genes of interest was verified using RNA 
obtained from additional cultures treated with mAb O4 or isotype control in the 
presence or absence of serum as a source of complement. 
 
 
 
2.9.1 Total RNA extraction from myelinating cultures 
RNA was prepared as previously described in Section 2.6.1. 
 
 
2.9.2 Reverse transcription of RNA to cDNA 
The RNA samples and QuantiTect Reverse Transcription kit (Qiagen) were 
thawed on ice. RNA samples were normalised to 500ng. cDNA synthesis reactions 
were accompanied by two control reactions:  
1. –RT control, where reverse transcriptase was substituted for RNase free 
water as a control for genomic DNA contamination. Sample with the 
highest template RNA was used. 
2. No template control, where template RNA was substitured for RNase free 
water for contamination of reagents. 
 
Genomic DNA (gDNA) was eliminated from the RNA template by adding the 
following into a RNase free PCR tubes: 
Template RNA  ≤ 12 µl 
RNase free water  * 
gDNA wipeout buffer 2 µl 
Total volume  14 µl 
* Reaction made up to 14 µl in H2O 
 
The solution was incubated at 42°C for two minutes, then immediately set on 
ice to stop the reaction. Meanwhile, reverse transcriptase mixture was prepared 
as following and added into the RNA sample: 
Reverse transcriptase mix  1 µl 
Quantitative RT buffer  4 µl 
RR primer mix   1 µl 
Total volume   6 µl 
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The tubes were vortexed and centrifuged. The reverse transcription was carried 
out in thermocycler set for the following programme: 
1. 42°C   20 minutes 
2. 95°C   3 minutes 
3. 4°C   Infinity 
RNase free water was used to dilute samples in 1:5 ratios, after which they were 
stored at -20°C. 
 
 
2.9.3 Primer design 
Specific primers were designed to amplify each target gene of interest identified 
on the microarray. Primer accuracy and efficiency was required to ensure 
accurate reaction. All primers were designed using Primer3: WWW primer tool 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi).  
 
 
Specification for qPCR primers: 
Primer size    18 to 23 base pairs (bp) (20bp optimal) 
Melting temperature (Tm)   59.0°C to 61.0°C (60.0°C optimal) 
GC content    40% to 65% (50% optimal) 
Max self-complementarity  2.00 
Max 3’ complementarity  1.00 
 
Basic local alignment search tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
was used to ensure primer sequence specificity for the gene of interest. In cases 
where Primer3 software did not result any suitable results or BLAST found 
similarities between biological sequences, maximum self-complementarity was 
increased to 3 on Primer3: WWW primer tool.  
 
Primer specificities were confirmed by qPCR reaction using any cDNA containing 
the transcript of interest. Specificity was considered accurate if appropriate size 
amplification occurred.  
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Table 2.8.3: Primer designs for the genes of interest.  
Gene Symbol Forward Primer (5' - 3') Reverse Primer (5' - 3') 
CCL2 TAGCATCCACGTGCTGTCTC TGCTGCTGGTGATTCTCTTG 
CCL5 CTT TGC CTA CCT CTC CCT CG TCC CCA GCT GGT TAG GAC T 
CCL7 CCA TCA GAA GTG GGT TGA GG CAG AAA GGA CAA GGG TGA GG 
CCL20 TTC ACA ACA CAG ATG GCC GA TGC AGT GAT GTG CAG GTG AA 
CXCL11 AAC GGT TCC AGG CTT CGT TA TTG TCA CAG CCG TTA CTG GA 
CXCL13 CCT GCT CGG AAT CTT AGT GTT TGG GTT GAG TAT GGG AAG GA 
IFN-α4 CTC ATC TGC TGC TTG GAA TG TTC TTG GGT TAG GGG AGG TT 
IFN-γ GCC CTC TCT GGC TGT TAC TG CCA AGA GGA GGC TCT TTC CT 
IL-1β AAA AAT GCC TCG TGC TGT CT TTG TCG TTG CTT GTC TCT CCT 
IRF7 CAA GAG GAA ATG CTG GGT TG AGA AGC CTG TGG TGG GAC T 
SOCS1 AGC CAT CCT CGT CCT CGT AAG GTG CGG AAG TGA GTG TC 
STAT4 ACG CAC AGG AAA GCC TCA CAC TGC TCA AGT CCA AAG TCA 
CD14 TGG TCA ACA AAT CCT CTG CTT ACC GAT GGA CAA CTT TCA GG 
TNF CCC CTT TAT CGT CTA CTC CTC A TTC AGC GTC TCG TGT GTT TC 
GAP-DH ATG ACT CTA CCC ACG CAA G TAC TCA GCA CCA GCA TCA CC 
 
 
2.9.4 RT-PCR 
The Affymetrix Array and chemokine array findings were validated by the use of 
primer specific qPCR. Front and reverse primers were mixed at 1:1 ratio. 
Quantitative PCR was performed on 7500 Fast machine set on the following 
programme: 
1. 50°C   5 seconds 
2. 95°C   10 minutes 
3. 95°C   15 seconds 
4. 60°C   1 minute 
 
Steps 3 and 4 were altered for 40 cycles, after which data collection was 
performed.  
 
 
2.10 Enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assay (ELISA) was run for quantitative 
determination of chemokine concentrations within the sample supernatants as 
they were collected following myelinating culture treatments from three 
biological replicates. They were centrifuged at 800 rpm for 5 min to remove any 
precipitate and stored as aliquots at -20°C.  
53 
 
Commercially available ELISAs were performed as described in the 
manufacturer’s instructions. All reactions were performed in duplicate. In all 
cases, reagents were prepared according to instructions. The standard curve was 
produced via two-fold dilution series. The samples of unknown protein 
concentrations were diluted based on values obtained from the RT-PCR Array 
and Affymetrix Array. 
 
 
2.10.1 Rat CCL2 and CCL5 ELISA 
Rat CCL2 and CCL5 were detected in the supernatants using ELISA construction 
kits from R&D Systems (MJE00 and MMR00, respectively). 50 µl of assay diluent 
was added into each well before they were topped up with 50ul of standard, 
control, or sample solution. The microplate was incubated for two hours in room 
temperature. The wells were aspirated and tapped on a paper towel, after 
which wash buffer was added. This was repeated five times. Then rat conjugate 
solution was added into the wells and left to incubate for two hours. Washing 
step was repeated five times and substrate solution was added into the wells for 
30 minutes in room temperature and protection from light. Stop solution was 
pipetted into the wells and mixed gently by tapping the sides of the microplate. 
Finally, the plate was inserted in a reader set at 450 nm. 
 
 
2.10.2  Rat CCL20 ELISA 
Rat macrophage inflammatory protein 3α (MIP-3α) (CCL20) was detected in the 
supernatants using ELISA construction kits from Abnova (KA2000). 100 µl of 
standard or samples were pipetted into pre-coated 96-well plate wells after 
which it was covered and incubated at 37°C for 90 min. The wells were blotted 
on a paper towel and 100 µl of biotinylated anti-rat CCL20 antibody working 
solution was added into each well. The plate was incubated at 37°C for 60 min. 
The plate was washed three times with 1x PBS, each time allowing the plate to 
sit on a shaker for 1-2 min. Then, 100 µl of prepared avidin-biotin-peroxidase 
complex working solution was added into the wells for 30 min at 37°C. The 
washing step was repeated five times, after which 90 µl of prepared TMB colour 
developing agent into each well and incubated at 37°C for 20-25 min. 100 µl of 
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TMB stop solution was added into wells, and microplate reader was used to read 
the optical density absorbance at 450 nm.  
 
 
2.10.3  Rat CXCL11 ELISA 
Rat interferon inducible T cell alpha chemo-attractant (CXCL11) was detected in 
the supernatants using ELISA construction kits from Uscn Life Science Inc 
(E92071Ra). 100 µl of standard or samples were pipetted into pre-coated 96-well 
plate wells, after which it was covered and incubated at 37°C for 2 hours. The 
wells were aspirated, 100 µl of prepared detection reagent A was added and 
incubated for 60 mins at 37°C. The solutions were discarded and the wells were 
washed three times. 100 µl detection reagent B was added into the wells for 30 
min incubation at 37°C. Washing step was repeated for five times and 90 µl of 
substrate solution was added. The well plate was incubated for 15-25 mins at 
37°C, after which 50 µl of stop solution was added. The absorbance was 
measured by using the microplate reader at 450 nm.   
 
 
2.10.4 Statistical Analysis 
Standard curve was created by plotting the mean standard absorbance of each 
standard against their concentration, and best fit line was drawn. To determine 
the concentration of the target protein, the data was linearised by plotting the 
log of the mean sample concentrations (n=3) against the log of optical density; 
best fit line was determined by regression analysis. Diluted concentrations were 
multiplied by their dilution factors. 
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3 Antibody-mediated effects on myelin in vitro 
3.1 Confirmation of antigen accessibility on myelin surface 
Myelinating cultures were generated from dissociated embryonic (E15.5) rat 
spinal cord as previously described (Sorensen et al., 2008). Neurite outgrowth 
and myelination were assessed by immune fluorescence microscopy using 
antibodies specific for phosphorylated neurofilaments (clone SMI-31, red, Fig. 
3.1 A-ii & B-ii) and PLP (clone AA3, green, Fig. 3.1 B-i). To confirm the epitope 
recognised by mAb O4 was exposed at the surface myelinating oligodendrocytes 
live cultures 24 DIV were incubated with mAb O4 at 4°C and then processed for 
immunofluorescence microscopy (green, Fig. 3.1 A-i). This confirmed that 
immunoreactivity for O4 was associated with the surfaces of linear structures 
identified as myelin sheaths and the cell bodies and processes of PLP+ cells 
identified on the basis of their morphology as OPCs and oligodendrocytes.  
 
 
 
Figure 3.1: The O4 antigen is exposed on the surface of OPC, myelinating 
oligodendrocytes and myelin sheaths. Live staining with mAb O4 (A-i, green) 
demonstrates its epitope(s) are accessible at the outer surface of OPC, myelinating 
oligodendrocytes and myelin sheaths. Two colour immunofluorescence microscopy for 
PLP (B-i, clone AA3, green) demonstrates the presence of terminally differentiated 
oligodendrocytes and myelin sheaths associated with axons (B-ii, clone SMI31, red); 
merged image (iii).All cultures analysed at 24 DIV. Bar represents 100 µm. 
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3.2 IgM antibody mediated demyelination  
Previous studies demonstrated myelinating cultures can be used to assess and 
quantify antibody-mediated demyelination in vitro (Elliott et al., 2012). To 
confirm mAb O4 was able to mediate this demyelinating effect in our cultures, 
they were treated with 20 µg/ml mAb O4 or its irrelevant mouse IgM (as an 
isotype control) in the presence of 2 % rabbit serum as a source of complement 
for 24 hours. Additional controls were provided by untreated cultures, and 
cultures treated with 2 % rabbit serum alone. 
 
 
Figure 3.2: Acute demyelination by mAb O4 is dependent on an exogenous source of 
complement. (b) Significant demyelination is only observed when cultures are 
incubated with mAb O4 in the presence of serum as an exogenous source of 
complement. mAb O4 has no corresponding effect on myelination (a & d, 5.80 ± 1.67 %) 
and neurite density (b, 77.90 ± 3.46 %) presented as (mean ± SD, n = 3, *p < 0.05, **p < 
0.01, one-way ANOVA). Representative immune fluorescence images: (a) overnight 
incubation of cultures with mAb O4, (b) culture treated overnight with mAb O4 and 2 % 
rabbit serum and (c) culture incubated over night with control IgM and 2 % rabbit 
serum. Bar represents 100µm. 
 
 
Axonal density and myelination were quantified by computer aided analysis of 
immunofluorescent images (Fig. 3.2a-c). Incubating cultures for 24 hours with 
mAb O4, the IgM isotype control or serum alone had no statistically significant (p 
> 0.05) effect on myelination. However, a trend was observed suggesting 
treatment with mAb O4 or serum alone did mediate a slight decrease in myelin, 
as determined by quantifying myelination using mAb Z2 (specific for MOG) and 
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SMI-31 (specific for neurofilaments). In contrast, treatment with mAb O4 in the 
presence of serum as a source of complement resulted in a reduction of 
myelination by > 70 % relative to controls treated with serum alone (serum 
alone, 7.47 ± 2.47 %; serum plus mAb O4, 2.17 ± 0.98 %; P<0.01) (Fig. 3.2). Data 
presented in Figure 3.2 were derived using three different preparations of mAb 
O4; one purified from culture supernatants in the laboratory, one purchased 
from R&D systems and the third provided by Miltenyi. There were no differences 
noted in their demyelinating activity in this in vitro study, and none had any 
effect on neurite density as determined by SMI-31 immunoreactivity. 
 
 
3.3 IgG antibody mediated demyelination is Fc dependent 
Demyelination by autoantibodies recognising epitopes exposed at the 
myelin/oligodendroglial surface is thought to be dependent on activation of 
complement (Elliot et al., 2012), a response which is Fc dependent. To test this 
hypothesis we investigated the demyelinating potential of the MOG-specific IgG2a 
mAb Fab fragment of Z2 and its Fab fragment in vitro.  
 
This Fab fragment (Fig. 3.3d) retained the ability of the parent antibody (Fig. 
3.3a) to recognise its epitope on myelin and oligodendrocytes but was unable to 
induce significant demyelination when added to myelinating cultures in the 
presence of serum as a source of complement (Fig. 3.3f). This is in striking 
contrast to mAb Z2 which reduced myelination by >50 % in the presence of 2 % 
rabbit serum (Fig. 3.3c & a). Neither the mAb Z2 nor its Fab fragment had any 
effect on neurite density under any of the conditions investigated in this study 
(Fig. 3.3h).   
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Figure 3.3: Acute antibody mediated demyelination is Fc- dependent. MOG-specific 
mAb Z2 (a) and Fab fragment (d) epitopes are accessible at the outer myelinating 
oligodendrocytes and myelin sheaths. Overnight treatment of myelinating cultures with 
20 µg/ml mAb Z2 or Z2 Fab in absence (b,e) or presence (c,f) of 2 % rabbit serum as a 
source of complement. As reported previously (Elliott et al., 2011) mAb Z2 mediates 
demyelination when an exogenous source of complement is available (c). In contrast, 
Z2 Fab is unable to mediate demyelination (f).  Myelin as visualised by immunostaining 
for PLP (clone AA3; green) and neurites visualized using the neurofilament-specific 
antibody SMI-31 (red; d,e,g & h). Quantification of myelination (g) and neurite density 
(h) demonstrates myelin loss was only observed in the presence of serum when mAb Z2 
was added to the cultures (3.16 ± 1.67 %), Z2 Fab had no effect (8.37 ± 2.80 %). 
Representative data from 30 images of one experiment (mean ± SD, ***p < 0.001, one-
way ANOVA). Bar represents 100 µm.  
 
 
3.4 Complement-independent IgM mediated inhibition of 
myelination  
Studies investigating the functional significance of autoantibody mediated 
effects in MS in general focus on their ability to induce demyelination by acute 
complement- and/or antibody-dependent cellular cytotoxicity (ADCC) dependent 
mechanism. Such experiments may replicate the situation seen in patients with 
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RRMS in which demyelination is associated with perivascular inflammation and 
BBB breakdown, but as outlined in the introduction this is not the case in 
patients with progressive disease in whom the BBB is apparently intact. In this 
situation availability of antibody and complement is effectively limited to that 
synthesised within the CNS compartment itself. In order to model this situation 
in vitro we decided to investigate the effects of longer treatments with mAb O4 
in myelinating cultures in the absence of serum. This mAb was chosen as it 
reproduces the cellular specificity of a sulphatide-specific mAb isolated from a 
patient with MS (Kirschning et al., 1995; 1997). We therefore treated 
myelinating cultures from 18 to 19 DIV or from 18 to 28 DIV with 20µg/ml mAb 
O4 or the IgM isotype control. 
 
 
 
Figure 3.4: Prolonged antibody treatment in the absence of complement inhibits 
myelination. Ten day treatment of myelinating cultures with 20 µg/ml O4 (sulphatide-
specific monoclonal antibody) in the absence of complement resulted in demyelination 
(a). Prolonged isotype control treatment did not affect myelination. Full axonal density 
was established 18 DIV and remained intact after demyelination (b). Percentage values 
of myelination (a) and axonal density (b) were calculated in relation to cultures 
treated with equivalent concentrations of antibody or their isotype controls in the 
absence of complement for 24 hours or ten days (Mean ± SD; n=2; ***P < 0.001; one-way 
ANOVA). 
 
 
Analysis of immune fluorescent images revealed mAb O4 had no significant 
effect on axonal density (Fig. 3.4b) but following prolonged exposure 
significantly inhibited myelination (Fig. 3.4a). As demonstrated above, overnight 
incubation with mAb O4 (18 to 19 DIV) in the absence of an exogenous source of 
complement had no effect on myelination. In contrast, treatment for ten days 
not only completely blocked any further myelination, but also appeared to 
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induce some loss of pre-existing myelin sheaths. This effect was antigen-specific 
as it was not observed when cultures were treated with the IgM isotype control. 
 
 
3.5 Antibody mediated inhibition of myelination is associated 
with increased microglial numbers  
In addition to myelin and oligodendrocyte loss, previous studies demonstrate 
microglia are activated in demyelinating MS lesions (Barnett and Prineas, 2004) 
either in response to local injury or BBB disruption (Denk and Svoboda, 1997; 
Nimmerjahn, Kirchhoff and Helmchen, 2005). To investigate whether a similar 
effect can be induced in vitro, myelinating cultures (18 DIV) were treated with 
mAb O4 or isotype control and immunostained to identify Iba-1+ microglial cells 
after 24 hours and ten days.  
 
 
Figure 3.5a: Overnight antibody treatment has no effect on microglial numbers. 
Antibody treatment in the absence of complement from 18 to 19 DIV did not affect 
microglial (a) or whole cell population (b) numbers. Representative data calculated as 
total of 30 images (mean ± SD, n=3, one-way ANOVA).  
 
 
Our results revealed no difference between Iba-1+ or total cell numbers per 30 
fields in untreated (Iba-1 493 ± 183; DAPI 10091 ± 578), and isotype control (Iba-
1 537 ± 79; DAPI 10023 ± 1556) or mAb O4 (Iba-1 580 ± 163; DAPI 10103 ± 601) 
treated myelinating cultures after 24 hours.  
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Figure 3.5b: Ten day antibody treatment increases number of microglia. 
Myelinating cultures were treated from 18 to 28 DIV with an IgM isotype control (a) or 
mAb O4 (b). Prolonged treatment with isotype control IgM had no effect on microglial 
and total cell number (c) visualised by microglial-specific Iba-1 (red) and DAPI (blue), 
respectively. In contrast, ten day treatment with mAb O4 resulted in ~50 % increase in 
Iba-1+ cells when total DAPI number remained the same (a, b, c). Values shown 
represent total numbers of Iba1 and DAPI cells per 30 images. Representative data 
from one of three experiments (***p < 0.001, one-way ANOVA). Bar represents 50 µm. 
 
 
However, Iba-1+ microglial numbers in myelinating cultures treated for ten days 
with mAb O4 were found to more than double those in untreated or isotype 
control treated cultures (Fig. 3.5b; p < 0.001). This was not apparent in the total 
cell counts as microglial numbers account for < 5% of cells in these cultures. 
Comparison of untreated cultures at these two time points indicates there is no 
significant increase in microglial numbers over the course of this experiment in 
the absence of mAb O4.  
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3.6 Discussion 
MS is a devastating disease that results in extensive demyelination associated 
with axonal loss and injury. Studies on patients indicate antibody-dependent 
mechanisms are involved in lesion formation (Cross et al., 2011). This data, 
however, is largely circumstantial (Cross et al., 2011), although numerous 
studies report MS is associated with increased levels of (auto-)antibodies in 
serum and CSF (Weber, Hemmer and Cepok, 2011). It is therefore important to 
develop in vitro techniques to determine how these antibodies may contribute 
to disease development and identify potential therapeutic leads to counter their 
effects in patients.  
 
Myelinating cultures provide a valuable approach to study antibody mediated 
effects in vitro and in our study we decided to use the sulphatide-specific IgM 
mAb O4 as this antibody replicates multiple features associated with intrathecal 
autoantibody repertoire in MS patients. First, sulphatide is a major target for the 
intrathecal antibody response in patients with MS (Ilyas et al., 2003; Villar et al., 
2005; Kanter et al., 2006; Brennan et al., 2011). Second, the presence of 
oligoclonal IgM anti-lipid antibodies in the CSF of MS patients is associated with a 
poor prognosis involving earlier second relapses, more relapses, and severed 
disability (Villar et al., 2005). Third, a human IgM mAb isolated from an MS 
patient is sulphatide-specific and exhibits a similar pattern of binding to the 
surface of oligodendrocytes in the rat brain cell cultures and tissue sections as 
mAb O4 (Kirschening et al., 1995; 1997). In addition, animal experiments 
demonstrate intrathecal synthesis of mAb O4 by hybridomal cells induces 
demyelination in vivo (Rosenbluth et al., 2003), whilst passive transfer of this 
antibody exacerbates disease severity in mice with EAE (Kanter et al., 2006). 
Lastly, in vitro studies from this laboratory demonstrated mAb O4 can mediate 
complement-dependent demyelination (see Section 3.2; 3.3; Elliot et al., 2012).  
 
Our data confirm these experiments in that binding of mAb O4 to the 
myelin/oligodendrocyte surface induces rapid complement-mediated 
demyelination (Elliot et al., 2012). In addition, we also found prolonged 
exposure to mAb O4 inhibits myelination even in the absence of serum as a 
source of complement. These results support the dominant view that anti-
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glycolipid autoantibodies are pathogenic in patients with CNS demyelinating 
diseases. However, this interpretation has been questioned following reports 
stating mAb O4 and natural occurring human IgM autoantibodies enhance 
remyelination in TMEV model of inflammatory demyelination (Miller et al., 1994; 
Asakura et al., 1998; Warrington et al., 2000). This effect is attributed in part to 
surface binding of IgM antibodies inducing OPC proliferation and differentiation 
(Bansal, Gard and Pfeiffer, 1988). Why mAb O4 blocked rather than stimulated 
myelination in our current studies remains unclear, however, the outcome of 
antibody binding may be concentration dependent as we used antibody 
concentrations higher than those reported by Bansal and colleagues. Moreover, 
the myelinating cultures used in the present study contain large numbers of 
astrocytes and neurons that may provide an intrinsic source of complement 
components. Determining whether the myelination block and/or increase in 
microglial numbers seen following extended treatment with mAb O4 is 
complement-dependent is important and requires further investigation. 
However, it is apparent acute loss of myelin in this culture system is dependent 
on the availability of serum to provide an exogenous source of complement 
(Elliot et al., 2012); an effect we now confirm is Fc dependent. In this situation 
demyelination is presumed to be initiated by activation of the classical 
complement pathways following binding of C1q by antibody on the 
myelin/oligodendrocyte surface (Linington et al., 1989), although this has still to 
be formally demonstrated.  
 
In our cultures, we observed rabbit serum alone induced a variable reduction in 
myelin. This was not statistically significant (p > 0.05) but may reflect rat 
oligodendrocyte sensitivity to damage mediated by antibody-independent 
activation of complement; an effect attributed to the failure of rat 
oligodendrocytes to the express membrane complement regulator CD59 (Zajicek 
et al., 1992; Wing et al., 1992; Piddlesden and Morgan, 1993). The significance 
of this effect in vivo is difficult to evaluate; however, it may be important in 
diseases associated with catastrophic damage to the BBB such as stroke. 
However, BBB damage is more subtle in MS and moreover, unlike the situation in 
experimental rodents, human oligodendrocytes do express CD59 (Scolding et al., 
1998).  
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In the context of MS, the effect of prolonged treatment with mAb O4 in the 
absence of serum may in fact be more interesting than its ability to induce acute 
complement dependent demyelination. This experimental setting can be argued 
to mimic the situation within the CNS of patients with progressive forms of MS 
that exhibit little evidence of BBB dysfunction. In these patients there is very 
limited availability of complement and antibodies derived from the periphery, 
but there is substantial intrathecal synthesis of autoantibodies and possibly also, 
complement components. The former include antibodies recognising sulphatide, 
dominant target of mAb O4 in CNS myelin (Villar et al., 2005), whilst 
complement components in the CNS may be produced by microglia and 
astrocytes (Passinetti et al., 1992; Levi-Strauss and Mallat, 1987; Gasque et al., 
1995; Jongen et al., 1997). 
 
Our in vitro data demonstrate there is no obvious effect of mAb O4 on 
myelination after 24 hours, but after 10 days its presence not only completely 
blocks myelination but also mediates some loss of myelin already present at the 
start of the experiment. This observation supports the view intrathecal antibody 
responses to myelin-associated glycolipids are pathogenic rather than beneficial 
in MS. It will now be important to determine how mAb O4 disturbs myelination, 
and if this is specific for sulphatide or is a generalised effect mediated by any 
antibody that binds to the myelin/oligodendrocyte surface. Potential 
mechanisms include: 
1) Steric hindrance due to the high density of Ig bound to the 
oligodendrocyte surface blocking molecular interactions with the 
extracellular matrix and/or axonal surface required to support OPC 
differentiation and myelination. 
2) Dysmyelination due to destabilisation of immature myelin sheaths due to 
incorporation of Ig into the extracellular apposition (Rosenbluth and 
Moon, 2002; Rosenbluth and Schiff, 2009).  
3) Cross-linking of surface microdomains leading to disruption of 
cytoskeleton and process retraction (Dyer and Benjamins, 1989; Dyer, 
1993; Dyer and Matthieu, 1994), and/or a cellular stress response (Marta 
et al., 2005; Marta et al., 2008).  
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4) FcR mediated interactions between Ig on the myelin/oligodendrocyte and 
microglial cells (Marta et al., 2005).  
 
The relative importance of these mechanisms can now be explored using Fab 
fragments derived from mAb O4 and other mAb recognising epitopes exposed at 
the myelin surface (eg. O1, an IgM mAb specific for galactocerebroside; O10, an 
IgM mAb specific for PLP; Z2, an IgG2a mAb specific for MOG). These reagents 
would also be useful in investigating the relationship between inhibition of 
myelination by mAb O4 in the absence of serum and its effect on microglial cell 
numbers.  
 
The demonstration continuous treatment with mAb O4 induced a significant 
increase in microglial cell numbers is potentially the most exciting result from 
these experiments, as it suggests a functional relationship may exist between 
the intrathecal antibody response (in the case represented by mAb O4) and 
microglial proliferation in patients with PMS (Prineas et al., 2001). This response 
could result, as previously mentioned, from antibody-mediated cross-linkage of 
microglial surface receptors, a concept supported by the observation treating 
mixed glial cell cultures with pentameric human Fcµ activates microglia (Howe 
et al., 2006). It was this observation that launched our interest in mapping 
transcriptional changes induced by mAb O4 in myelinating cultures.  
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4 Transcriptional profiling of antibody induced 
demyelination 
In order to identify potential biomarkers associated with acute autoantibody-
mediated demyelination a gene microarray study was performed on myelinating 
cultures. Five conditions were analysed (1) untreated cultures; (2) IgM isotype 
control alone (3) serum alone; (4) mAb O4 alone; (5) mAb O4 plus serum. All 
incubations were carried out for 24 hours at 37°C in 7 % CO2/93 % air. 
 
 
4.1 Processing of RNA samples 
Total RNA was extracted from myelinating cultures (n = 3; in each case using 3 
coverslips) treated as described above. In each case sample purity and RNA 
concentrations were determined by absorbance before samples were sent out for 
analysis at the Edinburgh Genomics laboratory. RNA integrity and quality was 
confirmed using the Agilent Bioanalyzer 6000 Nano LabChip platform system that 
utilises the RNA Integrity Number (RIN) algorithm to analyse RNA 
electropherograms (Fig. 4.1a). The RIN algorithm is calculated on the basis of 
the presence of degradation products (marked ‘lower’ in Fig. 4.1b) and the ratio 
of 28S to 18S ribosomal RNA. Samples were only deemed acceptable for the 
analysis if they had RIN scores of >8 (score of 10 corresponding to completely 
intact RNA, whilst a score of 1 indicating a completely degraded sample). All of 
our samples scored RIN ≥ 8.7, thus being eligible for further analysis. 
 
 
 
Figure 4.1: Quality of RNA samples. RNA was isolated from myelinating cultures 
treated overnight with mAb O4 or its isotype control in the presence or absence of 
serum as a source of complement. Additional controls were provided from untreated 
and serum alone treated cultures.  a) Gel image assessment on Agilent Tapestation 
System expressing individual RIN scores. b) Representative electropherogram of high 
quality total RNA with and RNA integrity value of 9.  
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4.2 Determining how antibodies influence gene expression in the 
myelinating culture  
To establish how the different treatments influenced gene expression, the 
transcriptional profiles of myelinating cultures treated as described above were 
compared using Affymetrix GeneChip Rat Gene 2.1 ST array which comprise 
28,407 distinct RefSeq probes that equate to 16,771 well-annotated gene 
transcripts. This was performed by Edinburgh Genomics at the University of 
Edinburgh Roslin Institute (https://genomics.ed.ac.uk/) using RNA samples 
labelled with biotin by means of the Ambion® WT Hybridisation protocol in 
combination with a Fluidics Station 450. After hybridisation the microarrays 
were scanned on the Gene Array Scanner 3000-7G and analysed using Partek 
Genomic Suite.   
 
 
4.2.1 Pre-Processing of Affymetrix chip data using Partek Genomics Suite 
Data processing was done using Partek Genomics Suite 6.6 Software after 
Edinburgh Genomics assessed the raw data qualitatively and pre-processed it 
using probe summarisation algorithms in series of stages to generate a set of 
expression measures for subsequent analysis. In brief this involved the following 
series of steps. 
 
Background signal intensity was corrected on a chip-by-chip basis by a Robust 
Multi-array Average adjusted for GC content (GCRMA) algorithm which is 
designed to eliminate background noise due to non-specific hybridisation. Probe 
affinity occurs as a result of position-dependent base effect that can be 
calculated for each perfect match and mismatch value. Correction of the 
background noise occurs based on assumption that these values consist of optical 
noise, non-specific binding noise, and ‘true’ signal.  
Therefore, three steps are required:  
1 Optical background correction as   optical noise is introduced by a 
scanner measuring hybridisation strength 
2 Probe intensity adjustment via non-specific binding (NSB) that 
operates on the basis of affinity information and optical noise-
adjusted mismatch intensities.  
68 
 
3 Probe intensity adjustment via gene-specific binding (GSB) that 
uses NSB-adjusted perfect match intensities for further correction 
of perfect match probe affinities. 
Each of these values is adjusted by subtracting an affinity corrected 
mismatch value. 
 
Normalisation is executed to unify the signal intensity distribution of each chip, 
therefore enabling the comparison and coordination of data analysis. This is 
done as all chips should have approximately the same distribution of perfect 
match values. In GCRMA, quantile normalisation is performed, where each 
perfect match value is plotted in number of dimensions and projected onto the 
diagonal, resulting in perfect match values on individual chips having the same 
distribution. 
 
Probe summarisation. Signal intensities of individual probe sets are summarised 
to exons followed by summarisation to the corresponding genes, giving each 
entity a normalised expression measure. This is driven by the assumption that 
observed log-transformed perfect match values follow a linear additive model 
containing a probe affinity effect, a gene specific effect and an error term. 
Probe affinity effects are assumed to sum to zero, and the expression level is 
estimated by median polishing that protects against outlier probes. 
Summarisation to transcript cluster was performed by using One-step Tukey’s 
Biweight method. 
 
 
4.2.2 Signal plot of normalised data  
Monitoring sample hybridisation is essential for quality control of the array data. 
Any variations in the data may result in irreproducible results. This can be 
avoided by using a set of control transcripts to detect differences in the 
hybridisation efficiency. Prior to hybridisation, fragmented cDNA is added in 
hybridisation cocktail containing controls that consist of standard concentrations 
(from the lowest to the highest) of four transcripts, bioB, bioC, bioD and creX. 
Signal intensities of the control transcripts on each chip are plotted, thus 
allowing differences in hybridisation efficacy to be limited. Figure 4.2.2a shows 
the signal intensities of the four hybridisation controls each of the 15 GeneChip 
69 
 
used in the array study. The plot suggests little variation between the 
hybridisation efficiency of each individual chip.  
 
The frequency of the signal intensities of each chip was also plotted on a signal 
histogram (Fig. 4.2.2b). After labelled cDNA is hybridised to the chip, signal 
intensities are calculated for each set. Frequency of a range of signal intensities 
was plotted against probe sets on each chip. This allows control for hybridisation 
quality and sources for other non-biological variation, including efficiency of 
cDNA labelling or starting RNA quantity or quality. Each line represents an 
individual sample grouped into colour coded triplicates. Due to similar pattern, 
non-biological variables can be ruled out.   
   
 
Figure 4.2.2: Signal plot of normalised intensity values. Biotin labelled sense-strand 
cDNA was generated from RNA samples and hybridised to each GeneChip and four 
control transcripts at control concentrations. The normalised signal intensities of 
colour coded hybridised controls (BioB, BioC, BioD, and CreX) indicated small variation 
within the control group (a). The occurring frequency of signal intensities for all probe 
sets on each chip. Each line represents represents individual GeneChip and thus an 
individual sample. Lines are coloured according to experimental grouping (n=3/group). 
 
 
4.2.3 Principle component analysis 
Principle component analysis (PCA) is a statistical method that uses orthogonal 
transformation to allow easy visualisation of data sets by transforming a number 
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of correlated variables into a number of uncorrelated variables known as 
principle components. These are estimated from the eigenvectors of the 
covariance or correlation matrix of the original variables. Thus, PCA is a 
dimensionality reduction method, in which data is reduced into basic 
components deprived of any unnecessary parts allowing it to be easily visualised. 
The underlying assumption being that different conditions should result in 
different groups within a three dimensional plot. 
 
The plot of PCA scores from our GeneChip data is illustrated in Figure 4.2.3. 
Samples from each condition were grouped in clusters, coloured accordingly to 
allow distinction between different groups of data and highlighting any outliers. 
Control untreated cultures (C-) and IgM isotype treated cultures in the absence 
of serum (IgM-) cluster together indicating treatment with an irrelevant IgM had 
little effect on gene transcription. Similarly data from cultures treated with 
serum alone (C+) and mAb O4 and serum (O4+) clustered together but at the 
other side of the plot. This was unexpected as this treatment results in 
demyelination and was therefore anticipated to be associated with a completely 
different profile. However, our results suggest the dominant effect is due to the 
presence of serum, rather than complement-dependent demyelination mediated 
by mAb O4. In contrast, cultures treated with mAb O4 alone (O4-) showed loose 
clustering that was well separated from all other conditions. This indicates this 
group to exhibit a markedly different transcriptional profile to the other four 
groups, but at the same time, more inter-group variance.  
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Figure 4.2.3: Principal component analysis of microarray samples. Each sphere on 
the graph represents data from an individual GeneChip. Closer grouping indicates 
closer similarity of the transcriptional profiles. Samples are colour coded, thus 
allowing visualisation of the experimental groupings [untreated control (C-) blue; 
isotype control in the absence of serum (IgM-) red; mAb O4 in the absence of serum 
(O4-) purple; serum treated control (C+) green;  mAb O4 in the presence of serum (O4+) 
yellow].   
 
 
4.2.4 Hierarchical cluster analysis 
PCA indicates that adding mAb O4 to the cultures had a very different effect on 
gene expression compared to that seen in cultures treated with serum whether 
or not mAb O4 was present. To investigate this further hierarchical clustering 
was performed as this allows patterns of expression to be revealed within these 
large data sets. Hierarchy of the data sets is indicated by a dendrogram that 
shows how the microarrays are segmented together based on similarity of 
features. Groups merging at high values relative to their subgroup branching 
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values are candidates for natural clustering (Tibshirani et al., 2001). This 
method is considered unsupervised and unbiased as it does not take into account 
any experimental variables. The intergroup similarity can be measured via 
single-linkage, complete linkage or by group average. Therefore, hierarchical 
clustering should be treated with caution as using different methods generates 
in different dendrograms.  
 
Our microarray data were clustered using Partek Genomic Suite and the results 
are shown in Figure 4.2.4. Hierarchy of the samples is indicated by the vertical 
dendrogram and is annotated by different colours for each set of triplicates. 
Gene clustering is specified by the horizontal dendrogram. Based on 
standardised intensities, the biological triplicates of each condition were similar 
and therefore cluster together. As already indicated by PCA untreated cultures 
(C-) and cultures treated with the IgM isotype control antibody in the absence of 
serum (IgM-) were very similar, indicating this control antibody had little effect 
of gene expression. However a completely different pattern was observed after 
cultures were incubated with mAb O4 alone (O4-) and this differed again from 
those derived from cultures exposed to serum whether or not mAb O4 was 
present. The latter observation indicates the effects of serum alone (C+) are 
more pronounced than those associated with antibody-mediated, complement-
dependent demyelination. 
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Figure 4.2.4: Hierarchical cluster analysis of antibody treated myelinating cultures. 
This clustering displays signal intensities of 16,300 individual expressions relative to 
baseline. Only entities with a fold change of 1.4 or greater and -1.4 or lower were 
included. The signal intensity of each sample [untreated control (C-) blue; isotype 
control in the absence of serum (IgM-) red; mAb O4 in the absence of serum (O4-) 
purple; serum treated control (C+) green;  mAb O4 in the presence of serum (O4+) 
yellow] is coloured according to their expression level relative to baseline. The 
algorithm scaled the normalised intensity to fit within the range -2.98 and 2.98. Green 
box marks the surprisingly different signal intensities of mAb O4 alone treatment.  
 
 
4.3 Gene expression analysis of Affymetrix chips using Partek 
Genomic Suite 
Quality control processes should account for variation due to differences in RNA 
quality, sample labelling and hybridisation quality, so any differences observed 
between the sample groups should reflect genuine shifts in gene expression.  To 
explore which of these changes may reflect biologically relevant effects 
normalised intensity values were analysed statistically using a GCRMA algorithm 
in Partek Genomic Suite. Differential expression analysis between groups was 
carried out by one-way ANOVA on the normalised expression values in 
combination with a Benjamini-Hochberg multiple testing corrections with a false 
discovery rate of 0.1. Initial gene lists were generated using the criteria ANOVA 
log2 fold change ≥ ± 1.4 with p-values ≤ 0.05. 
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4.3.1 The IgM isotype control antibody has no significant effects on gene 
expression in  myelinating cultures  
Comparison of untreated cultures and those exposed to the IgM isotype control 
antibody revealed the presence of this IgM had no significant effect on gene 
expression; threshold being set at ANOVA log2 fold change ≥ ± 1.4; p-value ≤ 
0.05). Thus, data from both untreated control and IgM isotype control treated 
cultures can be used as a baseline for comparative studies. 
 
 
4.3.2 Genes identified as being differentially expressed in mAb O4 treated 
myelinating cultures 
To investigate the effect of mAb O4 on gene expression in the absence of serum 
we compared the data sets obtained from cultures treated overnight with the 
IgM isotype control or mAb O4. The presence of mAb O4 was associated with the 
differential expression of 586 transcripts (ANOVA log2 fold change ≥ ± 1.4, p-
values ≤ 0.05) of which 273 exhibited > 2.0-fold changes (Appendix 8.1.1). 
Presenting this data in the form of a Volcano plot (Fig. 4.3.2) demonstrates the 
effect of mAb O4 is skewed in favour of increased expression, 458 genes being 
up regulated against the 128 being down-regulated. The thirty-six most highly up 
regulated transcripts are listed in Table 4.3.2. Visual inspection of this data set 
reveals members of the chemokine family account for many of the most highly 
up regulated transcripts (9 of 36), in particular Cxc11, Ccl9 and Cxcl13, the 
three genes most highly up regulated by mAb O4. In total, expression of 17 
members of this family of 47 ligands was increased significantly, whereas only 
one family member was down regulated (Ccl24) (Fig. 4.3.2).  In contrast, mAb 
O4 modulated the expression of only two chemokine receptors, Ccr5 and Cxcr5 
which were up-regulated 1.9 and 1.5 fold respectively (Appendix 8.1.1). It 
should be noted mAb O4 also increased expression of a large number of other 
genes more commonly associated with innate immunity and infectious agents, 
including 2'-5'-oligoadenylate synthetase-like, myxovirus (influenza virus) 
resistance 1, Il-1β, Il-1α and Cd14. 
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Table 4.3.2: Differentially expressed genes in O4 antibody treated myelinating 
cultures in the absence of serum identified by Partek. Microarray analysis was 
performed on Partek Genomic Suite. The data shown is sorted in manner of highest 
fold change to the cut-off of 1.4 in antibody treated cultures in comparison to isotype 
control treated cultures. Significance was calculated using one-way ANOVA. First 36 
genes listed, rest can be found in the Appendix 8.1.1.  
Gene Symbol Gene Name Fold-Change P-value 
Cxcl11 chemokine (C-X-C motif) ligand 11  79.74 2.76E-10 
Cxcl9 chemokine (C-X-C motif) ligand 9   59.29 2.49E-10 
Cxcl13 chemokine (C-X-C motif) ligand 13  40.25 1.05E-07 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3   39.28 3.84E-07 
Cxcl10 chemokine (C-X-C motif) ligand 10  34.87 5.75E-06 
Oasl 2'-5'-oligoadenylate synthetase-like  32.03 1.55E-07 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 25.12 6.36E-07 
Mx1 myxovirus (influenza virus) resistance 1  23.25 5.58E-07 
Rsad2 radical S-adenosyl methionine domain containing 2 22.19 7.29E-06 
Cxcl17 chemokine (C-X-C motif) ligand 17 18.81 1.52E-09 
Irf7 interferon regulatory factor 7  18.67 1.09E-07 
Isg20 interferon stimulated exonuclease gene 20   17.34 1.01E-07 
Gbp5 guanylate binding protein 5  16.10 2.29E-09 
Ccl5 chemokine (C-C motif) ligand 5  16.05 3.26E-10 
Apol9a apolipoprotein L 9a    15.35 1.87E-08 
F10 coagulation factor X   13.51 3.13E-08 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60  13.06 1.70E-06 
Zbp1 Z-DNA binding protein 1  NM_133564 12.93 1.10E-07 
Ccl7 chemokine (C-C motif) ligand 7   12.86 4.22E-09 
Lcn2 lipocalin 2  12.15 2.75E-08 
Isg15 ISG15 ubiquitin-like modifier  12.04 2.96E-07 
Usp18 ubiquitin specific peptidase 18 11.70 3.11E-06 
LOC685067 similar to guanylate binding protein family, member  11.32 1.52E-07 
LOC100366216 nuclear antigen Sp100-like  11.14 4.99E-08 
Oas2 2'-5' oligoadenylate synthetase 2 9.82 9.20E-08 
Lgals9 lectin, galactoside-binding, soluble, 9  9.60 1.31E-07 
RT1-T24-3 RT1 class I, locus T24, gene 3 9.56 6.03E-09 
Oas1b 2-5 oligoadenylate synthetase 1B 9.48 1.33E-06 
Ccl19 chemokine (C-C motif) ligand 19  9.15 2.99E-07 
Serpine1 serpin peptidase inhibitor, clade E (nexin, plasminog 8.99 7.34E-07 
Cd72 Cd72 molecule  8.89 1.07E-06 
Ccl12 chemokine (C-C motif) ligand 12 8.70 5.01E-07 
Clec4a2 C-type lectin domain family 4, member A2  8.15 1.64E-07 
Ifi27l2b interferon, alpha-inducible protein 27 like 2B  8.05 1.85E-08 
Mpa2l macrophage activation 2 like 7.99 1.98E-07 
Il1b interleukin 1 beta  7.81 9.17E-08 
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Figure 4.3.2: Volcano plot demonstrating significance and expression values of 
chemokines, cytokines and other genes of interest in antibody treated myelinating 
cultures. Chemokines (red), cytokines (blue) and others (black). The highest rank 
corresponds to the highest fold change indicated by ANOVA. Genes marked by * have 
been validated by qPCR.    
 
 
4.3.3 Genes identified in serum only treated myelinating cultures 
Cluster analysis indicated that the presence of serum alone also induced 
significant changes in gene expression; however, these differed from the effect 
of mAb O4. Analysis of genes differently expressed in serum treated cultures 
compared to the untreated controls demonstrated this to be the case. The 
presence of serum was associated with differential expression of 959 transcripts 
(619 up-regulated, 340 down-regulated, ANOVA log2 fold change ≥ ± 1.4, p-
values ≤ 0.05) of which 232 exhibited > 2.0-fold changes (Fig. 4.3.3a; Appendix 
8.1.2). Again visual inspection of this data reveals many of the most 
differentially expressed genes belong to the chemokine family, although their 
ranking order differs from that seen in mAb O4 treated cultures (Table 4.3.3b) 
e.g. fold changes for Cxcl13 (+40.25) and Cxcl17 (+18.81) were far higher in mAb 
O4 treated cultures, than in cultures treated with serum (fold changes +3.45 and 
+2.30, respectively). Another interesting difference was found in the expression 
of Ccl24; in serum alone cultures it was up-regulated (fold change +2.10), 
whereas in mAb O4 treated cultures it was down-regulated (fold change -2.17).  
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Table 4.3.3a: Differentially expressed genes in serum alone treated myelinating 
cultures identified by Partek Genomic Suite. These data show the fold change and 
significance of the entities that were up-regulated ≥ 1.4 serum treated cultures in 
comparison to control cultures. Significance was calculated using one-way ANOVA. First 
36 genes listed, rest can be found in the Appendix 8.1.2. 
 
Gene Symbol Gene Name Fold Change p-value 
Lcn2 lipocalin 2  39.40 6.41E-10 
Cxcl11 chemokine (C-X-C motif) ligand 11  34.86 2.15E-09 
Ccl7 chemokine (C-C motif) ligand 7  28.72 2.89E-10 
Cxcl5 chemokine (C-X-C motif) ligand 5 27.14 1.95E-05 
Cxcl1 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 
23.12 1.69E-07 
LOC363060 similar to RIKEN cDNA 1600029D21  14.93 9.30E-07 
Cxcl9 chemokine (C-X-C motif) ligand 9 12.50 2.70E-08 
Serpine1 
serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
10.06 4.61E-07 
Cxcl2 chemokine (C-X-C motif) ligand 2  9.78 1.64E-06 
Cxcl10 chemokine (C-X-C motif) ligand 10  9.23 2.89E-04 
Trem1 triggering receptor expressed on myeloid cells 1 9.20 1.72E-05 
C3 complement component 3  8.92 5.49E-08 
Mx1 myxovirus (influenza virus) resistance 1 7.95 2.38E-05 
Ccl20 chemokine (C-C motif) ligand 20 7.86 1.07E-06 
Ass1 argininosuccinate synthase 1 7.63 9.18E-07 
Ifit3 
interferon-induced protein with tetratricopeptide 
repeats 3 
7.60 7.44E-05 
Gbp5 guanylate binding protein 5 7.53 5.06E-08 
Tgm1 transglutaminase 1 7.01 3.59E-07 
Ptx3 pentraxin 3, long  6.96 9.55E-06 
Il1rn interleukin 1 receptor antagonist  6.74 1.11E-07 
Slpi secretory leukocyte peptidase inhibitor 6.49 2.13E-04 
Bcl3 lymphoma 3  6.48 4.44E-06 
Sell selectin L 6.10 1.15E-03 
Ccl6 chemokine (C-C motif) ligand 6 5.88 7.46E-04 
Irf7 interferon regulatory factor 7  5.76 1.23E-05 
Zc3h12a zinc finger CCCH type containing 12A  5.60 1.35E-07 
Birc3 baculoviral IAP repeat-containing 3 5.36 2.76E-09 
Cd93 CD93 molecule  5.32 5.93E-07 
Tnfaip2 tumor necrosis factor, alpha-induced protein 2 5.21 4.11E-09 
Msr1 macrophage scavenger receptor 1  5.05 8.77E-06 
Ccl4 chemokine (C-C motif) ligand 4 5.05 1.58E-05 
Ifit2 
interferon-induced protein with tetratricopeptide 
repeats 2 
4.90 2.83E-04 
Apol9a apolipoprotein L 9a 4.80 3.40E-06 
Rbp1 retinol binding protein 1, cellular  4.80 2.15E-06 
Isg15 ISG15 ubiquitin-like modifier  4.71 2.15E-05 
Mmp9 matrix metallopeptidase 9 4.69 7.11E-03 
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Table 4.3.3b: Differential expression of chemokines and their receptors by mAb O4 
and serum.  
mAb O4 alone 
 
Serum alone 
Rank Gene Fold Change p-value Rank Gene Fold Change p-value 
1 Cxcl11 79.74 2.76E-10 2 Cxcl11 34.86 2.15E-09 
2 Cxcl9 59.29 2.49E-10 3 Ccl7 28.72 2.89E-10 
3 Cxcl13 40.25 1.05E-07 4 Cxcl5 27.14 1.95E-05 
5 Cxcl10 34.87 5.75E-06 5 Cxcl1 23.12 1.69E-07 
10 Cxcl17 18.81 1.52E-09 7 Cxcl9 12.50 2.7E-08 
14 Ccl5 16.05 3.26E-10 9 Cxcl2 9.78 1.64E-06 
19 Ccl7 12.86 4.22E-09 10 Cxcl10 9.23 0.000289 
29 Ccl19 9.15 2.99E-07 14 Ccl20 7.86 1.07E-06 
32 Ccl12 8.70 5.01E-07 24 Ccl6 5.88 0.000746 
82 Ccl4 4.76 2.19E-05 30 Ccl4 5.05 1.58E-05 
102 Cxcl16 3.97 1.79E-08 41 Ccl2 4.57 2.09E-07 
120 Ccl3 3.62 0.000536 44 Ccl5 4.40 1.45E-07 
129 Cxcl1 3.45 0.000524 59 Cxcl16 3.67 3.14E-08 
172 Ccl20 2.82 0.000374 71 Cxcl13 3.45 0.001169 
186 Ccl2 2.71 9.99E-06 78 Ccl3 3.22 0.002625 
205 Cxcl2 2.55 0.001393 108 Ccl12 2.78 0.000325 
304 Ccl9 1.96 0.044243 161 Cxcl17 2.30 0.000154 
331 Ccr5 1.88 1.18E-04 213 Ccl24 2.10 0.000755 
503 Cxcr5 1.54 2.08E-04 281 Ccl19 1.89 0.00625 
16374 Ccl24 -2.17 0.000536     
 
 
 
4.3.4 Genes differentially expressed in response to antibody-mediated, 
complement-dependent demyelination (mAb O4 plus serum) 
To identify genes differentially expressed in response to antibody-mediated 
demyelination we compared cultures treated with serum in the presence or 
absence of mAb O4. This analysis identified 21 differentially expressed genes 
(ANOVA log2 fold change ≥ ± 1.4, p-values ≤ 0.05) (Table 4.3.4) of which 4 were 
up-regulated and 17 down-regulated. In concordance with the observed loss of 
myelin induced by mAb O4 in the presence of serum, nine of these down 
regulated genes are expressed by oligodendrocytes and play important roles in 
myelination (Devaux and Gow, 2008; Soundarapadian et al., 2011; Van Strien, et 
al., 2011; Yao et al., 2012). Surprisingly no further enhancement of chemokine 
or immune gene expression was recognised. 
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Table 4.3.4: Differentially expressed genes in serum alone treated myelinating 
cultures identified by Partek. These data show the fold change and significance of the 
entities that were up-regulated ≥ 1.4 serum treated cultures in comparison to control 
cultures. Significance was calculated using one-way ANOVA. Genes marked by * are 
myelin/oligodendrocyte associated.  
Gene Symbol Gene Name Fold Change p-value 
Siglec5 sialic acid binding Ig-like lectin 5 5.46 5.96E-06 
Clec4a2 C-type lectin domain family 4, member A2  2.92 6.68E-05 
Tlr5 toll-like receptor 5  2.13 7.83E-05 
Irg1 immunoresponsive gene 1  2.05 3.85E-05 
Myo1d myosin ID  -1.45 9.96E-06 
*Sox10 SRY (sex determining region Y)-box 10 -1.70 4.47E-05 
*Plp1 proteolipid protein 1  -1.75 1.47E-08 
Gpr17 G protein-coupled receptor 17  -1.95 4.78E-05 
Hhip Hedgehog-interacting protein  -1.97 5.16E-06 
Rdh5 retinol dehydrogenase 5 (11-cis/9-cis)  -1.99 6.95E-05 
Map6d1 MAP6 domain containing 1 -2.02 1.38E-07 
*Zfp488 zinc finger protein 488 -2.12 4.28E-05 
Fa2h fatty acid 2-hydroxylase -2.25 1.70E-08 
*Myrf myelin regulatory factor -2.26 7.16E-05 
Ugt8 UDP glycosyltransferase 8 -2.33 1.91E-07 
Plxnb3 plexin B3 -2.34 7.05E-08 
*Cldn11 claudin 11 -2.42 2.91E-05 
*Mir2964 microRNA mir-2964 -2.71 1.31E-05 
*Mag myelin-associated glycoprotein -3.00 3.07E-08 
*Mog myelin oligodendrocyte glycoprotein -3.17 3.58E-06 
*Tgm1 transglutaminase 1 -3.24 3.36E-05 
 
 
4.4 Gene ontology clustering and pathway analysis 
The initial gene ontology (GO) clustering was performed on Partek Genomic 
Suite to group genes on the basis of their functional hierarchy. The genes are 
functionally clustered according to three different factors, biological processes, 
molecular functions and cellular components. We performed GO clustering on 
differentially expressed genes with a fold change of 1.4 or higher with 
significance greater than 0.05.  This was followed by pathway analysis on Partek 
PathwayTM that allows unbiased biological interpretation of the differentially 
expressed genes and groups them into influential pathways by utilising the KEGG 
database for rat.  
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Analysis of the Affymetrix dataset on Partek Genomic Suite generated long lists 
of differentially expressed genes for each treatment. To further analyse and 
validate this data we used two additional programmes, Panther and Interferome.   
 
Panther (protein analysis through evolutionary relationships) Classification 
System 9.0 (http://www.pantherdb.org) is free online software that allows 
functional organisation of proteins and their genes. The system contains 7180 
protein families that can be further divided into 52,768 functional subfamilies. 
The genes are mapped according to their biological functions by determining 
significant enrichment of functionally related genes. This then allows 
determination of the biological relevance of the data. Statistical enrichment is 
defined by the use of Mann-Whitney test that determines non-random 
distribution of numeric values in respect to the entire list of values.  Expression 
of genes was considered significant whenever P < 0.05. Panther Gene OntologyTM 
allows organisation of proteins and their genes according to their molecular 
function, biological processes and cellular components.  Panther Pathway 
Analysis consists of 176 pathways with over 21,000 components, therefore 
permitting mapping of the differently expressed genes into functional pathways. 
 
Interferome v2.01 (http://interferome.its.monash.edu.au/interferome/home. 
jspx), is free online database that allows determination of type I, II and III 
interferon (IFN) regulated gene involvement. IFNs regulate cell proliferation, 
survival, migration and specialised functions in homeostatic and pathological 
processes, thus being heavily involved in infections, autoimmunity and 
inflammation. The programme has a default limit of 2.0 fold change for the gene 
expression, which we maintained in our search. Interferome database consists of 
human and mouse experiments, thus this can only be used as indicator as our 
experiments were performed on rat myelinating cultures. 
 
 
4.4.1 Gene ontology clustering of cultures treated with O4 antibody in the 
absence of serum 
When GO clustering was performed on the differentially expressed gene list 
obtained when mAb O4 treated cultures compared to those treated with IgM 
isotype control, 1358 biological processes were enriched with higher than P<0.05. 
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The ten most highly enriched processes identified using Partek Genomic Suite 
are listed in Table 4.4.1a. These processes are in general all associated with 
different aspects of immunity and/or responses to pathogens.  
 
Table 4.4.1a: Top 10 significantly enriched biological processes by Partek Genomic 
Suite. Gene ontology clustering was performed on the genes differentially regulated by 
fold change of 1.4 or greater in the antibody in comparison to isotype treated cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4- vs IgM- 
score 
immune system process 162.80 1.97E-71 19.71 5.02 
response to external biotic stimulus 115.01 1.13E-50 20.19 4.98 
response to external stimulus 113.32 6.10E-50 14.24 4.96 
response to biotic stimulus 113.08 7.77E-50 19.60 4.98 
immune response 113.05 8.00E-50 23.88 5.09 
defense response 111.20 5.10E-49 20.12 5.11 
regulation of immune system process 90.82 3.60E-40 16.45 4.90 
positive regulation of immune system 
process 
86.10 4.05E-38 20.91 5.01 
response to cytokine 76.22 7.93E-34 20.00 5.33 
response to other organism 75.21 2.18E-33 21.41 5.19 
 
 
To complement this data we reanalysed this set of differentially expressed genes 
using Panther. This identified 20 biological processes that were significantly 
altered (Fig. 4.4.1a). Once again the most highly enriched processes were 
involved in various aspects of the immune response.  
 
Figure 4.4.1a: Top 10 enriched biological processes. Using Panther software, gene 
ontology clustering was performed on the genes differentially expressed by ≥ 1.4-fold 
in the cultures treated with mAb O4compared to isotype cultures alone. The co-
expression of functionally-related gene clusters was rated in order of significance. 
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These analyses indicate that addition of mAb O4 to the myelinating cultures 
results in a transcriptional response that suggests binding of mAb O4 to the 
myelin/oligodendrocyte surface induces a state of ‘heightened immune 
awareness’. This concept is supported by the observation that the most highly 
enriched molecular functions identified using Partek Genomic Suite (Table 
4.4.1b) and Panther (Fig. 4.4.1b) are associated with over representation and 
enrichment of functions associated with cytokine/chemokine signalling. 
 
 
Table 4.4.1b: Top 10 enriched molecular functions by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the antibody in comparison to isotype treated cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4- vs IgM- 
score 
cytokine receptor binding 37.07 7.96E-17 20.61 5.17 
chemokine receptor binding 33.36 3.24E-15 44.74 5.82 
cytokine activity 27.90 7.67E-13 20.00 5.42 
binding 26.53 3.02E-12 4.58 4.75 
receptor binding 25.06 1.30E-11 8.14 4.90 
CCR chemokine receptor binding 20.85 8.79E-10 56.25 6.01 
protein binding 20.44 1.33E-09 5.16 4.68 
double-stranded RNA binding 18.52 9.09E-09 27.08 5.57 
carbohydrate derivative binding 15.50 1.85E-07 6.18 4.99 
G-protein coupled receptor binding 14.31 6.07E-07 12.15 5.45 
 
 
Panther analysis found only eight molecular functions (Fig. 4.4.1b) to be 
significantly enriched. Again, the findings were similar to findings on Partek, as 
cytokine and chemokine activity, and receptor binding were found to be most 
highly overrepresented. Also peptidase and enzyme inhibitory activity were 
significantly overrepresented.  
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Figure 4.4.1b: Significant alteration of molecular function. Reassessment of 
antibody treated cultures by Panther in similar manner as previously stated. 
 
 
Analysis using the Partek Genomic suite also identified significant enrichment for 
90 cellular components. The ten most highly enriched are listed in Table 4.4.1c 
and include plasma membrane, cytoplasm and MHC protein complex. In contrast 
Panther analysis only identified enrichment for MHC protein complex. 
 
 
Table 4.4.1c: Top 10 enriched cellular components by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the antibody in comparison to isotype treated cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4- vs. IgM- 
score 
plasma membrane part 35.19 5.20E-16 8.38 4.41 
extracellular region part 23.22 8.25E-11 6.39 5.06 
external side of plasma membrane 22.19 2.31E-10 15.17 4.76 
extracellular space 21.60 4.14E-10 8.30 4.99 
side of membrane 19.71 2.75E-09 13.21 4.70 
cell surface 17.99 1.54E-08 10.66 4.58 
MHC protein complex 16.94 4.40E-08 29.73 5.31 
cytoplasm 15.49 1.87E-07 5.33 4.73 
receptor complex 13.15 1.95E-06 11.73 4.44 
vesicle 12.09 5.60E-06 5.67 5.10 
 
 
The above analyses indicate that although mAb O4 is unable to induce acute 
demyelination in the absence of an exogenous source of complement, it triggers 
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a rapid transcriptional response involving genes commonly associated with 
innate and adaptive immunity. These include a number of interferon sensitive 
genes (ISG) which prompted us to use Interferome to analyse the 273 genes that 
were up regulated ≥ 2.0 –fold in this data set. Expression of the majority of 
these differentially expressed genes across all data bases was reported to be 
modulated by interferons. Limiting the search to data obtained using the 
nervous system revealed 53% (144 genes) were interferon sensitive. These genes 
were regulated by type I and II interferons, in most cases by both (Fig. 4.4.1c). 
Type I interferons are involved in immune and inflammatory regulations, when 
type II IFNs have been implicated in tumour growth inhibition.  
 
 
 
Figure 4.4.1c: Interferon regulated genes identified in the differentially regulated 
gene list. Interferon sensitive genes were found using Interferome software. Search 
limited to nervous system identified our genes to be type I and II specific.    
 
 
Pathway Analysis of serum independent antibody effect  
Analysis of the differentially expressed gene list (mAb O4 vs IgM treated cultures) 
with Partek PathwayTM analysis software identified 29 enriched human disease 
pathways (Table 4.4.1d). These include a wide variety of viral, bacterial and 
parasitic disease associated pathways that share many common features in 
particular induction of chemokines (Ccl2, Ccl5, Cxcl1, Cxcl2, Cxcl11), 
interleukins (Il-1α, Il-1β, Il-18), and interferon regulatory factors (Irf7, Irf9). 
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Table 4.4.1d: Significantly altered human disease pathways. Using Partek 
PathwayTM analysis software, differentially expressed genes with fold change of 1.4 or 
higher were organised in pathways in the cultures independently treated with 
monoclonal O4 antibody.  
Pathway Name Function 
% genes present in 
pathway  
Enrichment 
Score 
Enrichment 
p-value 
Herpes simplex 
infection 
Infectious diseases: Viral 24.68 42.14 5.00E-19 
Influenza A Infectious diseases: Viral 25.41 35.26 4.84E-16 
Legionellosis Infectious diseases: Bacterial 40.00 29.54 1.49E-13 
Leishmaniasis Infectious diseases: Parasitic 33.33 25.86 5.86E-12 
Viral myocarditis Cardiovascular diseases 28.99 25.67 7.10E-12 
Tuberculosis Infectious diseases: Bacterial 20.77 25.55 8.01E-12 
Graft-versus-host 
disease 
Immune diseases 34.69 25.23 1.11E-11 
Staphylococcus 
aureus infection 
Infectious diseases: Bacterial 40.00 23.20 8.37E-11 
Type I diabetes 
mellitus 
Endocrine and metabolic 
diseases 
30.36 22.79 1.26E-10 
Allograft rejection Immune diseases 31.37 22.07 2.60E-10 
Rheumatoid 
arthritis 
Immune diseases 26.47 21.55 4.39E-10 
Autoimmune 
thyroid disease 
Immune diseases 28.07 20.22 1.65E-09 
Measles Infectious diseases: Viral 20.21 17.78 1.89E-08 
Pertussis Infectious diseases: Bacterial 25.00 17.29 3.09E-08 
Malaria Infectious diseases: Parasitic 30.00 16.28 8.54E-08 
Viral carcinogenesis Cancers: Overview 14.19 13.78 1.03E-06 
Salmonella 
infection 
Infectious diseases: Bacterial 20.59 13.64 1.19E-06 
Epstein-Barr virus 
infection 
Infectious diseases: Viral 13.02 12.30 4.53E-06 
Chagas disease 
(American 
trypanosomiasis) 
Infectious diseases: Parasitic 17.50 11.62 9.00E-06 
HTLV-I infection Infectious diseases: Viral 11.36 11.35 1.18E-05 
Toxoplasmosis Infectious diseases: Parasitic 16.47 10.89 1.86E-05 
African 
trypanosomiasis 
Infectious diseases: Parasitic 30.43 10.07 4.24E-05 
Hepatitis C Infectious diseases: Viral 15.48 9.53 7.29E-05 
Hepatitis B Infectious diseases: Viral 13.13 7.83 3.97E-04 
Asthma Immune diseases 21.74 5.83 2.93E-03 
Systemic lupus 
erythematosus 
Immune diseases 12.35 5.83 2.95E-03 
Amoebiasis Infectious diseases: Parasitic 10.00 4.01 1.81E-02 
Amyotrophic lateral 
sclerosis (ALS) 
Neurodegenerative diseases 12.20 3.38 3.41E-02 
Prion diseases Neurodegenerative diseases 13.79 3.27 3.80E-02 
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We also identified 13 enriched organismal system pathways (Table 4.4.1e) which 
with the exception of the osteoclast differentiation pathway are all 
involved/associated with immune functions. The immune system pathways 
involved factors including chemokines (Ccl2, Ccl4, Ccl5), interleukins (Il-1α, Il-1β) 
and Cd80. 
 
 
Table 4.4.1e: Significantly altered organismal system pathways determined using 
Partek PathwayTM. The enriched pathways were determined as previously stated.  
Pathway Name Function 
% genes present 
in pathway  
Enrichment 
Score 
Enrichment 
p-value 
NOD-like receptor signaling pathway Immune system 37.78 26.84 2.21E-12 
Chemokine signaling pathway Immune system 19.72 25.14 1.21E-11 
Antigen processing and presentation Immune system 28.17 25.08 1.28E-11 
Toll-like receptor signaling pathway Immune system 26.67 23.97 3.88E-11 
Cytosolic DNA-sensing pathway Immune system 34.78 23.85 4.39E-11 
Osteoclast differentiation Development 18.29 12.94 2.40E-06 
RIG-I-like receptor signaling pathway Immune system 22.64 12.93 2.43E-06 
Leukocyte transendothelial migration Immune system 14.89 9.73 5.95E-05 
Natural killer cell mediated 
cytotoxicity 
Immune system 15.38 8.83 1.47E-04 
Hematopoietic cell lineage Immune system 15.15 7.43 5.95E-04 
Intestinal immune network for IgA 
production 
Immune system 14.29 4.00 1.83E-02 
Complement and coagulation cascades Immune system 12.50 3.98 1.88E-02 
B cell receptor signaling pathway Immune system 11.76 3.70 2.47E-02 
 
 
Ten other enriched pathways (Table 4.4.1f) were also noted to be altered in the 
antibody treated cultures in comparison to their isotype control, these involved 
environmental and genetic information processing, cellular processes and 
metabolism.  
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Table 4.4.1f: Other significantly enriched pathways identified on Partek 
PathwayTM. The determination was done as previously stated. 
Pathway 
Name 
Class Function 
% genes present 
in pathway  
Enrichment 
Score 
Enrichment 
p-value 
Phagosome Cellular Processes 
Transport and 
catabolism 
23.13 32.42 8.35E-15 
Cytokine-
cytokine 
receptor 
interaction 
Environmental 
Information 
Processing 
Signaling 
molecules and 
interaction 
18.34 25.76 6.50E-12 
Cell 
adhesion 
molecules 
(CAMs) 
Environmental 
Information 
Processing 
Signaling 
molecules and 
interaction 
21.19 24.17 3.17E-11 
NF-kappa B 
signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
24.24 17.89 1.70E-08 
Apoptosis Cellular Processes 
Cell growth and 
death 
21.43 12.31 4.52E-06 
Jak-STAT 
signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
10.58 5.08 6.21E-03 
Proteasome 
Genetic 
Information 
Processing 
Folding, sorting 
and degradation 
14.63 4.72 8.90E-03 
Primary bile 
acid 
biosynthesis 
Metabolism 
Lipid 
metabolism 
23.08 4.02 1.79E-02 
SNARE 
interactions 
in vesicular 
transport 
Genetic 
Information 
Processing 
Folding, sorting 
and degradation 
15.38 3.63 2.65E-02 
Endocytosis Cellular Processes 
Transport and 
catabolism 
8.02 3.58 2.78E-02 
 
 
Reanalysis of the significantly enriched gene set using Panther provided similar 
data in that five pathways were statistically overrepresented in particular 
inflammation pathway mediated by chemokine and cytokine signalling (Fig. 
4.4.1d) that involved 25 out of the 241 differentially enriched genes including 
Ccl2, Ccl5, Ccl7 and Ccl20.  
 
Using statistical enrichment test on Panther recognised only immune response 
pathway to be to be significant. It involved 71 differentially enriched genes, 
including interleukins (Il-1α, Il-1β), interferon factors (Irf7, Irf9), tumor necrosis 
factor involved genes (Tnf-αip2, Tnf-rsf1β, Tnf-sf10).  
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Figure 4.4.1d: Significantly altered biological pathways. Panther Pathway analysis 
of genes upregulated by ≥ 1.4 fold change in complement independent antibody 
mediated effector mechanisms in myelinating cultures. Bonferroni correction for 
multiple testing was used to calculate the significance. 
 
 
4.4.2 Gene ontology clustering of cultures treated with serum alone 
Presence of serum alone in the myelinating cultures indicated significantly 
regulated genes to be grouped into biological functions that respond to different 
stimuli, including stress, organic substance and biotic stimuli (Table 4.4.2a). 
Overall, Partek Genomic Suite analysis found 1449 biological processes to be 
enriched. 
 
 
Table 4.4.2a: Top 10 enriched biological processes by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the serum treated cultures in comparison to control cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group 
C+ vs C- 
score 
response to external stimulus 75.67 1.38E-33 15.83 4.45 
single-organism process 67.09 7.31E-30 8.17 4.17 
response to external biotic 
stimulus 
66.77 1.00E-29 19.81 4.36 
response to biotic stimulus 63.36 3.05E-28 19.05 4.36 
response to stress 62.87 4.95E-28 12.57 4.29 
positive regulation of biological 
process 
54.45 2.26E-24 10.09 4.25 
response to organic substance 53.13 8.45E-24 12.02 4.31 
single-organism cellular process 53.04 9.27E-24 8.40 4.22 
defense response 52.92 1.04E-23 18.16 4.75 
response to lipopolysaccharide 51.94 2.77E-23 24.42 4.53 
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When the microarray data was reanalysed on Panther, 26 significantly altered 
biological processes were recognised. Ten most highly altered processes 
presented in Figure 4.4.2a. These were involved in immune system processes 
and responses, and cellular death.  
 
 
 
Figure 4.4.2a: Top 10 altered biological processes. Panther analysis of differentially 
expressed gene list in serum treated cultures compared to control. Analysis was 
performed similar to the method explained in section 4.4.1.  
 
 
In serum alone compared to untreated cultures, Partek Genomic Suite analysis 
reported 204 significant molecular functions. These, as in the mAb O4 treated 
cultures, were involved in chemokine activity and receptor binding (Table 
4.4.2b). This was further recognised by using Panther analysis programme (Fig. 
4.4.2b).  
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Table 4.4.2b: Top 10 enriched molecular function by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the serum treated cultures in comparison to control cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present in 
group 
C+ vs C-
score 
chemokine receptor binding 33.97 1.76E-15 52.63 5.38 
chemokine activity 33.05 4.45E-15 58.06 5.32 
cytokine receptor binding 24.98 1.42E-11 21.21 4.80 
binding 24.53 2.23E-11 6.95 4.21 
protein binding 24.06 3.54E-11 7.90 4.16 
CCR chemokine receptor binding 19.88 2.32E-09 62.50 5.08 
receptor binding 19.31 4.11E-09 10.49 4.14 
identical protein binding 17.95 1.60E-08 10.85 4.01 
G-protein coupled receptor binding 15.64 1.62E-07 16.57 4.78 
cytokine activity 14.82 3.68E-07 18.46 4.95 
 
 
 
Figure 4.4.2b: Significantly altered molecular functions analysed on Panther.  
 
 
Partek Genomic Suite analysis indicated genes differentially expressed by ≥ 1.4-
fold to be grouped into 80 significantly enriched cellular components. Ten most 
significant components are shown in the Table 4.4.2c. Interestingly, these did 
not include the MHC protein complex function that was found to be the only 
enriched component by Panther analysis.  
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Table 4.4.2c: Top 10 enriched cellular components by Partek Genomic Suite.  Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the serum treated cultures in comparison to control cultures.  
Function 
Enrichment 
Score 
Enrichment  
p-value 
% genes present 
in group 
C+ vs C- 
score 
extracellular region part 32.34 9.02E-15 9.93 4.55 
extracellular space 30.40 6.29E-14 12.78 4.60 
cytoplasm 22.74 1.33E-10 8.46 4.14 
receptor complex 15.89 1.26E-07 16.76 4.66 
vesicle 15.03 2.96E-07 8.69 4.69 
plasma membrane part 13.99 8.43E-07 9.13 4.39 
membrane-bounded vesicle 13.47 1.41E-06 8.58 4.72 
extracellular vesicular exosome 11.86 7.07E-06 8.85 4.80 
extracellular organelle 11.82 7.34E-06 8.84 4.80 
extracellular membrane-bounded 
organelle 
11.82 7.34E-06 8.84 4.80 
 
 
Further analysis of the 232 genes regulated by ≥ 2.0-fold in serum only 
treatment on Interferome revealed 91% (212) to be ISGs. The number decreased 
to 100 genes (43%) after the search was limited to nervous system. These genes 
indicated specificity to type I or II, or them both (Fig. 4.4.2c), thus indicating a 
strong immunological signature.  
 
 
Figure 4.4.2c: Serum alone compared to control treated differentially regulated 
genes are sensitive to type I and II interferons. Interferome search limited to nervous 
system found 43% of the genes regulated by ≥ 2.0-fold to be interferon sensitive. 
 
 
Pathways in serum alone treated cultures 
The genes differentially expressed in cultures treated with serum alone were 
grouped into human disease pathways by Partek PathwayTM. These pathways 
function in different infectious diseases and cancer (Table 4.4.2d). The genes 
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present in these significantly enriched pathways include complement component 
3 (C3), chemokines (Ccl2, Ccl3, Ccl5), interleukin (Il-1α and Il-1β), interferon 
factors (Irf7, Irf9), and Rt1 genes.  
 
Table 4.4.2d: Significantly altered human disease pathways. Using Partek 
PathwayTM analysis software, differentially expressed genes with fold change of 1.4 or 
higher were organised in pathways in the cultures treated with serum alone.  
Pathway Name Function 
% genes present 
in pathway  
Enrichment 
Score 
Enrichment 
p-value 
Influenza A Infectious diseases: Viral 21.31 20.59 1.14E-09 
Herpes simplex infection Infectious diseases: Viral 18.83 19.77 2.60E-09 
Legionellosis 
Infectious diseases: 
Bacterial 
33.33 18.84 6.57E-09 
Rheumatoid arthritis Immune diseases 22.06 12.83 2.67E-06 
Pertussis 
Infectious diseases: 
Bacterial 
23.33 12.77 2.85E-06 
HTLV-I infection Infectious diseases: Viral 13.18 11.84 7.21E-06 
Viral carcinogenesis Cancers: Overview 14.84 11.57 9.49E-06 
Salmonella infection 
Infectious diseases: 
Bacterial 
20.59 11.21 1.36E-05 
Measles Infectious diseases: Viral 17.02 10.10 4.12E-05 
Graft-versus-host disease Immune diseases 22.45 9.91 4.98E-05 
Chagas disease (American 
trypanosomiasis) 
Infectious diseases: 
Parasitic 
17.50 9.30 9.15E-05 
Type I diabetes mellitus 
Endocrine and metabolic 
diseases 
19.64 8.62 1.80E-04 
Hepatitis B Infectious diseases: Viral 15.15 8.19 2.77E-04 
Hepatitis C Infectious diseases: Viral 15.48 7.47 5.71E-04 
Epstein-Barr virus 
infection 
Infectious diseases: Viral 11.83 7.09 8.36E-04 
Viral myocarditis Cardiovascular diseases 15.94 6.75 1.17E-03 
Malaria 
Infectious diseases: 
Parasitic 
20.00 6.71 1.22E-03 
Allograft rejection Immune diseases 17.65 6.46 1.56E-03 
Tuberculosis 
Infectious diseases: 
Bacterial 
12.31 6.31 1.81E-03 
Pathways in cancer Cancers: Overview 10.53 6.11 2.21E-03 
Leishmaniasis 
Infectious diseases: 
Parasitic 
16.67 6.05 2.36E-03 
Autoimmune thyroid 
disease 
Immune diseases 15.79 5.67 3.46E-03 
Toxoplasmosis 
Infectious diseases: 
Parasitic 
12.94 5.07 6.27E-03 
African trypanosomiasis 
Infectious diseases: 
Parasitic 
21.74 4.95 7.10E-03 
Transcriptional 
misregulation in cancer 
Cancers: Overview 10.08 3.54 2.89E-02 
Renal cell carcinoma Cancers: Specific types 12.24 3.00 4.96E-02 
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Altogether 10 organismal pathways were enriched in the Partek PathwayTM 
(Table 4.4.2e). The differentially expressed genes were mainly grouped in 
immune system pathways, apart from osteoclast differentiation, adipocytokine 
signalling and mineral absorption pathways that function in development, 
endocrine and digestive systems, respectively. The immune system pathways 
involved chemokines (Ccl5, Cxcl10), interleukins (Il-1α, Il-1β) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB).  
 
 
Table 4.4.2e: Significantly enriched organismal system pathways identified by 
Partek PathwayTM.  
Pathway Name Function 
% genes present 
in pathway  
Enrichment 
Score 
Enrichment 
p-value 
NOD-like receptor signaling 
pathway 
Immune system 33.33 18.84 6.57E-09 
Chemokine signaling pathway Immune system 17.61 15.79 1.39E-07 
Toll-like receptor signaling 
pathway 
Immune system 22.67 14.80 3.75E-07 
Cytosolic DNA-sensing pathway Immune system 26.09 12.37 4.24E-06 
RIG-I-like receptor signaling 
pathway 
Immune system 22.64 10.79 2.06E-05 
Antigen processing and 
presentation 
Immune system 19.72 10.69 2.28E-05 
Osteoclast differentiation Development 18.29 10.42 2.99E-05 
Adipocytokine signaling pathway 
Endocrine 
system 
13.21 3.71 2.44E-02 
Hematopoietic cell lineage Immune system 12.12 3.62 2.67E-02 
Leukocyte transendothelial 
migration 
Immune system 10.64 3.44 3.20E-02 
Mineral absorption Digestive system 13.51 3.01 4.94E-02 
 
 
 
Other pathways (Table 4.4.2f) associated with the effect of addition of serum 
included pathways classified as indicative of environmental and genetic 
information processing, cellular processes, and metabolism.  
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Table 4.4.2f: Other significantly altered pathways in serum treated cultures 
identified using Partek PathwaysTM. 
Pathway Name Class Group 
% genes present 
in pathway  
Enrichment 
Score 
Enrichment 
p-value 
Cytokine-
cytokine 
receptor 
interaction 
Environmental 
Information 
Processing 
Signaling 
molecules and 
interaction 
17.75 18.95 5.88E-09 
NF-kappa B 
signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
25.76 16.81 5.00E-08 
Apoptosis 
Cellular 
Processes 
Cell growth and 
death 
23.21 11.88 6.90E-06 
Phagosome 
Cellular 
Processes 
Transport and 
catabolism 
14.93 10.30 3.38E-05 
HIF-1 signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
16.47 8.62 1.80E-04 
Jak-STAT 
signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
14.42 7.65 4.78E-04 
Cell adhesion 
molecules 
(CAMs) 
Environmental 
Information 
Processing 
Signaling 
molecules and 
interaction 
13.56 7.37 6.31E-04 
MAPK signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
10.23 4.91 7.36E-03 
Pyrimidine 
metabolism 
Metabolism 
Nucleotide 
metabolism 
12.99 4.74 8.77E-03 
Purine 
metabolism 
Metabolism 
Nucleotide 
metabolism 
11.02 4.69 9.20E-03 
One carbon pool 
by folate 
Metabolism 
Metabolism of 
cofactors and 
vitamins 
25.00 4.65 9.52E-03 
Cyanoamino acid 
metabolism 
Metabolism 
Metabolism of 
other amino 
acids 
50.00 4.09 1.67E-02 
DNA replication 
Genetic 
Information 
Processing 
Replication and 
repair 
17.24 3.95 1.92E-02 
Galactose 
metabolism 
Metabolism 
Carbohydrate 
metabolism 
20.00 3.85 2.13E-02 
Proteasome 
Genetic 
Information 
Processing 
Folding, sorting 
and degradation 
14.63 3.78 2.29E-02 
ErbB signaling 
pathway 
Environmental 
Information 
Processing 
Signal 
transduction 
12.28 3.36 3.48E-02 
Fanconi anemia 
pathway 
Genetic 
Information 
Processing 
Replication and 
repair 
13.89 3.11 4.47E-02 
Glycine, serine 
and threonine 
metabolism 
Metabolism 
Amino acid 
metabolism 
16.00 3.10 4.50E-02 
Cell cycle 
Cellular 
Processes 
Cell growth and 
death 
10.34 3.05 4.75E-02 
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Reanalysis of the differentially expressed genes in the serum alone compared to 
control cultures on Panther (Fig. 4.4.2d) resulted in them being grouped into 
only four biological pathways that were significantly overrepresented.  
 
 
 
Figure 4.4.2d: Significantly overrepresented biological pathways determined using 
Panther software.  
 
 
4.4.3 Gene ontology clustering of cultures treated with O4 antibody in the 
presence of serum 
In previous chapter we observed complement dependent antibody mediated 
demyelination of myelinating cultures to occur after overnight incubation. 
Microarray data from this treatment in comparison to serum alone incubation 
interestingly resulted in only 4 genes (Siglec5, Clec4a2, Tlr5, Irg1) to be 
differentially expressed.  When these were clustered together, 149 biological 
processes were found to be significantly enriched based on the Partek GO 
analysis. They were involved in central nervous system regulation by affecting its 
development and maintenance (Table 4.4.3a).  When the differentially 
expressed genes by fold change of ≥1.4 were entered on Panther, no 
significantly altered pathways were found. 
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Table 4.4.3a: Top 10 enriched biological processes by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the mAb O4 and serum treated cultures in comparison to serum 
only cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4+ vs C+ 
score 
regulation of toll-like receptor 
signaling pathway 
13.09 2.07E-06 11.54 4.66 
central nervous system myelin 
maintenance 
12.78 2.81E-06 66.67 5.96 
ensheathment of neurons 10.58 2.53E-05 5.08 5.13 
axon ensheathment 10.58 2.53E-05 5.08 5.13 
myelin maintenance 10.08 4.19E-05 20.00 5.96 
positive regulation of toll-like 
receptor signaling pathway 
9.70 6.14E-05 16.67 4.78 
oligodendrocyte development 9.10 1.11E-04 12.50 4.26 
glial cell development 7.51 5.46E-04 5.71 4.26 
epidermal cell differentiation 6.84 1.07E-03 4.08 6.12 
plasma membrane organization 6.61 1.35E-03 3.64 5.96 
 
 
The Partek Genomic Suite GO analysis determined 11 molecular functions to be 
significantly enriched; these included different enzyme activities that allow 
chemical reaction catalysis (Table 4.4.3b). Again, none of them were found to 
be significant by the Panther analysis.  
 
Table 4.4.3b: All 11 enriched molecular functions by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the mAb O4 and serum treated cultures in comparison to serum 
alone cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4+ vs C+ 
score 
semaphorin receptor activity 5.11 6.01E-03 16.67 7.15 
protein-glutamine gamma-
glutamyltransferase activity 
5.11 6.01E-03 16.67 4.47 
transferase activity, transferring 
amino-acyl groups 
4.61 1.00E-02 10.00 4.47 
interleukin-1 receptor binding 4.42 1.20E-02 8.33 4.11 
carbohydrate binding 4.02 1.79E-02 0.96 4.70 
UDP-galactosyltransferase activity 4.02 1.79E-02 5.56 6.72 
carboxy-lyase activity 3.87 2.09E-02 4.76 4.41 
galactosyltransferase activity 3.52 2.97E-02 3.33 6.72 
hydro-lyase activity 3.48 3.07E-02 3.23 4.41 
carbon-carbon lyase activity 3.36 3.46E-02 2.86 4.41 
carbon-oxygen lyase activity 3.14 4.33E-02 2.27 4.41 
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In addition, Partek Genomics Suite grouped the significantly expressed genes 
into nine significantly altered cellular components (Table 4.4.3c), the most 
highly enriched including neural modules such as paranode junction of axon, 
Schmidt-Lanterman incisures and myelin sheath, and cell associated junctions.  
 
Table 4.4.3c: All 9 enriched cellular components by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by fold change 
of 1.4 or greater in the mAb O4 and serum treated cultures in comparison to serum 
alone cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4+ vs C+ 
score 
paranode region of axon 5.30 5.01E-03 20.00 7.51 
basal part of cell 5.11 6.01E-03 16.67 4.54 
Schmidt-Lanterman incisure 4.71 9.00E-03 11.11 7.51 
myelin sheath 4.14 1.60E-02 6.25 7.51 
Golgi-associated vesicle 3.92 1.99E-02 5.00 6.86 
cis-Golgi network 3.82 2.19E-02 4.55 6.86 
cell-cell junction 3.73 2.40E-02 0.82 4.51 
intrinsic component of membrane 3.42 3.26E-02 3.03 4.47 
cell-cell adherens junction 3.36 3.46E-02 2.86 4.47 
 
 
Pathways associated with antibody mediated demyelinating cultures 
The genes differentially expressed in cultures treated with antibody in the 
presence serum only identified three significantly enriched pathways (Table 
4.4.3d), the cell adhesion molecules (CAMs), sphingolipid metabolism, and 
legionellosis. In all of them only approximately 2 % of genes were present in the 
pathway, these included Cldn-11, Mag, Ugt-8 and Tlr-5. These genes encode for 
proteins that are involved in tight junctions, myelin protein and sphingolipids, 
and innate immunity. Reanalysis of the microarray data on Panther software 
found no pathways to be significantly altered.  
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Table 4.4.3d: Significantly altered biological pathways. Using Partek PathwaysTM, 
the list of genes identified as being differentially expressed by ≥1.4, in the cultures 
treated with antibody in the presence of serum compared to serum treated cultures, 
was grouped into biological pathways.  
Pathway Name Class Function 
% genes present 
in pathway  
Enrichment 
Score 
Enrichment 
p-value 
Cell adhesion 
molecules 
(CAMs) 
Environmental 
Information 
Processing 
Signaling molecules 
and interaction 
1.69 5.38 4.59E-03 
Sphingolipid 
metabolism 
Metabolism Lipid metabolism 2.44 3.28 3.76E-02 
Legionellosis 
Human 
diseases 
Infectious diseases: 
Bacterial 
2.22 3.19 4.13E-02 
 
 
Cultures treated with mAb O4 in the absence of serum and serum alone treated 
cultures share an immunological signature. The affecting pathways modulate 
similar groups of genes, chemokines being highly involved. In cultures treated 
with mAb O4 in the presence of serum, this signature disappears.  
 
 
4.5 Validations 
The Affymetrix array data allowed us to identify genes differentially expressed 
in myelinating cultures in response to a variety of conditions. Validation of this 
data with respect to the effects of mAb O4 in the presence and absence of 
serum was carried out by qPCR and by ELISA on a subset of genes of biological 
interest.  
 
 
4.5.1 RT-PCR array 
As the microarray data indicated there were pronounced differential effects of 
mAb and serum on expression of chemokines and cytokines, this was initially 
validated using a commercially available RT-PCR Array, which allowed us to 
profile changes in expression of 84 genes. This strategy confirmed mAb O4 had a 
pronounced effect on chemokine gene expression (Fig 4.5.1a).  
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Figure 4.5.1a: Scatterplot of O4 treatment independent of complement indicating 
induced  chemokine and cytokine response. Myelinating cultures were treated as 
previously stated for 24 hours. mRNA was extracted from cultures at 25 DIV. cDNA was 
synthesised and analysed using RT2 Profiler PCR Array as per manufactures instruction. 
Values shown are expression levels of each gene in the complement independent 
antibody samples versus their complment independent isotype control sample (n=1). 
Cut-off of 2.0, indicated by red lines, was used to indicate significantly regulated 
genes on the plot.  
 
 
When RNA extracted from the cultures treated with mAb O4 or the isotype 
control in the presence of serum were analysed using the same arrays it is 
apparent differential gene expression was far less. In this case (Table 4.5.1b), 
we observed Cxcl13, Il-11 and Bmp7 were differentially regulated to some 
extent, although this was not apparent from the microarray. 
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Figure 4.5.1b: O4 treatment with complement indicates no response in chemokine 
and cytokine expression. Myelinating cultures were treated as previously stated for 
24 hours. mRNA was extracted from cultures at 25 DIV. cDNA was synthesised and 
analysed using RT2 Profiler PCR Array as per manufactures instruction. Values shown 
are expression levels of each gene in the complement independent antibody samples 
versus their complment independent isotype control sample (n=1). Cut-off of 2.0, 
indicated by red lines, was used to indicate significantly regulated genes on the plot. 
 
 
4.5.2 Real-time PCR 
In addition to RT-PCR array for chemokines and cytokines, quantitative RT-PCR 
was performed on genes (Tables 4.5.2a) with significant fold changes presented 
on the microarray. Mixture of differentially expressed chemokines was chosen 
not only based on their fold change values but by practical primer design and 
commercially available rat ELISA kits. These validations were performed using 
RNA isolated from four biological replicates. Significance was calculated based 
on their dCT values.  
 
With the exception of Soc1, the genes of interest differentially expressed in mAb 
O4 treated cultures compared to the isotype control were all validated by qPCR 
(Table 4.5.2a). Two interferon genes, Ifn-γ and Ifn-α4, were included in this 
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analysis to see if they might contribute to induction of ISG by mAb O4. There 
was no evidence for increased expression of Ifn-γ at this point; however, qPCR 
indicated mAb O4 treatment induced expression of Ifn- α4. 
 
 
Table 4.5.2a: Antibody treatment without complement induces a chemokine and 
cytokine response. Up-regulation of chemokines and cytokines in the presence of 
complement was investigated by incubating 24 DIV myelinating cultures with 20µg/ml 
O4 or their isotype control, plus 2% rabbit sera for 24 hours, after which mRNA was 
extracted. The fold changes from 4 biological repeats were calculated. 
 
 
Repeating this analysis on samples obtained from cultures treated with mAb O4 
in the presence of serum revealed this abolished all of the differential effects 
induced by mAb O4 alone, with the exception of Il-1β, which was elevated. The 
4 differentially expressed genes (Siglec5, Clec4a2, Tlr5, Irg1) in the mAb O4 in 
the presence of serum compared to serum alone treated cultures were not 
validated in this study.  
 
 
 
  
 
 
 
             Array                      qPCR 
Gene Fold Change p-value Fold Change O4- dCT  SD IgM- dCT  SD Sig 
Cxcl11 79.74 2.76-10 936.55 0.86 1.43 10.06 1.56 ** 
Cxcl13 40.25 1.05-7 166.05 5.74 1.66 12.31 2.1 ** 
Irf7 18.67 1.09-7 247.53 -1.68 2.14 4.83 3.23 * 
Ccl5 16.05 3.26-10 975.20 2.78 2.37 12.37 1.89 *** 
Ccl7 12.86 4.22-9 129.04 -0.32 0.93 6 1.92 ** 
Il-1β 7.81 9.17-8 53.35 6.54 1.75 11.78 1.4 ** 
Cd14 5.94 2.88-6 5.69 5.7 1 8.83 1.49 * 
Socs1 4.29 2.67-7 2.79 11.94 1.24 12.8 2.64 ns 
Ccl20 2.82 3.74-4 865.68 2.78 2.37 12.37 1.89 * 
Ccl2 2.71 9.99-6 439.38 -0.04 0.85 7.4 2.6 * 
Tnf 2.44 9.47-3 11.00 5.91 1.04 9.02 1.56 * 
Ifn-γ 1.01 0.88 0.96 15.93 1.39 15.81 1.25 ns 
Ifn-α4 -1.1 0.44 21.39 12.23 1.03 16.22 2.69 * 
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Table 4.5.2b:  Antibody treatment with complement reduces chemokine and 
cytokine expression. Up-regulation of chemokines and cytokines in the presence of 
complement was investigated by incubating 24 DIV myelinating cultures with 20 µg/ml 
O4 or their isotype control, plus 2% rabbit sera for 24 hours, after which mRNA was 
extracted. The fold changes from 4 biological repeats were calculated. 
Array qPCR 
Gene Fold Change p-value Fold Change O4+ dCT  SD NT+ dCT  SD Sig 
Cxcl11 -1.21 0.32 2.72 1.65 2.03 2.38 1.3 ns 
Cxcl13 2.24 0.02 12.31 7.82 1.13 9.93 1 ns 
Irf7 1.28 0.29 2.88 -0.81 2.9 0.44 1.92 ns 
Ccl5 -1.42 0.01 3.29 4.61 2.79 5.64 3.15 ns 
Ccl7 -1.58 0.01 2.67 -1.17 1.53 -0.73 1.02 ns 
Il-1β 1.57 0.01 12.52 6.17 1.28 9.11 0.83 * 
Cd14 -1.01 0.85 6.77 4.31 0.94 6.06 0.95 ns 
Socs1 1.25 0.09 1.38 12.75 0.76 12.78 0.68 ns 
Ccl20 -1.3 0.21 5.89 4.61 2.79 5.64 3.15 ns 
Ccl2 -1.08 0.52 4.28 -0.15 1.28 0.83 1.26 ns 
Tnf 1.06 0.75 4.33 5.46 1.06 6.74 0.66 ns 
Ifn-γ 1.02 0.75 4.48 15.09 1.84 16.33 2.09 ns 
Ifn-α4 1.04 0.77 0.9 14.19 2.48 13.54 2.02 ns 
 
 
 
 
4.5.3 ELISA 
ELISA (enzyme-linked immunosorbent assay) allows measurement of total 
concentration of the cytokines in the culture supernatant. It should be noted 
that finding commercially available and effective rat ELISA kits was a challenge. 
Therefore, the analysis was only performed for five different cytokines, CCL2, 
CCL5, CCL20, CXCL11 and IL-1β. However, in all cases, the concentration of IL-
1β was below the detection level of the commercially available ELISA kit.  In the 
absence of serum, mAb O4 induced significant increases in CCL2, CCL5, CCL20 
(Fig. 4.5.3a). A similar trend was observed for CXCL11, but this did not reach 
significance (p < 0.05), although antibody induced > 1,000 fold change in 
concentration compared to the controls.  
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Figure 4.5.3a: Supernatant concentration of chemokines following complement 
independent antibody treatment. Treatment was performed as previously mentioned. 
Chemokine concentration in the myelinating culture supernatant was  measured by 
using ELISA. Significance was calculated using one-way ANOVA with Tukey’s post-hoc 
test. n=3/group. 
 
 
Unfortunately, factors present in rabbit serum confounded attempts to use these 
assays to measure changes in chemokine concentrations induced in the presence 
of serum. Rabbit serum already gave high background values, and unexpectedly 
chemokine concentrations were generally lower in cultures treated with mAb O4 
than in the presence of serum alone or the isotype control and serum (Fig. 
4.5.3b).  
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Figure 4.5.3b: Supernatant concentration of chemokines following antibody 
treatment in the presence of complement.  Treatment was performed as previously 
mentioned. Chemokine concentration in the myelinating culture supernatant was 
measured by using ELISA. Significance was calculated using one-way ANOVA with 
Tukey’s post-hoc test. n=3/group. 
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4.6 Discussion   
This study reveals addition of a sulphatide-specific IgM mAb to myelinating 
cultures initiates a complex transcriptional response. Our analysis focused on 
two conditions: 
1) The effect of mAb O4 in the absence of serum. We argue this model will 
allow us to explore the effects of intrathecal synthesis of sulphatide-
reactive antibodies in the CNS of patients with progressive forms of MS; a 
disease state with minimal BBB dysfunction. 
 
2) The effect of mAb O4 in the presence of serum. A model that may help in 
identification of specific transcriptional events associated with antibody-
dependent, complement-mediated demyelination; a mechanism believed 
to contribute to lesion formation in a majority of patients with MS.  
 
Our interest in the role of antibody-dependent effector mechanism(s) in MS 
derives from the fact there are no fully effective treatments for this devastating 
disease. Current treatments for MS are able to reduce relapse frequency in RRMS 
by targeting immune mechanisms that support the development of a T cell-
mediated inflammatory response in the CNS. This strategy is however ineffective 
in patients with progressive forms of the disease. The failure of these ‘anti-
inflammatory’ treatments in PMS led to speculation progressive MS was a purely 
neurodegenerative disease in which accumulation of disability was independent 
of any inflammatory disease process within the CNS. However, recent studies 
demonstrate this not the case (Frischer et al., 2009). Progressive (primary and 
secondary) MS is associated with extensive cortical pathology in which loss of 
myelin and neurites is associated with inflammation in the overlying meninges 
(Kutzelnigg et al., 2005; Magliozzi et al., 2007; Howell et al., 2011).These 
meningeal infiltrates are frequently enriched in B cells and may represent a 
ectopic lymphoid follicles (Magliozzi et al., 2007). In addition, widespread 
microglial activation is seen in throughout the CNS (Peterson et al., 2001; 
Prineas etal., 2001; Kutzelnigg et al., 2005; Magliozzi et al., 2007) and the 
active rim of slowly expanding lesions in white matter tracts is associated with 
recruitment of leukocytes, although this is far less pronounced than in early 
RRMS (Frischer et al., 2009). In response to these observations, a new hypothesis 
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was developed that attributed accumulation of disability in PMS to the effects of 
an inflammatory response sequestered in the CNS itself (Bradl and Lassmann, 
2009; Fischer et al., 2013). However, the mechanisms that maintain this 
inflammatory response remain unknown. The gene expression data obtained in 
this study provides new insight into this problem as they demonstrate an 
antibody mimicking the specificity of the disease associated intrathecal antibody 
repertoire can induce a pro-inflammatory signalling environment in vitro. 
 
In these experiments we used the sulphatide-specific mAb O4 to mimic the 
specificity of the intrathecal autoantibody repertoire in patients and explored its 
effects in myelinating cultures. In the absence of exogenous serum we believe 
this experimental model replicates the CNS environment in PMS in which BBB 
dysfunction is minimal. Unexpectedly this experiment revealed mAb O4 induced 
expression of a large number of chemokine genes [Cxcl11 (80-fold), Cxcl9 (59-
fold), Cxcl13 (40-fold), Cxcl10 (35-fold), Cxcl17 (19-fold); Ccl5 (16-fold), Ccl7 
(13-fold), Ccl20 (2.8-fold) and Ccl2 (2.7-fold)], as well as many other transcripts 
associated with innate and adaptive immunity. Intriguingly, the vast majority of 
these are interferon sensitive genes (ISG) suggesting binding of mAb O4 to the 
myelin/oligodendrocyte surface triggers a cascade of responses mimicking those 
induced by infectious agents; a concept supported by gene ontology and 
pathway analysis of these genes. Extrapolating these observations to PMS 
suggests an intrathecal response directed against sulphatide, in addition to any 
direct detrimental effects it might have on myelin and oligodendrocytes (Section 
3), will maintain inflammatory disease activity in the CNS. At present he 
mechanism(s) responsible for this state of ‘heightened immune awareness’ 
induced by mAb O4 are unknown. We speculate microglia and/or astrocytes are 
the major source of the chemokine response seen in these myelinating cultures, 
and that this is triggered by an activating signal derived from affected 
oligodendroglia. Potential candidates are damage associated molecular patterns 
(DAMPs) (Bianchi, 2007) generated in response to antibody-mediated cross-
linking of sulphatide at the cell surface. These may include membrane vesicles 
shed from the oligodendroglial/myelin surface (Scolding et al., 1989), as well as 
molecular signals derived from the intracellular compartment such as high-
mobility group box 1 (HMGB1), heat shock proteins, degraded DNA and RNA, S100 
proteins and purine derivatives. Intriguingly, mAb O4 increases expression of 
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several receptors predicted to be involved in this response in particular 
triggering receptor expressed on myeloid cells 1 (Trem-1; fold change +4.6) and 
several C-type lectin receptors (Clec4a2, fold change +8.2; Clec4a1, fold change 
+2.9; Clec4d, fold change +2.8; Clec2g, fold change +2.5; Clec4e, fold change 
+2.4; Clec4a3, fold change +2.2). Determining the molecular mechanisms by 
which mAb O4 induces this chemokine signal, the identity of relevant 
ligand/receptor pairs and their biological/pathophysiological relevance in MS 
will require further studies.  
 
However, with respect to chemokines they may not only provide signals to 
attract immune cells into the brain and spinal cord, but may also affect a wide 
range of resident cells that express appropriate receptors. CXCR1, CXCR2, and 
CXCR3 can be expressed by OPCs and oligodendrocytes (Nguyen and Stangel, 
2001; Tsai et al., 2002; Omari et al., 2005), but apart from CXCR2 mediating the 
migratory arrest of OPC during their development (Tsai et al., 2002) their roles 
are unknown. Other studies demonstrate microglia and astrocytes also express 
CXCR3, as well as variable levels of CCR3, CCR4, CCR5, CCR6, CXCL1, CXCR2, 
CXCR4 and CXCR5 (Ransohoff, 2009). In the context of this study the role of 
CXCR3 may be particularly important as it is a receptor for CXCL11, CXCL10 and 
CXCL9, three of the chemokines most highly up regulated by mAb O4. However, 
irrespective of any resident cellular response triggered by these chemokines, 
together with CXCL13 they are also implicated in the recruitment of B cells into 
the CNS in a variety of disease models (Sellebjerg et al., 2009; Rainey-Berger et 
al., 2011; Kalinowska-Lyszczarz et al., 2011; Kowarik et al., 2012; Phares et al., 
2013; Metcalf et al., 2013). This raises the possibility intrathecal synthesis of 
sulphatide-specific antibodies may support a positive feedback loop sustaining B 
cell recruitment into the CNS compartment. This hypothesis is supported by the 
observation mAb O4 also enhanced expression of Cxcr5 (fold change +1.5), the 
receptor for CXCL13 which is implicated in the development of B cell enriched 
lymphoid follicle-like structures in the meninges of patients (Cyster et al., 2000; 
Magliozzi et al., 2004 2007). However, it should be noted the spectrum of 
chemokines induced by mAb O4 is very broad and in addition to any effect on B 
cells this is also predicted to enhance monocyte and T-cell recruitment into the 
CNS (Table 6.0). It should also be appreciated a large number of chemokines are 
expressed in MS tissues and at present it is unknown what contribution might be 
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made by the antibody-mediated effect described in this study (Mahad and 
Ransohoff, 2003; Biber et al., 2002; Furlan et al., 2005; Banisor et al., 2005).  
 
 
Table 6.0: Chemokine receptor redundancy for the genes differentially expressed 
in our Affymetrix array (Peprotech, 2011).  
Gene Receptor Responding cell type 
 
Gene Receptor 
Responding 
cell type 
CCL2 CCR2 Bs, Mo, actT, NK, iDC CXCL1 CXCR1 > CXCR2 PMN 
CCL3 CCR1, CCR5 Eo, Mo, actT, NK, iDC CXCL2 CXCR2 PMN 
CCL4 CCR5 Mo, act (Th1), NK, iDC CXCL5 CXCR2 PMN 
CCL5 CCR1, CCR3, CCR5 Eo, Bs, Mo, act, NK, iDC CXCL9 CXCR3 act (TH1), NK 
CCL7 CCR1, CCR2, CCR3 Eo, Bs, Mo, act, NK, iDC CXCL10 CXCR3 act (TH1), NK 
CCL9 CCR1 PMN, act CXCL11 CXCR3, CXCR7 act (TH1), NK 
CCL12 CCR2 Bs, Mo, actT, NK, iDC CXCL13 CXCR3, CXCR5 B 
CCL19 CCR7 T, act, mDC CXCL16 CXCR6 actT 
CCL20 CCR6 Tm, B, iDC CXCL17 Unknown Mo, iDC 
CCL24 CCR3 Eo, Bs, actT (Th2), iDC   
 
* = qPCR validation, ** = qPCR and ELISA validation, Tm = memory T cell, B = B cell, 
actT = activated T cell, Bs = basophil, T = resting T cell, Eo = eosinophil, NK = natural 
killer cell, Mo = monocyte, PMN = neutrophil, mDC = mature dendritic cell, iDC = 
immature DC 
 
 
In summary, a significant body of evidence is now available demonstrating 
sulphatide-specific antibodies are a significant component of the intra-thecal 
repertoire and they are derived from clonally expanded B cell clones 
sequestered in the CNS (Baranzini et al., 1999; Qin et al., 1998; Owens et al., 
2003; Rainey-Barger et al., 2011; Phares et al., 2011). These clonal expansions 
can be identified in CSF, meningeal infiltrates and parenchyma of patients with 
MS but recent studies demonstrate they are not permanently sequestered in the 
CNS but participate in bidirectional exchange across the BBB (von Budingen et 
al., 2012; Palanichamy et al. 2014; Stern et al., 2014). These observations 
support the therapeutic use of B cell depleting antibodies and mAb derived 
therapeutics that prevent lymphocytes from crossing the BBB in MS. However, 
our data suggests these treatments should be complemented by strategies 
designed to eliminate intrathecal populations of B cells and antibody secreting 
cells (plasmablasts and plasma cells); a treatment strategy we suggest will 
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disrupt an important feedback loop contributing to the maintenance of disease 
activity within the CNS.  
 
In addition to effects on immune function within the CNS such treatments would 
also eliminate any direct effects of the intrathecal antibody response on myelin 
and/or axonal integrity.  In Section 3.4 we report prolonged exposure (ten days) 
to a high concentration of mAb O4 not only inhibited myelination, but also 
appeared induce demyelination. How these effects might be related to the 
transcriptional response induced by the antibody within 24 hours is unclear. 
However, the effect of mAb O4 on myelination was associated with a 50% 
increase in microglial numbers. Mitogenic colony-stimulating factors (CSFs) 
mediate microglial proliferation and/or activation (Sawada et al., 1990; 
Kreutzberg, 1996) and in this context it is interesting to note mAb O4 induced a 
significant increase in Csf1 expression within 24 hours (Appendix 8.1.2; fold 
change + 1.8, p = 9.7 x 10-5). However, this finding was not yet validated at the 
protein level and it is premature to link these in vitro effects of mAb O4 on 
myelin and microglia to the widespread changes in microglial numbers and 
phenotype associated with lesion formation in MS. 
  
Antibody-mediated demyelination is classically discussed as a complement-
dependent phenomenon, but it appears endogenous synthesis of complement 
components is insufficient to support acute antibody-mediated demyelination 
(Elliott et al., 2011; this study). Nonetheless within 24 hours mAb O4 up-
regulated expression of C3 (fold change +7.5, p = 1.2 x 10-7) and C3ar1 (fold 
change +2.6, p = 1.4 x 10-3) significantly. We therefore cannot rule antibody-
mediated induction of these endogenous complement components does not 
contribute to the longer term effects of exposure to mAb O4 on myelination. It 
should also be considered this increase in component availability may also 
influence dendritic spine/synapse remodelling (Stephan, Barres and Stevens, 
2012; Schafer and Stevens, 2010; Tremblay et al., 2011; Wang et al., 2010), and 
if so, it could play a significant role in the pathophysiology of MS, independently 
or in synergy with its effects on immune function and myelination.  
 
The arguments above all stress the pathogenic potential of a sulphatide specific 
antibody, but other studies indicate may be beneficial in that it can stimulate 
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remyelination (Miller and Rodriquez, 1995; Warrington et al., 2000; Wright et al., 
2009). We saw no evidence of this in the present study, but found binding mAb 
O4 to the oligodendrocyte/myelin surface was associated with a transcription 
response mimicking that induced by neurotrophic viruses. Why this occurs is 
unknown, however it suggests the ability of mAb O4 to enhance remyelination in 
TMEV infected mice is due to its ability to stimulate an immune response that 
enhances viral clearance rather than promoting OPC proliferation and 
differentiation.  
 
These acute effects of mAb O4 on gene expression in the myelinating cultures 
were largely unexpected; the anticipation being the most informative 
transcription figures would be associated with antibody-dependent, 
complement-mediated demyelination. This was not the case as unexpectedly 
addition of serum alone induced a wide spectrum of changes in gene expression. 
These transcriptional changes have not been validated, but they suggest serum 
leakage across the BBB has multiple far reaching effects that might contribute to 
the pathogenesis of many CNS diseases. This requires further investigation, but 
possibly the most unexpected result of this study was that although mAb O4 
induced demyelination in the presence of serum, this major pathogenic event 
was associated with only 21 significantly modulated transcripts (Table 4.3.4; 4 
up-regulated, 17 down-regulated). The majority of genes that were down 
regulated are expressed by oligodendrocytes, and this is attributed to an 
antibody-mediated, complement-dependent loss of oligodendrocytes (Elliott et 
al., 2011). However, only four genes (Siglec5, Clec4a2, Tlr5 and Irg1) were 
significantly up-regulated in this context. Validating these observations is 
important, but this should be performed using autologous serum to avoid 
potential artefacts due to xenogeneic serum effects.  
 
At present we can only speculate on the functional significance of these changes. 
SIGLEC5 and CLEC4A (also known as dendritic cell immunoreceptor) contain 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) suggesting they may 
limit induction of a pro-inflammatory response following antibody/complement 
mediated demyelination (Crocker et al., 2007). However allocating functional 
significance to increased expression of Tlr5 and Irg1 is more difficult. Classical 
studies demonstrate bacterial flagellin is a major ligand for TLR5 and suggest it 
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may play an important role in regulating mucosal immunity (Hayashi et al., 2001; 
Takeda and Akira, 2005) whilst in the CNS it is up regulated on microglia in 
response to Borrelia burgdorferi, the cause of Lyme Disease (Neuroborreliosis) 
(Bernardino et al, 2008). Immunoresponsive gene 1 (IRG1) is now known to 
encode an enzyme that generates itaconic acid from cis-aconitate, a 
tricarboxylic acid cycle intermediate in microglia (Michelucci et al., 2012) and is 
highly up regulated in the CNS of mice with EAE (Carmody et al., 2002), but its 
functional relevance is unknown. 
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5 Future studies   
This preliminary study of the effect of treating myelinating cultures with a 
sulphatide-specific mAb has many potential ramifications in particular with 
respect to the role a similar intrathecal response might play in the pathogenesis 
of PMS. In view that there are no treatments currently available to offer these 
patients it is a matter of some urgency this study is extended as soon as possible 
to: 
a) Determine if patient CSF contains antibody and/or antigen-antibody 
complexes that can mediate a similar response to mAb O4 in myelinating 
cultures in vitro. 
b) Define the antigen-specificity and mechanistic basis for this chemokine 
response in vitro and whether this can be reproduced using pre-formed 
antigen/antibody complexes.  
c) Develop an animal model to investigate the consequences of this effect in 
vivo.  
 
Our initial studies were performed using myelinating cultures derived from 
embryonic rat spinal cord, but to exploit the full range of genetic and 
immunobiological tools now available, future studies should be performed using 
cultures derived from embryonic mice. This methodology is well established and 
preliminary results suggest myelinating mouse and rat cultures respond in a 
similar manner to treatment with mAb O4 (Edgar, Linington, personal 
communication).  
To address the questions outlined above one approach would be to repeat the 
transcriptional profiling described in this thesis, but with mouse cultures as the 
target and using RNAseq to obtain more complete information on how the 
cultures respond to different treatments over time. Once this is completed using 
a variety of myelin and non-myelin specific antibodies, pre-formed antigen-
antibody complexes and all relevant controls, the most informative time point 
should be chosen to investigate the effects of selected CSF samples using the 
same methodology. In simple terms, size fractionation of CSF samples could be 
used to determine if effects on gene transcription are due to factors with a 
MW >100,000 but < 300,000 Daltons (potentially IgG) or immune complexes 
and/or monomeric IgM (MW > 300,000 Daltons). Ultimately this would provide a 
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series of differential gene expression profiles that can be compared directly to 
those induced using mAb O4 and other model antibodies/antibody-antigen 
complexes.  
 
This strategy would also provide data defining the antigen specificity of the 
response i.e. whether it is sulphatide-specific or replicated using other model 
reagents. Combining this approach with immunofluorescence and/or in situ 
hybridisation studies would also allow us to determine which cell types are 
responsible for specific aspects of the response. These studies would also 
determine how to best measure effects of CSF samples on chemokine synthesis. 
One possibility would be to use a multi-flex ELISA or Luminex based assays to 
determine the concentrations of selected chemokines in supernatants harvested 
from treated and control cultures. This data could then be used to investigate 
potential correlations between these in vitro responses with clinical parameters 
such as accumulation of disability or treatment responses. Developing an animal 
model to explore these phenomena in vivo will be more challenging, although 
acute effects on gene expression, leucocyte recruitment, myelination and 
synaptic remodelling may be studied by direct intrathecal injection of antibody 
or antigen-antibody complexes. Longer term studies may, however, have to rely 
on delivery via osmotic pumps attached to intra-ventricular catheters. 
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7 Appendix 1 
Unless otherwise stated reagents were obtained from Sigma. 
 
7.1 Buffers 
Phosphate buffer saline (PBS) 
8 g Sodium chloride 
0.2 g Potassium chloride 
0.2 g Potassium dihydrogen  
1.18 g Disodium phosphate 
Dissolved in approximately 800 ml of distilled water, adjusted to pH 7.4 
with 1 M hydrogen chloride and topped up to 1 L with distilled water.  
  
 
7.2 Myelinating culture media  
7.2.1 Supplements   
Soybean trypsin inhibitor  
13 mg Soybean trypsin inhibitor  
75 mg Bovine albumin factor V  
1 mg DNase I from bovine pancreas  
Made up in 25 ml Leibovitz medium 15 (Gibco, Invitrogen, Paisley) 
 
1% Collagenase  
20 ml Leibovitz medium 15 
20 mg Collagenase type I 
 
Insulin 
100 mg Insulin from bovine pancreas 
200 ml 10 mM Hydrogen chloride  
 
Biotin 
100 mg Biotin 
100 ml 1 M Sodium hydroxide 
Diluted 1:100 with distilled water 
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Hydrocortisone 
100 mg Water soluble hydrocortisone  
Dissolved in 27.6 ml distilled water 
 
30% Glucose 
30 g Glucose  
Dissolved in 100 ml of sterile water 
 
7.5% Sodium biocarbonate 
7.5 g NaHCO3  
100 ml sterile water 
 
1M HEPES 
 23.8 g HEPES  
 100 ml sterile water 
 
10x Hormone mix 
 5 ml 30% glucose 
 3.75 ml 7.5% NaHCO3  
 1 ml 1 M HEPES 
250 mg Transferrin: apo-human  
26 ml insulin solution 
 6.25 ml Human recombinant Insulin  
 19.75 ml Sterile water 
25 ml 200 µM Putrescine  
  96.6 mg Putrescine  
  100 ml sterile water 
 25 µl Selenium 
  1 mg Sodium selenite  
  1.93 ml sterile water 
 25 µl Progesterone 
  1 mg Progesterone  
  1.59 ml 95% Ethanol  
 Top up to 250 ml with DMEM/F-12 medium 
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7.2.2 Tissue culture media 
Differentiation medium 
500 ml DMEM medium  
5 ml Penicillin streptomycin 
5 ml Sodium pyruvate 
 
Insulin containing differentiation medium (DM+) 
48.5 ml 1XDMEM with penicillin (100 U/ml)/streptomycin (100 
μg/ml)/Glucose (4.500 mg/L) 
250 µl N1 supplement 
250 µl 10 µM Hydrocortisone 
50 µl 1 µg/ml Biotin 
1 ml 0.5 µg/ml Insulin 
 
Differentiation medium (DM-) 
49.5 ml 1XDMEM with penicillin (100 U/ml)/streptomycin (100 
μg/ml)/Glucose (4.500 mg/L) 
 250 µl N1 supplement 100x  
 250 µl 10µM Hydrocortisone 
 50 µl 1 µg/ml Biotin 
 
Neurosphere medium 
210 ml DMEM-F12  
25 ml 10x Hormone mix 
5 ml 30 % Glucose 
3.75 ml 7.5 % NaHCO3 
1.25 ml 1 M HEPES 
2.5 ml L-glutamate 
2.5 ml Penicillin Streptomycin 
625 µl 4 % BSA in L15 media 
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Astrocyte medium 
500 ml 1.0 g/L Glucose-containing DMEM 
50 ml 10 % Fetal bovine serum 
5 ml Penicillin streptomycin 
2.5 ml Glutamine 
 
Plating medium 
50 % 1X DMEM (Gibco, Invitrogen, Paisley) 
24 % Heat inactivated horse serum (Invitrogen, Paisley) 
24 % 1X HBSS with Mg2+ and Ca2+ (Gibco, Invitrogen, Paisley) 
2 % Glutamine (Sigma-Aldrich) 
 
1.33μg/ml Poly-L-Lysine (PLL) 
25 mg of poly-L-lysine hydrobromide  
Dissolved in 6.25 ml of distilled water  
 
 
7.3 Hybridoma media 
Feeding medium (RPMI-1640) 
 50 ml fetal bovine serum 
 5 ml Penicillin streptomycin 
 5 ml L-glutamine 
 5 ml Sodium puryvate 
  5 ml Non-essential amino acids 
 0.5 ml 1000x Mercaptoethanol  
 
Freezing medium  
 45 % Fetal Bovine Medium 
45 % RPMI-1640 feeding medium 
10 % Dimethyl sulphatide 
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7.4 IgG antibody purification buffers 
20 mM Sodium Phosphate, pH 7.0 (Binding buffer) 
0.542 g Sodium phosphate 
1.637 g Disodium phosphate, Na2HPO4 
1 L distilled water 
 
0.1 M Glycine buffer (Elution buffer) 
1.875 g Glycine 
0.7 ml Concentrated hydrochloric acid 
500 ml distilled water 
 
1 M Tris base (Neutraliser) 
70.55 Tris base 
500 distilled water 
 
 
7.5 IgM antibody purification buffers 
20 mM Sodium phosphate, 8.0 M (NH4)2SO4, pH 7.5 (Binding buffer) 
1.084 g NaH2PO4, anhydrous 
3.273 g Na2HPO4 x 7 H2O  
105.712 g (NH4)2SO4 
Quantum satis to 1 L with distilled water 
 
20 mM Sodium phosphate, pH 7.5 (Elution buffer) 
1.084 g NaH2PO4, anhydrous 
3.273 g Na2HPO4 x 7 H2O 
Quantum satis to 1 L with distilled water 
 
20 mM Sodium phosphate, pH 7.5 with 30 % isopropanol (Regeneration 
buffer) 
1.084 g NaH2PO4, anhydrous 
3.273 g Na2HPO4 x 7 H2O 
300 ml Isopropanol 
Quantum satis to 1 L with distilled water 
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7.6 Materials for mAb Z2 fragmentation to Fab  
Digestion buffer prepared fresh and stored on ice <10h 
10 ml 1 x PBS 
0.02 M EDTA  
0.02 M Cysteine 
Papain from papaya latex (equal volume to Ab, at 1:20 ratio) 
 
0.3 M Iodoacetamide 
10 ml PBS 
0.0056 g/ml Iodoacetamide 
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8 Appendix 2 
 
8.1 Partek Genomics Suite gene lists 
8.1.1 Genes identified as being differentially expressed in mAb O4 treated 
myelinating cultures 
 
Table 4.3.2: Differentially expressed genes in O4 antibody treated myelinating 
cultures in the absence of serum identified by Partek. Microarray analysis was 
performed on Partek Genomic Suite. The data shown is sorted in manner of highest 
fold change to the cut-off of 1.4 in antibody treated cultures in comparison to isotype 
control treated cultures. Significance was calculated using one-way ANOVA. 
Gene Symbol Gene Name 
Fold-
Change 
P-value 
Cxcl11 chemokine (C-X-C motif) ligand 11  79.74 2.76E-10 
Cxcl9 chemokine (C-X-C motif) ligand 9   59.29 2.49E-10 
Cxcl13 chemokine (C-X-C motif) ligand 13  40.25 1.05E-07 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3   39.28 3.84E-07 
Cxcl10 chemokine (C-X-C motif) ligand 10  34.87 5.75E-06 
Oasl 2'-5'-oligoadenylate synthetase-like  32.03 1.55E-07 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 25.12 6.36E-07 
Mx1 myxovirus (influenza virus) resistance 1  23.25 5.58E-07 
Rsad2 radical S-adenosyl methionine domain containing 2 22.19 7.29E-06 
Cxcl17 chemokine (C-X-C motif) ligand 17 18.81 1.52E-09 
Irf7 interferon regulatory factor 7  18.67 1.09E-07 
Isg20 interferon stimulated exonuclease gene 20   17.34 1.01E-07 
Gbp5 guanylate binding protein 5  16.10 2.29E-09 
Ccl5 chemokine (C-C motif) ligand 5  16.05 3.26E-10 
Apol9a apolipoprotein L 9a    15.35 1.87E-08 
F10 coagulation factor X   13.51 3.13E-08 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60  13.06 1.70E-06 
Zbp1 Z-DNA binding protein 1  NM_133564 12.93 1.10E-07 
Ccl7 chemokine (C-C motif) ligand 7   12.86 4.22E-09 
Lcn2 lipocalin 2  12.15 2.75E-08 
Isg15 ISG15 ubiquitin-like modifier  12.04 2.96E-07 
Usp18 ubiquitin specific peptidase 18 11.70 3.11E-06 
LOC685067 similar to guanylate binding protein family, member  11.32 1.52E-07 
LOC100366216 nuclear antigen Sp100-like  11.14 4.99E-08 
Oas2 2'-5' oligoadenylate synthetase 2 9.82 9.20E-08 
Lgals9 lectin, galactoside-binding, soluble, 9  9.60 1.31E-07 
RT1-T24-3 RT1 class I, locus T24, gene 3 9.56 6.03E-09 
Oas1b 2-5 oligoadenylate synthetase 1B 9.48 1.33E-06 
Ccl19 chemokine (C-C motif) ligand 19  9.15 2.99E-07 
Serpine1 serpin peptidase inhibitor, clade E (nexin, plasminog 8.99 7.34E-07 
Cd72 Cd72 molecule  8.89 1.07E-06 
Ccl12 chemokine (C-C motif) ligand 12 8.70 5.01E-07 
Clec4a2 C-type lectin domain family 4, member A2  8.15 1.64E-07 
Ifi27l2b interferon, alpha-inducible protein 27 like 2B  8.05 1.85E-08 
Mpa2l macrophage activation 2 like 7.99 1.98E-07 
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Il1b interleukin 1 beta  7.81 9.17E-08 
Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58  7.62 4.95E-07 
C3 complement component 3  7.50 1.20E-07 
Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TA 7.43 1.89E-09 
Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin 7.38 1.32E-06 
Slamf9 SLAM family member 9  7.38 2.45E-09 
Oas1i 2 ' -5 ' oligoadenylate synthetase 1I  7.11 6.62E-07 
RGD1305184 similar to CDNA sequence BC023105  6.94 8.61E-06 
Uba7 ubiquitin-like modifier activating enzyme 7   6.81 1.43E-06 
Siglec5 sialic acid binding Ig-like lectin 5  6.58 2.33E-06 
RT1-CE4 RT1 class I, locus CE4  6.38 1.46E-06 
Cmpk2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial  6.31 1.46E-06 
Il18bp interleukin 18 binding protein   6.31 1.29E-07 
Psmb9 proteasome (prosome, macropain) subunit, beta type, 9  6.23 1.15E-08 
Slfn3 schlafen 3 6.18 1.16E-04 
RGD1309362 similar to interferon-inducible GTPase 6.08 4.66E-06 
Cd14 CD14 molecule 5.94 2.88E-06 
Slfn1 schlafen 1 5.86 3.80E-07 
Birc3 baculoviral IAP repeat-containing 3 5.85 1.68E-09 
Emr1 EGF-like module containing, mucin-like, hormone receptor-like 1 5.82 1.30E-05 
RT1-CE12 RT1 class I, locus CE12 5.73 2.50E-08 
LOC684193 similar to sterile alpha motif domain containing 9-like  5.69 1.12E-08 
Ebi3 Epstein-Barr virus induced 3   5.67 7.26E-07 
Apol3 apolipoprotein L, 3  5.67 1.57E-05 
RT1-S3 RT1 class Ib, locus S3  5.66 1.45E-07 
Il1a interleukin 1 alpha 5.65 2.50E-06 
RT1-N3 RT1 class Ib, locus N3  5.58 1.69E-07 
Psmb8 proteasome (prosome, macropain) subunit, beta type, 8  5.57 3.80E-08 
Tmem106a transmembrane protein 106A 5.56 5.30E-08 
Sp100 SP100 nuclear antigen  5.50 6.07E-10 
Ch25h cholesterol 25-hydroxylase  5.49 9.81E-06 
Itgal integrin, alpha L  5.45 2.56E-06 
Tapbp TAP binding protein (tapasin)  5.43 5.82E-09 
LOC688318 similar to leucine rich repeat containing 45  5.42 5.53E-09 
Slc11a1 solute carrier family 11 (proton-coupled divalent metal ion tran 5.37 1.64E-07 
Apol3 apolipoprotein L, 3  5.30 7.95E-06 
Slpi secretory leukocyte peptidase inhibitor  5.16 5.77E-04 
Tnfaip2 tumor necrosis factor, alpha-induced protein 2 5.13 4.52E-09 
Ifi47 interferon gamma inducible protein 47  5.11 7.53E-10 
Rac2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP b 4.99 5.93E-05 
Plac8 placenta-specific 8  4.96 7.80E-05 
LOC681182 similar to paired immunoglobin-like type 2 receptor beta  4.96 2.26E-05 
Vcam1 vascular cell adhesion molecule 1 4.89 1.74E-08 
Ifih1 interferon induced with helicase C domain 1  4.88 1.71E-06 
Gpr31 G protein-coupled receptor 31  4.82 1.45E-05 
Ccl4 chemokine (C-C motif) ligand 4  4.76 2.19E-05 
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Trem1 triggering receptor expressed on myeloid cells 1  4.64 3.49E-04 
Scimp SLP adaptor and CSK interacting membrane protein  4.61 1.01E-06 
Tor3a torsin family 3, member A  4.42 1.51E-06 
Ms4a11 membrane-spanning 4-domains, subfamily A, member 11 4.34 2.99E-07 
Pric285 peroxisomal proliferator-activated receptor A interact 4.33 1.73E-06 
Oasl2 2'-5' oligoadenylate synthetase-like 2  4.30 6.23E-06 
Socs1 suppressor of cytokine signaling 1  4.29 2.67E-07 
Rtp4 receptor (chemosensory) transporter protein 4  4.29 1.09E-06 
Itgam integrin, alpha M  4.28 6.65E-04 
Casp12 caspase 12  4.28 6.92E-08 
Parp12 poly (ADP-ribose) polymerase family, member 12 4.27 7.06E-07 
Ly6e lymphocyte antigen 6 complex, locus E  4.24 7.49E-08 
Slfn13 schlafen family member 13  4.20 7.02E-11 
Irgm immunity-related GTPase family, M  4.10 1.06E-06 
MGC105567 similar to cDNA sequence BC023105 4.10 2.60E-05 
Hck hemopoietic cell kinase 4.09 4.71E-04 
Psmb10 proteasome (prosome, macropain) subunit, beta type 10 4.08 2.98E-07 
Cxcl16 chemokine (C-X-C motif) ligand 16  3.97 1.79E-08 
Tap2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 3.96 2.24E-06 
Ppm1n protein phosphatase, Mg2+/Mn2+ dependent, 1N  3.94 5.01E-10 
Cd274 CD274 molecule  3.91 5.09E-08 
Msr1 macrophage scavenger receptor 1  3.91 3.88E-05 
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B  3.90 1.47E-04 
Slfn5 schlafen family member 5 3.87 1.07E-07 
Fgr Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog  3.84 2.76E-07 
Cpne2 copine II  3.83 4.15E-09 
Tlr3 toll-like receptor 3  3.82 1.20E-09 
Pram1 PML-RARA regulated adaptor molecule 1  3.79 4.69E-04 
MGC108823 similar to interferon-inducible GTPase 3.77 4.71E-05 
Sp140 SP140 nuclear body protein  3.75 3.46E-08 
Ube2l6 ubiquitin-conjugating enzyme E2L 6  3.74 1.15E-07 
Fcgr3a Fc fragment of IgG, low affinity IIIa, receptor  3.72 4.02E-05 
Slc4a1 solute carrier family 4 (anion exchanger), member 1  3.68 6.24E-05 
Casp1 caspase 1 3.63 9.24E-07 
Lgals5 lectin, galactose binding, soluble 5  3.62 4.72E-07 
Ccl3 chemokine (C-C motif) ligand 3  3.62 1.39E-03 
Naaa N-acylethanolamine acid amidase  3.60 2.89E-03 
Samd9l sterile alpha motif domain containing 9-like  3.59 7.82E-07 
Ifi44 interferon-induced protein 44  3.56 1.40E-06 
Ly86 lymphocyte antigen 86 3.54 2.19E-04 
Slc6a12 solute carrier family 6 (neurotransmitter transporter, betaine/GAB 3.54 5.61E-05 
Cd74 Cd74 molecule, major histocompatibility complex, class II 3.52 7.13E-06 
Gbp1 guanylate binding protein 1, interferon-inducible  3.51 1.60E-06 
Pstpip1 proline-serine-threonine phosphatase-interacting protein 1 3.47 2.96E-04 
Cxcl1 
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activi 
3.45 5.24E-04 
Bcl3 B-cell CLL/lymphoma 3  3.35 1.77E-04 
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Ncf1 neutrophil cytosolic factor 1  3.35 1.30E-04 
Cd69 Cd69 molecule  3.32 1.65E-06 
Stat2 signal transducer and activator of transcription 2  3.31 7.31E-07 
LOC688318 similar to leucine rich repeat containing 45  3.29 9.24E-07 
Icam1 intercellular adhesion molecule 1 3.28 2.55E-07 
Lrrc25 leucine rich repeat containing 25 3.28 7.74E-04 
Il1rn interleukin 1 receptor antagonist 3.25 9.40E-06 
RT1-CE1 RT1 class I, locus1  3.20 1.29E-07 
Fam46a family with sequence similarity 46, member A  3.18 3.19E-08 
Has2 hyaluronan synthase 2   3.18 5.05E-04 
Serping1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  3.18 5.80E-08 
Rasa4 RAS p21 protein activator 4  3.17 3.09E-07 
Gpr114 G protein-coupled receptor 114  3.15 2.43E-06 
Plek pleckstrin  3.14 1.35E-04 
Trim21 tripartite motif-containing 21 3.14 1.02E-07 
Ripk3 receptor-interacting serine-threonine kinase 3  3.12 1.98E-04 
Car13 carbonic anhydrase 13  3.12 2.14E-06 
Itgb2 integrin, beta 2  3.10 7.00E-04 
Ido2 indoleamine 2,3-dioxygenase 2  3.08 3.35E-06 
Nfkbie nuclear factor of kappa light polypeptide gene enhancer in B-cell 3.08 2.41E-09 
Irf9 interferon regulatory factor 9  3.07 2.45E-08 
RT1-Da RT1 class II, locus Da  3.06 8.32E-07 
Nfkb2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 3.04 7.97E-08 
Gsap gamma-secretase activating protein  3.04 2.36E-06 
Upp1 uridine phosphorylase 1  3.03 1.47E-05 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein  3.03 9.08E-09 
Ifi35 interferon-induced protein 35  3.03 6.39E-07 
Mov10 Moloney leukemia virus 10 3.02 8.49E-09 
Trex1 three prime repair exonuclease 1   3.00 4.75E-09 
RT1-N2 RT1 class Ib, locus N2 2.98 3.61E-05 
Trim30 tripartite motif-containing 30 2.97 1.19E-06 
LOC688318 similar to leucine rich repeat containing 45  2.94 3.68E-07 
Rbp1 retinol binding protein 1, cellular 2.93 5.83E-05 
Znfx1 zinc finger, NFX1-type containing 1 2.93 2.39E-05 
Tuba1c tubulin, alpha 1C 2.93 4.27E-05 
Trim25 tripartite motif-containing 25 2.93 1.11E-07 
Pycard PYD and CARD domain containing  2.91 4.46E-08 
Clec4a1 C-type lectin domain family 4, member A1  2.88 9.11E-04 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 2.86 2.37E-06 
Mvp major vault protein  2.84 1.83E-08 
Ccl20 chemokine (C-C motif) ligand 20  2.82 3.74E-04 
Slfn2 schlafen 2  2.81 7.26E-07 
Tlr7 toll-like receptor 7  2.80 2.17E-05 
C1r complement component 1, r subcomponent  2.79 8.64E-08 
P2ry6 pyrimidinergic receptor P2Y, G-protein coupled, 6  2.79 1.84E-04 
Irg1 immunoresponsive gene 1  2.79 1.66E-06 
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Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4  2.79 7.22E-05 
Samd9l sterile alpha motif domain containing 9-like 2.79 2.47E-05 
Clec4d C-type lectin domain family 4, member D 2.78 9.39E-04 
Nmi N-myc (and STAT) interactor  2.78 2.88E-07 
Hcls1 hematopoietic cell specific Lyn substrate 1  2.73 2.50E-04 
Ripk2 receptor-interacting serine-threonine kinase 2  2.72 1.62E-07 
Ccl2 chemokine (C-C motif) ligand 2  2.71 9.99E-06 
Sod2 superoxide dismutase 2, mitochondrial  2.70 3.28E-09 
Tapbpl TAP binding protein-like  2.70 3.81E-06 
RT1-Ba RT1 class II, locus Ba  2.69 2.52E-05 
Relb v-rel reticuloendotheliosis viral oncogene homolog B  2.69 2.56E-07 
Ddr2 discoidin domain receptor tyrosine kinase 2  2.69 2.55E-06 
RGD1561730 similar to cell surface receptor FDFACT 2.65 4.85E-04 
Lyn v-yes-1 Yamaguchi sarcoma viral related oncogene homolog  2.62 4.59E-04 
RT1-M3-1 RT1 class Ib, locus M3, gene 1  2.61 7.12E-06 
RT1-CE5 RT1 class I, locus CE5  2.61 3.40E-05 
C3ar1 complement component 3a receptor 1  2.60 1.41E-03 
Il18 interleukin 18 2.60 6.49E-04 
Ptx3 pentraxin 3, long  2.59 2.42E-03 
Psme2 proteasome (prosome, macropain) activator subunit 2 2.59 5.41E-08 
Muc15 mucin 15, cell surface associated 2.59 1.73E-07 
Zc3h12a zinc finger CCCH type containing 12A  2.58 3.03E-05 
Sec14l4 SEC14-like 4 (S. cerevisiae)  2.57 4.31E-07 
Fyb FYN binding protein 2.55 2.60E-04 
Cxcl2 chemokine (C-X-C motif) ligand 2 2.55 2.18E-03 
Sla src-like adaptor   2.55 1.98E-03 
Itgax integrin, alpha X 2.54 9.34E-05 
Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1  2.49 3.09E-03 
LOC688318 similar to leucine rich repeat containing 45 2.48 8.98E-05 
Osmr oncostatin M receptor  2.47 8.88E-08 
Clec2g C-type lectin domain family 2, member G 2.47 2.36E-04 
LOC691141 hypothetical protein LOC691141  2.47 1.65E-04 
LOC688318 similar to leucine rich repeat containing 45 2.47 2.97E-04 
Piezo1 piezo-type mechanosensitive ion channel component 1  2.47 2.78E-04 
Ifitm3 interferon induced transmembrane protein 3 2.45 8.34E-08 
Clec4e C-type lectin domain family 4, member E  2.44 4.10E-04 
Casp7 caspase 7  2.42 3.40E-09 
Rarres2 retinoic acid receptor responder (tazarotene induced) 2  2.41 9.78E-05 
Epsti1 epithelial stromal interaction 1 (breast) 2.40 1.17E-04 
Slamf8 SLAM family member 8  2.40 2.57E-08 
Aif1 allograft inflammatory factor 1  2.39 8.01E-04 
Cd80 Cd80 molecule 2.38 9.20E-05 
Tf transferrin  2.37 1.81E-05 
Trim34 tripartite motif-containing 34 2.36 2.23E-06 
Zc3hav1 zinc finger CCCH type, antiviral 1  2.36 3.99E-06 
Trem3 triggering receptor expressed on myeloid cells 3 2.32 1.55E-03 
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Lsp1 lymphocyte-specific protein 1  2.32 1.45E-04 
Rhoh ras homolog family member H  2.32 7.71E-04 
Ifitm2 interferon induced transmembrane protein 2  2.31 3.04E-05 
Tlr2 toll-like receptor 2 2.31 2.35E-04 
Rnf125 ring finger protein 125  2.31 2.40E-03 
Aoah acyloxyacyl hydrolase (neutrophil)  2.31 1.47E-04 
Igsf6 immunoglobulin superfamily, member 6  2.29 9.78E-04 
Stx11 syntaxin 11  2.28 2.83E-03 
Cst7 cystatin F (leukocystatin)  2.28 1.47E-07 
Cyba cytochrome b-245, alpha polypeptide  2.26 4.35E-05 
Capg capping protein (actin filament), gelsolin-like  2.26 5.70E-04 
Slc12a7 solute carrier family 12 (potassium/chloride transporters) 2.25 2.06E-05 
Mrc2 mannose receptor, C type 2 2.25 1.69E-05 
Selplg selectin P ligand 2.25 7.85E-04 
Tor1b torsin family 1, member B  2.23 4.36E-06 
Clec4a3 C-type lectin domain family 4, member A3 2.23 2.71E-03 
Sh2d1b SH2 domain containing 1B  2.23 1.82E-04 
Pla2g16 phospholipase A2, group XVI  2.22 8.93E-05 
Anxa4 annexin A4 2.22 8.34E-08 
Exoc3l4 exocyst complex component 3-like 4   2.21 5.89E-07 
Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B- 2.21 5.32E-04 
Nlrp1a NLR family, pyrin domain containing 1A   2.21 1.82E-04 
Tnfrsf1b tumor necrosis factor receptor superfamily, member 1b  2.20 1.25E-04 
Mybphl myosin binding protein H-like  2.18 8.20E-04 
Batf2 basic leucine zipper transcription factor, ATF-like 2 2.18 4.91E-05 
Ifi27 interferon, alpha-inducible protein 27  2.16 1.69E-05 
LOC688318 similar to leucine rich repeat containing 45  2.16 7.18E-07 
Il13ra1 interleukin 13 receptor, alpha 1  2.16 2.82E-07 
Fbxw17 F-box and WD-40 domain protein 17  2.15 4.75E-07 
Rnase9 ribonuclease, RNase A family, 9 (non-active) 2.15 2.23E-03 
Parp10 poly (ADP-ribose) polymerase family, member 10  2.15 5.50E-06 
Psme1 proteasome (prosome, macropain) activator subunit 1  2.14 1.92E-07 
LOC498276 Fc gamma receptor II beta 2.14 5.41E-04 
LOC681325 hypothetical protein LOC681325  2.14 3.59E-05 
Xdh xanthine dehydrogenase  2.13 4.29E-05 
LOC691221 similar to CG1998-PA  2.13 6.36E-06 
Cyp4v3 cytochrome P450, family 4, subfamily v, polypeptide 3  2.11 6.86E-05 
Slc7a7 solute carrier family 7 (amino acid transporter light chain, y+L  2.11 9.41E-04 
LOC100912449 protein FAM115C-like  2.08 3.79E-05 
Trpm2 transient receptor potential cation channel, subfamily M 2.08 1.44E-04 
Il7 interleukin 7  2.06 4.00E-05 
Lif leukemia inhibitory factor 2.05 2.32E-03 
Sgms2 sphingomyelin synthase 2  2.05 2.15E-03 
Lst1 leukocyte specific transcript 1  2.04 1.33E-03 
LOC688318 similar to leucine rich repeat containing 45 2.03 9.62E-05 
Tspo translocator protein  2.03 1.71E-05 
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Il13ra1 interleukin 13 receptor, alpha 1  2.02 3.62E-06 
Chi3l1 chitinase 3-like 1 (cartilage glycoprotein-39)  2.01 1.12E-05 
Cdc42ep5 CDC42 effector protein (Rho GTPase binding) 5 2.01 1.30E-05 
Vamp5 vesicle-associated membrane protein 5  2.01 7.06E-09 
Bcl2a1 BCL2-related protein A1  2.01 1.34E-04 
Tmem140 transmembrane protein 140  2.00 9.99E-05 
Il4r interleukin 4 receptor  2.00 2.51E-04 
Slc15a3 solute carrier family 15, member 3  2.00 1.51E-03 
Fcgr1a Fc fragment of IgG, high affinity Ia, receptor (CD64)  1.99 2.67E-03 
Hk3 hexokinase 3 (white cell) 1.99 3.52E-03 
Dennd3 DENN/MADD domain containing 3  1.99 5.28E-04 
Cp ceruloplasmin (ferroxidase) 1.98 1.61E-09 
Fmo5 flavin containing monooxygenase 5  1.98 1.24E-05 
Rhbg Rh family, B glycoprotein  1.97 3.05E-04 
Stard5 StAR-related lipid transfer (START) domain containing 5  1.97 3.06E-06 
Pnp purine nucleoside phosphorylase  1.97 3.77E-07 
Fcer1g Fc fragment of IgE, high affinity I, receptor for; gamma polypept 1.96 2.43E-04 
Timp1 TIMP metallopeptidase inhibitor 1  1.96 1.35E-05 
Ubd ubiquitin D  1.96 5.66E-04 
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N  1.96 6.24E-05 
Slco4a1 solute carrier organic anion transporter family, member 4a1  1.95 3.21E-05 
Trib1 tribbles homolog 1 (Drosophila) 1.95 2.47E-03 
Parm1 prostate androgen-regulated mucin-like protein 1 1.95 1.02E-05 
Batf3 basic leucine zipper transcription factor, ATF-like 3  1.95 4.67E-04 
Cd97 CD97 molecule 1.95 1.32E-04 
Bicc1 bicaudal C homolog 1 (Drosophila)  1.94 1.99E-06 
Pter phosphotriesterase related  1.94 6.91E-07 
Arhgap8 Rho GTPase activating protein 8 1.93 2.77E-04 
Cd68 Cd68 molecule  1.93 1.70E-03 
Pgf placental growth factor  1.93 1.86E-03 
Cmklr1 chemokine-like receptor 1  1.92 4.77E-04 
Klrk1 killer cell lectin-like receptor subfamily K, member 1 1.92 4.64E-04 
C1qtnf1 C1q and tumor necrosis factor related protein 1  1.92 8.74E-05 
Il10 interleukin 10  1.91 3.90E-05 
Flt3l FMS-like tyrosine kinase 3 ligand  1.91 3.16E-06 
Slc2a9 solute carrier family 2 (facilitated glucose transporter), me 1.89 2.40E-04 
Ascc3 activating signal cointegrator 1 complex subunit 3 1.89 1.68E-05 
LOC688318 similar to leucine rich repeat containing 45 1.89 5.90E-04 
LOC689499 similar to Y97E10AL.1  1.88 5.90E-04 
Ccr5 chemokine (C-C motif) receptor 5  1.88 1.18E-04 
Parp3 poly (ADP-ribose) polymerase family, member 3 1.88 5.90E-06 
Mocos molybdenum cofactor sulfurase 1.88 4.52E-04 
Aida axin interactor, dorsalization associated 1.88 4.70E-07 
Psmf1 proteasome (prosome, macropain) inhibitor subunit 1 1.86 7.90E-07 
Ddit3 DNA-damage inducible transcript 3  1.86 8.13E-06 
Lilrc2 leukocyte immunoglobulin-like receptor, subfamily C, member 2 1.85 2.24E-04 
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LOC686120 hypothetical protein LOC686120  1.85 1.02E-04 
LOC686120 hypothetical protein LOC686120  1.85 1.02E-04 
LOC688318 similar to leucine rich repeat containing 45  1.84 4.28E-04 
Ifi204 interferon activated gene 204  1.83 1.38E-04 
Ikbke inhibitor of kappa light polypeptide gene enhancer in B-cells, 1.82 1.61E-04 
Slc22a18 solute carrier family 22, member 18  1.82 1.28E-03 
Cdk2ap2 cyclin-dependent kinase 2 associated protein 2 1.82 4.21E-05 
Map3k8 mitogen-activated protein kinase kinase kinase 8 1.81 1.32E-03 
Trim5 tripartite motif-containing 5  1.81 5.10E-05 
Plin2 perilipin 2 1.80 7.92E-04 
LOC688318 similar to leucine rich repeat containing 45  1.79 2.09E-05 
RGD1304982 similar to RIKEN cDNA 2810025M15  1.79 5.25E-05 
Lyz2 lysozyme 2  1.79 1.55E-04 
Batf basic leucine zipper transcription factor, ATF-like  1.78 9.77E-04 
Vamp8 vesicle-associated membrane protein 8 1.78 3.48E-06 
Dbx2 developing brain homeobox 2  1.78 3.53E-05 
Tmco4 transmembrane and coiled-coil domains 4  1.78 2.81E-04 
Csf1 colony stimulating factor 1 (macrophage) 1.78 9.70E-05 
Rnf114 ring finger protein 114  1.78 5.52E-09 
Tmem173 transmembrane protein 173  1.77 2.49E-03 
Rgs1 regulator of G-protein signaling 1  1.77 1.07E-03 
Pdlim1 PDZ and LIM domain 1  1.76 7.73E-04 
Casp8 caspase 8 1.75 1.22E-05 
Pnpt1 polyribonucleotide nucleotidyltransferase 1 1.75 1.07E-06 
Rab13 RAB13, member RAS oncogene family 1.75 8.41E-05 
RT1-CE15 RT1 class I, locus CE15 1.74 4.88E-04 
Tubb6 tubulin, beta 6 class V 1.72 7.55E-06 
Slc7a3 solute carrier family 7 (cationic amino acid transporte 1.72 5.34E-04 
Plxnd1 plexin D1  1.72 3.59E-05 
LOC688318 similar to leucine rich repeat containing 45  1.71 4.06E-04 
Tagln2 transgelin 2  1.71 2.31E-04 
Atp13a1 ATPase type 13A1 1.70 7.73E-07 
Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 1.70 5.02E-06 
Gsdmd gasdermin D  1.70 4.91E-08 
Clic4 chloride intracellular channel 4 1.70 3.02E-08 
LOC688318 similar to leucine rich repeat containing 45 1.69 4.66E-06 
Hpx hemopexin  1.68 1.08E-03 
Atp10a ATPase, class V, type 10A 1.68 3.26E-05 
Trim69 tripartite motif-containing 69  1.68 1.04E-03 
Hfe hemochromatosis 1.67 6.64E-08 
Frmpd1 FERM and PDZ domain containing 1  1.67 3.44E-03 
Rtp3 receptor (chemosensory) transporter protein 3 1.67 6.85E-05 
Rab19 RAB19, member RAS oncogene family  1.67 7.48E-05 
Isoc2b isochorismatase domain containing 2b  1.67 2.42E-04 
Rnasel ribonuclease L (2',5'-oligoisoadenylate synthetase-depe 1.66 2.51E-04 
Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B-c 1.66 2.89E-04 
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RGD1561157 RGD1561157  1.66 8.32E-04 
RT1-DMa RT1 class II, locus DMa 1.65 6.72E-04 
LOC688318 similar to leucine rich repeat containing 45 1.65 1.44E-04 
Chadl chondroadherin-like 1.65 2.97E-05 
Nod1 nucleotide-binding oligomerization domain containing 1  1.65 1.90E-04 
LOC685289 similar to paired immunoglobin-like type 2 receptor beta  1.64 1.81E-03 
Usp25 ubiquitin specific peptidase 25 1.64 8.79E-06 
LOC688318 similar to leucine rich repeat containing 45  1.63 3.12E-04 
Fam49a family with sequence similarity 49, member A 1.62 3.06E-06 
Mst1r macrophage stimulating 1 receptor (c-met-related tyrosine kina 1.62 1.27E-04 
Clic1 chloride intracellular channel 1  1.61 3.78E-05 
Irak3 interleukin-1 receptor-associated kinase 3 1.61 5.13E-04 
Ms4a4a membrane-spanning 4-domains, subfamily A, member 4A  1.61 2.91E-03 
Nr1h3 nuclear receptor subfamily 1, group H, member 3 1.60 1.34E-03 
AA926063 AA926063gene  1.60 1.24E-03 
LOC680923 similar to paired immunoglobin-like type 2 receptor beta  1.60 3.05E-06 
LOC688318 similar to leucine rich repeat containing 45 1.59 1.00E-03 
Tnip1 TNFAIP3 interacting protein 1  1.59 1.82E-04 
Fkbp11 FK506 binding protein 11 1.59 8.17E-04 
Eci3 enoyl-Coenzyme A delta isomerase 3 1.59 1.67E-03 
Bace2 beta-site APP-cleaving enzyme 2 1.58 2.41E-04 
Irak2 interleukin-1 receptor-associated kinase 2 1.58 2.57E-03 
LOC100910979 interferon-inducible GTPase 1-like  1.58 8.40E-04 
Rsl1 regulator of sex limited protein 1  1.58 1.63E-04 
Cnksr1 connector enhancer of kinase suppressor of Ras 1  1.58 1.92E-03 
Aldh1l2 aldehyde dehydrogenase 1 family, member L2  1.57 2.36E-04 
Pdpn podoplanin  1.57 2.32E-04 
Creb3l1 cAMP responsive element binding protein 3-like 1 1.56 7.17E-04 
Iah1 isoamyl acetate-hydrolyzing esterase 1 homolog (S. cerevisiae) 1.56 5.78E-06 
Erap1 endoplasmic reticulum aminopeptidase 1  1.56 3.12E-07 
Ogfr opioid growth factor receptor 1.56 3.21E-08 
Lgals3 lectin, galactoside-binding, soluble, 3  1.55 3.61E-04 
Pcsk1 proprotein convertase subtilisin/kexin type 1 1.55 1.25E-04 
Adar adenosine deaminase, RNA-specific  1.55 6.84E-05 
Rgs16 regulator of G-protein signaling 16  1.54 3.46E-05 
Trpv2 
transient receptor potential cation channel, subfamily V, member 
2 
1.54 2.02E-03 
Cxcr5 chemokine (C-X-C motif) receptor 5 1.54 2.08E-04 
Tpm3 tropomyosin 3 1.54 6.41E-05 
Agmo alkylglycerol monooxygenase 1.53 3.35E-03 
Lpcat3 lysophosphatidylcholine acyltransferase 3 1.53 7.56E-05 
Stxbp2 syntaxin binding protein 2  1.53 1.23E-03 
Tdrd7 tudor domain containing 7  1.53 4.66E-04 
Rnaset2 ribonuclease T2  1.53 2.18E-04 
Slc7a1 solute carrier family 7 (cationic amino acid transporter, y+ sys 1.52 9.67E-04 
Mertk c-mer proto-oncogene tyrosine kinase  1.52 1.00E-05 
Rab20 RAB20, member RAS oncogene family 1.52 1.24E-03 
161 
 
Mylk myosin light chain kinase  1.52 1.14E-05 
P2rx4 purinergic receptor P2X, ligand-gated ion channel 4  1.51 1.07E-03 
Sertad1 SERTA domain containing 1  1.51 1.70E-03 
Vasp vasodilator-stimulated phosphoprotein 1.51 1.34E-03 
LOC688318 similar to leucine rich repeat containing 45 1.51 4.35E-04 
Gch1 GTP cyclohydrolase 1  1.50 5.17E-04 
Msn moesin 1.49 5.56E-04 
Nradd neurotrophin receptor associated death domain 1.49 1.48E-03 
LOC688318 similar to leucine rich repeat containing 45  1.49 4.64E-06 
Ifngr2 interferon gamma receptor 2 1.49 1.38E-06 
Dok1 docking protein 1 1.49 1.41E-04 
Aldh3b1 aldehyde dehydrogenase 3 family, member B1 1.49 3.16E-03 
Myd88 myeloid differentiation primary response 88  1.48 2.95E-04 
Fkbp5 FK506 binding protein 5 1.48 1.17E-04 
Grn granulin  1.48 9.66E-05 
Shc1 SHC (Src homology 2 domain containing) transforming protein 1  1.48 2.16E-04 
Tmem243 transmembrane protein 243, mitochondrial 1.48 3.37E-07 
Serpinb9 serpin peptidase inhibitor, clade B (ovalbumin), member 9 1.47 2.04E-03 
LOC688318 similar to leucine rich repeat containing 45 1.47 5.97E-04 
Hsh2d hematopoietic SH2 domain containing  1.47 5.44E-06 
Mfsd2a major facilitator superfamily domain containing 2A  1.47 1.72E-03 
Cd1d1 CD1d1 molecule  1.47 4.27E-04 
Daxx death-domain associated protein 1.46 4.25E-06 
Slc35d2 solute carrier family 35, member D2 1.46 2.19E-03 
Slc50a1 solute carrier family 50 (sugar transporter), member 1  1.46 7.53E-07 
S1pr3 sphingosine-1-phosphate receptor 3  1.45 1.11E-04 
Ptk2b protein tyrosine kinase 2 beta 1.45 1.13E-04 
Ctsh cathepsin H 1.45 1.67E-05 
Tmem63a transmembrane protein 63a 1.45 2.67E-03 
Bak1 BCL2-antagonist/killer 1  1.45 7.60E-04 
Dnajc25 DnaJ (Hsp40) homolog, subfamily C, member 25  1.45 2.41E-04 
Anxa1 annexin A1  1.45 3.73E-04 
Mina myc induced nuclear antigen 1.45 3.01E-03 
Mad2l1bp MAD2L1 binding protein  1.44 1.36E-04 
B4galt1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1.44 1.55E-03 
Slc16a1 
solute carrier family 16, member 1 (monocarboxylic acid 
transporte 
1.43 3.26E-04 
Enpp4  ectonucleotide pyrophosphatase/phosphodiesterase 4  1.43 3.50E-06 
H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 1.43 3.13E-03 
Gda guanine deaminase 1.43 2.49E-03 
Fgfrl1 fibroblast growth factor receptor-like 1  1.43 3.85E-04 
Slc25a39 solute carrier family 25, member 39  1.43 6.82E-04 
Plscr1 phospholipid scramblase 1  1.42 2.91E-03 
Spats2l spermatogenesis associated, serine-rich 2-like  1.42 3.87E-05 
Prcp  prolylcarboxypeptidase (angiotensinase C)  1.42 4.33E-05 
Vamp3 vesicle-associated membrane protein 3  1.42 1.16E-05 
Ece1 endothelin converting enzyme 1 1.42 2.82E-08 
162 
 
Jag1 jagged 1  1.42 1.86E-04 
Mgmt O-6-methylguanine-DNA methyltransferase  1.42 1.49E-03 
Ephx1 epoxide hydrolase 1, microsomal (xenobiotic)  1.41 1.53E-03 
Il10rb interleukin 10 receptor, beta  1.41 9.06E-05 
RT1-CE10 RT1 class I, locus CE10 1.41 6.60E-04 
Sectm1b secreted and transmembrane 1B  1.41 1.54E-04 
Coro1b coronin, actin-binding protein, 1B 1.41 5.78E-05 
Litaf lipopolysaccharide-induced TNF factor  1.40 1.10E-04 
Ethe1 ethylmalonic encephalopathy 1 1.40 2.09E-03 
Eqtn equatorin, sperm acrosome associated  -1.40 3.91E-04 
LOC688318 similar to leucine rich repeat containing 45  -1.40 9.59E-04 
Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2 -1.40 1.51E-04 
PCDH8 PCDH8  -1.41 3.39E-04 
Smoc1 
FQ222878 // Smoc1 // SPARC related modular calcium binding 1 // 
6q24 // 314280 ///  
-1.41 1.26E-04 
Notch2 notch 2  -1.41 2.65E-05 
Cav2 caveolin 2  -1.41 8.37E-04 
Hrsp12 heat-responsive protein 12  -1.41 8.06E-08 
Dgcr8 DiGeorge syndrome critical region gene 8 -1.41 3.56E-03 
Thsd7b thrombospondin, type I, domain containing 7B  -1.41 3.39E-03 
Tst thiosulfate sulfurtransferase  -1.41 2.29E-04 
Gabrg1 gamma-aminobutyric acid (GABA) A receptor, gamma 1  -1.41 1.15E-04 
Fat3 FAT atypical cadherin 3 -1.41 6.86E-04 
RGD1563159 RGD1563159  -1.41 3.12E-03 
Ttpa tocopherol (alpha) transfer protein  -1.41 8.21E-04 
Tenm3 teneurin transmembrane protein 3  -1.41 1.69E-04 
Clcn4 chloride channel, voltage-sensitive 4  -1.41 1.17E-03 
Kndc1 kinase non-catalytic C-lobe domain (KIND) containing 1 -1.42 1.95E-04 
Nme3 NME/NM23 nucleoside diphosphate kinase 3  -1.42 1.15E-04 
LOC100363155 HAUS augmin-like complex, subunit 4-like  -1.42 4.03E-04 
Htr3a 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic  -1.42 2.78E-03 
Cdh20 cadherin 20 -1.43 1.03E-04 
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase)  -1.43 2.06E-06 
Slc38a3 solute carrier family 38, member 3  -1.43 1.64E-03 
Pdgfrb platelet derived growth factor receptor, beta polypeptide  -1.43 1.89E-04 
Gstt3 glutathione S-transferase, theta 3  -1.43 1.08E-04 
Glud1 glutamate dehydrogenase 1  -1.43 3.23E-06 
Fbxo2 F-box protein 2 -1.44 1.26E-05 
Cav2 caveolin 2  -1.44 7.37E-05 
Slc6a11 solute carrier family 6 (neurotransmitter transporter, -1.44 1.03E-03 
Parvb parvin, beta  -1.44 3.82E-05 
Enox1 ecto-NOX disulfide-thiol exchanger 1  -1.45 3.54E-04 
Nckap5 NCK-associated protein 5  -1.45 1.11E-04 
Rgs13 regulator of G-protein signaling 13 -1.45 3.48E-04 
Plxnb3 plexin B3  -1.45 1.22E-04 
Mmd2 monocyte to macrophage differentiation-associated 2 -1.45 8.01E-05 
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Ndp Norrie disease (pseudoglioma)  -1.45 1.19E-05 
Frem1 Fras1 related extracellular matrix 1  -1.45 2.07E-03 
Pcdhb6 protocadherin beta 6  -1.45 1.18E-03 
Nog noggin  -1.46 4.26E-04 
Dnai1 dynein, axonemal, intermediate chain 1 -1.46 2.70E-03 
RGD1564308 similar to LOC495042 protein -1.46 7.05E-05 
Metrn meteorin, glial cell differentiation regulator  -1.47 3.24E-05 
Lrp4 low density lipoprotein receptor-related protein 4  -1.48 2.14E-04 
Mfge8 milk fat globule-EGF factor 8 protein -1.48 2.67E-04 
Kcne1l KCNE1-like  -1.48 2.75E-04 
Dnah9 dynein, axonemal, heavy polypeptide 9 -1.49 4.81E-04 
Zswim2 zinc finger, SWIM-type containing 2 -1.49 3.20E-05 
Scrg1 stimulator of chondrogenesis 1  -1.49 1.11E-06 
Sox5l1 SRY-box containing gene 5-like 1 -1.49 8.82E-04 
Dnah9 dynein, axonemal, heavy polypeptide 9  -1.49 8.78E-04 
Ago3 argonaute RISC catalytic component 3  -1.50 6.12E-05 
Celsr2 cadherin, EGF LAG seven-pass G-type receptor 2  -1.50 3.11E-04 
5031425E22Rik RIKEN cDNA 5031425E22 gene  -1.51 1.27E-03 
Ramp1 receptor (G protein-coupled) activity modifying protein 1  -1.51 2.14E-03 
Folh1 folate hydrolase 1 -1.51 1.41E-04 
Id4 inhibitor of DNA binding 4  -1.52 4.04E-05 
Gpld1 glycosylphosphatidylinositol specific phospholipase D1  -1.52 3.62E-05 
Lpar4 lysophosphatidic acid receptor 4 -1.52 2.08E-05 
Mir568 microRNA mir-568  -1.52 5.93E-04 
Lair1 leukocyte-associated immunoglobulin-like receptor 1 -1.52 1.70E-03 
Ms4a14 membrane-spanning 4-domains, subfamily A, member 14 -1.53 3.55E-04 
Mreg melanoregulin  -1.53 1.37E-03 
Cldn9 claudin 9  -1.54 9.51E-05 
Kcnb2 
M77482 // Kcnb2 // potassium voltage gated channel, Shab-
related subfamily, member 2 // 
-1.54 4.65E-04 
Abhd3 abhydrolase domain containing 3  -1.54 2.76E-04 
Zbtb20 zinc finger and BTB domain containing 20  -1.54 5.06E-04 
Aamdc adipogenesis associated, Mth938 domain containing -1.54 1.67E-05 
Btbd17 BTB (POZ) domain containing 17  -1.55 4.58E-04 
Gabrb1 gamma-aminobutyric acid (GABA) A receptor, beta 1  -1.55 1.53E-04 
Krtap3-3 keratin associated protein 3-3  -1.55 7.61E-04 
Ntn4 netrin 4 -1.56 7.01E-06 
Cd109 CD109 molecule -1.56 6.39E-04 
Smad9 SMAD family member 9  -1.56 2.87E-03 
Hes5 hairy and enhancer of split 5 (Drosophila)  -1.59 1.14E-03 
Slc15a2 solute carrier family 15 (H+/peptide transporter), member 2 // 1 -1.59 2.36E-05 
Dnah9 dynein, axonemal, heavy polypeptide 9 -1.59 5.66E-04 
Efemp1 EGF-containing fibulin-like extracellular matrix protein 1  -1.60 1.04E-03 
Dnah9 dynein, axonemal, heavy polypeptide 9 -1.60 2.95E-03 
Sorbs1 sorbin and SH3 domain containing 1  -1.61 1.30E-09 
Igsf1 immunoglobulin superfamily, member 1  -1.61 1.07E-04 
Veph1 ventricular zone expressed PH domain-containing 1  -1.61 6.10E-04 
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LOC688318 similar to leucine rich repeat containing 45  -1.62 2.70E-04 
Tril TLR4 interactor with leucine-rich repeats -1.63 1.30E-04 
LOC688318 similar to leucine rich repeat containing 45 -1.63 2.15E-03 
LOC100363035 LOC100363035 -1.64 2.65E-06 
C1ql1 complement component 1, q subcomponent-like 1 -1.64 2.72E-03 
Pdzrn3 PDZ domain containing RING finger 3 -1.65 8.01E-06 
LOC100909587 zinc finger protein 397-like  -1.66 1.02E-03 
Lrrc55 leucine rich repeat containing 55  -1.68 4.64E-04 
Ankfn1 ankyrin-repeat and fibronectin type III domain containing 1  -1.68 1.74E-04 
LOC685158 similar to CG8138-PA  -1.69 3.21E-03 
Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 -1.69 9.34E-07 
Notch3 notch 3  -1.70 1.17E-04 
Capn6 calpain 6  -1.71 3.74E-04 
Adamts9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 -1.72 2.94E-03 
Mir99a microRNA mir-99a -1.74 3.30E-03 
Scn7a sodium channel, voltage-gated, type VII, alpha -1.77 1.95E-05 
Slc26a3 solute carrier family 26, member 3  -1.78 1.63E-03 
Gmnc geminin coiled-coil domain containing  -1.78 3.70E-04 
Rlbp1 retinaldehyde binding protein 1  -1.78 4.84E-05 
Slco1c1 solute carrier organic anion transporter family, member 1c1  -1.79 1.10E-03 
Timp4 tissue inhibitor of metalloproteinase 4  -1.79 2.15E-03 
Rftn2 raftlin family member 2  -1.79 1.24E-05 
Lix1 Lix1 homolog (chicken) -1.79 4.38E-05 
Gfral GDNF family receptor alpha like  -1.81 2.22E-05 
Pla2g5 phospholipase A2, group V -1.81 1.82E-03 
LOC100363484 DNA-damage-inducible transcript 4-like protein-like  -1.82 6.20E-04 
Olr522 olfactory receptor 522 -1.84 7.35E-04 
Mfap3l microfibrillar-associated protein 3-like  -1.98 4.14E-06 
Fzd8 frizzled family receptor 8  -1.99 5.88E-05 
Aadat aminoadipate aminotransferase  -1.99 2.43E-04 
Aox1 aldehyde oxidase 1  -1.99 3.25E-04 
Fezf2 Fez family zinc finger 2 -2.01 2.12E-03 
Lrrc2 leucine rich repeat containing 2  -2.08 2.11E-05 
Nkain4 K+ transporting ATPase interacting 4 -2.10 1.04E-03 
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C  -2.11 1.78E-05 
Galp galanin-like peptide -2.12 6.78E-05 
Cldn19 claudin 19 -2.15 1.91E-05 
Ccl24 chemokine (C-C motif) ligand 24  -2.17 5.36E-04 
Fmo1 flavin containing monooxygenase 1  -2.24 1.80E-03 
Doc2g  double C2-like domains, gamma  -2.32 5.55E-04 
Tlr5 toll-like receptor 5  -2.44 1.89E-05 
Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B  -2.56 2.16E-05 
Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 -2.84 4.93E-07 
Stab1 stabilin 1  -3.08 2.76E-04 
Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 -3.20 4.70E-08 
Sucnr1 succinate receptor 1  -3.29 1.32E-06 
 
165 
 
8.1.2 Genes identified in serum only treated myelinating cultures 
Table 4.3.3a: Differentially expressed genes in serum alone treated myelinating 
cultures identified by Partek. These data show the fold change and significance of the 
entities that were upregulated ≥ 1.4 serum treated cultures in comparison to control 
cultures. Significance was calculated using one-way ANOVA. 
Gene Symbol Gene Name 
Fold 
Change 
p-value 
Lcn2 lipocalin 2  39.40 6.41E-10 
Cxcl11 chemokine (C-X-C motif) ligand 11  34.86 2.15E-09 
Ccl7 chemokine (C-C motif) ligand 7  28.72 2.89E-10 
Cxcl5 chemokine (C-X-C motif) ligand 5 27.14 1.95E-05 
Cxcl1 
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity 
23.12 1.69E-07 
LOC363060 similar to RIKEN cDNA 1600029D21  14.93 9.30E-07 
Cxcl9 chemokine (C-X-C motif) ligand 9 12.50 2.70E-08 
Serpine1 serpin peptidase inhibitor, clade E (nexin, plasminog 10.06 4.61E-07 
Cxcl2 chemokine (C-X-C motif) ligand 2  9.78 1.64E-06 
Cxcl10 chemokine (C-X-C motif) ligand 10  9.23 2.89E-04 
Trem1 triggering receptor expressed on myeloid cells 1 9.20 1.72E-05 
C3 complement component 3  8.92 5.49E-08 
Mx1 myxovirus (influenza virus) resistance 1 7.95 2.38E-05 
Ccl20 chemokine (C-C motif) ligand 20 7.86 1.07E-06 
Ass1 argininosuccinate synthase 1 7.63 9.18E-07 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 7.60 7.44E-05 
Gbp5 guanylate binding protein 5 7.53 5.06E-08 
Tgm1 transglutaminase 1 7.01 3.59E-07 
Ptx3 pentraxin 3, long  6.96 9.55E-06 
Il1rn interleukin 1 receptor antagonist  6.74 1.11E-07 
Slpi secretory leukocyte peptidase inhibitor 6.49 2.13E-04 
Bcl3 lymphoma 3  6.48 4.44E-06 
Sell selectin L 6.10 1.15E-03 
Ccl6 chemokine (C-C motif) ligand 6 5.88 7.46E-04 
Irf7 interferon regulatory factor 7  5.76 1.23E-05 
Zc3h12a zinc finger CCCH type containing 12A  5.60 1.35E-07 
Birc3 baculoviral IAP repeat-containing 3 5.36 2.76E-09 
Cd93 CD93 molecule  5.32 5.93E-07 
Tnfaip2 tumor necrosis factor, alpha-induced protein 2 5.21 4.11E-09 
Msr1 macrophage scavenger receptor 1  5.05 8.77E-06 
Ccl4 chemokine (C-C motif) ligand 4 5.05 1.58E-05 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 4.90 2.83E-04 
Apol9a apolipoprotein L 9a 4.80 3.40E-06 
Rbp1 retinol binding protein 1, cellular  4.80 2.15E-06 
Isg15 ISG15 ubiquitin-like modifier  4.71 2.15E-05 
Mmp9 matrix metallopeptidase 9 4.69 7.11E-03 
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N  4.69 3.18E-08 
Lgals9 lectin, galactoside-binding, soluble, 9 4.66 4.61E-06 
Ch25h cholesterol 25-hydroxylase  4.64 2.42E-05 
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Lif leukemia inhibitory factor  4.61 6.20E-06 
Lyve1 lymphatic vessel endothelial hyaluronan receptor 1  4.60 6.88E-05 
Usp18 ubiquitin specific peptidase 18  4.59 1.84E-04 
Ccl2 chemokine (C-C motif) ligand 2  4.57 2.09E-07 
Oasl 2'-5'-oligoadenylate synthetase-like 4.42 2.60E-04 
Orm1 orosomucoid 1 4.41 1.31E-06 
Ccl5 chemokine (C-C motif) ligand 5  4.40 1.45E-07 
Chi3l1 chitinase 3-like 1 (cartilage glycoprotein-39) 4.18 1.45E-08 
Cd14 CD14 molecule  4.15 2.11E-05 
LOC688318 similar to leucine rich repeat containing 45 4.09 2.79E-03 
Rab32 RAB32, member RAS oncogene family 4.07 3.92E-06 
Upp1 uridine phosphorylase 1 3.98 2.09E-06 
Tubb6 tubulin, beta 6 class V 3.97 1.17E-09 
Itgam integrin, alpha M 3.96 9.82E-04 
Akr1b8 aldo-keto reductase family 1, member B8 3.93 2.07E-03 
Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 3.90 1.81E-04 
Gldn gliomedin 3.84 1.01E-04 
Rsad2 radical S-adenosyl methionine domain containing 2 3.79 4.60E-03 
Il1r2 interleukin 1 receptor, type II 3.79 2.71E-03 
Isg20 interferon stimulated exonuclease gene 20 3.77 9.59E-05 
Pgf placental growth factor  3.74 7.41E-06 
Ifi27l2b interferon, alpha-inducible protein 27 like 2B 3.70 1.51E-06 
Cxcl16 chemokine (C-X-C motif) ligand 16  3.67 3.14E-08 
RT1-CE4 RT1 class I, locus CE4  3.65 3.46E-05 
Cd36 CD36 molecule (thrombospondin receptor) 3.63 1.30E-03 
Osmr oncostatin M receptor  3.61 3.05E-09 
Mpa2l macrophage activation 2 like  3.58 1.70E-05 
Psmb8 proteasome (prosome, macropain) subunit, beta type, 8  3.58 6.37E-07 
Fmo5 flavin containing monooxygenase 5 3.56 4.07E-08 
Gal GMAP prepropeptide 3.56 2.48E-05 
Tf transferrin  3.48 6.55E-07 
Sod2 superoxide dismutase 2, mitochondrial  3.48 3.58E-10 
Cxcl13 chemokine (C-X-C motif) ligand 13 3.45 1.17E-03 
Hrct1 histidine rich carboxyl terminus 1 3.43 8.26E-07 
Fosl1 fos-like antigen 1 3.34 1.09E-04 
Slfn3 schlafen 3 3.31 2.47E-03 
Psmb9 proteasome (prosome, macropain) subunit, beta type, 9 3.30 6.68E-07 
Casp12 caspase 12 3.29 4.51E-07 
Lsp1 lymphocyte-specific protein 1 3.23 8.81E-06 
Ccl3 chemokine (C-C motif) ligand 3 3.22 2.63E-03 
Fgr Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog 3.20 1.07E-06 
Clec4d C-type lectin domain family 4, member D 3.16 4.02E-04 
LOC685067 similar to guanylate binding protein family, member  3.11 1.29E-04 
Il17rb interleukin 17 receptor B  3.07 1.42E-05 
Ube2l6 ubiquitin-conjugating enzyme E2L 6  3.07 5.31E-07 
Oas2 2'-5' oligoadenylate synthetase 2 3.06 5.80E-05 
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Serping1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  3.05 8.20E-08 
Vsig4 V-set and immunoglobulin domain containing 4 3.03 1.07E-04 
Srgn serglycin 3.03 1.33E-03 
Clec4a2 C-type lectin domain family 4, member A2  3.03 5.13E-05 
Gda guanine deaminase 3.02 2.13E-07 
Piezo1 piezo-type mechanosensitive ion channel component 1 3.00 5.77E-05 
P4ha3 prolyl 4-hydroxylase, alpha polypeptide III 2.99 6.00E-06 
Il1a interleukin 1 alpha 2.99 1.30E-04 
Fndc3c1 fibronectin type III domain containing 3C1  2.98 4.55E-07 
RT1-CE12 RT1 class I, locus CE12  2.98 2.10E-06 
LOC688318 similar to leucine rich repeat containing 45 2.97 8.15E-07 
Vgf VGF nerve growth factor inducible 2.97 4.77E-05 
Spry4 sprouty homolog 4 (Drosophila) 2.96 1.97E-03 
Timp1 TIMP metallopeptidase inhibitor 1  2.93 1.87E-07 
Reg3b regenerating islet-derived 3 beta 2.91 1.21E-04 
Csf2rb colony stimulating factor 2 receptor, beta, low-affinit 2.90 5.32E-03 
Rgs1 regulator of G-protein signaling 1 2.88 7.45E-06 
Alpl alkaline phosphatase, liver/bone/kidney 2.86 3.31E-07 
Trib1 tribbles homolog 1 (Drosophila)  2.86 8.90E-05 
Ptgs1 prostaglandin-endoperoxide synthase 1 2.85 3.56E-04 
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 2.84 1.07E-03 
Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 2.84 6.24E-05 
Vcam1 vascular cell adhesion molecule 1  2.83 9.71E-07 
Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 2.82 1.77E-04 
Oas1b 2-5 oligoadenylate synthetase 1B 2.80 8.88E-04 
Uba7 ubiquitin-like modifier activating enzyme 7  2.79 2.99E-04 
Ccl12 chemokine (C-C motif) ligand 12  2.78 3.25E-04 
Itgax integrin, alpha X 2.76 4.68E-05 
LOC681182 similar to paired immunoglobin-like type 2 receptor beta 2.75 8.56E-04 
LOC688318 similar to leucine rich repeat containing 45 2.74 3.80E-05 
Serpinb2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.73 1.79E-04 
Itga8 integrin, alpha 8  2.72 5.30E-07 
Tuba1c tubulin, alpha 1C 2.71 7.94E-05 
Ier3 immediate early response 3  2.66 2.14E-04 
Stat5a signal transducer and activator of transcription 5A 2.63 1.69E-05 
Ripk3 receptor-interacting serine-threonine kinase 3 2.62 7.04E-04 
Oaf OAF homolog (Drosophila) 2.61 6.10E-06 
Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 2.60 1.66E-04 
Oas1i 2 ' -5 ' oligoadenylate synthetase 1I 2.58 3.43E-04 
Rab20 RAB20, member RAS oncogene family 2.56 1.56E-06 
Gda guanine deaminase 2.55 2.34E-07 
Tmem106a transmembrane protein 106A 2.55 1.40E-05 
Icam1 intercellular adhesion molecule 1  2.54 2.44E-06 
Rtp4 receptor (chemosensory) transporter protein 4 2.53 5.65E-05 
Dhrs9 dehydrogenase/reductase (SDR family) member 9  2.52 8.06E-05 
Rab27b RAB27B, member RAS oncogene family  2.52 4.36E-05 
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Rnf125 ring finger protein 125 2.52 1.23E-03 
Ms4a11 membrane-spanning 4-domains, subfamily A, member 11 2.50 2.14E-05 
Ido2 indoleamine 2,3-dioxygenase 2 2.50 2.08E-05 
Sp140 SP140 nuclear body protein  2.49 1.13E-06 
Pdlim1 PDZ and LIM domain 1  2.48 1.81E-05 
Dbx2 developing brain homeobox 2  2.47 6.35E-07 
Calcb calcitonin-related polypeptide, beta  2.47 7.56E-06 
Pram1 PML-RARA regulated adaptor molecule 1 2.45 6.52E-03 
Rgs16 regulator of G-protein signaling 16 2.45 4.56E-08 
Slc16a3 
solute carrier family 16, member 3 (monocarboxylic acid 
transporter) 
2.44 8.01E-05 
Shc4 SHC (Src homology 2 domain containing) family, member 4 2.43 7.52E-05 
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 2.43 9.91E-05 
Mmp3 matrix metallopeptidase 3  2.43 1.85E-03 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 2.42 6.60E-03 
Rdh5 retinol dehydrogenase 5 (11-cis/9-cis) 2.41 8.51E-06 
Parm1 prostate androgen-regulated mucin-like protein 1 2.41 8.51E-07 
Oasl2 2'-5' oligoadenylate synthetase-like 2 2.38 4.54E-04 
Tap1  transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2.37 5.51E-06 
Sox7 SRY (sex determining region Y)-box 7  2.37 1.81E-04 
Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B-cells 2.37 2.86E-04 
Fstl3 follistatin-like 3 (secreted glycoprotein)  2.36 3.34E-04 
Cdc42ep5 CDC42 effector protein (Rho GTPase binding) 5  2.36 2.01E-06 
Psmb10 proteasome (prosome, macropain) subunit, beta type 10  2.36 2.61E-05 
Phlda1 pleckstrin homology-like domain, family A, member 1 2.35 1.18E-03 
Cmpk2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 2.35 8.64E-04 
Cp ceruloplasmin (ferroxidase) 2.34 1.85E-10 
Eya2 eyes absent homolog 2 (Drosophila)  2.33 1.09E-07 
LOC689800 similar to osteoclast inhibitory lectin 2.33 9.26E-04 
C1r complement component 1, r subcomponent  2.31 5.91E-07 
Emp3 epithelial membrane protein 3 2.31 3.46E-04 
Cxcl17 chemokine (C-X-C motif) ligand 17 2.30 1.54E-04 
Slc26a2 solute carrier family 26 (sulfate transporter), member 2.29 1.39E-04 
Anxa1 annexin A1  2.29 3.50E-07 
Aldh1l2 aldehyde dehydrogenase 1 family, member L2 2.29 1.39E-06 
RT1-T24-3 RT1 class I, locus T24, gene 3 2.28 6.26E-05 
Galnt3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosam 
2.28 1.93E-05 
Ifih1 interferon induced with helicase C domain 1  2.27 4.50E-04 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 2.26 1.72E-07 
Sema3a 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted 
2.26 3.51E-06 
Sp100 SP100 nuclear antigen  2.26 7.39E-07 
Tap2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 2.25 2.03E-04 
Micall2 MICAL-like 2 2.25 1.39E-07 
Tapbp TAP binding protein (tapasin) 2.24 6.11E-06 
Nfkb2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2.24 1.62E-06 
Il18bp interleukin 18 binding protein  2.24 1.93E-04 
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Gsap gamma-secretase activating protein  2.23 4.11E-05 
Lgals3 lectin, galactoside-binding, soluble, 3  2.23 2.31E-06 
Lrrc15 leucine rich repeat containing 15  2.23 2.99E-06 
Slc2a9 solute carrier family 2 (facilitated glucose transporter), member 9 2.22 4.00E-05 
Clcf1 cardiotrophin-like cytokine factor 1  2.21 1.84E-03 
Ifi44 interferon-induced protein 44 2.21 8.68E-05 
Batf3 basic leucine zipper transcription factor, ATF-like 3  2.20 1.29E-04 
LOC688318 similar to leucine rich repeat containing 45 2.19 3.73E-05 
Il1b interleukin 1 beta 2.19 4.18E-04 
Mmp13 matrix metallopeptidase 13  2.19 5.12E-03 
Cd80 Cd80 molecule  2.19 2.07E-04 
Ifitm3 interferon induced transmembrane protein 3  2.18 3.25E-07 
Scimp SLP adaptor and CSK interacting membrane protein 2.17 3.33E-04 
Clic1 chloride intracellular channel 1  2.17 5.13E-07 
Parp12 poly (ADP-ribose) polymerase family, member 12 2.16 1.74E-04 
Hmga2 high mobility group AT-hook 2  2.15 6.09E-03 
Slc35d3 solute carrier family 35, member D3 2.14 5.37E-05 
Frmpd1 FERM and PDZ domain containing 1 2.14 2.11E-04 
S100a6 S100 calcium binding protein A6  2.14 4.71E-05 
Plp2 proteolipid protein 2 (colonic epithelium-enriched)  2.14 1.06E-04 
RT1-CE1 RT1 class I, locus1 2.13 6.66E-06 
Dennd3 DENN/MADD domain containing 3 2.13 2.61E-04 
Il13ra1 interleukin 13 receptor, alpha 1  2.12 3.55E-07 
Nyx nyctalopin // Xq12 // 302516 ///  2.11 2.74E-06 
RT1-S3 RT1 class Ib, locus S3 2.11 2.40E-04 
Junb jun B proto-oncogene  2.11 3.39E-04 
Rasl11a RAS-like family 11 member A  2.10 4.46E-05 
Irgm immunity-related GTPase family, M  2.10 2.59E-04 
Tagln2 transgelin 2  2.10 1.57E-05 
Tnfrsf12a tumor necrosis factor receptor superfamily, member 1 2.10 2.27E-04 
A3galt2 alpha 1,3-galactosyltransferase 2  2.10 4.76E-04 
Ccl24 chemokine (C-C motif) ligand 24 2.10 7.55E-04 
Il13ra1 interleukin 13 receptor, alpha 1  2.09 2.33E-06 
RGD1561113 similar to Hypothetical UPF0184 protein C9orf16 homolog 2.08 2.83E-06 
Hbegf heparin-binding EGF-like growth factor  2.08 2.87E-03 
Slc11a1 
solute carrier family 11 (proton-coupled divalent metal ion 
transporter), member 1 
2.07 2.54E-04 
LOC688318 similar to leucine rich repeat containing 45 2.07 2.99E-03 
LOC686151 similar to cell division cycle associated 5 2.07 2.13E-04 
Cckbr cholecystokinin B receptor  2.06 4.44E-04 
LOC691141 hypothetical protein LOC691141  2.06 8.84E-04 
Ripk2 receptor-interacting serine-threonine kinase 2 2.06 3.25E-06 
Slc16a1 
solute carrier family 16, member 1 (monocarboxylic acid 
transporter0, member 1 
2.06 8.62E-07 
Ckap2 cytoskeleton associated protein 2 2.05 1.56E-04 
Tgfb3 transforming growth factor, beta 3 2.05 8.10E-05 
Met met proto-oncogene 2.05 7.60E-06 
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Glb1l2 galactosidase, beta 1-like 2  2.05 1.83E-05 
Hectd2 ECT domain containing 2 2.04 7.24E-08 
Irak2 interleukin-1 receptor-associated kinase 2 2.03 1.08E-04 
Bicc1 bicaudal C homolog 1 (Drosophila) 2.03 1.15E-06 
Prg4 proteoglycan 4 2.02 3.78E-04 
Spry1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 2.02 1.29E-03 
LOC688318 similar to leucine rich repeat containing 45 2.00 2.16E-05 
Mybl2 myeloblastosis oncogene-like 2 2.00 2.57E-03 
Ttk Ttk protein kinase  2.00 8.84E-04 
Galp galanin-like peptide 2.00 1.28E-04 
Slfn13 schlafen family member 13  2.00 8.45E-08 
Trem3 triggering receptor expressed on myeloid cells 3 1.99 5.56E-03 
Fgfrl1 fibroblast growth factor receptor-like 1  1.99 1.44E-06 
Stat2 signal transducer and activator of transcription 2 1.99 9.56E-05 
Relb v-rel reticuloendotheliosis viral oncogene homolog B 1.99 7.35E-06 
Rin1 Ras and Rab interactor 1  1.98 5.32E-07 
Ifi27 interferon, alpha-inducible protein 27  1.98 4.67E-05 
P2ry6 pyrimidinergic receptor P2Y, G-protein coupled, 6  1.98 3.37E-03 
Nmi N-myc (and STAT) interactor  1.97 1.20E-05 
Il4r interleukin 4 receptor 1.97 2.87E-04 
Ppat phosphoribosyl pyrophosphate amidotransferase  1.97 1.77E-05 
Cdkn2b cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)  1.97 6.78E-05 
Eno3 enolase 3, beta, muscle  1.97 9.49E-04 
Mlf1ip MLF1 interacting protein  1.97 8.15E-04 
Shmt1 serine hydroxymethyltransferase 1 (soluble) 1.96 3.41E-04 
Mvp major vault protein  1.96 1.15E-06 
Mcm3 minichromosome maintenance complex component 3 1.95 1.69E-03 
Cd97  CD97 molecule  1.95 1.27E-04 
Dtl denticleless E3 ubiquitin protein ligase homolog (Drosophila) 1.94 7.58E-04 
Parp3 poly (ADP-ribose) polymerase family, member 3  1.94 3.89E-06 
Gli2 GLI family zinc finger 2  1.93 9.93E-06 
Uhrf1 ubiquitin-like with PHD and ring finger domains 1  1.91 4.49E-04 
Ier5l immediate early response 5-like 1.91 4.21E-05 
Aurkb aurora kinase B  1.91 4.82E-07 
Rmi2 RMI2, RecQ mediated genome instability 2, homolog (S. cerevisiae) 1.90 1.53E-05 
S100a4 S100 calcium-binding protein A4 1.90 8.84E-04 
Ccl19 chemokine (C-C motif) ligand 19 1.89 6.25E-03 
Slamf8 SLAM family member 8  1.89 5.16E-07 
Tuba8 tubulin, alpha 8 1.89 1.44E-04 
Etv5 ets variant 5  1.89 5.99E-05 
Extl1 exostosin-like glycosyltransferase 1 1.88 1.86E-04 
Gpr114 G protein-coupled receptor 114 1.88 3.86E-04 
Mocos molybdenum cofactor sulfurase  1.87 4.85E-04 
Znfx1 zinc finger, NFX1-type containing 1 1.86 1.66E-03 
Arsj arylsulfatase family, member J  1.86 5.07E-04 
Npy2r neuropeptide Y receptor Y2  1.86 6.00E-05 
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Irf9 interferon regulatory factor 9  1.85 6.46E-06 
Pnp purine nucleoside phosphorylase 1.85 9.20E-07 
Slc13a5 
solute carrier family 13 (sodium-dependent citrate transporter), 
member 
1.84 3.82E-05 
Rarres2 retinoic acid receptor responder (tazarotene induced) 2 1.84 1.48E-03 
Egln3 EGL nine homolog 3 (C. elegans)  1.84 6.26E-06 
Ly6e lymphocyte antigen 6 complex, locus E  1.84 1.61E-04 
RT1-CE5 RT1 class I, locus CE5 1.84 1.18E-03 
RT1-N3 RT1 class Ib, locus N3 1.84 1.15E-03 
Adck4 aarF domain containing kinase 4  1.84 1.06E-04 
Clec2d C-type lectin domain family 2, member D  1.83 9.75E-05 
Eci3 enoyl-Coenzyme A delta isomerase 3  1.83 2.31E-04 
Pric285 
peroxisomal proliferator-activated receptor A interacting complex 
285 
1.83 2.18E-03 
Vav3 vav 3 guanine nucleotide exchange factor 1.83 3.11E-06 
Cd274 CD274 molecule 1.82 8.27E-05 
Acy1 aminoacylase 1  1.82 2.81E-06 
Ppm1n protein phosphatase, Mg2+/Mn2+ dependent, 1N 1.82 1.37E-06 
Npm3 nucleophosmin/nucleoplasmin, 3 1.82 1.20E-05 
Dusp6 dual specificity phosphatase 6  1.82 1.70E-03 
Rgs8 regulator of G-protein signaling 8  1.81 8.87E-07 
Gas7 growth arrest specific 7 1.81 2.61E-03 
Mcm3 minichromosome maintenance complex component 3  1.81 7.60E-04 
Cdt1 chromatin licensing and DNA replication factor 1  1.80 1.06E-04 
Casp7 caspase 7  1.80 1.73E-07 
Ccdc74a coiled-coil domain containing 74A  1.80 1.69E-04 
Mybl1 myeloblastosis oncogene-like 1  1.80 3.90E-03 
Nab2 Ngfi-A binding protein 2  1.80 4.59E-06 
Nptxr neuronal pentraxin receptor 1.79 6.48E-06 
Tpx2 TPX2, microtubule-associated, homolog (Xenopus laevis)  1.79 5.34E-04 
Wdyhv1 WDYHV motif containing 1  1.79 1.18E-05 
Psme2 proteasome (prosome, macropain) activator subunit 2  1.79 5.16E-06 
Cdc6 cell division cycle 6  1.79 4.96E-04 
LOC498276 Fc gamma receptor II beta 1.78 3.57E-03 
Bub1 BUB1 mitotic checkpoint serine/threonine kinase  1.78 8.42E-04 
Sec14l4 SEC14-like 4 (S. cerevisiae) 1.77 3.77E-05 
LOC681325 hypothetical protein LOC681325  1.77 3.53E-04 
Npy2r neuropeptide Y receptor Y2  1.77 1.49E-04 
Socs2 suppressor of cytokine signaling 2  1.77 1.15E-03 
LOC688318 similar to leucine rich repeat containing 45 1.77 1.02E-04 
Ebi3 Epstein-Barr virus induced 3 1.77 5.04E-03 
Mir1949 microRNA mir-1949  1.77 5.15E-03 
Hmga1 high mobility group AT-hook 1 1.76 5.44E-05 
LOC100360619 ribosomal protein L28-like 1.76 1.11E-03 
Tagln transgelin  1.76 1.66E-03 
Ifitm2 interferon induced transmembrane protein 2  1.76 6.87E-04 
Tspo translocator protein  1.76 1.13E-04 
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Trip10 thyroid hormone receptor interactor 10 1.76 1.31E-04 
Chdh choline dehydrogenase  1.76 3.90E-05 
Mcm10 minichromosome maintenance complex component 10  1.76 7.88E-04 
Nes nestin  1.76 1.40E-05 
Sdf2l1 stromal cell-derived factor 2-like 1 1.76 2.17E-04 
Hk2 hexokinase 2 1.75 3.52E-03 
Ntn1 netrin 1  1.75 8.17E-04 
Cpne2 copine II  1.75 1.46E-05 
Tmem26 transmembrane protein 26 1.75 4.68E-03 
Dnph1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1  1.74 8.03E-04 
Pola2 polymerase (DNA directed), alpha 2, accessory subunit 1.74 2.48E-04 
Galr2 galanin receptor 2  1.74 1.52E-05 
Ifi35 interferon-induced protein 35 1.74 2.61E-04 
Ier2 immediate early response 2  1.74 4.51E-03 
Ucn2 NM_133385 // Ucn2 // urocortin 2 // 8q32 // 170896 1.73 1.37E-03 
Fam26e family with sequence similarity 26, member E 1.73 3.28E-03 
H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 1.73 1.47E-04 
Samd9l sterile alpha motif domain containing 9-like 1.73 9.51E-04 
Spc25 
SPC25, NDC80 kinetochore complex component, homolog (S. 
cerevisiae) 
1.72 1.37E-03 
Ehd2 EH-domain containing 2  1.72 2.51E-06 
Phf19 PHD finger protein 19 1.72 1.03E-04 
Slfn2 schlafen 2  1.72 1.98E-04 
Slamf9 SLAM family member 9  1.71 3.44E-04 
Myl12a myosin, light chain 12A, regulatory, non-sarcomeric 1.71 4.45E-05 
Hspa2 heat shock protein 2 1.71 7.16E-06 
Nradd neurotrophin receptor associated death domain 1.71 1.79E-04 
Pkp2 plakophilin 2 1.71 4.15E-04 
Slc5a3 
solute carrier family 5 (sodium/myo-inositol cotransporter), 
member 
1.71 1.27E-04 
Csf1 colony stimulating factor 1 (macrophage) 1.71 1.75E-04 
Tnip1 TNFAIP3 interacting protein 1 1.70 6.02E-05 
Ptpn9 protein tyrosine phosphatase, non-receptor type 9 1.70 3.71E-06 
Hjurp Holliday junction recognition protein  1.70 1.55E-03 
LOC100911280 vascular endothelial growth factor receptor 1-like 1.70 5.65E-03 
Mov10 Moloney leukemia virus 10  1.70 8.48E-06 
Slc39a8 solute carrier family 39 (zinc transporter), member 8  1.69 1.42E-05 
Hist1h1b histone cluster 1, H1b 1.69 2.44E-03 
Galnt4 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4 
1.69 3.22E-04 
LOC684193 similar to sterile alpha motif domain containing 9-like  1.69 4.74E-04 
Fbxw17 F-box and WD-40 domain protein 17  1.69 1.49E-05 
Kcnn3 
potassium intermediate/small conductance calcium-activated 
channel 
1.69 1.93E-04 
LOC100359563 ribosomal protein S20-like 1.69 3.54E-05 
Plcd3 phospholipase C, delta 3  1.69 3.93E-03 
Gss glutathione synthetase 1.68 5.05E-07 
Msn moesin 1.68 7.41E-05 
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Ece1 endothelin converting enzyme 1  1.68 5.93E-10 
Slc35d2 solute carrier family 35, member D2 1.68 2.25E-04 
Car13 carbonic anhydrase 13 1.68 1.33E-03 
Asgr1 asialoglycoprotein receptor 1 1.67 6.00E-03 
LOC688318 similar to leucine rich repeat containing 45 1.67 6.19E-05 
Ifi47 interferon gamma inducible protein 47  1.67 3.73E-05 
Casp1 caspase 1 1.67 1.80E-03 
Gtse1 G-2 and S-phase expressed 1 1.67 5.40E-05 
Kif22 kinesin family member 22  1.67 1.80E-03 
Lingo3 leucine rich repeat and Ig domain containing 3  1.67 1.67E-03 
Pdpn podoplanin  1.67 8.81E-05 
RGD1304982 similar to RIKEN cDNA 2810025M15 1.66 1.55E-04 
Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 1.66 1.48E-03 
Agpat9 1-acylglycerol-3-phosphate O-acyltransferase 9 1.66 3.96E-04 
LOC100359600 karyopherin alpha 2-like 1.65 6.05E-04 
Trim25 tripartite motif-containing 25 1.65 9.70E-05 
Mzt2b mitotic spindle organizing protein 2B  1.65 3.16E-06 
Pcsk1 proprotein convertase subtilisin/kexin type 1 1.65 4.47E-05 
Prrg4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane)  1.65 1.27E-03 
Tapbpl TAP binding protein-like 1.64 1.06E-03 
Tmem100 transmembrane protein 100  1.64 3.48E-04 
Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1.64 3.46E-04 
Chtf18 
CTF18, chromosome transmission fidelity factor 18 homolog (S. 
Cerevisiae) 
1.64 1.56E-05 
Shmt2 serine hydroxymethyltransferase 2 (mitochondrial)  1.64 2.25E-06 
Slc25a39 solute carrier family 25, member 39 1.64 4.98E-05 
Ebpl emopamil binding protein-like 1.64 3.15E-04 
Nts neurotensin 1.64 5.36E-03 
Rras related RAS viral (r-ras) oncogene homolog 1.64 3.30E-06 
RGD1563065 similar to 3110047P20Rik protein 1.64 6.38E-04 
Birc2 baculoviral IAP repeat-containing 2 1.64 4.25E-05 
Nr1h3 nuclear receptor subfamily 1, group H, member 3 1.63 1.02E-03 
Gys1 glycogen synthase 1, muscle 1.63 4.81E-05 
Casp8 caspase 8  1.63 4.02E-05 
Slfn5 schlafen family member 5 1.63 7.17E-04 
Mcm6 minichromosome maintenance complex component 6  1.63 5.39E-03 
Kif18a kinesin family member 18A 1.63 5.68E-03 
Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 1.63 3.43E-03 
Mms22l MMS22-like, DNA repair protein 1.62 4.67E-03 
Creld2 cysteine-rich with EGF-like domains 2 1.62 1.44E-04 
Prdx5 peroxiredoxin 5  1.62 1.79E-04 
Ccnf cyclin F  1.62 4.73E-03 
Dio3 deiodinase, iodothyronine, type III 1.62 9.13E-04 
Bard1 BRCA1 associated RING domain 1  1.62 6.98E-03 
LOC681766 hypothetical protein LOC681766  1.61 1.40E-04 
Gadd45b growth arrest and DNA-damage-inducible, beta 1.61 9.52E-04 
Trip13 thyroid hormone receptor interactor 13  1.61 3.05E-05 
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Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3  1.61 1.04E-05 
Rad18 RAD18 homolog (S. cerevisiae)  1.61 1.31E-05 
Emp2 epithelial membrane protein 2  1.61 3.97E-03 
Myo1e myosin IE 1.61 2.07E-05 
Sertad1 SERTA domain containing 1 1.61 6.76E-04 
Tradd TNFRSF1A-associated via death domain 1.61 7.10E-04 
Tmem154 transmembrane protein 154  1.61 2.86E-03 
Slc44a5 solute carrier family 44, member 5 1.60 3.06E-05 
B4galt1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1.60 2.31E-04 
Ethe1 ethylmalonic encephalopathy 1  1.60 1.80E-04 
Gbp1 guanylate binding protein 1, interferon-inducible 1.60 3.82E-03 
Trex1 three prime repair exonuclease 1  1.60 1.33E-05 
Fsip1 fibrous sheath interacting protein 1  1.60 3.04E-05 
Serinc2 serine incorporator 2  1.60 1.16E-03 
Cmklr1 chemokine-like receptor 1 1.60 4.54E-03 
RGD1565054 similar to 60S acidic ribosomal protein P1  1.60 5.34E-03 
Scp2 sterol carrier protein 2 1.60 3.11E-04 
F3 coagulation factor III (thromboplastin, tissue factor)  1.59 9.42E-05 
Ikbke 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase epsilon 
1.59 1.09E-03 
Kcnf1 potassium voltage-gated channel, subfamily F, member 1 1.59 1.35E-03 
LOC303566 E2F1-inducible gene  1.59 2.89E-03 
Stard5 StAR-related lipid transfer (START) domain containing 5 1.59 8.53E-05 
Plin2 perilipin 2 1.59 3.98E-03 
Trmt61a tRNA methyltransferase 61 homolog A (S. cerevisiae) 1.59 4.25E-05 
Anxa4 annexin A4  1.59 1.29E-05 
RT1-CE15 RT1 class I, locus CE15  1.58 1.77E-03 
Nfkbie nuclear factor of kappa light polypeptide gene enhancer in B-cell 1.58 1.08E-05 
Tecta tectorin alpha 1.58 1.36E-03 
Hist1h2ao histone cluster 1, H2ao  1.58 6.01E-03 
LOC688318 similar to leucine rich repeat containing 45 1.58 7.10E-04 
Chst11 carbohydrate (chondroitin 4) sulfotransferase 11  1.58 2.27E-05 
Pak1ip1 PAK1 interacting protein 1  1.58 3.70E-03 
Rangrf RAN guanine nucleotide release factor 1.58 2.72E-04 
LOC685108 similar to proteolipid protein 2  1.58 1.77E-03 
Socs1 suppressor of cytokine signaling 1 1.57 3.62E-03 
Cenpm centromere protein M  1.57 8.42E-04 
Creb3l1 cAMP responsive element binding protein 3-like 1  1.57 6.54E-04 
Poc1b POC1 centriolar protein homolog B (Chlamydomonas)  1.57 6.07E-04 
Cdc45 cell division cycle 45 1.57 6.64E-04 
Phlda3 pleckstrin homology-like domain, family A, member 3 1.57 2.89E-04 
Fam49a family with sequence similarity 49, member A 1.57 6.22E-06 
Dyrk3 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3  1.57 1.58E-03 
Slc7a8 
solute carrier family 7 (amino acid transporter light chain, L 
system), member 8 
1.56 8.57E-05 
Axl Axl receptor tyrosine kinase 1.56 1.47E-05 
Trim34 tripartite motif-containing 34 1.56 5.55E-04 
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Trim21 tripartite motif-containing 21  1.56 4.12E-04 
LOC688318 similar to leucine rich repeat containing 45 1.55 3.01E-04 
Ap1s1 adaptor-related protein complex 1, sigma 1 subunit 1.55 9.16E-07 
Layn layilin 1.55 1.70E-03 
Itpkb inositol-trisphosphate 3-kinase B  1.55 3.95E-05 
Sowahc sosondowah ankyrin repeat domain family member C 1.55 1.04E-05 
RGD1564552 similar to ribosomal protein L21 1.55 5.88E-03 
Pno1 partner of NOB1 homolog (S. cerevisiae)  1.55 1.14E-05 
Pycard PYD and CARD domain containing  1.55 1.37E-04 
S1pr3 sphingosine-1-phosphate receptor 3 1.54 3.18E-05 
Arhgap18 Rho GTPase activating protein 18 1.54 3.92E-05 
Ubash3b ubiquitin associated and SH3 domain containing, B  1.54 2.13E-07 
LOC688318 similar to leucine rich repeat containing 45 1.54 2.63E-04 
Sema7a semaphorin 7A, GPI membrane anchor 1.54 1.94E-04 
Hopx HOP homeobox  1.54 1.72E-05 
Fau 
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously 
expressed 
1.54 1.02E-03 
Fbl fibrillarin 1.54 4.27E-04 
Tpm4 tropomyosin 4  1.54 1.51E-04 
Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B 1.54 8.83E-04 
Pter phosphotriesterase related 1.53 3.42E-05 
Phldb3 pleckstrin homology-like domain, family B, member 3 1.53 1.17E-04 
LOC688318 similar to leucine rich repeat containing 45  1.53 2.16E-07 
Klf10 Kruppel-like factor 10 1.53 3.18E-03 
Iffo2 intermediate filament family orphan 2  1.53 2.13E-06 
Edf1 endothelial differentiation-related factor 1  1.53 1.08E-04 
Lgals5 lectin, galactose binding, soluble 5  1.53 3.72E-03 
Litaf lipopolysaccharide-induced TNF factor 1.53 1.66E-05 
Ereg epiregulin 1.53 3.73E-04 
Aida axin interactor, dorsalization associated  1.53 1.69E-05 
Flna filamin A, alpha 1.53 2.66E-05 
C1qtnf5 C1q and tumor necrosis factor related protein 5 1.53 1.04E-04 
Bdnf brain-derived neurotrophic factor 1.53 2.36E-03 
RGD1562079 RGD1562079 1.53 3.14E-06 
Nod1 nucleotide-binding oligomerization domain containing 1 1.53 6.58E-04 
Pdxk pyridoxal (pyridoxine, vitamin B6) kinase  1.53 9.00E-05 
Mrps18b mitochondrial ribosomal protein S18B 1.52 1.88E-04 
Steap1 six transmembrane epithelial antigen of the prostate 1  1.52 3.50E-03 
Pinx1 PIN2/TERF1 interacting, telomerase inhibitor 1 1.52 2.10E-06 
Rbp2 retinol binding protein 2, cellular  1.52 1.76E-03 
Pnpt1 polyribonucleotide nucleotidyltransferase 1  1.52 1.44E-05 
Nme2 NME/NM23 nucleoside diphosphate kinase 2 1.52 2.92E-03 
Xbp1 X-box binding protein 1  1.52 1.49E-07 
Prr16 proline rich 16 1.52 1.91E-05 
Lipa lipase A, lysosomal acid, cholesterol esterase  1.52 9.71E-05 
Fkbp11 FK506 binding protein 11  1.52 1.67E-03 
Flt3l FMS-like tyrosine kinase 3 ligand 1.52 1.34E-04 
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Rbpms2 RNA binding protein with multiple splicing 2  1.52 1.08E-04 
LOC100362338 ribosomal protein L35a-like 1.52 3.68E-05 
Kctd14 potassium channel tetramerisation domain containing 14 1.51 1.08E-03 
Ginm1 glycoprotein integral membrane 1  1.51 4.68E-04 
Srebf1 sterol regulatory element binding transcription factor 1  1.51 2.80E-03 
Cyp4v3 cytochrome P450, family 4, subfamily v, polypeptide 3  1.51 4.76E-03 
Elk3 ELK3, member of ETS oncogene family  1.51 6.54E-06 
LOC688318 similar to leucine rich repeat containing 45  1.51 4.56E-03 
Lbh limb bud and heart development  1.51 1.01E-05 
Lta4h leukotriene A4 hydrolase  1.51 1.23E-04 
LOC100363408 BolA-like protein 2-like  1.51 2.91E-04 
Pde9a phosphodiesterase 9A  1.51 4.66E-05 
Abcg3l3 ATP-binding cassette, subfamily G (WHITE), member 3-like 3 1.51 1.98E-06 
LOC100360439 ribosomal protein L36-like 1.51 3.44E-04 
Tgif1 TGFB-induced factor homeobox 1  1.51 2.45E-03 
LOC100362751 ribosomal protein P2-like 1.50 3.54E-04 
LOC680700 similar to ribosomal protein L10a  1.50 7.66E-04 
Pold1 polymerase (DNA directed), delta 1, catalytic subunit 1.50 1.28E-04 
Pfdn1 Pfdn1 // prefoldin subunit 1  1.50 2.24E-04 
Lrrc10b leucine rich repeat containing 10B  1.50 5.35E-04 
Pdzrn4 PDZ domain containing RING finger 4  1.50 5.52E-04 
Zc3hav1 zinc finger CCCH type, antiviral 1  1.50 1.66E-03 
Myl9 myosin, light chain 9, regulatory 1.50 2.10E-03 
Mob3a MOB kinase activator 3A 1.50 3.50E-06 
RGD1561530 similar to Tle6 protein  1.50 8.11E-04 
Wdr62 WD repeat domain 62 1.49 1.17E-05 
Dnaaf3 dynein, axonemal, assembly factor 3 1.49 1.20E-03 
Brca1 breast cancer 1, early onset  1.49 6.11E-04 
RGD1559639 similar to ribosomal protein L10a  1.48 4.39E-04 
Plekho2 pleckstrin homology domain containing, family O member 2 1.48 1.26E-04 
Cth cystathionase (cystathionine gamma-lyase)  1.48 2.88E-03 
Slc12a7 
solute carrier family 12 (potassium/chloride transporters),  
member 7 
1.48 4.60E-03 
Aprt adenine phosphoribosyl transferase  1.48 4.11E-04 
Tlr3 toll-like receptor 3 1.48 1.01E-04 
Sema3e 
sema domain, immunoglobulin domain (Ig), short basic domain,  
secreted, (semaphorin) 3E 
1.48 2.54E-06 
Hspb1 heat shock protein 1  1.48 3.16E-04 
P2rx4 purinergic receptor P2X, ligand-gated ion channel 4 1.48 1.62E-03 
Snx18 sorting nexin 18 1.48 5.87E-03 
Prkcdbp protein kinase C, delta binding protein 1.48 2.79E-03 
Lsm7 LSM7 homolog, U6 small nuclear RNA associated (S. cerevisiae)  1.48 9.30E-04 
Slco4a1 solute carrier organic anion transporter family, member 4a1 1.47 2.07E-03 
RGD1310335 similar to RIKEN cDNA C330027C09  1.47 6.56E-03 
LOC686066 similar to 60S ribosomal protein L38  1.47 1.13E-04 
Mt2A metallothionein 2A  1.47 8.43E-05 
Tnfrsf1a tumor necrosis factor receptor superfamily, member 1a 1.47 1.92E-05 
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St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 1.47 6.08E-03 
Ipo5 importin 5 1.47 1.33E-04 
Gins2 GINS complex subunit 2 (Psf2 homolog) 1.47 3.67E-03 
Erbb2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 1.47 1.96E-03 
Aspg asparaginase homolog (S. cerevisiae) 1.46 1.06E-03 
Iqgap3 IQ motif containing GTPase activating protein 3 1.46 8.13E-05 
Tpm3 tropomyosin 3  1.46 1.75E-04 
Dph5 DPH5 homolog (S. cerevisiae)  1.46 7.69E-04 
LOC688318 similar to leucine rich repeat containing 45 1.46 6.17E-04 
Ftsj3 FtsJ homolog 3 (E. coli) 1.46 5.75E-05 
Tmem2 transmembrane protein 2 1.46 2.50E-03 
Stat3 
signal transducer and activator of transcription 3 (acute-phase 
response factor) 
1.46 1.18E-07 
Thop1 thimet oligopeptidase 1 1.46 1.06E-05 
Chadl chondroadherin-like  1.46 2.94E-04 
Lyar Ly1 antibody reactive  1.46 2.45E-04 
LOC688318 similar to leucine rich repeat containing 45  1.46 2.37E-08 
Spry2 sprouty homolog 2 (Drosophila)  1.46 9.77E-06 
C1qtnf1 C1q and tumor necrosis factor related protein 1  1.45 4.61E-03 
LOC688318 similar to leucine rich repeat containing 45 1.45 2.00E-03 
Fanci Fanconi anemia, complementation group I 1.45 3.99E-03 
Ift43 intraflagellar transport 43 homolog (Chlamydomonas)  1.45 1.48E-03 
Kpna2 karyopherin alpha 2  1.45 1.84E-05 
Galr1 galanin receptor 1  1.45 7.62E-04 
Psme1 proteasome (prosome, macropain) activator subunit 1  1.45 1.10E-04 
Vhl von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase 1.45 3.95E-05 
Ube2t ubiquitin-conjugating enzyme E2T (putative) 1.45 4.59E-03 
Chaf1b chromatin assembly factor 1, subunit B (p60) 1.45 5.34E-03 
Slc20a1 solute carrier family 20 (phosphate transporter), member 1  1.44 5.51E-06 
Aifm2 apoptosis-inducing factor, mitochondrion-associated 2  1.44 8.43E-05 
Ercc1 excision repair cross-complementing rodent repair deficiency 1.44 1.41E-03 
Aimp2 
aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 2 
1.44 2.54E-06 
Rps13 ribosomal protein S13 1.44 4.90E-05 
RGD1309350 similar to transthyretin (4L369) 1.44 2.21E-03 
LOC688318 similar to leucine rich repeat containing 45 1.44 9.11E-04 
Polr1b polymerase (RNA) I polypeptide B 1.44 1.53E-04 
Dnajc25 DnaJ (Hsp40) homolog, subfamily C, member 25  1.44 2.68E-04 
Tor1b torsin family 1, member B 1.44 2.35E-03 
Bhlhe40 basic helix-loop-helix family, member e40 1.44 2.55E-04 
Gale UDP-galactose-4-epimerase  1.44 1.94E-04 
Mthfd1l 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-
like 
1.44 2.46E-03 
LOC100910714 60S ribosomal protein L36a-like  1.44 7.43E-04 
Cebpb enhancer binding protein (C/EBP), beta 1.44 2.44E-04 
Polr1e polymerase (RNA) I polypeptide E 1.43 3.43E-06 
Psma6 proteasome (prosome, macropain) subunit, alpha type 6  1.43 4.42E-04 
Pole2 polymerase (DNA directed), epsilon 2, accessory subunit 1.43 3.48E-03 
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Rgs4 regulator of G-protein signaling 4 1.43 2.62E-03 
Timeless timeless circadian clock  1.43 1.95E-03 
Orai3 ORAI calcium release-activated calcium modulator 3  1.43 5.39E-04 
Gins4 GINS complex subunit 4 (Sld5 homolog) 1.43 1.88E-03 
Dnali1 dynein, axonemal, light intermediate chain 1 1.43 5.29E-04 
Ifngr2 interferon gamma receptor 2  1.43 3.92E-06 
Snrpa small nuclear ribonucleoprotein polypeptide A 1.43 5.16E-06 
Zmym6nb ZMYM6 neighbor 1.43 1.02E-03 
Tmco4 transmembrane and coiled-coil domains 4 1.43 7.01E-03 
Dnai2 dynein, axonemal, intermediate chain 2  1.43 5.76E-03 
LOC100361103 ribosomal protein L21-like  1.43 6.66E-03 
Psrc1 proline/serine-rich coiled-coil 1  1.43 3.72E-04 
Scg2 secretogranin II  1.43 1.16E-04 
Ap5b1 adaptor-related protein complex 5, beta 1 subunit 1.42 2.11E-03 
RGD1564259 similar to OTTHUMP00000040155  1.42 4.22E-03 
Mphosph10 M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) 1.42 3.27E-03 
Ezr ezrin 1.42 2.79E-05 
B3galnt1 
beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood 
group) 
1.42 6.93E-04 
Tes testis derived transcript 1.42 1.17E-04 
Tonsl tonsoku-like, DNA repair protein  1.42 1.75E-03 
LOC688318 similar to leucine rich repeat containing 45  1.42 4.60E-03 
LOC100360501 ribonuclease inhibitor-like  1.41 5.26E-06 
Dsn1 
DSN1, MIND kinetochore complex component, homolog (S. 
cerevisiae) 
1.41 5.87E-03 
Slc37a1 
solute carrier family 37 (glycerol-3-phosphate transporter), 
member 1 
1.41 5.43E-04 
Tfcp2l1 transcription factor CP2-like 1 1.41 3.82E-03 
Efemp2 EGF-containing fibulin-like extracellular matrix protein 2 1.41 7.66E-05 
Eif5a eukaryotic translation initiation factor 5A 1.41 1.29E-04 
Dok5 docking protein 5  1.41 1.26E-04 
Fpgs folylpolyglutamate synthase  1.41 1.54E-03 
Heatr2 HEAT repeat containing 2  1.41 1.26E-04 
Ncapg2 non-SMC condensin II complex, subunit G2  1.40 1.85E-03 
Mtmr11 myotubularin related protein 11  1.40 8.78E-05 
RGD1311458 
similar to cDNA sequence BC027231; hypothetical protein 
MGC27931 
1.40 1.29E-03 
Jun jun proto-oncogene 1.40 3.51E-04 
Rps5 ribosomal protein S5  1.40 2.01E-04 
Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 1.40 1.28E-04 
Arhgef37 Rho guanine nucleotide exchange factor (GEF) 37 -1.40 8.18E-04 
Wwc2 WW and C2 domain containing 2  -1.40 2.65E-04 
Adcy8 adenylate cyclase 8 (brain)  -1.40 8.79E-05 
Slc2a13 solute carrier family 2 (facilitated glucose transporter), member 13 -1.41 4.15E-04 
Klf11 Kruppel-like factor 11  -1.41 1.90E-05 
Gpr155 G protein-coupled receptor 155  -1.41 1.18E-03 
Itga9 integrin, alpha 9 -1.41 2.48E-03 
Shisa9 shisa homolog 9 (Xenopus laevis) -1.41 3.27E-05 
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Sez6l seizure related 6 homolog (mouse)-like  -1.41 9.12E-05 
Mdk midkine  -1.41 1.79E-03 
Ctnna2 catenin (cadherin associated protein), alpha 2  -1.41 5.25E-05 
LOC688318 similar to leucine rich repeat containing 45  -1.41 3.74E-05 
Acot2 acyl-CoA thioesterase 2 -1.41 2.86E-03 
Bcas1 breast carcinoma amplified sequence 1  -1.41 1.83E-03 
Zdhhc14 zinc finger, DHHC-type containing 14  -1.41 6.81E-06 
Reps2 RALBP1 associated Eps domain containing 2  -1.41 5.63E-05 
L1cam L1 cell adhesion molecule -1.41 3.62E-03 
Hrsp12 heat-responsive protein 12  -1.41 7.30E-08 
Map2k6 mitogen-activated protein kinase kinase 6 -1.42 9.95E-04 
Hmgn5 high mobility group nucleosome binding domain 5  -1.42 3.84E-03 
Csrp2 cysteine and glycine-rich protein 2  -1.42 4.30E-03 
Abtb1 ankyrin repeat and BTB (POZ) domain containing 1  -1.42 1.05E-03 
Kank1 KN motif and ankyrin repeat domains 1 -1.42 1.04E-04 
Galnt6 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 
-1.42 2.71E-03 
Mob3b MOB kinase activator 3B -1.42 7.59E-06 
Galnt13 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 
-1.42 2.30E-06 
Mei4 meiosis-specific, MEI4 homolog (S. cerevisiae)  -1.43 3.83E-03 
Ctnna2 catenin (cadherin associated protein), alpha 2 -1.43 6.61E-06 
Dscaml1 Down syndrome cell adhesion molecule-like 1 -1.43 7.15E-04 
LOC688318 similar to leucine rich repeat containing 45  -1.43 4.80E-05 
Tp53bp2 tumor protein p53 binding protein, 2  -1.43 2.28E-05 
Mir342 microRNA mir-342 -1.43 2.11E-03 
Tspan11 tetraspanin 11 -1.43 3.37E-04 
LOC688318 similar to leucine rich repeat containing 45  -1.43 6.32E-03 
LOC688318 similar to leucine rich repeat containing 45 -1.43 6.32E-03 
Stap1 signal transducing adaptor family member 1 -1.44 8.24E-04 
Omg oligodendrocyte-myelin glycoprotein -1.44 9.34E-06 
Pde1b phosphodiesterase 1B, calmodulin-dependent -1.44 6.65E-03 
Hps4 Hermansky-Pudlak syndrome 4 -1.44 3.19E-03 
Rnf144a ring finger protein 144A  -1.44 5.64E-07 
Limch1 LIM and calponin homology domains 1 -1.44 1.58E-04 
LOC688318 similar to leucine rich repeat containing 45 -1.45 2.42E-03 
LOC689081 similar to cystatin E2  -1.45 2.34E-05 
Slc38a3 solute carrier family 38, member 3  -1.45 1.27E-03 
Adrbk2 adrenergic, beta, receptor kinase 2  -1.45 7.67E-04 
Nanos1 nanos homolog 1 (Drosophila) -1.45 3.96E-04 
Dkk3 dickkopf WNT signaling pathway inhibitor 3 -1.45 2.09E-03 
Snx30 sorting nexin family member 30  -1.46 2.94E-04 
Gpld1 glycosylphosphatidylinositol specific phospholipase D1 -1.46 8.68E-05 
LOC100912162 uncharacterized LOC100912162  -1.46 2.69E-06 
Rnase2 
ribonuclease, RNase A family, 2 (liver, eosinophil-derived 
neurotoxin) 
-1.46 9.13E-04 
Als2cl ALS2 C-terminal like  -1.46 3.97E-07 
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Tspan8 tetraspanin 8  -1.46 1.01E-03 
LOC688318 similar to leucine rich repeat containing 45  -1.46 1.85E-04 
Grm3 glutamate receptor, metabotropic 3  -1.46 1.24E-03 
RGD1565616 RGD1565616 -1.46 3.02E-07 
Igsf9b immunoglobulin superfamily, member 9B -1.46 4.46E-05 
Pllp plasmolipin -1.46 3.70E-04 
LOC688318 similar to leucine rich repeat containing 45  -1.47 1.75E-04 
Gabbr1 gamma-aminobutyric acid (GABA) B receptor 1 -1.47 9.42E-08 
Hs3st1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 -1.47 1.93E-03 
Doc2a double C2-like domains, alpha -1.47 2.35E-03 
Cdkn1c cyclin-dependent kinase inhibitor 1C -1.47 3.43E-04 
Map6d1 MAP6 domain containing 1  -1.47 3.09E-05 
Fbrsl1 fibrosin-like 1 -1.47 9.82E-06 
Tmcc2 transmembrane and coiled-coil domain family 2 -1.47 1.13E-04 
Cbln1 cerebellin 1 precursor -1.47 1.57E-03 
Sv2b synaptic vesicle glycoprotein 2b  -1.47 4.16E-04 
Vwa3a von Willebrand factor A domain containing 3A  -1.47 2.60E-03 
Pthlh parathyroid hormone-like hormone -1.47 4.46E-03 
Ankfn1 ankyrin-repeat and fibronectin type III domain containing 1 -1.48 1.49E-03 
Fam227a family with sequence similarity 227, member A  -1.48 6.82E-03 
Phactr3 phosphatase and actin regulator 3  -1.48 1.07E-03 
LOC689725 similar to chromosome 9 open reading frame 79 -1.48 3.92E-04 
Akr1c19 aldo-keto reductase family 1, member C19 -1.48 6.06E-03 
Plp1 proteolipid protein 1 -1.48 4.29E-07 
Cfd complement factor D (adipsin) -1.48 4.66E-03 
Bmf Bcl2 modifying factor -1.48 6.11E-03 
Gjc2 gap junction protein, gamma 2 -1.49 5.80E-04 
Erbb3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) -1.49 1.68E-04 
Cmtm5 CKLF-like MARVEL transmembrane domain containing 5  -1.49 1.58E-03 
Cdc42ep2 CDC42 effector protein (Rho GTPase binding) 2  -1.49 9.51E-04 
Astn2 astrotactin 2  -1.49 3.02E-04 
Car8 carbonic anhydrase 8  -1.49 5.35E-05 
Dnah9 dynein, axonemal, heavy polypeptide 9 -1.49 8.56E-04 
Fam53b family with sequence similarity 53, member B  -1.49 3.32E-05 
Gstt3 glutathione S-transferase, theta 3 -1.49 4.26E-05 
Adhfe1 alcohol dehydrogenase, iron containing, 1 -1.50 2.16E-03 
Ms4a14 membrane-spanning 4-domains, subfamily A, member 14 -1.50 5.04E-04 
LOC685513 
similar to Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
gamma-12 subunit precursor 
-1.50 5.74E-04 
Gpr146 G protein-coupled receptor 146 -1.50 7.34E-04 
Cdh20 cadherin 20 -1.50 3.56E-05 
Timp3 TIMP metallopeptidase inhibitor 3  -1.50 2.86E-03 
Plag1 pleiomorphic adenoma gene 1  -1.50 2.60E-04 
Tnfrsf11a 
tumor necrosis factor receptor superfamily, member 11a, NFKB 
activator 
-1.50 4.16E-05 
LOC100359766 LOC100359766  -1.51 1.79E-03 
Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A -1.51 1.05E-04 
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Zfhx4 zinc finger homeobox 4  -1.51 2.28E-03 
Tmem229a transmembrane protein 229A  -1.51 2.28E-03 
Ly6h lymphocyte antigen 6 complex, locus H  -1.51 9.31E-04 
LOC688318 similar to leucine rich repeat containing 45 -1.51 3.42E-03 
LOC688318 similar to leucine rich repeat containing 45 -1.51 6.95E-03 
Slitrk6 SLIT and NTRK-like family, member 6  -1.51 1.58E-04 
Nppc natriuretic peptide C  -1.52 5.82E-03 
Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase -1.52 1.79E-06 
Tspan33 tetraspanin 33 -1.52 3.33E-05 
Clstn2 calsyntenin 2  -1.52 9.79E-07 
Scd1 stearoyl-Coenzyme A desaturase 1 -1.52 1.02E-06 
Paqr8 progestin and adipoQ receptor family member VIII -1.52 1.55E-06 
Adcy5 adenylate cyclase 5 -1.53 8.08E-08 
Utp14b UTP14, U3 small nucleolar ribonucleoprotein, homolog B  -1.53 1.54E-03 
Abca2 ATP-binding cassette, subfamily A (ABC1), member 2  -1.53 2.57E-08 
Lhfpl1 lipoma HMGIC fusion partner-like 1  -1.53 9.31E-04 
LOC688318 similar to leucine rich repeat containing 45 -1.53 1.75E-03 
Gfral GDNF family receptor alpha like  -1.53 3.40E-04 
Gng7 guanine nucleotide binding protein (G protein), gamma 7  -1.53 4.15E-04 
Pex5l peroxisomal biogenesis factor 5-like -1.53 6.61E-03 
Npc1 Niemann-Pick disease, type C1 -1.54 1.01E-06 
LOC688318 similar to leucine rich repeat containing 45  -1.54 5.96E-03 
Mme membrane metallo-endopeptidase  -1.54 1.64E-04 
Pdk4 pyruvate dehydrogenase kinase, isozyme 4 -1.55 7.08E-03 
Samt2 spermatogenesis associated multipass transmembrane protein 2 -1.55 8.98E-05 
Pdgfb platelet-derived growth factor beta polypeptide -1.55 3.50E-03 
Fbxo32 F-box protein 32  -1.55 1.48E-03 
Pip4k2a phosphatidylinositol-5-phosphate 4-kinase, type II, alpha  -1.55 8.67E-06 
Sema5a 
sema domain, seven thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A 
-1.55 3.55E-07 
Cux2 cut-like homeobox 2 -1.55 4.42E-05 
Mmd2 monocyte to macrophage differentiation-associated 2 -1.55 1.90E-05 
Mfge8 milk fat globule-EGF factor 8 protein -1.56 1.05E-04 
Atrn attractin -1.56 1.57E-08 
Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1 -1.56 1.26E-06 
Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2 -1.56 8.78E-05 
Prkcg protein kinase C, gamma -1.56 2.92E-03 
Mir2964 microRNA mir-2964  -1.57 6.88E-03 
Lrrc1 leucine rich repeat containing 1  -1.57 3.14E-04 
Trim36 tripartite motif-containing 36 -1.57 4.93E-05 
LOC365085 similar to nidogen 2 -1.57 5.68E-04 
C1ql1 complement component 1, q subcomponent-like 1 -1.58 4.61E-03 
Dnah9 dynein, axonemal, heavy polypeptide 9  -1.58 6.77E-04 
Zdhhc22 zinc finger, DHHC-type containing 22 -1.58 2.89E-03 
Pip4k2a phosphatidylinositol-5-phosphate 4-kinase, type II, alpha -1.58 3.05E-07 
Cxxc4 CXXC finger protein 4  -1.58 1.87E-03 
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Hes1 hairy and enhancer of split 1 (Drosophila) -1.58 1.58E-03 
Caskin2 cask-interacting protein 2  -1.58 1.11E-06 
Id4 inhibitor of DNA binding 4  -1.58 1.76E-05 
LOC100360891 LOC100360891  -1.58 8.81E-06 
Zfp804a zinc finger protein 804A  -1.59 4.43E-05 
RGD1309821 similar to KIAA1161 protein  -1.59 7.33E-07 
RGD1559896 similar to RIKEN cDNA 2310022B05  -1.60 3.78E-05 
Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 -1.60 1.81E-03 
Cbr1 carbonyl reductase 1 -1.60 7.62E-05 
Dnah9 dynein, axonemal, heavy polypeptide 9 -1.60 1.34E-04 
RGD1561963 similar to Dedicator of cytokinesis protein 10 (Protein zizimin 3) -1.60 8.07E-08 
Csmd1 CUB and Sushi multiple domains 1  -1.60 1.27E-03 
St6galnac3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 3 
-1.60 1.51E-06 
Notch2 notch 2  -1.60 1.52E-06 
Ndrg1 N-myc downstream regulated 1  -1.60 7.72E-04 
Elmo1 engulfment and cell motility 1 -1.60 2.96E-07 
Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B  -1.60 3.73E-03 
Hrh3 histamine receptor H3  -1.61 1.94E-04 
LOC688318 similar to leucine rich repeat containing 45 -1.61 5.76E-03 
Plekha1 
pleckstrin homology domain containing, family A (phosphoinositide 
binding specific) member 1 
-1.61 1.53E-06 
Rlbp1 retinaldehyde binding protein 1  -1.61 2.21E-04 
Pdzrn3 PDZ domain containing RING finger 3 -1.62 1.10E-05 
LOC688318 similar to leucine rich repeat containing 45  -1.62 3.30E-03 
Myo1d myosin ID  -1.63 8.68E-07 
Scrg1 stimulator of chondrogenesis 1  -1.63 1.64E-07 
Gabrb1 gamma-aminobutyric acid (GABA) A receptor, beta 1 -1.63 6.04E-05 
Unc5b unc-5 homolog B (C. elegans)  -1.63 2.02E-06 
Scube2 signal peptide, CUB domain, EGF-like 2 -1.64 4.62E-03 
Plcl1 phospholipase C-like 1  -1.64 1.20E-04 
Col23a1 collagen, type XXIII, alpha 1 -1.64 6.21E-03 
Nrbp2 nuclear receptor binding protein 2  -1.64 1.04E-06 
Eya4 eyes absent homolog 4 (Drosophila)  -1.64 4.12E-03 
Mir99a microRNA mir-99a  -1.64 6.50E-03 
Adam11 ADAM metallopeptidase domain 11  -1.65 4.08E-04 
LOC100360891 LOC100360891 -1.65 1.47E-05 
Fzd4 frizzled family receptor 4  -1.65 2.86E-03 
Mycl1 
v-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma 
derived (avian) 
-1.65 2.11E-04 
Thsd7a thrombospondin, type I, domain containing 7A  -1.66 8.34E-05 
Grin3a glutamate receptor, ionotropic, N-methyl-D-aspartate 3A -1.66 9.88E-07 
Bche butyrylcholinesterase  -1.66 1.25E-04 
Dnah9 dynein, axonemal, heavy polypeptide 9  -1.66 1.70E-03 
Olfml1 olfactomedin-like 1  -1.66 8.86E-05 
Tst thiosulfate sulfurtransferase  -1.66 8.85E-06 
Slc15a2 solute carrier family 15 (H+/peptide transporter), member 2  -1.66 1.12E-05 
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Gamt guanidinoacetate N-methyltransferase  -1.66 3.63E-06 
Mfsd4 major facilitator superfamily domain containing 4 -1.66 1.37E-03 
Lrp4 low density lipoprotein receptor-related protein 4 -1.67 2.32E-05 
LOC688318 similar to leucine rich repeat containing 45 -1.67 1.09E-04 
Slc12a2 
solute carrier family 12 (sodium/potassium/chloride transporter), 
member 2 
-1.67 3.81E-08 
Fat3 FAT atypical cadherin 3 -1.67 2.93E-05 
Amotl2 angiomotin like 2 -1.68 1.99E-04 
Kcne1l KCNE1-like -1.68 2.90E-05 
Gmnc geminin coiled-coil domain containing  -1.68 7.89E-04 
Nkd1 naked cuticle homolog 1 (Drosophila)  -1.69 7.46E-04 
St18 suppression of tumorigenicity 18  -1.69 2.23E-05 
Csmd3 CUB and Sushi multiple domains 3 -1.69 5.28E-05 
LOC688318 similar to leucine rich repeat containing 45 -1.69 3.23E-04 
Adamtsl2 ADAMTS-like 2 -1.69 1.06E-03 
Slc7a10 
solute carrier family 7 (neutral amino acid transporter light chain, 
Asc system), member 10 
-1.69 4.17E-03 
Eci2 enoyl-CoA delta isomerase 2  -1.69 1.97E-04 
Slco1c1 solute carrier organic anion transporter family, member 1c1 -1.69 2.12E-03 
LOC688318 similar to leucine rich repeat containing 45  -1.69 1.55E-04 
Abhd3 abhydrolase domain containing 3 -1.70 5.20E-05 
Wisp2 WNT1 inducible signaling pathway protein 2 -1.70 5.36E-03 
Glud1 glutamate dehydrogenase 1 -1.70 8.66E-08 
Akr1b10 aldo-keto reductase family 1, member B10 (aldose reductase) -1.71 1.08E-04 
Mrc2 mannose receptor, C type 2 -1.71 4.72E-04 
Rbpjl 
ecombination signal binding protein for immunoglobulin kappa J 
region 
-1.71 1.57E-04 
Nuak1 NUAK family, SNF1-like kinase, 1  -1.71 1.30E-03 
P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6  -1.72 1.00E-03 
LOC688318 similar to leucine rich repeat containing 45  -1.72 2.14E-03 
LOC688318 similar to leucine rich repeat containing 45  -1.72 2.14E-03 
Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1 -1.73 8.96E-05 
Pex11a peroxisomal biogenesis factor 11 alpha  -1.73 1.83E-04 
Ldlrap1 low density lipoprotein receptor adaptor protein 1 -1.74 2.07E-04 
Tmem63c transmembrane protein 63c -1.74 5.21E-05 
Mfap3l microfibrillar-associated protein 3-like  -1.75 2.44E-05 
LOC691920 similar to kinesin-like motor protein C20orf23 -1.75 1.91E-03 
Mat2a methionine adenosyltransferase II, alpha  -1.76 1.08E-03 
Klhl4 kelch-like family member 4  -1.77 9.03E-05 
Dusp15 dual specificity phosphatase 15 -1.78 1.99E-04 
Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1 -1.79 6.56E-04 
Mir9-2 microRNA mir-9-2  -1.80 9.77E-05 
Padi2 peptidyl arginine deiminase, type II -1.80 2.37E-05 
Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 -1.80 4.62E-03 
Lrrc55 leucine rich repeat containing 55  -1.80 1.71E-04 
Cpxm1 carboxypeptidase X (M14 family), member 1  -1.81 1.53E-03 
Lmx1a LIM homeobox transcription factor 1 alpha -1.81 5.75E-04 
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Ano4 anoctamin 4 -1.81 5.71E-07 
Cd74 
Cd74 molecule, major histocompatibility complex, class II invariant 
chain 
-1.81 2.52E-03 
Ephb1 Eph receptor B1  -1.81 9.43E-07 
Slc26a3 solute carrier family 26, member 3 -1.82 1.27E-03 
Omd osteomodulin -1.82 8.14E-04 
Dnah9 dynein, axonemal, heavy polypeptide 9  -1.82 5.66E-04 
Nipal4 NIPA-like domain containing 4  -1.83 1.34E-03 
Klk6 kallikrein related-peptidase 6  -1.83 3.05E-05 
Slc4a4 
solute carrier family 4, sodium bicarbonate cotransporter, member 
4 
-1.84 1.30E-06 
LOC100359587 LOC100359587 -1.84 5.59E-05 
Slc13a3 
solute carrier family 13 (sodium-dependent dicarboxylate 
transporter), member 3 
-1.86 2.48E-05 
Cldn11 claudin 11 -1.86 4.73E-04 
Fam92b family with sequence similarity 92, member B  -1.86 7.90E-04 
Capn6 calpain 6  -1.87 1.10E-04 
Bbox1 
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-
butyrobetaine hydroxylase) 1 
-1.87 1.41E-03 
Draxin dorsal inhibitory axon guidance protein  -1.87 6.77E-03 
Fa2h fatty acid 2-hydroxylase  -1.87 1.97E-07 
Adrb2 adrenoceptor beta 2, surface  -1.87 1.81E-03 
Cldn19 claudin 19  -1.88 9.96E-05 
Sox10 SRY (sex determining region Y)-box 10  -1.88 1.06E-05 
LOC688318 similar to leucine rich repeat containing 45 -1.89 1.34E-03 
Lix1 Lix1 homolog (chicken)  -1.89 2.08E-05 
Ppp1r16b protein phosphatase 1, regulatory subunit 16B -1.89 4.75E-07 
Slc6a9 
solute carrier family 6 (neurotransmitter transporter, glycine), 
member 9 
-1.90 2.48E-07 
Ugt8 UDP glycosyltransferase 8 -1.90 2.42E-06 
Agmo alkylglycerol monooxygenase  -1.91 1.75E-04 
Pbld1 phenazine biosynthesis-like protein domain containing 1 -1.91 6.57E-05 
Tmem200c transmembrane protein 200C -1.93 3.24E-05 
LOC688318 similar to leucine rich repeat containing 45  -1.93 3.51E-03 
Ca2 carbonic anhydrase 2  -1.95 5.50E-04 
Pla2g5 phospholipase A2, group V -1.95 8.10E-04 
Aspa aspartoacylase -1.97 8.85E-04 
Thsd7b thrombospondin, type I, domain containing 7B -1.98 1.92E-05 
Gabrg1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 -1.98 2.70E-07 
LOC688318 similar to leucine rich repeat containing 45  -1.98 2.31E-03 
LOC100362373 LOC100362373 -1.98 4.08E-06 
Bcan brevican -1.98 1.42E-07 
Plxnb3 plexin B3  -1.98 5.58E-07 
LOC100359587 LOC100359587 -1.98 2.24E-05 
Sult1a1 
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 
1 
-1.98 1.72E-03 
Mcam melanoma cell adhesion molecule -2.01 9.51E-04 
Prodh proline dehydrogenase (oxidase) 1 -2.01 4.81E-04 
LOC100910790 spondin-2-like -2.03 1.96E-03 
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Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 -2.06 3.28E-05 
Ppp1r14a protein phosphatase 1, regulatory (inhibitor) subunit 14A  -2.06 5.68E-04 
Gpr62 G protein-coupled receptor 62 -2.06 1.03E-04 
Atp10b ATPase, class V, type 10B -2.06 1.44E-06 
LOC100910367 uncharacterized LOC100910367 -2.07 1.96E-05 
LOC100362373 LOC100362373 -2.10 1.83E-06 
Igfbpl1 insulin-like growth factor binding protein-like 1  -2.11 6.11E-03 
Cdh19 cadherin 19, type 2  -2.11 1.85E-05 
Gpr17 G protein-coupled receptor 17  -2.13 1.71E-05 
Rftn2 raftlin family member 2 -2.15 1.03E-06 
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C  -2.16 1.38E-05 
Tll2 tolloid-like 2  -2.17 6.76E-05 
Pygm phosphorylase, glycogen, muscle  -2.18 5.76E-05 
Tspan2 tetraspanin 2  -2.18 3.57E-09 
Hes5 hairy and enhancer of split 5 (Drosophila) -2.19 1.83E-05 
Notch3 notch 3  -2.20 4.11E-06 
Mir3546 microRNA mir-3546 -2.20 1.24E-03 
LOC688318 similar to leucine rich repeat containing 45  -2.22 1.26E-05 
LOC360228 WDNM1 homolog  -2.22 5.76E-03 
Kndc1 kinase non-catalytic C-lobe domain (KIND) containing 1 -2.25 1.07E-07 
Mir2964 microRNA mir-2964  -2.26 7.21E-05 
Fam69c family with sequence similarity 69, member C  -2.27 2.94E-06 
Evi2a ecotropic viral integration site 2A  -2.29 4.27E-05 
Veph1 ventricular zone expressed PH domain-containing 1 -2.30 6.62E-06 
Kank4 KN motif and ankyrin repeat domains 4  -2.32 4.17E-05 
Tmem88b transmembrane protein 88B -2.34 1.10E-04 
Timp4 tissue inhibitor of metalloproteinase 4  -2.39 1.09E-04 
Aox1 aldehyde oxidase 1 -2.39 4.89E-05 
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) -2.43 2.85E-05 
Ccdc3 coiled-coil domain containing 3 -2.45 7.07E-03 
Acot1 acyl-CoA thioesterase 1  -2.46 1.12E-03 
Mag myelin-associated glycoprotein  -2.48 1.89E-07 
LOC363337 similar to RIKEN cDNA 1700081O22 -2.48 4.46E-04 
Myrf myelin regulatory factor  -2.50 2.69E-05 
Nkain4 Na+/K+ transporting ATPase interacting 4  -2.51 2.14E-04 
Slc6a11 solute carrier family 6 (neurotransmitter transporter), member 11 -2.52 4.24E-07 
Fmo1 flavin containing monooxygenase 1 -2.54 6.73E-04 
Ctnna3 catenin (cadherin associated protein), alpha 3 -2.54 6.53E-03 
Tmem125 transmembrane protein 125  -2.55 1.39E-05 
Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble)  -2.69 2.56E-05 
Tril TLR4 interactor with leucine-rich repeats -2.71 2.28E-07 
Gpr20 G protein-coupled receptor 20  -2.73 1.42E-06 
Stab1 stabilin 1  -2.74 6.25E-04 
Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2  -2.76 6.44E-07 
S1pr5 sphingosine-1-phosphate receptor 5  -2.77 1.19E-07 
Gpr37 G protein-coupled receptor 37  -2.79 7.74E-07 
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Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 -2.80 1.48E-07 
LOC100910839 leucine zipper protein 2-like  -2.82 4.45E-04 
P2ry12 purinergic receptor P2Y, G-protein coupled, 12  -2.82 8.86E-04 
Hapln2 hyaluronan and proteoglycan link protein 2  -2.83 5.79E-06 
Clmn calmin -2.85 4.36E-08 
Mog myelin oligodendrocyte glycoprotein -2.98 5.85E-06 
Gpr34 G protein-coupled receptor 34  -3.01 2.56E-03 
Slc4a5 
solute carrier family 4, sodium bicarbonate cotransporter, member 
5 
-3.14 6.97E-03 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) -3.22 3.41E-03 
LOC679711 similar to RIKEN cDNA 5031410I06 -3.39 7.12E-05 
Tlr5 toll-like receptor 5  -3.47 9.56E-07 
Car14 carbonic anhydrase 14 -3.70 1.12E-04 
P2ry13 purinergic receptor P2Y, G-protein coupled, 13  -4.13 1.50E-06 
Sucnr1 succinate receptor 1   -4.15 2.54E-07 
Opalin oligodendrocytic myelin paranodal and inner loop protein -4.20 1.12E-06 
Hhip Hedgehog-interacting protein -4.32 3.57E-09 
Wnt2b wingless-type MMTV integration site family, member 2B  -4.84 4.18E-03 
Cckar cholecystokinin A receptor -4.93 6.44E-03 
Mal mal, T-cell differentiation protein  -5.15 4.78E-06 
C1qtnf3 C1q and tumor necrosis factor related protein 3 -5.63 5.19E-03 
Aplnr apelin receptor -7.35 5.22E-03 
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8.2 Gene ontology  
8.2.1 Gene ontology clustering of cultures treated with O4 antibody in the 
absence of serum 
 
8.2.1.1 Table 4.4.1a: Significantly enriched biological processes by Partek 
Genomic Suite. Gene ontology clustering was performed on the genes 
differentially regulated by fold change of 1.4 or greater in the antibody in 
comparison to isotype treated cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4- vs IgM- 
score 
immune system process 162.80 1.97E-71 19.71 5.02 
response to external biotic 
stimulus 
115.01 1.13E-50 20.19 4.98 
response to external stimulus 113.32 6.10E-50 14.24 4.96 
response to biotic stimulus 113.08 7.77E-50 19.60 4.98 
immune response 113.05 8.00E-50 23.88 5.09 
defense response 111.20 5.10E-49 20.12 5.11 
regulation of immune system 
process 
90.82 3.60E-40 16.45 4.90 
positive regulation of immune 
system process 
86.10 4.05E-38 20.91 5.01 
response to cytokine 76.22 7.93E-34 20.00 5.33 
response to other organism 75.21 2.18E-33 21.41 5.19 
response to stress 71.11 1.31E-31 9.60 4.93 
multi-organism process 68.64 1.55E-30 15.85 5.20 
positive regulation of biological 
process 
66.97 8.22E-30 7.53 4.79 
positive regulation of response to 
stimulus 
66.53 1.28E-29 11.57 5.02 
defense response to other organism 64.12 1.42E-28 23.45 5.07 
response to molecule of bacterial 
origin 
63.30 3.24E-28 21.19 4.88 
immune effector process 63.00 4.36E-28 24.06 5.06 
response to lipopolysaccharide 61.39 2.19E-27 21.32 4.86 
regulation of response to stimulus 58.64 3.42E-26 8.55 4.85 
response to organic substance 58.02 6.31E-26 9.00 4.85 
cellular response to chemical 
stimulus 
57.26 1.35E-25 10.15 4.94 
positive regulation of cellular 
process 
57.02 1.72E-25 7.52 4.72 
cellular response to organic 
substance 
53.42 6.31E-24 10.87 4.91 
cellular response to cytokine 
stimulus 
52.31 1.91E-23 19.39 5.40 
cellular response to molecule of 
bacterial origin 
51.30 5.24E-23 28.80 4.77 
cellular response to biotic stimulus 50.50 1.18E-22 27.21 4.78 
cellular response to 
lipopolysaccharide 
50.06 1.81E-22 28.93 4.80 
regulation of immune response 48.63 7.60E-22 16.93 4.91 
regulation of cytokine production 48.20 1.16E-21 17.10 4.82 
response to stimulus 47.33 2.77E-21 5.59 4.76 
inflammatory response 46.58 5.87E-21 20.57 4.64 
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response to wounding 44.06 7.35E-20 15.38 4.66 
regulation of defense response 43.80 9.49E-20 17.90 5.07 
response to virus 43.53 1.25E-19 25.00 5.75 
regulation of response to stress 42.82 2.54E-19 12.45 5.00 
response to lipid 42.53 3.39E-19 11.24 4.76 
regulation of immune effector 
process 
42.23 4.55E-19 20.53 4.94 
regulation of multicellular 
organismal process 
41.96 5.98E-19 8.17 4.52 
response to interferon-gamma 41.45 9.98E-19 45.65 5.87 
regulation of leukocyte migration 40.90 1.73E-18 31.03 5.00 
positive regulation of immune 
response 
40.48 2.64E-18 19.05 4.97 
innate immune response 39.19 9.59E-18 22.76 5.05 
taxis 38.90 1.27E-17 21.79 5.04 
chemotaxis 38.90 1.27E-17 21.79 5.04 
regulation of innate immune 
response 
38.37 2.17E-17 28.42 5.23 
cellular response to lipid 38.07 2.93E-17 16.60 4.62 
regulation of response to external 
stimulus 
37.19 7.03E-17 13.90 4.92 
positive regulation of leukocyte 
migration 
37.19 7.04E-17 33.82 5.15 
response to oxygen-containing 
compound 
37.05 8.09E-17 9.05 4.77 
antigen processing and 
presentation 
36.95 9.01E-17 31.58 5.80 
leukocyte activation 36.47 1.45E-16 16.28 4.57 
negative regulation of viral process 35.81 2.81E-16 42.22 5.70 
negative regulation of multi-
organism process 
35.75 2.99E-16 31.94 5.49 
regulation of localization 35.73 3.04E-16 8.40 4.70 
positive regulation of cytokine 
production 
35.65 3.29E-16 20.37 5.09 
response to bacterium 35.46 3.99E-16 20.25 5.16 
cell chemotaxis 35.41 4.19E-16 26.80 5.33 
regulation of locomotion 34.97 6.51E-16 12.59 5.13 
regulation of multi-organism 
process 
34.89 7.05E-16 19.88 5.12 
positive regulation of signal 
transduction 
34.76 8.05E-16 10.07 5.10 
chemokine activity 34.37 1.18E-15 51.61 5.94 
positive regulation of signaling 34.27 1.31E-15 9.80 5.09 
response to interferon-beta 34.20 1.40E-15 91.67 5.88 
regulation of signal transduction 34.12 1.52E-15 7.91 4.87 
cell activation 33.93 1.84E-15 14.57 4.64 
positive regulation of response to 
external stimulus 
33.59 2.57E-15 20.39 5.21 
positive regulation of transport 33.17 3.94E-15 11.90 4.86 
positive regulation of cell 
communication 
33.09 4.25E-15 9.67 5.10 
positive regulation of locomotion 33.00 4.67E-15 16.24 5.15 
response to interleukin-1 32.87 5.32E-15 30.14 4.94 
defense response to virus 31.98 1.29E-14 27.38 5.72 
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positive regulation of immune 
effector process 
31.75 1.62E-14 22.31 5.03 
myeloid leukocyte activation 31.47 2.16E-14 32.26 4.76 
positive regulation of cell motility 31.41 2.28E-14 16.29 4.97 
regulation of leukocyte chemotaxis 31.02 3.39E-14 33.93 5.17 
regulation of intracellular signal 
transduction 
31.01 3.40E-14 9.30 4.94 
regulation of cell proliferation 30.96 3.57E-14 8.80 4.67 
single-organism process 30.66 4.82E-14 4.87 4.58 
regulation of cell migration 30.55 5.42E-14 12.60 4.95 
positive regulation of cellular 
component movement 
30.43 6.10E-14 15.79 4.97 
positive regulation of intracellular 
signal transduction 
30.40 6.27E-14 11.16 5.15 
regulation of symbiosis, 
encompassing mutualism through 
parasitism 
30.35 6.60E-14 25.56 5.39 
regulation of cell motility 30.28 7.08E-14 12.31 4.95 
defense response to bacterium 30.13 8.20E-14 20.14 4.89 
positive regulation of cell 
migration 
30.12 8.27E-14 16.06 4.98 
regulation of signaling 30.09 8.54E-14 7.26 4.88 
response to tumor necrosis factor 29.91 1.03E-13 26.51 5.35 
negative regulation of viral genome 
replication 
29.72 1.23E-13 56.52 5.65 
positive regulation of adaptive 
immune response 
28.87 2.90E-13 28.57 5.44 
leukocyte migration 28.71 3.39E-13 22.64 5.10 
positive regulation of leukocyte 
chemotaxis 
28.71 3.42E-13 35.42 5.21 
adaptive immune response based 
on somatic recombination of 
immune receptors built from 
immunoglobulin superfamily 
domains 
28.71 3.42E-13 35.42 4.46 
regulation of cellular component 
movement 
28.65 3.60E-13 11.61 4.91 
leukocyte chemotaxis 28.57 3.90E-13 28.17 5.29 
regulation of mononuclear cell 
proliferation 
28.55 4.01E-13 19.71 5.07 
cellular response to oxygen-
containing compound 
28.50 4.21E-13 10.53 4.86 
regulation of cell activation 28.47 4.34E-13 13.83 4.70 
regulation of cell communication 28.20 5.64E-13 7.12 4.86 
positive regulation of defense 
response 
27.84 8.10E-13 20.83 4.80 
regulation of leukocyte 
proliferation 
27.82 8.28E-13 19.15 5.07 
response to organic cyclic 
compound 
27.76 8.81E-13 9.41 4.52 
regulation of viral process 27.05 1.79E-12 27.94 5.70 
regulation of adaptive immune 
response 
26.83 2.23E-12 21.90 5.35 
regulation of lymphocyte 
proliferation 
26.80 2.30E-12 19.12 5.11 
positive regulation of adaptive 
immune response based on somatic 
recombination of immune 
receptors built from 
26.76 2.39E-12 27.54 5.34 
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immunoglobulin superfamily 
domains 
cellular response to interferon-
beta 
26.63 2.71E-12 100.00 6.31 
regulation of leukocyte activation 26.51 3.07E-12 13.90 4.77 
regulation of I-kappaB kinase/NF-
kappaB signaling 
26.45 3.27E-12 18.84 5.06 
cellular response to interferon-
gamma 
26.40 3.42E-12 46.43 5.91 
positive regulation of multicellular 
organismal process 
26.09 4.65E-12 11.16 5.03 
antigen processing and 
presentation of peptide antigen 
26.02 5.03E-12 33.33 5.50 
positive regulation of leukocyte 
mediated immunity 
25.93 5.49E-12 26.39 5.10 
regulation of transport 25.92 5.52E-12 8.40 4.79 
regulation of leukocyte mediated 
immunity 
25.66 7.15E-12 19.83 4.86 
cellular response to interleukin-1 24.96 1.45E-11 31.37 5.10 
regulation of leukocyte apoptotic 
process 
24.89 1.55E-11 28.81 4.69 
single-organism cellular process 24.88 1.57E-11 5.00 4.57 
positive regulation of metabolic 
process 
24.73 1.82E-11 6.88 4.71 
regulation of lymphocyte migration 24.38 2.59E-11 46.15 5.42 
regulation of viral genome 
replication 
24.31 2.78E-11 40.63 5.65 
lipopolysaccharide-mediated 
signaling pathway 
24.21 3.07E-11 52.38 4.85 
positive regulation of lymphocyte 
mediated immunity 
24.16 3.22E-11 25.71 5.10 
positive regulation of chemotaxis 24.15 3.26E-11 24.05 5.36 
regulation of chemotaxis 23.97 3.91E-11 21.21 5.31 
adaptive immune response 23.90 4.17E-11 25.35 4.59 
regulation of adaptive immune 
response based on somatic 
recombination of immune 
receptors built from 
immunoglobulin superfamily 
domains 
23.56 5.84E-11 20.79 5.18 
regulation of nitric oxide 
biosynthetic process 
23.30 7.59E-11 34.15 4.68 
regulation of tumor necrosis factor 
production 
23.19 8.51E-11 26.15 4.62 
cellular response to tumor necrosis 
factor 
22.92 1.11E-10 25.76 5.47 
positive regulation of cell 
activation 
22.69 1.40E-10 16.05 5.16 
regulation of developmental 
process 
22.65 1.46E-10 7.19 4.48 
positive regulation of behavior 22.54 1.62E-10 20.83 5.40 
single-organism transport 22.48 1.72E-10 6.79 4.59 
response to endogenous stimulus 22.47 1.75E-10 7.76 4.50 
negative regulation of biological 
process 
22.46 1.75E-10 5.94 4.72 
positive regulation of calcium ion 
transport 
22.45 1.78E-10 29.41 5.30 
leukocyte mediated immunity 22.45 1.78E-10 29.41 3.97 
positive regulation of T cell 
activation 
22.35 1.97E-10 20.62 5.31 
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regulation of protein metabolic 
process 
21.97 2.88E-10 7.17 4.76 
positive regulation of tumor 
necrosis factor production 
21.86 3.21E-10 38.71 4.81 
regulation of apoptotic process 21.85 3.25E-10 8.03 5.01 
granulocyte chemotaxis 21.39 5.16E-10 33.33 4.52 
regulation of lymphocyte 
activation 
21.37 5.23E-10 13.39 4.99 
positive regulation of cellular 
metabolic process 
21.37 5.26E-10 6.74 4.63 
response to nitrogen compound 21.32 5.52E-10 8.78 4.65 
regulation of programmed cell 
death 
21.30 5.64E-10 7.93 5.01 
myeloid leukocyte migration 21.26 5.82E-10 27.27 4.78 
positive regulation of cell 
proliferation 
21.18 6.33E-10 9.33 4.54 
positive regulation of innate 
immune response 
21.17 6.39E-10 25.00 4.64 
granulocyte migration 21.03 7.39E-10 32.50 4.52 
regulation of molecular function 20.94 8.08E-10 6.89 4.78 
regulation of cell killing 20.92 8.20E-10 24.62 5.21 
positive regulation of molecular 
function 
20.75 9.72E-10 8.33 4.82 
positive regulation of 
developmental process 
20.74 9.88E-10 8.91 4.37 
biological regulation 20.72 1.00E-09 4.55 4.71 
antigen processing and 
presentation of peptide antigen via 
MHC class I 
20.60 1.13E-09 35.29 5.68 
regulation of T cell proliferation 20.56 1.17E-09 19.79 5.39 
regulation of cell death 20.48 1.27E-09 7.67 4.95 
positive regulation of cell killing 20.45 1.32E-09 25.86 5.31 
response to chemical 20.39 1.40E-09 5.44 4.83 
positive regulation of leukocyte 
activation 
20.30 1.53E-09 15.48 5.27 
immune response-regulating 
signaling pathway 
20.20 1.69E-09 19.39 4.22 
regulation of lymphocyte mediated 
immunity 
20.02 2.02E-09 19.19 5.03 
regulation of behavior 19.99 2.08E-09 15.86 5.25 
antigen processing and 
presentation of endogenous 
antigen 
19.96 2.14E-09 100.00 6.33 
activation of innate immune 
response 
19.84 2.42E-09 33.33 4.67 
antigen processing and 
presentation of exogenous antigen 
19.78 2.56E-09 43.48 4.82 
regulation of T cell activation 19.77 2.59E-09 15.09 5.15 
regulation of phosphorylation 19.70 2.78E-09 8.11 4.80 
cellular response to organic cyclic 
compound 
19.69 2.80E-09 12.83 4.50 
regulation of leukocyte mediated 
cytotoxicity 
19.68 2.82E-09 24.59 5.29 
regulation of phosphate metabolic 
process 
19.54 3.27E-09 7.31 4.79 
activation of immune response 19.51 3.35E-09 17.70 4.86 
regulation of interferon-gamma 
production 
19.44 3.60E-09 24.19 5.25 
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regulation of phosphorus metabolic 
process 
19.37 3.88E-09 7.28 4.79 
positive regulation of leukocyte 
proliferation 
19.36 3.90E-09 19.57 5.27 
negative regulation of cellular 
process 
19.36 3.92E-09 5.89 4.69 
regulation of biological process 19.24 4.39E-09 4.55 4.71 
positive regulation of leukocyte 
mediated cytotoxicity 
19.21 4.54E-09 25.93 5.40 
regulation of biological quality 19.15 4.81E-09 6.39 4.82 
positive regulation of lymphocyte 
activation 
19.14 4.87E-09 15.83 5.29 
regulation of inflammatory 
response 
19.01 5.53E-09 14.55 5.05 
positive regulation of leukocyte 
differentiation 
18.90 6.17E-09 20.24 4.61 
negative regulation of immune 
system process 
18.89 6.25E-09 14.46 5.02 
cytokine-mediated signaling 
pathway 
18.85 6.51E-09 16.28 5.40 
response to organonitrogen 
compound 
18.51 9.12E-09 8.53 4.55 
lymphocyte mediated immunity 18.48 9.46E-09 30.00 4.11 
regulation of natural killer cell 
chemotaxis 
18.05 1.45E-08 85.71 6.11 
locomotion 17.99 1.54E-08 8.98 4.79 
positive regulation of mononuclear 
cell proliferation 
17.98 1.55E-08 19.10 5.38 
regulation of lymphocyte apoptotic 
process 
17.86 1.75E-08 28.57 4.88 
regulation of T cell mediated 
cytotoxicity 
17.86 1.75E-08 28.57 5.61 
regulation of sequence-specific 
DNA binding transcription factor 
activity 
17.79 1.88E-08 12.12 5.05 
regulation of metabolic process 17.68 2.09E-08 5.24 4.72 
regulation of protein transport 17.55 2.38E-08 11.41 4.82 
defense response to protozoan 17.43 2.70E-08 50.00 5.10 
regulation of lymphocyte 
chemotaxis 
17.43 2.70E-08 50.00 5.95 
positive regulation of interleukin-6 
production 
17.26 3.20E-08 30.56 5.34 
positive regulation of cytokine 
secretion 
17.21 3.36E-08 24.53 4.92 
positive regulation of nitric oxide 
biosynthetic process 
17.12 3.68E-08 34.48 4.78 
positive regulation of I-kappaB 
kinase/NF-kappaB signaling 
17.03 4.02E-08 16.98 5.49 
regulation of ERK1 and ERK2 
cascade 
17.00 4.12E-08 16.10 5.16 
regulation of phagocytosis 16.94 4.40E-08 29.73 4.85 
transport 16.88 4.65E-08 5.92 4.58 
regulation of establishment of 
protein localization 
16.82 4.96E-08 10.80 4.95 
positive regulation of phosphorus 
metabolic process 
16.81 5.02E-08 8.44 4.92 
positive regulation of phosphate 
metabolic process 
16.81 5.02E-08 8.44 4.92 
positive regulation of 
macromolecule metabolic process 
16.79 5.12E-08 6.41 4.57 
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response to interferon-alpha 16.78 5.16E-08 58.33 5.31 
regulation of calcium ion transport 16.72 5.45E-08 15.83 5.11 
regulation of macrophage 
chemotaxis 
16.69 5.63E-08 75.00 4.77 
positive regulation of NF-kappaB 
transcription factor activity 
16.67 5.73E-08 20.00 5.15 
response to abiotic stimulus 16.66 5.83E-08 7.64 4.74 
antigen processing and 
presentation of endogenous 
peptide antigen 
16.63 5.99E-08 100.00 6.92 
positive regulation of T cell 
mediated cytotoxicity 
16.63 5.99E-08 28.95 5.78 
positive regulation of ion transport 16.59 6.25E-08 15.70 5.21 
positive regulation of sequence-
specific DNA binding transcription 
factor activity 
16.51 6.74E-08 14.93 5.42 
regulation of T cell mediated 
immunity 
16.50 6.84E-08 23.21 5.57 
positive regulation of T cell 
mediated immunity 
16.47 7.03E-08 25.53 5.73 
positive regulation of lymphocyte 
proliferation 
16.28 8.51E-08 18.18 5.46 
positive regulation of interleukin-8 
production 
16.27 8.62E-08 44.44 5.42 
regulation of multicellular 
organismal development 
16.25 8.74E-08 7.00 4.37 
T cell activation 16.14 9.83E-08 14.60 4.65 
biological_process 16.11 1.01E-07 3.99 4.68 
neutrophil migration 16.05 1.08E-07 31.25 3.77 
neutrophil chemotaxis 16.05 1.08E-07 31.25 3.77 
innate immune response-activating 
signal transduction 
16.05 1.08E-07 31.25 4.61 
lymphocyte chemotaxis 16.04 1.08E-07 53.85 6.70 
cell migration 15.99 1.14E-07 9.34 4.92 
defense response to Gram-positive 
bacterium 
15.97 1.16E-07 24.49 4.82 
positive regulation of phagocytosis 15.96 1.17E-07 36.00 4.83 
cell activation involved in immune 
response 
15.95 1.19E-07 18.99 4.89 
leukocyte activation involved in 
immune response 
15.95 1.19E-07 18.99 4.89 
regulation of interleukin-6 
production 
15.84 1.31E-07 20.29 5.07 
regulation of vasculature 
development 
15.79 1.39E-07 13.73 5.04 
regulation of angiogenesis 15.77 1.42E-07 14.29 5.07 
lymphocyte activation 15.77 1.42E-07 11.96 4.48 
positive regulation of lymphocyte 
migration 
15.75 1.44E-07 42.11 5.84 
antigen processing and 
presentation of exogenous peptide 
antigen 
15.75 1.44E-07 42.11 4.77 
regulation of leukocyte 
differentiation 
15.68 1.56E-07 13.64 4.63 
positive regulation of cell 
differentiation 
15.67 1.56E-07 9.09 4.38 
regulation of mononuclear cell 
migration 
15.63 1.64E-07 66.67 4.69 
regulation of protein secretion 15.60 1.68E-07 15.52 4.59 
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regulation of NF-kappaB import 
into nucleus 
15.57 1.74E-07 34.62 4.99 
positive regulation of chemokine 
production 
15.57 1.74E-07 34.62 5.59 
regulation of toll-like receptor 
signaling pathway 
15.57 1.74E-07 34.62 4.96 
positive regulation of 
phosphorylation 
15.56 1.75E-07 8.57 4.68 
cellular response to stimulus 15.48 1.90E-07 4.92 4.71 
leukocyte cell-cell adhesion 15.40 2.05E-07 29.41 5.29 
ion transport 15.39 2.07E-07 7.74 4.41 
regulation of primary metabolic 
process 
15.39 2.08E-07 5.26 4.74 
positive regulation of protein 
transport 
15.34 2.17E-07 13.38 4.97 
establishment of localization 15.30 2.26E-07 5.75 4.58 
response to protozoan 15.27 2.33E-07 40.00 5.10 
toll-like receptor signaling pathway 15.27 2.33E-07 40.00 4.80 
regulation of type I interferon 
production 
15.19 2.52E-07 33.33 6.09 
regulation of macromolecule 
metabolic process 
15.11 2.75E-07 5.27 4.72 
regulation of cellular localization 15.08 2.83E-07 7.88 4.83 
regulation of protein localization 15.06 2.88E-07 9.62 4.84 
positive regulation of ERK1 and 
ERK2 cascade 
14.94 3.24E-07 17.65 5.38 
response to ionizing radiation 14.89 3.42E-07 15.60 5.17 
positive regulation of macrophage 
chemotaxis 
14.87 3.49E-07 83.33 4.93 
secretion by cell 14.86 3.51E-07 11.42 5.08 
regulation of protein 
phosphorylation 
14.85 3.56E-07 7.90 4.76 
negative regulation of innate 
immune response 
14.83 3.64E-07 38.10 5.95 
eosinophil chemotaxis 14.74 3.97E-07 60.00 5.41 
regulation of antigen processing 
and presentation 
14.74 3.97E-07 60.00 5.38 
regulation of cellular protein 
metabolic process 
14.72 4.04E-07 6.83 4.82 
positive regulation of catalytic 
activity 
14.64 4.39E-07 8.01 4.67 
peptide antigen binding 14.52 4.94E-07 27.03 5.84 
regulation of cytokine secretion 14.42 5.48E-07 18.18 4.81 
acute inflammatory response 14.40 5.59E-07 21.43 4.58 
positive regulation of protein 
secretion 
14.25 6.46E-07 17.95 4.85 
negative regulation of leukocyte 
apoptotic process 
14.25 6.48E-07 26.32 5.06 
cellular chemical homeostasis 14.24 6.54E-07 9.63 5.27 
immunoglobulin mediated immune 
response 
14.24 6.57E-07 43.75 4.11 
regulation of protein modification 
process 
14.23 6.61E-07 7.27 4.90 
regulation of cellular metabolic 
process 
14.22 6.70E-07 5.19 4.68 
regulation of anatomical structure 
morphogenesis 
14.20 6.78E-07 8.25 4.76 
pattern recognition receptor 14.17 6.99E-07 30.00 4.75 
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signaling pathway 
response to alcohol 14.17 7.00E-07 9.60 5.14 
positive regulation of MAPK 
cascade 
14.06 7.86E-07 10.66 5.00 
eosinophil migration 13.98 8.46E-07 54.55 5.41 
response to drug 13.91 9.12E-07 8.99 5.27 
regulation of endocytosis 13.90 9.16E-07 15.38 4.80 
regulation of catalytic activity 13.90 9.22E-07 6.60 4.76 
regulation of MAPK cascade 13.83 9.81E-07 9.12 4.84 
positive regulation of T cell 
proliferation 
13.80 1.01E-06 20.34 5.65 
cellular response to mechanical 
stimulus 
13.80 1.01E-06 20.34 5.01 
cellular response to external 
stimulus 
13.78 1.03E-06 12.66 5.48 
regulation of interleukin-8 
production 
13.73 1.09E-06 25.00 5.45 
regulation of cytokine-mediated 
signaling pathway 
13.73 1.09E-06 25.00 5.99 
positive regulation of inflammatory 
response 
13.61 1.23E-06 20.00 5.18 
response to gamma radiation 13.59 1.26E-06 22.00 5.42 
regulation of chemokine 
production 
13.48 1.39E-06 24.39 5.39 
immune response-activating signal 
transduction 
13.47 1.42E-06 16.87 4.31 
response to hormone 13.46 1.42E-06 7.45 4.61 
cell motility 13.39 1.53E-06 8.41 4.92 
regulation of transcription factor 
import into nucleus 
13.38 1.55E-06 21.57 4.65 
NIK/NF-kappaB signaling 13.30 1.67E-06 100.00 5.30 
immune response-inhibiting cell 
surface receptor signaling pathway 
13.30 1.67E-06 100.00 3.97 
2'-5'-oligoadenylate synthetase 
activity 
13.30 1.67E-06 100.00 6.23 
positive regulation of protein 
metabolic process 
13.29 1.70E-06 7.41 4.50 
regulation of granulocyte 
chemotaxis 
13.28 1.70E-06 32.00 5.42 
positive regulation of transcription 
factor import into nucleus 
13.28 1.70E-06 32.00 5.02 
B cell mediated immunity 13.28 1.72E-06 38.89 4.11 
secretion 13.22 1.82E-06 9.54 4.88 
MAPK cascade 13.19 1.87E-06 15.46 4.59 
positive regulation of angiogenesis 13.17 1.90E-06 16.47 5.09 
regulation of cell-cell adhesion 13.06 2.12E-06 19.05 5.07 
positive regulation of stress-
activated protein kinase signaling 
cascade 
12.97 2.33E-06 20.75 5.56 
regulation of metal ion transport 12.97 2.34E-06 11.60 4.95 
aging 12.96 2.35E-06 11.22 5.94 
exocytosis 12.92 2.44E-06 15.15 5.22 
negative regulation of response to 
stimulus 
12.89 2.53E-06 7.24 4.90 
positive regulation of T cell 
differentiation 
12.79 2.80E-06 22.73 4.63 
cellular response to abiotic 12.77 2.83E-06 12.34 4.76 
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stimulus 
myeloid dendritic cell activation 12.73 2.95E-06 46.15 4.64 
homeostatic process 12.62 3.29E-06 7.00 5.02 
response to extracellular stimulus 12.57 3.47E-06 9.24 5.56 
regulation of response to cytokine 
stimulus 
12.57 3.49E-06 22.22 5.99 
negative regulation of cell 
activation 
12.54 3.58E-06 14.71 4.39 
signal transduction by 
phosphorylation 
12.54 3.59E-06 13.91 4.53 
single-organism developmental 
process 
12.51 3.67E-06 5.11 4.61 
wound healing 12.46 3.86E-06 16.67 4.59 
regulation of cellular process 12.41 4.09E-06 4.39 4.64 
negative regulation of cell 
proliferation 
12.32 4.48E-06 8.51 4.51 
positive regulation of endocytosis 12.22 4.94E-06 19.30 5.01 
regulation of monocyte chemotaxis 12.20 5.01E-06 42.86 5.16 
positive regulation of NF-kappaB 
import into nucleus 
12.20 5.01E-06 42.86 5.66 
positive regulation of cellular 
component organization 
12.15 5.31E-06 7.97 4.70 
lymphocyte migration 12.07 5.70E-06 33.33 6.70 
leukocyte mediated cytotoxicity 12.07 5.70E-06 33.33 3.26 
regulation of cell shape 12.07 5.76E-06 17.39 4.93 
positive regulation of cell-cell 
adhesion 
12.03 5.95E-06 27.59 5.61 
positive regulation of reactive 
oxygen species metabolic process 
12.03 5.95E-06 27.59 4.25 
anion transport 11.99 6.21E-06 9.77 4.02 
negative regulation of leukocyte 
activation 
11.95 6.49E-06 14.89 4.41 
positive regulation of antigen 
processing and presentation 
11.92 6.69E-06 55.56 5.73 
regulation of interferon-alpha 
production 
11.92 6.69E-06 55.56 6.34 
positive regulation of programmed 
cell death 
11.83 7.31E-06 9.45 5.17 
positive regulation of hydrolase 
activity 
11.83 7.31E-06 9.45 4.70 
cellular cation homeostasis 11.78 7.62E-06 9.65 5.27 
negative regulation of lymphocyte 
activation 
11.75 7.86E-06 15.66 4.53 
regulation of interleukin-1 
production 
11.75 7.86E-06 26.67 4.31 
cytokine metabolic process 11.72 8.10E-06 40.00 4.74 
regulation of T cell apoptotic 
process 
11.72 8.10E-06 31.82 5.22 
positive regulation of natural killer 
cell chemotaxis 
11.72 8.12E-06 80.00 6.34 
ISG15-protein conjugation 11.72 8.12E-06 80.00 6.20 
immune response-inhibiting signal 
transduction 
11.72 8.12E-06 80.00 3.97 
response to mechanical stimulus 11.69 8.40E-06 11.92 5.02 
regulation of homeostatic process 11.60 9.18E-06 10.04 5.10 
response to toxic substance 11.55 9.60E-06 12.32 4.56 
cellular homeostasis 11.51 1.00E-05 8.31 5.25 
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T cell proliferation 11.49 1.03E-05 25.81 5.06 
regulation of intracellular 
transport 
11.48 1.03E-05 9.72 5.11 
positive regulation of lymphocyte 
differentiation 
11.37 1.15E-05 19.61 4.63 
positive regulation of cellular 
protein metabolic process 
11.34 1.19E-05 7.28 4.56 
negative regulation of NF-kappaB 
transcription factor activity 
11.33 1.20E-05 21.95 4.71 
regulation of vesicle-mediated 
transport 
11.31 1.23E-05 10.45 4.41 
positive regulation of monocyte 
chemotaxis 
11.25 1.30E-05 50.00 5.53 
response to inorganic substance 11.25 1.31E-05 8.21 5.67 
negative regulation of defense 
response 
11.23 1.33E-05 14.94 5.09 
positive regulation of cell death 11.20 1.37E-05 8.94 5.08 
positive regulation of stress-
activated MAPK cascade 
11.19 1.38E-05 19.23 5.78 
regulation of stress-activated 
protein kinase signaling cascade 
11.15 1.44E-05 13.16 5.43 
cellular ion homeostasis 11.13 1.47E-05 9.29 5.27 
response to peptide 11.07 1.56E-05 9.06 4.80 
positive regulation of apoptotic 
process 
11.00 1.67E-05 9.23 5.23 
positive regulation of interleukin-1 
beta production 
10.88 1.88E-05 35.29 4.52 
positive regulation of type I 
interferon production 
10.88 1.88E-05 35.29 6.16 
regulation of cell differentiation 10.85 1.93E-05 6.36 4.23 
negative regulation of programmed 
cell death 
10.80 2.05E-05 7.80 5.09 
organ development 10.79 2.06E-05 6.35 4.86 
positive regulation of interferon-
gamma production 
10.75 2.15E-05 23.53 5.42 
positive regulation of JNK cascade 10.72 2.21E-05 20.45 5.94 
chemical homeostasis 10.71 2.22E-05 7.39 5.16 
cytokine biosynthetic process 10.68 2.31E-05 45.45 5.00 
integrin-mediated signaling 
pathway 
10.67 2.31E-05 18.18 3.98 
positive regulation of homeostatic 
process 
10.67 2.31E-05 18.18 5.86 
T-helper 1 type immune response 10.65 2.37E-05 66.67 5.11 
cellular extravasation 10.65 2.37E-05 66.67 3.70 
antigen processing and 
presentation via MHC class Ib 
10.65 2.37E-05 66.67 5.25 
phosphorylation 10.61 2.48E-05 7.53 4.37 
negative regulation of cell death 10.56 2.59E-05 7.52 4.97 
positive regulation of protein 
phosphorylation 
10.54 2.64E-05 7.92 4.73 
response to nutrient levels 10.53 2.67E-05 8.78 5.67 
T cell activation involved in 
immune response 
10.52 2.70E-05 22.86 5.00 
macrophage activation 10.51 2.74E-05 33.33 5.52 
positive regulation of interleukin-1 
production 
10.51 2.74E-05 33.33 4.52 
cation homeostasis 10.51 2.74E-05 8.60 5.37 
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regulation of myeloid leukocyte 
mediated immunity 
10.50 2.76E-05 26.92 4.18 
regulation of interleukin-1 beta 
production 
10.50 2.76E-05 26.92 4.44 
inflammatory response to antigenic 
stimulus 
10.50 2.76E-05 26.92 4.63 
immune response-regulating cell 
surface receptor signaling pathway 
10.46 2.87E-05 16.18 3.92 
negative regulation of locomotion 10.45 2.90E-05 11.33 5.34 
developmental process 10.44 2.92E-05 4.89 4.59 
response to steroid hormone 10.42 2.99E-05 7.99 4.55 
regulation of JNK cascade 10.38 3.12E-05 13.83 5.67 
negative regulation of apoptotic 
process 
10.34 3.24E-05 7.73 5.10 
positive regulation of intracellular 
transport 
10.33 3.26E-05 12.30 5.39 
cell killing 10.23 3.61E-05 25.93 3.26 
regulation of ion transport 10.21 3.68E-05 8.80 5.04 
regulation of reactive oxygen 
species metabolic process 
10.19 3.74E-05 17.24 4.71 
inorganic anion transport 10.18 3.79E-05 15.71 4.47 
myeloid dendritic cell 
differentiation 
10.17 3.84E-05 41.67 4.10 
positive regulation of interleukin-1 
secretion 
10.17 3.84E-05 41.67 4.78 
positive regulation of interleukin-1 
beta secretion 
10.17 3.84E-05 41.67 4.78 
positive regulation of calcium ion 
import 
10.17 3.84E-05 41.67 4.46 
positive regulation of toll-like 
receptor signaling pathway 
10.17 3.84E-05 41.67 5.06 
positive regulation of cytokine 
biosynthetic process 
10.16 3.86E-05 19.15 4.88 
regulation of cytokine biosynthetic 
process 
10.04 4.35E-05 15.49 4.72 
interspecies interaction between 
organisms 
10.04 4.35E-05 15.49 5.25 
positive regulation of smooth 
muscle cell proliferation 
9.99 4.60E-05 18.75 4.18 
negative regulation of mononuclear 
cell proliferation 
9.99 4.60E-05 18.75 4.63 
negative regulation of lymphocyte 
proliferation 
9.99 4.60E-05 18.75 4.63 
apoptotic signaling pathway 9.99 4.60E-05 10.53 5.49 
negative regulation of protein 
metabolic process 
9.98 4.64E-05 8.06 4.95 
alpha-beta T cell activation 9.97 4.66E-05 25.00 4.49 
regulation of interleukin-12 
production 
9.97 4.66E-05 25.00 4.61 
response to type I interferon 9.97 4.67E-05 100.00 7.61 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class Ib 
9.97 4.67E-05 100.00 5.88 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class I 
9.97 4.67E-05 100.00 7.54 
regulation of T cell differentiation 9.91 4.97E-05 15.28 4.85 
cell death 9.90 4.99E-05 8.31 4.77 
tolerance induction 9.83 5.37E-05 57.14 4.72 
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response to platelet-derived 
growth factor 
9.83 5.37E-05 57.14 4.54 
cellular response to platelet-
derived growth factor stimulus 
9.83 5.37E-05 57.14 4.54 
negative regulation of interleukin-
12 production 
9.83 5.37E-05 57.14 3.66 
activated T cell proliferation 9.83 5.37E-05 57.14 3.99 
negative regulation of viral 
transcription 
9.83 5.38E-05 30.00 6.71 
regulation of stress-activated MAPK 
cascade 
9.82 5.46E-05 12.39 5.58 
cellular response to endogenous 
stimulus 
9.77 5.70E-05 7.16 4.56 
endothelial cell migration 9.73 5.96E-05 24.14 4.47 
response to temperature stimulus 9.72 6.02E-05 12.28 4.88 
regulation of myeloid cell 
differentiation 
9.72 6.02E-05 12.28 4.38 
regulation of interleukin-1 beta 
secretion 
9.71 6.06E-05 38.46 4.78 
cellular process 9.70 6.15E-05 4.07 4.61 
regulation of peptidyl-tyrosine 
phosphorylation 
9.67 6.30E-05 11.11 4.78 
negative regulation of leukocyte 
proliferation 
9.65 6.44E-05 18.00 4.63 
chloride transport 9.65 6.44E-05 18.00 4.32 
cellular developmental process 9.64 6.54E-05 5.43 4.33 
regulation of proteolysis 9.59 6.83E-05 8.16 4.89 
programmed cell death 9.59 6.85E-05 8.47 4.89 
intracellular signal transduction 9.55 7.13E-05 6.34 4.68 
death 9.54 7.19E-05 8.13 4.77 
myeloid cell activation involved in 
immune response 
9.52 7.30E-05 28.57 4.70 
regulation of protein processing 9.51 7.43E-05 7.98 4.96 
modification of morphology or 
physiology of other organism 
involved in symbiotic interaction 
9.50 7.52E-05 20.00 4.46 
response to exogenous dsRNA 9.49 7.53E-05 23.33 5.03 
cellular component movement 9.41 8.22E-05 6.70 4.60 
cellular response to nitrogen 
compound 
9.37 8.52E-05 8.36 5.00 
regulation of response to biotic 
stimulus 
9.33 8.87E-05 17.31 4.86 
negative regulation of multicellular 
organismal process 
9.32 8.93E-05 8.51 4.52 
negative regulation of sequence-
specific DNA binding transcription 
factor activity 
9.32 9.00E-05 13.33 4.94 
intracellular pH reduction 9.30 9.14E-05 35.71 5.58 
regulation of membrane protein 
ectodomain proteolysis 
9.30 9.14E-05 35.71 4.93 
regulation of viral entry into host 
cell 
9.30 9.14E-05 35.71 5.97 
regulation of secretion 9.29 9.24E-05 7.63 4.42 
dendritic cell differentiation 9.24 9.74E-05 27.27 3.97 
positive regulation of ion 
transmembrane transport 
9.24 9.74E-05 27.27 4.31 
response to lipoteichoic acid 9.17 1.04E-04 50.00 4.85 
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cellular response to lipoteichoic 
acid 
9.17 1.04E-04 50.00 4.85 
I-kappaB phosphorylation 9.17 1.04E-04 50.00 5.25 
response to peptidoglycan 9.17 1.04E-04 50.00 4.31 
response to muramyl dipeptide 9.17 1.04E-04 50.00 4.38 
negative regulation of natural 
killer cell mediated immunity 
9.17 1.04E-04 50.00 6.24 
negative regulation of natural 
killer cell mediated cytotoxicity 
9.17 1.04E-04 50.00 6.24 
basic amino acid transport 9.17 1.04E-04 50.00 3.96 
response to oxidative stress 9.14 1.07E-04 8.80 5.06 
response to progesterone 9.13 1.08E-04 19.05 4.92 
modification of morphology or 
physiology of other organism 
9.13 1.08E-04 19.05 4.46 
ion homeostasis 9.09 1.13E-04 7.92 5.37 
response to metal ion 9.08 1.14E-04 8.76 5.96 
regulation of intracellular pH 8.97 1.28E-04 26.09 5.11 
regulation of interferon-beta 
production 
8.97 1.28E-04 26.09 5.95 
regulation of natural killer cell 
mediated immunity 
8.97 1.28E-04 26.09 5.57 
regulation of natural killer cell 
mediated cytotoxicity 
8.97 1.28E-04 26.09 5.57 
regulation of interleukin-1 
secretion 
8.92 1.33E-04 33.33 4.78 
positive regulation of cytokine-
mediated signaling pathway 
8.92 1.33E-04 33.33 5.76 
pH reduction 8.92 1.33E-04 33.33 5.58 
regulation of myeloid leukocyte 
differentiation 
8.92 1.33E-04 14.93 4.38 
negative regulation of cytokine 
production 
8.89 1.38E-04 12.77 4.79 
positive regulation of secretion 8.87 1.41E-04 9.09 4.76 
positive regulation of multi-
organism process 
8.85 1.44E-04 21.21 5.48 
regulation of protein localization 
to nucleus 
8.82 1.48E-04 11.93 4.54 
regulation of wound healing 8.80 1.51E-04 14.71 4.55 
negative regulation of 
phosphorylation 
8.74 1.60E-04 9.27 4.82 
regulation of hydrolase activity 8.73 1.61E-04 6.80 4.63 
positive regulation of acute 
inflammatory response 
8.71 1.65E-04 25.00 5.59 
positive regulation of 
transmembrane transport 
8.71 1.65E-04 25.00 4.31 
positive regulation of production of 
molecular mediator of immune 
response 
8.71 1.65E-04 25.00 4.64 
regulation of cellular response to 
stress 
8.68 1.69E-04 8.53 5.27 
regulation of cytokine production 
involved in immune response 
8.65 1.76E-04 20.59 4.16 
regulation of ion homeostasis 8.63 1.78E-04 11.71 5.09 
regulation of type IIa 
hypersensitivity 
8.61 1.82E-04 75.00 4.37 
positive regulation of type IIa 
hypersensitivity 
8.61 1.82E-04 75.00 4.37 
regulation of type II 
hypersensitivity 
8.61 1.82E-04 75.00 4.37 
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positive regulation of type II 
hypersensitivity 
8.61 1.82E-04 75.00 4.37 
regulation of dendritic cell antigen 
processing and presentation 
8.61 1.82E-04 75.00 5.22 
positive regulation of dendritic cell 
antigen processing and 
presentation 
8.61 1.82E-04 75.00 5.22 
positive regulation of integrin 
activation 
8.61 1.82E-04 75.00 4.80 
positive regulation of RIG-I 
signaling pathway 
8.61 1.82E-04 75.00 5.82 
antigen processing and 
presentation of peptide antigen via 
MHC class Ib 
8.61 1.82E-04 75.00 5.88 
protection from natural killer cell 
mediated cytotoxicity 
8.61 1.82E-04 75.00 7.07 
negative regulation of immune 
response 
8.60 1.85E-04 15.79 5.77 
cell differentiation 8.59 1.87E-04 5.74 4.37 
positive regulation of leukocyte 
apoptotic process 
8.58 1.88E-04 31.25 5.31 
granulocyte activation 8.58 1.88E-04 31.25 4.28 
positive regulation of response to 
cytokine stimulus 
8.58 1.88E-04 31.25 5.76 
positive regulation of biosynthetic 
process 
8.57 1.90E-04 5.85 4.42 
regulation of cell adhesion 8.55 1.93E-04 9.13 4.87 
regulation of nucleocytoplasmic 
transport 
8.55 1.94E-04 11.02 5.13 
nitrogen compound transport 8.47 2.11E-04 8.40 4.65 
negative regulation of lymphocyte 
apoptotic process 
8.46 2.11E-04 24.00 5.48 
membrane docking 8.46 2.11E-04 24.00 4.51 
vesicle fusion 8.46 2.11E-04 24.00 4.92 
regulation of cellular pH 8.46 2.11E-04 24.00 5.11 
positive regulation of nitrogen 
compound metabolic process 
8.46 2.12E-04 5.92 4.61 
lymphocyte activation involved in 
immune response 
8.46 2.12E-04 15.52 4.88 
positive regulation of myeloid 
leukocyte differentiation 
8.46 2.13E-04 20.00 4.58 
regulation of extrinsic apoptotic 
signaling pathway 
8.39 2.27E-04 12.12 5.81 
positive regulation of protein 
modification process 
8.34 2.38E-04 6.88 4.78 
positive regulation of myeloid cell 
differentiation 
8.33 2.42E-04 15.25 4.70 
cell adhesion 8.32 2.44E-04 7.13 4.42 
negative regulation of response to 
external stimulus 
8.30 2.49E-04 10.77 4.57 
regulation of nitrogen compound 
metabolic process 
8.29 2.52E-04 4.99 4.59 
biological adhesion 8.28 2.54E-04 7.11 4.42 
response to dsRNA 8.27 2.56E-04 19.44 5.03 
regulation of T cell migration 8.26 2.58E-04 29.41 6.12 
positive regulation of neutrophil 
migration 
8.26 2.58E-04 29.41 5.43 
regulation of apoptotic signaling 
pathway 
8.16 2.87E-04 8.62 5.31 
response to reactive oxygen 8.14 2.92E-04 10.61 5.31 
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species 
response to ethanol 8.14 2.92E-04 10.61 5.91 
positive regulation of macrophage 
differentiation 
8.13 2.95E-04 40.00 3.79 
T cell migration 8.13 2.95E-04 40.00 5.66 
chaperone mediated protein 
folding requiring cofactor 
8.13 2.95E-04 40.00 4.88 
negative regulation of viral entry 
into host cell 
8.13 2.95E-04 40.00 5.71 
oligopeptide transport 8.13 2.95E-04 40.00 5.46 
leukocyte differentiation 8.12 2.99E-04 9.39 4.11 
regulation of protein import into 
nucleus 
8.11 3.00E-04 11.76 4.70 
response to peptide hormone 8.09 3.05E-04 8.18 4.88 
regulation of gliogenesis 8.07 3.14E-04 14.75 4.10 
positive regulation of cellular 
biosynthetic process 
8.03 3.24E-04 5.79 4.43 
positive regulation of lipid 
metabolic process 
7.97 3.46E-04 12.36 5.12 
regulation of vascular endothelial 
growth factor production 
7.97 3.47E-04 27.78 5.48 
T cell mediated immunity 7.97 3.47E-04 27.78 4.11 
regulation of production of 
molecular mediator of immune 
response 
7.94 3.55E-04 14.52 4.41 
positive regulation of peptidyl-
tyrosine phosphorylation 
7.93 3.60E-04 11.54 4.60 
regulation of cellular component 
organization 
7.88 3.78E-04 5.62 4.59 
negative regulation of phosphorus 
metabolic process 
7.88 3.79E-04 8.44 4.78 
negative regulation of phosphate 
metabolic process 
7.88 3.79E-04 8.44 4.78 
cellular metal ion homeostasis 7.88 3.79E-04 8.44 5.40 
single-organism membrane fusion 7.87 3.83E-04 16.00 4.59 
intrinsic apoptotic signaling 
pathway in response to DNA 
damage 
7.87 3.83E-04 16.00 4.92 
regulation of smooth muscle cell 
proliferation 
7.87 3.84E-04 13.16 4.02 
response to nutrient 7.86 3.86E-04 9.19 5.75 
angiogenesis 7.83 3.97E-04 10.29 4.34 
negative regulation of T cell 
activation 
7.82 4.02E-04 14.29 4.80 
regulation of lymphocyte 
differentiation 
7.77 4.20E-04 12.09 4.85 
organic substance transport 7.76 4.26E-04 5.70 4.55 
positive regulation of myeloid 
leukocyte mediated immunity 
7.72 4.42E-04 60.00 4.37 
T cell chemotaxis 7.72 4.42E-04 60.00 5.89 
positive regulation of cell-cell 
adhesion mediated by integrin 
7.72 4.42E-04 60.00 6.67 
endothelial cell chemotaxis 7.72 4.42E-04 60.00 5.10 
hydrogen peroxide biosynthetic 
process 
7.72 4.42E-04 60.00 5.58 
antigen processing and 
presentation of exogenous peptide 
antigen via MHC class I 
7.72 4.42E-04 60.00 4.81 
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membrane to membrane docking 7.72 4.42E-04 60.00 5.87 
type I interferon biosynthetic 
process 
7.72 4.42E-04 60.00 6.03 
toll-like receptor 4 signaling 
pathway 
7.72 4.42E-04 60.00 4.65 
arginine transport 7.72 4.42E-04 60.00 4.36 
positive regulation of humoral 
immune response 
7.70 4.51E-04 36.36 4.71 
microglial cell activation 7.70 4.51E-04 36.36 5.81 
monocyte chemotaxis 7.70 4.51E-04 36.36 4.40 
macrophage chemotaxis 7.70 4.51E-04 36.36 4.40 
myeloid leukocyte mediated 
immunity 
7.70 4.51E-04 36.36 3.15 
regulation of B cell apoptotic 
process 
7.69 4.57E-04 26.32 4.41 
regulation of neutrophil migration 7.69 4.57E-04 26.32 5.43 
regulation of calcium ion import 7.69 4.57E-04 26.32 4.46 
positive regulation of 
phosphatidylinositol 3-kinase 
activity 
7.69 4.57E-04 26.32 4.82 
protein trimerization 7.60 5.00E-04 20.69 5.75 
protein kinase B signaling 7.60 5.00E-04 20.69 5.95 
regulation of viral transcription 7.60 5.00E-04 20.69 6.71 
cellular monovalent inorganic 
cation homeostasis 
7.60 5.00E-04 20.69 5.11 
activation of cysteine-type 
endopeptidase activity involved in 
apoptotic process 
7.59 5.04E-04 15.38 4.60 
cytokine production 7.59 5.04E-04 15.38 5.47 
regulation of hemostasis 7.59 5.04E-04 15.38 4.67 
regulation of blood coagulation 7.59 5.04E-04 15.38 4.67 
cellular response to organonitrogen 
compound 
7.59 5.04E-04 7.89 4.91 
regulation of tyrosine 
phosphorylation of STAT protein 
7.59 5.05E-04 17.50 4.51 
epithelial cell migration 7.59 5.05E-04 17.50 4.47 
leukocyte proliferation 7.58 5.09E-04 13.85 4.94 
protein processing 7.58 5.09E-04 6.83 5.39 
peptidyl-tyrosine phosphorylation 7.55 5.26E-04 12.66 4.08 
negative regulation of cell 
migration 
7.54 5.32E-04 10.48 5.23 
negative regulation of cellular 
protein metabolic process 
7.53 5.38E-04 7.55 5.03 
positive regulation of 
endopeptidase activity 
7.49 5.56E-04 11.70 5.12 
response to vitamin 7.49 5.56E-04 11.70 5.80 
single organism cell adhesion 7.48 5.63E-04 9.20 4.85 
carboxylic acid transport 7.46 5.73E-04 9.93 3.97 
positive regulation of protein 
import into nucleus 
7.46 5.75E-04 15.09 5.02 
regulation of acute inflammatory 
response 
7.44 5.90E-04 17.07 5.83 
regulation of humoral immune 
response 
7.43 5.92E-04 25.00 5.22 
response to ATP 7.43 5.92E-04 25.00 5.44 
positive regulation of lipid kinase 7.43 5.92E-04 25.00 4.82 
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activity 
antigen processing and 
presentation of peptide or 
polysaccharide antigen via MHC 
class II 
7.43 5.92E-04 25.00 4.52 
cytokine secretion 7.43 5.92E-04 25.00 4.55 
regulation of astrocyte 
differentiation 
7.43 5.92E-04 25.00 4.08 
cellular response to osmotic stress 7.43 5.92E-04 25.00 4.61 
metal ion homeostasis 7.40 6.11E-04 7.77 5.51 
organic acid transport 7.39 6.16E-04 9.86 3.97 
negative regulation of signal 
transduction 
7.37 6.30E-04 6.46 4.81 
positive regulation of cysteine-type 
endopeptidase activity involved in 
apoptotic process 
7.35 6.43E-04 12.35 4.96 
peptidyl-tyrosine modification 7.35 6.43E-04 12.35 4.08 
regulation of coagulation 7.33 6.54E-04 14.81 4.67 
negative regulation of immune 
effector process 
7.33 6.54E-04 14.81 5.32 
alpha-beta T cell activation 
involved in immune response 
7.33 6.57E-04 33.33 4.63 
positive regulation of B cell 
mediated immunity 
7.33 6.57E-04 33.33 4.02 
positive regulation of 
immunoglobulin mediated immune 
response 
7.33 6.57E-04 33.33 4.02 
negative regulation of leukocyte 
mediated cytotoxicity 
7.33 6.57E-04 33.33 6.24 
negative regulation of cell killing 7.33 6.57E-04 33.33 6.24 
positive regulation of transferase 
activity 
7.32 6.61E-04 7.89 4.90 
response to hydrogen peroxide 7.31 6.66E-04 11.46 5.02 
organic anion transport 7.31 6.66E-04 8.76 3.83 
regulation of biosynthetic process 7.30 6.77E-04 4.90 4.51 
organelle fusion 7.28 6.86E-04 16.67 4.72 
multicellular organismal 
homeostasis 
7.28 6.86E-04 16.67 6.19 
response to oxygen levels 7.27 6.94E-04 7.87 5.05 
protein maturation 7.26 7.06E-04 6.70 5.39 
regulation of cellular biosynthetic 
process 
7.25 7.10E-04 4.91 4.52 
regulation of G-protein coupled 
receptor protein signaling pathway 
7.25 7.13E-04 13.24 4.86 
regulation of actin filament length 7.25 7.13E-04 13.24 4.40 
regulation of actin polymerization 
or depolymerization 
7.25 7.13E-04 13.24 4.40 
negative regulation of cell motility 7.23 7.21E-04 10.16 5.23 
response to glucocorticoid 7.23 7.22E-04 8.99 4.73 
protein activation cascade 7.22 7.29E-04 19.35 6.52 
positive regulation of actin 
filament polymerization 
7.22 7.29E-04 19.35 4.82 
response to osmotic stress 7.21 7.41E-04 14.55 4.90 
response to estrogen 7.20 7.48E-04 8.67 4.95 
alpha-beta T cell differentiation 7.19 7.54E-04 23.81 4.38 
regulation of platelet activation 7.19 7.54E-04 23.81 3.70 
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positive regulation of response to 
biotic stimulus 
7.19 7.54E-04 23.81 5.38 
cellular response to fibroblast 
growth factor stimulus 
7.14 7.95E-04 16.28 5.81 
protein secretion 7.14 7.95E-04 16.28 4.55 
activation of cysteine-type 
endopeptidase activity 
7.08 8.38E-04 14.29 4.60 
myeloid leukocyte differentiation 7.08 8.38E-04 14.29 4.27 
regulation of actin filament 
polymerization 
7.08 8.38E-04 14.29 4.47 
astrocyte cell migration 7.06 8.60E-04 50.00 4.72 
cellular response to lipoprotein 
particle stimulus 
7.06 8.60E-04 50.00 6.87 
superoxide anion generation 7.06 8.60E-04 50.00 5.58 
regulation of viral-induced 
cytoplasmic pattern recognition 
receptor signaling pathway 
7.06 8.60E-04 50.00 5.82 
regulation of RIG-I signaling 
pathway 
7.06 8.60E-04 50.00 5.82 
fever generation 7.06 8.60E-04 50.00 5.89 
positive regulation of tolerance 
induction 
7.06 8.60E-04 50.00 4.03 
MyD88-dependent toll-like receptor 
signaling pathway 
7.06 8.60E-04 50.00 3.63 
oligopeptide transmembrane 
transport 
7.06 8.60E-04 50.00 5.73 
cellular response to exogenous 
dsRNA 
7.06 8.60E-04 50.00 5.64 
positive regulation of kinase 
activity 
7.05 8.67E-04 7.91 4.89 
response to cold 7.05 8.70E-04 18.75 5.52 
regulation of calcium-mediated 
signaling 
7.05 8.70E-04 18.75 3.89 
response to radiation 7.03 8.81E-04 7.72 5.14 
regulation of gene expression 7.03 8.84E-04 4.79 4.64 
response to decreased oxygen 
levels 
7.03 8.85E-04 8.09 5.20 
negative regulation of cellular 
component movement 
7.02 8.97E-04 9.92 5.23 
drug transport 6.99 9.22E-04 30.77 3.75 
phagocytosis, engulfment 6.99 9.22E-04 30.77 3.21 
chronic inflammatory response 6.99 9.22E-04 30.77 7.33 
antigen processing and 
presentation of exogenous peptide 
antigen via MHC class II 
6.99 9.22E-04 30.77 4.13 
regulation of phosphatidylinositol 
3-kinase activity 
6.96 9.47E-04 22.73 4.82 
chemokine-mediated signaling 
pathway 
6.96 9.47E-04 22.73 5.54 
positive regulation of peptidase 
activity 
6.89 1.02E-03 10.89 5.12 
regulation of cell morphogenesis 6.88 1.03E-03 7.98 4.45 
positive regulation of cysteine-type 
endopeptidase activity 
6.88 1.03E-03 11.63 4.96 
negative regulation of signaling 6.86 1.05E-03 6.22 4.89 
response to fibroblast growth 
factor 
6.86 1.05E-03 15.56 5.81 
regulation of protein kinase 
activity 
6.78 1.14E-03 6.93 4.97 
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response to corticosteroid 6.76 1.16E-03 8.60 4.73 
regulation of endopeptidase 
activity 
6.76 1.16E-03 8.11 5.06 
modification by host of symbiont 
morphology or physiology 
6.75 1.17E-03 21.74 4.87 
chaperone-mediated protein 
folding 
6.75 1.17E-03 21.74 4.69 
regulation of leukocyte 
degranulation 
6.75 1.17E-03 21.74 3.95 
regulation of extrinsic apoptotic 
signaling pathway via death 
domain receptors 
6.75 1.17E-03 21.74 5.98 
response to heat 6.73 1.20E-03 12.33 4.49 
positive regulation of epithelial 
cell proliferation 
6.72 1.20E-03 10.68 4.35 
response to organophosphorus 6.71 1.22E-03 10.08 4.57 
positive regulation of alpha-beta T 
cell activation 
6.71 1.22E-03 17.65 4.57 
establishment of endothelial 
barrier 
6.68 1.25E-03 28.57 4.30 
positive regulation vascular 
endothelial growth factor 
production 
6.68 1.25E-03 28.57 5.60 
negative regulation of I-kappaB 
kinase/NF-kappaB signaling 
6.68 1.25E-03 28.57 4.78 
regulation of macrophage 
differentiation 
6.68 1.25E-03 28.57 3.79 
glial cell migration 6.68 1.25E-03 28.57 4.73 
neutrophil activation 6.68 1.25E-03 28.57 4.64 
regulation of lipopolysaccharide-
mediated signaling pathway 
6.68 1.25E-03 28.57 4.08 
single organismal cell-cell adhesion 6.66 1.28E-03 9.15 4.84 
lymphocyte proliferation 6.62 1.33E-03 13.33 5.06 
regulation of transferase activity 6.61 1.35E-03 6.67 5.07 
regulation of nucleobase-
containing compound metabolic 
process 
6.60 1.36E-03 4.81 4.63 
regulation of kinase activity 6.60 1.36E-03 6.75 5.07 
regulation of calcium ion transport 
into cytosol 
6.59 1.37E-03 14.89 5.40 
positive regulation of tyrosine 
phosphorylation of STAT protein 
6.56 1.42E-03 17.14 4.16 
regulation of mast cell activation 6.54 1.44E-03 20.83 3.79 
regulation of cysteine-type 
endopeptidase activity involved in 
apoptotic process 
6.54 1.45E-03 9.42 4.76 
positive regulation of 
hypersensitivity 
6.53 1.46E-03 42.86 4.37 
interleukin-1 beta production 6.53 1.46E-03 42.86 6.81 
interleukin-1 production 6.53 1.46E-03 42.86 6.81 
cellular response to ATP 6.53 1.46E-03 42.86 4.70 
regulation of cell-cell adhesion 
mediated by integrin 
6.53 1.46E-03 42.86 6.67 
regulation of integrin activation 6.53 1.46E-03 42.86 4.80 
negative regulation of type I 
interferon production 
6.53 1.46E-03 42.86 6.48 
positive regulation of interferon-
alpha production 
6.53 1.46E-03 42.86 6.04 
positive regulation of chemokine 6.53 1.46E-03 42.86 6.50 
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biosynthetic process 
regulation of tolerance induction 6.53 1.46E-03 42.86 4.03 
positive regulation of 
nucleocytoplasmic transport 
6.51 1.49E-03 13.11 5.02 
mononuclear cell proliferation 6.51 1.49E-03 13.11 5.06 
negative regulation of protein 
phosphorylation 
6.50 1.51E-03 8.67 4.89 
apoptotic process 6.49 1.52E-03 7.55 4.66 
cellular response to drug 6.47 1.55E-03 14.58 6.42 
regeneration 6.43 1.62E-03 9.76 4.38 
myeloid cell differentiation 6.41 1.64E-03 10.28 3.97 
positive regulation of cytosolic 
calcium ion concentration 
6.41 1.64E-03 10.28 4.47 
membrane fusion 6.41 1.65E-03 12.90 4.59 
regulation of smooth muscle cell 
migration 
6.40 1.66E-03 16.67 4.80 
positive regulation of gliogenesis 6.40 1.66E-03 16.67 4.36 
membrane invagination 6.40 1.66E-03 26.67 3.21 
positive regulation of T cell 
migration 
6.40 1.66E-03 26.67 6.73 
CD4-positive, alpha-beta T cell 
differentiation 
6.40 1.66E-03 26.67 4.62 
regulation of homotypic cell-cell 
adhesion 
6.40 1.66E-03 26.67 5.05 
execution phase of apoptosis 6.40 1.66E-03 26.67 6.64 
antigen processing and 
presentation of peptide antigen via 
MHC class II 
6.40 1.66E-03 26.67 4.13 
positive regulation of interferon-
beta production 
6.40 1.66E-03 26.67 5.93 
cellular divalent inorganic cation 
homeostasis 
6.38 1.70E-03 8.29 4.99 
response to hypoxia 6.36 1.73E-03 7.83 5.09 
positive regulation of calcium ion 
transport into cytosol 
6.35 1.75E-03 20.00 6.10 
interaction with symbiont 6.35 1.75E-03 20.00 4.87 
positive regulation of protein 
complex assembly 
6.35 1.75E-03 11.69 4.81 
amino acid transport 6.35 1.75E-03 11.69 4.43 
response to alkaloid 6.34 1.77E-03 10.19 5.58 
regulation of peptidase activity 6.31 1.81E-03 7.79 5.06 
establishment of localization in 
cell 
6.29 1.86E-03 5.62 4.86 
intrinsic apoptotic signaling 
pathway 
6.27 1.88E-03 10.75 5.16 
proteolysis 6.25 1.93E-03 6.78 5.61 
negative regulation of cell 
communication 
6.17 2.09E-03 6.02 4.81 
regulation of lipid storage 6.17 2.10E-03 19.23 4.40 
regulation of lipid kinase activity 6.17 2.10E-03 19.23 4.82 
regulation of cell adhesion 
mediated by integrin 
6.17 2.10E-03 19.23 5.90 
regulation of defense response to 
virus 
6.17 2.10E-03 19.23 5.49 
positive regulation of neutrophil 
chemotaxis 
6.14 2.15E-03 25.00 5.39 
'de novo' posttranslational protein 6.14 2.15E-03 25.00 4.88 
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folding 
'de novo' protein folding 6.14 2.15E-03 25.00 4.88 
mast cell activation 6.14 2.15E-03 25.00 4.11 
negative regulation of protein 
modification process 
6.12 2.19E-03 7.66 5.12 
positive regulation of cell adhesion 6.12 2.21E-03 9.91 5.16 
chloride transmembrane transport 6.12 2.21E-03 15.79 4.43 
regulation of lipid metabolic 
process 
6.11 2.23E-03 8.33 5.04 
zymogen activation 6.10 2.25E-03 12.31 4.60 
peptide metabolic process 6.10 2.25E-03 12.31 5.65 
positive regulation of acute 
inflammatory response to antigenic 
stimulus 
6.08 2.28E-03 37.50 4.37 
regulation of cellular extravasation 6.08 2.28E-03 37.50 5.10 
positive regulation of interferon-
gamma biosynthetic process 
6.08 2.28E-03 37.50 5.65 
positive regulation of interleukin-2 
biosynthetic process 
6.08 2.28E-03 37.50 5.34 
respiratory burst 6.08 2.28E-03 37.50 5.01 
neutrophil activation involved in 
immune response 
6.08 2.28E-03 37.50 3.02 
multicellular organismal iron ion 
homeostasis 
6.08 2.28E-03 37.50 7.10 
negative regulation of nitric oxide 
biosynthetic process 
6.08 2.28E-03 37.50 4.56 
regulation of cysteine-type 
endopeptidase activity 
6.03 2.41E-03 8.90 4.76 
regulation of intracellular protein 
transport 
6.03 2.41E-03 8.90 5.05 
spleen development 5.99 2.50E-03 18.52 5.43 
negative regulation of T cell 
proliferation 
5.98 2.53E-03 15.38 5.17 
regulation of pH 5.98 2.53E-03 15.38 5.11 
phosphate-containing compound 
metabolic process 
5.92 2.67E-03 5.22 4.35 
cell communication 5.90 2.73E-03 6.92 4.89 
CD4-positive, alpha-beta T cell 
activation 
5.90 2.74E-03 23.53 4.62 
regulation of necrotic cell death 5.90 2.74E-03 23.53 5.54 
positive regulation of cytokine 
production involved in immune 
response 
5.90 2.74E-03 23.53 4.38 
membrane organization 5.90 2.75E-03 7.69 4.06 
positive regulation of protein 
kinase activity 
5.90 2.75E-03 7.50 4.89 
cellular calcium ion homeostasis 5.89 2.75E-03 8.15 4.87 
ion transmembrane transport 5.87 2.82E-03 6.78 4.46 
regulation of ossification 5.83 2.94E-03 9.09 4.01 
regulation of interleukin-10 
production 
5.82 2.96E-03 17.86 5.13 
interaction with host 5.82 2.96E-03 17.86 5.13 
reproductive process 5.79 3.05E-03 5.67 4.75 
monovalent inorganic cation 
homeostasis 
5.77 3.11E-03 12.96 5.05 
response to purine-containing 
compound 
5.77 3.12E-03 9.02 4.57 
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regulation of hypersensitivity 5.70 3.33E-03 33.33 4.37 
cellular response to ethanol 5.70 3.33E-03 33.33 8.78 
regulation of interferon-gamma 
biosynthetic process 
5.70 3.33E-03 33.33 5.65 
positive regulation of myeloid 
leukocyte cytokine production 
involved in immune response 
5.70 3.33E-03 33.33 4.13 
T cell mediated cytotoxicity 5.70 3.33E-03 33.33 3.34 
acute inflammatory response to 
antigenic stimulus 
5.70 3.33E-03 33.33 3.95 
negative regulation of astrocyte 
differentiation 
5.70 3.33E-03 33.33 3.57 
heat generation 5.70 3.33E-03 33.33 5.89 
negative regulation of viral release 
from host cell 
5.70 3.33E-03 33.33 6.08 
cellular response to oxidative 
stress 
5.70 3.34E-03 9.40 5.42 
transmembrane transport 5.69 3.39E-03 6.18 4.48 
response to insulin 5.68 3.42E-03 8.55 5.06 
positive regulation of granulocyte 
chemotaxis 
5.68 3.42E-03 22.22 5.39 
regulation of neutrophil 
chemotaxis 
5.68 3.42E-03 22.22 5.39 
positive regulation of osteoclast 
differentiation 
5.68 3.42E-03 22.22 5.23 
regulation of mast cell activation 
involved in immune response 
5.68 3.42E-03 22.22 4.11 
regulation of mast cell 
degranulation 
5.68 3.42E-03 22.22 4.11 
divalent inorganic cation 
homeostasis 
5.67 3.44E-03 7.73 4.99 
immune response-activating cell 
surface receptor signaling pathway 
5.67 3.45E-03 12.73 4.00 
positive regulation of gene 
expression 
5.67 3.45E-03 5.47 4.55 
response to increased oxygen 
levels 
5.66 3.47E-03 17.24 5.03 
response to hyperoxia 5.66 3.47E-03 17.24 5.03 
phosphorus metabolic process 5.62 3.61E-03 5.13 4.34 
cation transport 5.62 3.63E-03 6.22 4.76 
regulation of glial cell 
differentiation 
5.59 3.72E-03 14.29 4.00 
cell proliferation 5.58 3.77E-03 6.63 4.63 
negative regulation of lymphocyte 
chemotaxis 
5.57 3.80E-03 66.67 5.65 
negative regulation of lymphocyte 
migration 
5.57 3.80E-03 66.67 5.65 
vacuolar acidification 5.57 3.80E-03 66.67 7.15 
positive regulation of MDA-5 
signaling pathway 
5.57 3.80E-03 66.67 6.04 
regulation of type III 
hypersensitivity 
5.57 3.80E-03 66.67 3.09 
positive regulation of type III 
hypersensitivity 
5.57 3.80E-03 66.67 3.09 
type I interferon production 5.57 3.80E-03 66.67 4.78 
ciliary body morphogenesis 5.57 3.80E-03 66.67 4.15 
innate immune response activating 
cell surface receptor signaling 
pathway 
5.57 3.80E-03 66.67 3.48 
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platelet degranulation 5.57 3.80E-03 66.67 3.60 
positive regulation of 
oligodendrocyte progenitor 
proliferation 
5.57 3.80E-03 66.67 4.04 
nucleotide-binding domain, leucine 
rich repeat containing receptor 
signaling pathway 
5.57 3.80E-03 66.67 5.03 
nucleotide-binding oligomerization 
domain containing signaling 
pathway 
5.57 3.80E-03 66.67 5.03 
nucleotide-binding oligomerization 
domain containing 2 signaling 
pathway 
5.57 3.80E-03 66.67 5.03 
RNA import into mitochondrion 5.57 3.80E-03 66.67 4.81 
rRNA import into mitochondrion 5.57 3.80E-03 66.67 4.81 
antigen processing and 
presentation of exogenous peptide 
antigen via MHC class Ib 
5.57 3.80E-03 66.67 5.40 
antigen processing and 
presentation of exogenous protein 
antigen via MHC class Ib, TAP-
dependent 
5.57 3.80E-03 66.67 5.40 
toll-like receptor 2 signaling 
pathway 
5.57 3.80E-03 66.67 5.21 
cellular response to peptidoglycan 5.57 3.80E-03 66.67 5.21 
antibiotic transport 5.57 3.80E-03 66.67 4.13 
intracellular transport of viral 
protein in host cell 
5.57 3.80E-03 66.67 7.19 
symbiont intracellular protein 
transport in host 
5.57 3.80E-03 66.67 7.19 
intracellular protein transport in 
other organism involved in 
symbiotic interaction 
5.57 3.80E-03 66.67 7.19 
extracellular transport 5.57 3.80E-03 66.67 7.19 
positive regulation of apoptotic 
signaling pathway 
5.50 4.07E-03 10.34 4.96 
positive regulation of protein 
polymerization 
5.47 4.19E-03 13.95 4.82 
positive regulation of JAK-STAT 
cascade 
5.47 4.19E-03 13.95 4.16 
response to interleukin-6 5.47 4.21E-03 21.05 4.31 
response to sterol 5.47 4.21E-03 21.05 5.18 
response to cholesterol 5.47 4.21E-03 21.05 5.18 
bone resorption 5.47 4.21E-03 21.05 4.23 
positive regulation of natural killer 
cell mediated immunity 
5.47 4.21E-03 21.05 4.76 
negative regulation of leukocyte 
mediated immunity 
5.47 4.21E-03 21.05 6.24 
negative regulation of lymphocyte 
mediated immunity 
5.47 4.21E-03 21.05 6.24 
regulation of fat cell 
differentiation 
5.47 4.23E-03 12.28 4.75 
positive regulation of protein 
kinase B signaling 
5.47 4.23E-03 12.28 4.77 
cellular response to stress 5.42 4.43E-03 5.59 5.00 
transmembrane receptor protein 
tyrosine kinase signaling pathway 
5.42 4.45E-03 8.00 4.49 
calcium ion homeostasis 5.40 4.53E-03 7.73 4.87 
CD4-positive, alpha-beta T cell 
differentiation involved in immune 
5.38 4.63E-03 30.00 4.45 
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response 
T-helper cell differentiation 5.38 4.63E-03 30.00 4.45 
negative regulation by host of viral 
transcription 
5.38 4.63E-03 30.00 5.67 
positive regulation of fever 
generation 
5.38 4.63E-03 30.00 6.82 
positive T cell selection 5.38 4.63E-03 30.00 3.90 
positive thymic T cell selection 5.38 4.63E-03 30.00 3.90 
regulation of macrophage cytokine 
production 
5.38 4.63E-03 30.00 4.02 
positive regulation of membrane 
protein ectodomain proteolysis 
5.38 4.63E-03 30.00 5.13 
regulation of chemokine 
biosynthetic process 
5.38 4.63E-03 30.00 6.50 
cellular response to hormone 
stimulus 
5.37 4.65E-03 6.99 4.29 
negative regulation of molecular 
function 
5.37 4.66E-03 5.93 4.89 
amide transport 5.37 4.66E-03 12.07 4.72 
regulation of JAK-STAT cascade 5.37 4.66E-03 12.07 4.51 
response to amphetamine 5.37 4.68E-03 16.13 4.46 
natural killer cell activation 5.37 4.68E-03 16.13 3.44 
T cell differentiation 5.29 5.06E-03 10.81 4.12 
cellular response to steroid 
hormone stimulus 
5.28 5.10E-03 10.00 4.34 
release of sequestered calcium ion 
into cytosol 
5.28 5.11E-03 20.00 4.60 
negative regulation of sequestering 
of calcium ion 
5.28 5.11E-03 20.00 4.60 
negative regulation of 
developmental process 
5.26 5.19E-03 6.06 4.25 
regulation of JUN kinase activity 5.25 5.27E-03 13.33 5.22 
regulation of macromolecule 
biosynthetic process 
5.24 5.30E-03 4.68 4.51 
regulation of actin cytoskeleton 
organization 
5.24 5.30E-03 8.45 4.24 
acute-phase response 5.22 5.38E-03 15.63 4.99 
cytosolic calcium ion homeostasis 5.20 5.52E-03 8.80 4.47 
regulation of MAP kinase activity 5.19 5.56E-03 8.07 4.38 
single organism reproductive 
process 
5.18 5.61E-03 5.70 4.81 
negative regulation of cell 
differentiation 
5.17 5.67E-03 6.41 4.17 
response to estradiol 5.14 5.85E-03 8.73 4.70 
leukocyte homeostasis 5.14 5.88E-03 13.04 4.13 
regulation of alpha-beta T cell 
activation 
5.14 5.88E-03 13.04 4.57 
regulation of protein 
polymerization 
5.12 5.95E-03 10.53 4.47 
organonitrogen compound 
metabolic process 
5.09 6.14E-03 5.25 4.86 
endothelial cell development 5.09 6.14E-03 19.05 4.30 
negative regulation of chemotaxis 5.09 6.14E-03 19.05 5.34 
regulation of sequestering of 
calcium ion 
5.09 6.14E-03 19.05 4.60 
positive regulation of alpha-beta T 
cell differentiation 
5.09 6.14E-03 19.05 5.05 
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negative regulation of smooth 
muscle cell migration 
5.08 6.20E-03 27.27 3.95 
T cell differentiation involved in 
immune response 
5.08 6.20E-03 27.27 4.45 
alpha-beta T cell differentiation 
involved in immune response 
5.08 6.20E-03 27.27 4.45 
regulation of necroptotic process 5.08 6.20E-03 27.27 5.80 
regulation of triglyceride 
biosynthetic process 
5.08 6.20E-03 27.27 4.74 
leukocyte migration involved in 
inflammatory response 
5.08 6.20E-03 27.27 3.78 
regulation of fever generation 5.08 6.20E-03 27.27 6.82 
regulation of toll-like receptor 4 
signaling pathway 
5.08 6.20E-03 27.27 4.00 
cellular response to dsRNA 5.08 6.20E-03 27.27 5.64 
regulation of viral release from 
host cell 
5.08 6.20E-03 27.27 6.08 
response to ketone 5.07 6.25E-03 8.28 5.71 
cellular iron ion homeostasis 4.96 7.01E-03 14.71 6.97 
positive regulation of organelle 
organization 
4.94 7.15E-03 7.35 4.49 
cellular glucose homeostasis 4.93 7.25E-03 12.50 5.72 
regulation of oxidoreductase 
activity 
4.93 7.25E-03 12.50 4.85 
positive regulation of phosphatase 
activity 
4.92 7.29E-03 18.18 3.93 
cellular response to morphine 4.90 7.42E-03 50.00 6.29 
T-helper 2 cell differentiation 4.90 7.42E-03 50.00 3.38 
negative regulation of tumor 
necrosis factor biosynthetic 
process 
4.90 7.42E-03 50.00 4.08 
regulation of apoptotic cell 
clearance 
4.90 7.42E-03 50.00 4.29 
negative regulation of macrophage 
apoptotic process 
4.90 7.42E-03 50.00 6.71 
modulation by symbiont of host 
cellular process 
4.90 7.42E-03 50.00 3.83 
regulation of interleukin-10 
secretion 
4.90 7.42E-03 50.00 7.32 
regulation of MDA-5 signaling 
pathway 
4.90 7.42E-03 50.00 6.04 
hyaluronan biosynthetic process 4.90 7.42E-03 50.00 5.17 
negative regulation of membrane 
protein ectodomain proteolysis 
4.90 7.42E-03 50.00 4.64 
chronic inflammatory response to 
antigenic stimulus 
4.90 7.42E-03 50.00 6.03 
regulation of toll-like receptor 2 
signaling pathway 
4.90 7.42E-03 50.00 4.56 
positive regulation of regulatory T 
cell differentiation 
4.90 7.42E-03 50.00 4.40 
hypotonic response 4.90 7.42E-03 50.00 4.86 
cellular hypotonic response 4.90 7.42E-03 50.00 4.86 
neutrophil mediated killing of 
bacterium 
4.90 7.42E-03 50.00 3.67 
extracellular matrix-cell signaling 4.90 7.42E-03 50.00 5.04 
positive regulation of platelet 
activation 
4.90 7.42E-03 50.00 3.75 
phagosome acidification 4.90 7.42E-03 50.00 5.25 
manganese ion transport 4.90 7.42E-03 50.00 5.31 
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manganese ion transmembrane 
transport 
4.90 7.42E-03 50.00 5.31 
positive regulation of interferon-
beta biosynthetic process 
4.90 7.42E-03 50.00 6.79 
cellular amide metabolic process 4.86 7.75E-03 9.38 5.32 
positive regulation of JUN kinase 
activity 
4.84 7.94E-03 14.29 5.00 
response to hydroperoxide 4.82 8.04E-03 25.00 5.47 
positive regulation of inflammatory 
response to antigenic stimulus 
4.82 8.04E-03 25.00 4.37 
positive regulation of nitric-oxide 
synthase biosynthetic process 
4.82 8.04E-03 25.00 4.02 
positive regulation of heat 
generation 
4.82 8.04E-03 25.00 6.82 
positive regulation of lymphocyte 
apoptotic process 
4.82 8.04E-03 25.00 6.59 
positive regulation of cAMP-
mediated signaling 
4.82 8.04E-03 25.00 8.13 
response to L-ascorbic acid 4.82 8.04E-03 25.00 7.04 
developmental process involved in 
reproduction 
4.82 8.06E-03 6.40 4.57 
regulation of epithelial cell 
migration 
4.82 8.08E-03 10.00 5.47 
positive regulation of nucleobase-
containing compound metabolic 
process 
4.81 8.16E-03 5.19 4.60 
regulation of catabolic process 4.79 8.31E-03 5.91 4.57 
positive regulation of smooth 
muscle cell migration 
4.76 8.58E-03 17.39 5.01 
regulation of inflammatory 
response to antigenic stimulus 
4.76 8.58E-03 17.39 4.38 
calcium ion transport into cytosol 4.76 8.58E-03 17.39 4.60 
positive regulation of calcium-
mediated signaling 
4.76 8.58E-03 17.39 4.02 
peptide transport 4.73 8.85E-03 12.00 5.05 
cellular response to glucocorticoid 
stimulus 
4.73 8.85E-03 12.00 4.36 
negative regulation of leukocyte 
differentiation 
4.73 8.85E-03 12.00 4.04 
negative regulation of G-protein 
coupled receptor protein signaling 
pathway 
4.72 8.96E-03 13.89 4.85 
regulation of release of 
sequestered calcium ion into 
cytosol 
4.72 8.96E-03 13.89 6.34 
amine metabolic process 4.66 9.45E-03 10.61 5.17 
regulation of protein complex 
assembly 
4.66 9.45E-03 7.84 4.46 
cellular response to corticosteroid 
stimulus 
4.63 9.73E-03 11.76 4.36 
positive regulation of endothelial 
cell proliferation 
4.63 9.73E-03 11.76 3.78 
negative regulation of protein 
processing 
4.63 9.73E-03 11.76 5.27 
single-organism membrane 
organization 
4.62 9.85E-03 7.29 4.24 
regulation of actin filament-based 
process 
4.61 9.92E-03 7.79 4.24 
cellular response to alkaloid 4.60 1.00E-02 16.67 6.33 
regulation of myeloid cell 
apoptotic process 
4.60 1.00E-02 16.67 5.11 
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cytosolic calcium ion transport 4.60 1.00E-02 16.67 4.60 
positive chemotaxis 4.60 1.00E-02 16.67 4.92 
negative regulation of tumor 
necrosis factor production 
4.60 1.00E-02 16.67 4.25 
regulation of protein kinase B 
signaling 
4.60 1.00E-02 9.64 4.72 
regulation of osteoclast 
differentiation 
4.60 1.01E-02 13.51 5.01 
metabolic process 4.59 1.01E-02 4.12 4.76 
ruffle organization 4.59 1.02E-02 23.08 3.73 
positive regulation of tissue 
remodeling 
4.59 1.02E-02 23.08 3.58 
release of cytochrome c from 
mitochondria 
4.59 1.02E-02 23.08 6.69 
positive regulation of release of 
cytochrome c from mitochondria 
4.59 1.02E-02 23.08 5.37 
negative regulation of B cell 
apoptotic process 
4.59 1.02E-02 23.08 4.76 
I-kappaB kinase/NF-kappaB 
signaling 
4.59 1.02E-02 23.08 4.75 
regulation of acute inflammatory 
response to antigenic stimulus 
4.59 1.02E-02 23.08 4.37 
response to lipoprotein particle 4.59 1.02E-02 23.08 6.87 
cellular response to interleukin-6 4.59 1.02E-02 23.08 4.10 
positive regulation of cell adhesion 
mediated by integrin 
4.59 1.02E-02 23.08 6.67 
negative regulation of T cell 
apoptotic process 
4.59 1.02E-02 23.08 6.20 
regulation of interleukin-2 
biosynthetic process 
4.59 1.02E-02 23.08 5.34 
protein destabilization 4.59 1.02E-02 23.08 5.13 
positive regulation of intracellular 
protein transport 
4.53 1.07E-02 9.52 5.02 
monocarboxylic acid transport 4.50 1.11E-02 10.29 3.28 
metal ion transport 4.50 1.11E-02 6.31 4.97 
positive regulation of 
macromolecule biosynthetic 
process 
4.49 1.12E-02 5.11 4.22 
positive regulation of lipid 
transport 
4.49 1.12E-02 13.16 4.57 
regulation of lipid biosynthetic 
process 
4.48 1.13E-02 8.82 5.28 
anatomical structure development 4.48 1.14E-02 4.57 4.63 
positive regulation of fat cell 
differentiation 
4.46 1.16E-02 16.00 4.16 
response to morphine 4.46 1.16E-02 16.00 5.88 
actin filament bundle assembly 4.46 1.16E-02 16.00 5.04 
actin filament bundle organization 4.46 1.16E-02 16.00 5.04 
regulation of mitochondrial 
membrane potential 
4.46 1.16E-02 16.00 5.52 
regulation of sensory perception of 
pain 
4.46 1.16E-02 16.00 4.32 
regulation of sensory perception 4.46 1.16E-02 16.00 4.32 
positive regulation of 
oxidoreductase activity 
4.46 1.16E-02 16.00 4.49 
negative regulation of gliogenesis 4.46 1.16E-02 16.00 3.87 
defense response to Gram-negative 
bacterium 
4.46 1.16E-02 16.00 6.02 
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iron ion homeostasis 4.45 1.17E-02 11.32 7.22 
organ regeneration 4.43 1.19E-02 10.14 3.92 
tryptophan catabolic process to 
kynurenine 
4.42 1.21E-02 40.00 4.55 
cellular response to isoquinoline 
alkaloid 
4.42 1.21E-02 40.00 6.29 
DNA dealkylation involved in DNA 
repair 
4.42 1.21E-02 40.00 3.80 
regulation of interleukin-1 alpha 
production 
4.42 1.21E-02 40.00 4.73 
positive regulation of cellular 
extravasation 
4.42 1.21E-02 40.00 5.80 
response to high density 
lipoprotein particle 
4.42 1.21E-02 40.00 7.24 
sarcoplasmic reticulum calcium ion 
transport 
4.42 1.21E-02 40.00 3.39 
regulation of macrophage 
apoptotic process 
4.42 1.21E-02 40.00 6.71 
positive regulation of homotypic 
cell-cell adhesion 
4.42 1.21E-02 40.00 6.39 
negative regulation of wound 
healing 
4.42 1.21E-02 40.00 4.66 
comma-shaped body 
morphogenesis 
4.42 1.21E-02 40.00 3.33 
regulation of response to 
interferon-gamma 
4.42 1.21E-02 40.00 4.77 
regulation of interferon-gamma-
mediated signaling pathway 
4.42 1.21E-02 40.00 4.77 
positive regulation of granulocyte 
macrophage colony-stimulating 
factor production 
4.42 1.21E-02 40.00 5.11 
positive regulation of immature T 
cell proliferation 
4.42 1.21E-02 40.00 6.91 
negative regulation of toll-like 
receptor 4 signaling pathway 
4.42 1.21E-02 40.00 4.56 
positive regulation of T cell 
tolerance induction 
4.42 1.21E-02 40.00 4.40 
regulation of Fc receptor mediated 
stimulatory signaling pathway 
4.42 1.21E-02 40.00 2.94 
regulation of oligodendrocyte 
progenitor proliferation 
4.42 1.21E-02 40.00 4.04 
response to molecule of fungal 
origin 
4.42 1.21E-02 40.00 3.58 
neutrophil mediated cytotoxicity 4.42 1.21E-02 40.00 3.67 
neutrophil mediated killing of 
symbiont cell 
4.42 1.21E-02 40.00 3.67 
cytoplasmic pattern recognition 
receptor signaling pathway 
4.42 1.21E-02 40.00 5.03 
glomerular capillary formation 4.42 1.21E-02 40.00 3.83 
neutrophil degranulation 4.42 1.21E-02 40.00 2.73 
regulation of interferon-beta 
biosynthetic process 
4.42 1.21E-02 40.00 6.79 
response to monosaccharide 4.41 1.21E-02 8.26 5.83 
homeostasis of number of cells 4.40 1.23E-02 9.30 4.15 
lymphocyte homeostasis 4.38 1.25E-02 12.82 4.27 
negative regulation of protein 
catabolic process 
4.38 1.25E-02 12.82 4.68 
regulation of heat generation 4.37 1.26E-02 21.43 6.82 
positive regulation of alpha-beta T 
cell proliferation 
4.37 1.26E-02 21.43 4.67 
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purine nucleobase metabolic 
process 
4.37 1.26E-02 21.43 4.67 
transepithelial transport 4.37 1.26E-02 21.43 3.90 
negative regulation of toll-like 
receptor signaling pathway 
4.37 1.26E-02 21.43 4.14 
regulation of cellular component 
size 
4.36 1.28E-02 8.65 4.40 
regulation of endothelial cell 
proliferation 
4.35 1.29E-02 10.00 3.86 
protein phosphorylation 4.35 1.29E-02 6.12 4.29 
response to isoquinoline alkaloid 4.32 1.33E-02 15.38 5.88 
blood vessel remodeling 4.32 1.33E-02 15.38 3.35 
complement activation 4.32 1.33E-02 15.38 6.75 
response to copper ion 4.32 1.33E-02 15.38 6.13 
response to fluid shear stress 4.32 1.33E-02 15.38 4.03 
vesicle-mediated transport 4.29 1.38E-02 5.73 4.99 
positive regulation of protein 
processing 
4.28 1.38E-02 9.86 4.71 
negative regulation of protein 
transport 
4.27 1.40E-02 9.09 4.69 
divalent metal ion transport 4.25 1.42E-02 8.06 4.93 
regulation of anatomical structure 
size 
4.24 1.44E-02 7.41 4.53 
response to carbohydrate 4.24 1.45E-02 7.69 5.60 
negative regulation of transport 4.21 1.48E-02 6.46 4.62 
response to ammonium ion 4.19 1.51E-02 10.71 5.00 
regulation of tumor necrosis factor 
biosynthetic process 
4.18 1.54E-02 20.00 3.93 
positive regulation of lipid storage 4.18 1.54E-02 20.00 5.28 
positive regulation of G-protein 
coupled receptor protein signaling 
pathway 
4.18 1.54E-02 20.00 5.42 
modulation by host of viral 
transcription 
4.18 1.54E-02 20.00 5.67 
modulation of transcription in 
other organism involved in 
symbiotic interaction 
4.18 1.54E-02 20.00 5.67 
modulation by host of symbiont 
transcription 
4.18 1.54E-02 20.00 5.67 
regulation of macrophage 
activation 
4.18 1.54E-02 20.00 3.28 
positive regulation of 
monooxygenase activity 
4.18 1.54E-02 20.00 4.76 
regulation of defense response to 
virus by host 
4.18 1.54E-02 20.00 5.12 
catabolic process 4.14 1.59E-02 4.91 4.90 
endocytosis 4.13 1.60E-02 7.07 4.59 
negative regulation of intracellular 
signal transduction 
4.13 1.61E-02 6.86 5.19 
regulation of protein 
serine/threonine kinase activity 
4.12 1.62E-02 6.53 4.49 
regulation of neuron 
differentiation 
4.12 1.63E-02 6.17 4.05 
negative regulation of ion transport 4.11 1.64E-02 10.53 4.97 
response to acid 4.11 1.64E-02 6.27 5.42 
signal transduction 4.09 1.68E-02 4.25 4.53 
response to transition metal 4.08 1.68E-02 8.79 6.40 
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nanoparticle 
tissue homeostasis 4.08 1.68E-02 8.79 4.27 
positive regulation of extrinsic 
apoptotic signaling pathway 
4.08 1.70E-02 11.90 5.65 
regulation of neurological system 
process 
4.08 1.70E-02 11.90 4.40 
cellular response to glucose 
stimulus 
4.08 1.70E-02 11.90 6.38 
negative regulation of proteolysis 4.08 1.70E-02 11.90 4.88 
cellular response to cAMP 4.08 1.70E-02 11.90 4.21 
negative regulation of neurogenesis 4.07 1.71E-02 9.46 4.30 
regulation of monooxygenase 
activity 
4.06 1.72E-02 14.29 4.45 
lymphocyte differentiation 4.05 1.74E-02 7.81 4.19 
indole-containing compound 
catabolic process 
4.04 1.77E-02 33.33 4.55 
indolalkylamine catabolic process 4.04 1.77E-02 33.33 4.55 
tryptophan catabolic process 4.04 1.77E-02 33.33 4.55 
kynurenine metabolic process 4.04 1.77E-02 33.33 4.55 
cellular response to hydroperoxide 4.04 1.77E-02 33.33 6.29 
regulation of protein activation 
cascade 
4.04 1.77E-02 33.33 7.08 
regulation of complement 
activation 
4.04 1.77E-02 33.33 7.08 
regulation of glial cell apoptotic 
process 
4.04 1.77E-02 33.33 5.65 
negative regulation of glial cell 
apoptotic process 
4.04 1.77E-02 33.33 5.65 
bradykinin catabolic process 4.04 1.77E-02 33.33 6.16 
chondrocyte proliferation 4.04 1.77E-02 33.33 4.80 
S-shaped body morphogenesis 4.04 1.77E-02 33.33 3.33 
cellular response to interferon-
alpha 
4.04 1.77E-02 33.33 6.31 
response to ozone 4.04 1.77E-02 33.33 6.32 
ectopic germ cell programmed cell 
death 
4.04 1.77E-02 33.33 6.32 
regulation of calcidiol 1-
monooxygenase activity 
4.04 1.77E-02 33.33 5.29 
regulation of T-helper 1 cell 
differentiation 
4.04 1.77E-02 33.33 5.20 
positive regulation of chemokine 
secretion 
4.04 1.77E-02 33.33 5.48 
negative regulation of 
lipopolysaccharide-mediated 
signaling pathway 
4.04 1.77E-02 33.33 4.19 
pulmonary valve morphogenesis 4.04 1.77E-02 33.33 4.15 
regulation of T cell tolerance 
induction 
4.04 1.77E-02 33.33 4.40 
regulation of regulatory T cell 
differentiation 
4.04 1.77E-02 33.33 4.40 
rRNA transport 4.04 1.77E-02 33.33 4.81 
positive regulation of defense 
response to virus by host 
4.04 1.77E-02 33.33 4.98 
positive regulation of necrotic cell 
death 
4.04 1.77E-02 33.33 4.23 
cellular amine metabolic process 4.03 1.77E-02 10.34 4.74 
cellular biogenic amine metabolic 
process 
4.03 1.77E-02 10.34 4.74 
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regulation of endothelial cell 
migration 
4.03 1.77E-02 10.34 5.48 
actin filament organization 4.00 1.83E-02 9.33 4.78 
leukocyte degranulation 4.00 1.84E-02 18.75 2.77 
thymic T cell selection 4.00 1.84E-02 18.75 3.90 
regulation of macrophage derived 
foam cell differentiation 
4.00 1.84E-02 18.75 3.90 
regulation of cAMP-mediated 
signaling 
4.00 1.84E-02 18.75 8.13 
lymph node development 4.00 1.84E-02 18.75 4.79 
negative regulation of response to 
biotic stimulus 
4.00 1.84E-02 18.75 4.90 
regulation of growth of symbiont in 
host 
4.00 1.84E-02 18.75 3.86 
negative regulation of growth of 
symbiont in host 
4.00 1.84E-02 18.75 3.86 
modulation of growth of symbiont 
involved in interaction with host 
4.00 1.84E-02 18.75 3.86 
negative regulation of growth of 
symbiont involved in interaction 
with host 
4.00 1.84E-02 18.75 3.86 
regulation of interleukin-17 
production 
4.00 1.84E-02 18.75 3.45 
regulation of T-helper 1 type 
immune response 
4.00 1.84E-02 18.75 5.73 
tumor necrosis factor-mediated 
signaling pathway 
4.00 1.84E-02 18.75 5.07 
positive regulation of interleukin-
12 production 
4.00 1.84E-02 18.75 5.90 
negative regulation of neuron 
differentiation 
3.98 1.86E-02 11.63 4.41 
regulation of protein catabolic 
process 
3.96 1.91E-02 7.38 4.67 
negative regulation of extrinsic 
apoptotic signaling pathway 
3.96 1.91E-02 10.17 5.38 
cellular modified amino acid 
metabolic process 
3.95 1.92E-02 7.69 4.41 
anatomical structure homeostasis 3.95 1.92E-02 7.69 4.86 
signal transduction in absence of 
ligand 
3.94 1.94E-02 13.79 5.83 
extrinsic apoptotic signaling 
pathway in absence of ligand 
3.94 1.94E-02 13.79 5.83 
regulation of alpha-beta T cell 
differentiation 
3.94 1.94E-02 13.79 5.05 
RNA phosphodiester bond 
hydrolysis 
3.94 1.94E-02 13.79 5.06 
cellular response to alcohol 3.93 1.95E-02 9.21 6.62 
calcium ion transport 3.92 1.99E-02 8.04 4.72 
regulation of cellular catabolic 
process 
3.92 1.99E-02 5.72 4.58 
cellular response to hexose 
stimulus 
3.89 2.04E-02 11.36 6.38 
signaling 3.89 2.05E-02 6.49 4.59 
single organism signaling 3.89 2.05E-02 6.49 4.59 
proteolysis involved in cellular 
protein catabolic process 
3.87 2.09E-02 6.64 5.88 
regulation of neurogenesis 3.86 2.11E-02 5.76 4.09 
divalent inorganic cation transport 3.86 2.11E-02 7.58 4.93 
regulation of purine nucleotide 
metabolic process 
3.83 2.17E-02 6.08 5.04 
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regulation of triglyceride metabolic 
process 
3.83 2.18E-02 17.65 4.74 
regulation of nitric-oxide synthase 
biosynthetic process 
3.83 2.18E-02 17.65 4.02 
negative regulation of myeloid cell 
apoptotic process 
3.83 2.18E-02 17.65 5.68 
modification by symbiont of host 
morphology or physiology 
3.83 2.18E-02 17.65 3.77 
regulation of alpha-beta T cell 
proliferation 
3.83 2.18E-02 17.65 4.67 
positive regulation of release of 
sequestered calcium ion into 
cytosol 
3.83 2.18E-02 17.65 8.13 
heart valve morphogenesis 3.83 2.18E-02 17.65 3.91 
positive regulation of MAP kinase 
activity 
3.81 2.21E-02 7.89 4.60 
negative regulation of catabolic 
process 
3.81 2.22E-02 8.97 4.99 
positive regulation of epithelial 
cell migration 
3.80 2.23E-02 11.11 4.65 
response to amine 3.80 2.23E-02 11.11 4.46 
cellular response to 
monosaccharide stimulus 
3.80 2.23E-02 11.11 6.38 
positive regulation of cytoskeleton 
organization 
3.79 2.25E-02 8.33 4.51 
negative regulation of cell 
development 
3.79 2.25E-02 8.33 4.15 
cell-cell adhesion 3.79 2.25E-02 8.33 4.24 
response to cAMP 3.79 2.25E-02 8.33 4.22 
activation of protein kinase 
activity 
3.76 2.32E-02 7.46 4.54 
regulation of nucleotide metabolic 
process 
3.74 2.37E-02 6.02 5.04 
protein metabolic process 3.74 2.37E-02 4.40 5.11 
positive regulation of proteolysis 3.73 2.39E-02 9.68 4.34 
regulation of cytoskeleton 
organization 
3.73 2.41E-02 6.51 4.26 
negative regulation of cellular 
metabolic process 
3.72 2.41E-02 4.78 4.79 
drug transmembrane transport 3.72 2.42E-02 28.57 3.36 
response to UV-C 3.72 2.42E-02 28.57 3.44 
mature B cell differentiation 
involved in immune response 
3.72 2.42E-02 28.57 3.85 
germinal center formation 3.72 2.42E-02 28.57 5.42 
macrophage differentiation 3.72 2.42E-02 28.57 4.46 
negative regulation of leukocyte 
chemotaxis 
3.72 2.42E-02 28.57 5.65 
positive regulation of T cell 
apoptotic process 
3.72 2.42E-02 28.57 7.68 
positive regulation of macrophage 
cytokine production 
3.72 2.42E-02 28.57 4.39 
positive regulation of triglyceride 
biosynthetic process 
3.72 2.42E-02 28.57 3.66 
auditory receptor cell 
differentiation 
3.72 2.42E-02 28.57 3.34 
positive regulation of tyrosine 
phosphorylation of Stat1 protein 
3.72 2.42E-02 28.57 2.80 
negative regulation of glutamate 
secretion 
3.72 2.42E-02 28.57 6.03 
regulation of vitamin D 3.72 2.42E-02 28.57 5.29 
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biosynthetic process 
positive regulation of T-helper cell 
differentiation 
3.72 2.42E-02 28.57 5.20 
regulation of chemokine secretion 3.72 2.42E-02 28.57 5.48 
interleukin-1-mediated signaling 
pathway 
3.72 2.42E-02 28.57 2.94 
positive regulation of type I 
interferon-mediated signaling 
pathway 
3.72 2.42E-02 28.57 6.96 
response to yeast 3.72 2.42E-02 28.57 3.25 
neutrophil mediated immunity 3.72 2.42E-02 28.57 3.67 
disruption by host of symbiont cells 3.72 2.42E-02 28.57 3.67 
killing by host of symbiont cells 3.72 2.42E-02 28.57 3.67 
GTP biosynthetic process 3.72 2.42E-02 28.57 5.18 
toxin transport 3.72 2.42E-02 28.57 4.13 
hematopoietic or lymphoid organ 
development 
3.72 2.43E-02 7.41 5.35 
negative regulation of myeloid cell 
differentiation 
3.72 2.43E-02 10.87 3.51 
protein import into nucleus, 
translocation 
3.67 2.54E-02 16.67 4.60 
regulation of type 2 immune 
response 
3.67 2.54E-02 16.67 4.63 
negative regulation of interleukin-6 
production 
3.67 2.54E-02 16.67 4.07 
positive regulation of natural killer 
cell mediated cytotoxicity 
3.67 2.54E-02 16.67 4.07 
leukotriene metabolic process 3.67 2.54E-02 16.67 3.42 
regulation of cellular 
macromolecule biosynthetic 
process 
3.67 2.55E-02 4.45 4.45 
tissue remodeling 3.66 2.56E-02 9.52 3.57 
steroid biosynthetic process 3.66 2.56E-02 9.52 5.25 
response to axon injury 3.63 2.64E-02 10.64 4.72 
positive regulation of lipid 
biosynthetic process 
3.63 2.64E-02 10.64 5.05 
regulation of B cell proliferation 3.63 2.64E-02 10.64 4.88 
carbohydrate homeostasis 3.62 2.69E-02 7.63 5.14 
glucose homeostasis 3.62 2.69E-02 7.63 5.14 
protein autophosphorylation 3.62 2.69E-02 7.63 4.01 
positive regulation of glucose 
transport 
3.61 2.70E-02 12.50 5.97 
regulation of B cell mediated 
immunity 
3.61 2.70E-02 12.50 4.02 
regulation of immunoglobulin 
mediated immune response 
3.61 2.70E-02 12.50 4.02 
regulation of interleukin-2 
production 
3.61 2.70E-02 12.50 5.70 
regulation of RNA biosynthetic 
process 
3.61 2.72E-02 4.48 4.59 
regulation of RNA metabolic 
process 
3.60 2.73E-02 4.47 4.62 
extrinsic apoptotic signaling 
pathway 
3.60 2.75E-02 9.38 6.19 
cellular response to extracellular 
stimulus 
3.58 2.80E-02 8.00 6.17 
organic substance catabolic 
process 
3.57 2.81E-02 4.84 4.97 
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negative regulation of apoptotic 
signaling pathway 
3.57 2.82E-02 7.56 5.47 
single-organism metabolic process 3.56 2.85E-02 4.31 4.61 
positive regulation of cell 
projection organization 
3.54 2.90E-02 7.19 4.16 
positive regulation of protein 
serine/threonine kinase activity 
3.53 2.92E-02 6.92 4.45 
developmental programmed cell 
death 
3.53 2.94E-02 15.79 5.25 
positive regulation of collagen 
biosynthetic process 
3.53 2.94E-02 15.79 3.97 
T cell selection 3.53 2.94E-02 15.79 3.90 
regulation of activated T cell 
proliferation 
3.53 2.94E-02 15.79 4.75 
positive regulation of GTPase 
activity 
3.53 2.94E-02 7.92 4.40 
negative regulation of behavior 3.51 2.99E-02 12.12 5.34 
apoptotic mitochondrial changes 3.51 2.99E-02 12.12 6.62 
response to glucose 3.47 3.10E-02 7.84 5.52 
positive regulation of neurogenesis 3.47 3.10E-02 7.84 4.17 
coagulation 3.47 3.10E-02 10.20 6.40 
blood coagulation 3.47 3.10E-02 10.20 6.40 
tryptophan metabolic process 3.46 3.15E-02 25.00 4.55 
indolalkylamine metabolic process 3.46 3.15E-02 25.00 4.55 
angiogenesis involved in wound 
healing 
3.46 3.15E-02 25.00 3.59 
negative regulation of necroptotic 
process 
3.46 3.15E-02 25.00 6.84 
positive regulation of macrophage 
activation 
3.46 3.15E-02 25.00 3.49 
retina vasculature morphogenesis 
in camera-type eye 
3.46 3.15E-02 25.00 6.22 
dichotomous subdivision of an 
epithelial terminal unit 
3.46 3.15E-02 25.00 4.61 
Fc receptor signaling pathway 3.46 3.15E-02 25.00 3.09 
cellular response to iron ion 3.46 3.15E-02 25.00 5.88 
central nervous system myelination 3.46 3.15E-02 25.00 3.67 
axon ensheathment in central 
nervous system 
3.46 3.15E-02 25.00 3.67 
neuronal stem cell maintenance 3.46 3.15E-02 25.00 3.34 
regulation of granulocyte 
macrophage colony-stimulating 
factor production 
3.46 3.15E-02 25.00 5.11 
positive regulation of interleukin-
17 production 
3.46 3.15E-02 25.00 3.36 
regulation of vitamin metabolic 
process 
3.46 3.15E-02 25.00 5.29 
regulation of immature T cell 
proliferation 
3.46 3.15E-02 25.00 6.91 
response to stilbenoid 3.46 3.15E-02 25.00 6.27 
regulation of cholesterol storage 3.46 3.15E-02 25.00 3.64 
disruption of cells of other 
organism involved in symbiotic 
interaction 
3.46 3.15E-02 25.00 3.67 
killing of cells in other organism 
involved in symbiotic interaction 
3.46 3.15E-02 25.00 3.67 
urate metabolic process 3.46 3.15E-02 25.00 5.02 
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stress fiber assembly 3.46 3.15E-02 25.00 6.42 
gamma-aminobutyric acid 
transport 
3.46 3.15E-02 25.00 3.62 
stress-activated protein kinase 
signaling cascade 
3.41 3.30E-02 11.76 3.92 
negative regulation of 
inflammatory response 
3.40 3.34E-02 8.96 4.06 
transition metal ion transport 3.40 3.34E-02 8.96 6.44 
hemostasis 3.40 3.35E-02 10.00 6.40 
negative regulation of angiogenesis 3.40 3.35E-02 10.00 4.51 
positive regulation of cAMP 
metabolic process 
3.40 3.35E-02 10.00 6.92 
membrane protein proteolysis 3.39 3.37E-02 15.00 4.97 
B cell homeostasis 3.39 3.37E-02 15.00 3.44 
intrinsic apoptotic signaling 
pathway in response to 
endoplasmic reticulum stress 
3.39 3.37E-02 15.00 5.12 
negative regulation of cytokine 
biosynthetic process 
3.39 3.37E-02 15.00 3.90 
vesicle docking 3.39 3.37E-02 15.00 3.50 
positive regulation of collagen 
metabolic process 
3.39 3.37E-02 15.00 3.97 
superoxide metabolic process 3.39 3.37E-02 15.00 5.58 
negative regulation of glial cell 
differentiation 
3.39 3.37E-02 15.00 3.57 
regulation of GTPase activity 3.36 3.47E-02 6.52 4.46 
aromatic compound catabolic 
process 
3.33 3.59E-02 5.51 5.08 
regulation of epithelial cell 
proliferation 
3.32 3.60E-02 6.49 4.35 
regulation of cell cycle G1/S phase 
transition 
3.32 3.60E-02 9.80 4.10 
regulation of G1/S transition of 
mitotic cell cycle 
3.32 3.60E-02 9.80 4.10 
cellular transition metal ion 
homeostasis 
3.32 3.60E-02 9.80 6.97 
regulation of cellular response to 
insulin stimulus 
3.32 3.62E-02 11.43 5.52 
regulation of GTP catabolic process 3.29 3.73E-02 6.45 4.46 
regulation of nucleotide catabolic 
process 
3.29 3.73E-02 6.28 4.31 
regulation of purine nucleotide 
catabolic process 
3.29 3.73E-02 6.28 4.31 
cellular response to insulin 
stimulus 
3.28 3.75E-02 8.05 5.01 
ameboidal cell migration 3.28 3.75E-02 8.05 4.47 
negative regulation of metabolic 
process 
3.27 3.78E-02 4.61 4.80 
pyrimidine nucleotide metabolic 
process 
3.26 3.83E-02 14.29 4.87 
regulation of oligodendrocyte 
differentiation 
3.26 3.83E-02 14.29 3.66 
appendage development 3.26 3.83E-02 14.29 3.65 
limb development 3.26 3.83E-02 14.29 3.65 
regulation of glucose transport 3.25 3.87E-02 9.62 6.19 
cellular response to carbohydrate 
stimulus 
3.25 3.87E-02 9.62 6.38 
regulation of cell development 3.25 3.89E-02 5.25 4.04 
223 
 
cellular biogenic amine catabolic 
process 
3.23 3.95E-02 22.22 4.55 
amine catabolic process 3.23 3.95E-02 22.22 4.55 
mature B cell differentiation 3.23 3.95E-02 22.22 3.85 
necroptotic process 3.23 3.95E-02 22.22 6.24 
regulation of platelet aggregation 3.23 3.95E-02 22.22 3.70 
regulation of circadian sleep/wake 
cycle, non-REM sleep 
3.23 3.95E-02 22.22 4.61 
positive regulation of vascular 
permeability 
3.23 3.95E-02 22.22 3.92 
regulation of T cell chemotaxis 3.23 3.95E-02 22.22 8.23 
positive regulation of T cell 
chemotaxis 
3.23 3.95E-02 22.22 8.23 
peptide hormone processing 3.23 3.95E-02 22.22 5.73 
positive regulation of receptor 
recycling 
3.23 3.95E-02 22.22 6.24 
nucleobase catabolic process 3.23 3.95E-02 22.22 3.49 
regulation of granulocyte 
differentiation 
3.23 3.95E-02 22.22 3.92 
hair cell differentiation 3.23 3.95E-02 22.22 3.34 
iron ion transmembrane transport 3.23 3.95E-02 22.22 7.25 
positive regulation of 
immunoglobulin production 
3.23 3.95E-02 22.22 4.99 
regulation of tyrosine 
phosphorylation of Stat1 protein 
3.23 3.95E-02 22.22 2.80 
positive regulation of astrocyte 
differentiation 
3.23 3.95E-02 22.22 4.84 
negative regulation of NF-kappaB 
import into nucleus 
3.23 3.95E-02 22.22 3.62 
positive regulation of glial cell 
proliferation 
3.23 3.95E-02 22.22 4.05 
cellular defense response 3.23 3.95E-02 22.22 3.92 
regulation of inositol phosphate 
biosynthetic process 
3.23 3.95E-02 22.22 3.91 
positive regulation of T-helper 1 
type immune response 
3.23 3.95E-02 22.22 6.79 
cellular response to follicle-
stimulating hormone stimulus 
3.23 3.95E-02 22.22 5.44 
bicarbonate transport 3.23 3.95E-02 22.22 3.50 
multi-organism intracellular 
transport 
3.23 3.95E-02 22.22 7.19 
multi-organism transport 3.23 3.95E-02 22.22 7.19 
transport of virus 3.23 3.95E-02 22.22 7.19 
intracellular transport of virus 3.23 3.95E-02 22.22 7.19 
negative regulation of protein 
secretion 
3.23 3.96E-02 11.11 3.96 
ethanolamine-containing 
compound metabolic process 
3.23 3.96E-02 11.11 4.83 
phagocytosis 3.23 3.96E-02 11.11 4.50 
iron ion transport 3.23 3.96E-02 11.11 6.51 
regulation of membrane potential 3.22 3.99E-02 6.38 4.45 
enzyme linked receptor protein 
signaling pathway 
3.22 4.02E-02 5.84 4.25 
memory 3.21 4.02E-02 8.57 5.51 
fat cell differentiation 3.21 4.02E-02 8.57 5.07 
tissue morphogenesis 3.19 4.11E-02 5.93 4.46 
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fatty acid derivative metabolic 
process 
3.18 4.16E-02 9.43 3.81 
icosanoid metabolic process 3.18 4.16E-02 9.43 3.81 
regulation of nucleoside metabolic 
process 
3.16 4.25E-02 6.16 4.31 
DNA damage response, signal 
transduction by p53 class mediator 
3.14 4.32E-02 13.64 5.33 
negative regulation of myeloid 
leukocyte differentiation 
3.14 4.32E-02 13.64 3.45 
adrenal gland development 3.14 4.32E-02 13.64 5.21 
protein polymerization 3.14 4.32E-02 10.81 4.05 
insulin receptor signaling pathway 3.14 4.32E-02 10.81 4.97 
response to hexose 3.14 4.33E-02 7.34 5.52 
morphogenesis of an epithelium 3.13 4.38E-02 6.13 4.22 
cellular response to hydrogen 
peroxide 
3.11 4.45E-02 9.26 5.44 
hormone transport 3.11 4.45E-02 9.26 4.68 
response to activity 3.11 4.45E-02 9.26 6.48 
epithelial cell development 3.10 4.51E-02 8.33 4.02 
regulation of protein binding 3.08 4.60E-02 7.69 4.09 
cellular response to growth factor 
stimulus 
3.07 4.66E-02 6.07 4.96 
protein oligomerization 3.06 4.69E-02 5.63 5.32 
positive regulation of neuron 
apoptotic process 
3.06 4.70E-02 10.53 4.90 
tissue regeneration 3.06 4.70E-02 10.53 5.08 
cellular response to reactive 
oxygen species 
3.04 4.78E-02 8.22 5.95 
humoral immune response 3.04 4.78E-02 8.22 5.89 
transition metal ion homeostasis 3.04 4.78E-02 8.22 7.22 
vagina development 3.03 4.82E-02 20.00 4.06 
programmed necrotic cell death 3.03 4.82E-02 20.00 6.24 
protein autoprocessing 3.03 4.82E-02 20.00 5.53 
negative regulation of bone 
mineralization 
3.03 4.82E-02 20.00 3.40 
positive regulation of macrophage 
derived foam cell differentiation 
3.03 4.82E-02 20.00 4.21 
positive regulation of mast cell 
activation involved in immune 
response 
3.03 4.82E-02 20.00 5.09 
positive regulation of mast cell 
degranulation 
3.03 4.82E-02 20.00 5.09 
phagocytosis, recognition 3.03 4.82E-02 20.00 3.07 
response to aluminum ion 3.03 4.82E-02 20.00 4.93 
negative regulation of stem cell 
differentiation 
3.03 4.82E-02 20.00 3.34 
astrocyte differentiation 3.03 4.82E-02 20.00 2.79 
negative regulation of 
oligodendrocyte differentiation 
3.03 4.82E-02 20.00 3.67 
inner ear receptor cell 
differentiation 
3.03 4.82E-02 20.00 3.34 
positive regulation of prostaglandin 
secretion 
3.03 4.82E-02 20.00 6.32 
killing of cells of other organism 3.03 4.82E-02 20.00 3.67 
disruption of cells of other 
organism 
3.03 4.82E-02 20.00 3.67 
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negative regulation of lipid storage 3.03 4.82E-02 20.00 3.07 
nitric oxide metabolic process 3.03 4.82E-02 20.00 3.30 
leukocyte tethering or rolling 3.03 4.82E-02 20.00 5.43 
benzene-containing compound 
metabolic process 
3.03 4.84E-02 13.04 3.87 
positive regulation of glial cell 
differentiation 
3.03 4.84E-02 13.04 4.43 
anatomical structure formation 
involved in morphogenesis 
3.00 4.99E-02 5.16 4.24 
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8.2.1.2 Significantly enriched biological processes by Panther 
 
 
 
Figure 4.4.1a: Significantly enriched biological processes. Using Panther software, 
gene ontology clustering was performed on the genes differentially expressed by ≥ 1.4-
fold in the cultures treated with mAb O4compared to isotype cultures alone. The co-
expression of functionally-related gene clusters was rated in order of significance 
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8.2.1.3 Table 4.4.1b: Enriched molecular functions by Partek Genomic Suite. 
Gene ontology clustering was performed on the genes differentially 
regulated by fold change of 1.4 or greater in the antibody in comparison to 
isotype treated cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4- vs IgM- 
score 
cytokine receptor binding 37.07 7.96E-17 20.61 5.17 
chemokine receptor binding 33.36 3.24E-15 44.74 5.82 
cytokine activity 27.90 7.67E-13 20.00 5.42 
binding 26.53 3.02E-12 4.58 4.75 
receptor binding 25.06 1.30E-11 8.14 4.90 
CCR chemokine receptor binding 20.85 8.79E-10 56.25 6.01 
protein binding 20.44 1.33E-09 5.16 4.68 
double-stranded RNA binding 18.52 9.09E-09 27.08 5.57 
carbohydrate derivative binding 15.50 1.85E-07 6.18 4.99 
G-protein coupled receptor binding 14.31 6.07E-07 12.15 5.45 
CCR1 chemokine receptor binding 13.30 1.67E-06 100.00 6.34 
growth factor receptor binding 12.74 2.92E-06 15.91 4.30 
antigen binding 12.22 4.91E-06 17.65 5.65 
MHC protein binding 12.20 5.01E-06 42.86 5.56 
MHC class I protein binding 11.92 6.69E-06 55.56 5.64 
CCR2 chemokine receptor binding 11.72 8.12E-06 80.00 5.90 
CXCR3 chemokine receptor binding 11.72 8.12E-06 80.00 7.85 
anion transmembrane transporter 
activity 
10.74 2.16E-05 10.73 3.78 
interleukin-1 receptor binding 10.17 3.84E-05 41.67 5.18 
MHC class Ib protein binding 9.97 4.67E-05 100.00 6.01 
TAP binding 9.97 4.67E-05 100.00 7.54 
TAP1 binding 9.97 4.67E-05 100.00 7.54 
TAP2 binding 9.97 4.67E-05 100.00 7.54 
CXCR chemokine receptor binding 9.83 5.37E-05 57.14 7.85 
oligopeptide transporter activity 9.83 5.37E-05 57.14 5.46 
anion binding 9.77 5.69E-05 5.33 4.93 
protein homodimerization activity 9.58 6.89E-05 7.34 4.80 
nucleoside binding 9.58 6.93E-05 5.74 4.99 
peptide binding 9.47 7.74E-05 10.49 5.19 
purine nucleotide binding 9.46 7.78E-05 5.70 4.98 
purine ribonucleoside triphosphate 
binding 
9.41 8.16E-05 5.73 4.97 
purine ribonucleotide binding 9.27 9.39E-05 5.68 4.93 
purine ribonucleoside binding 9.26 9.50E-05 5.70 4.97 
amide binding 9.24 9.73E-05 10.30 5.19 
purine nucleoside binding 9.21 9.99E-05 5.70 4.97 
ribonucleoside binding 9.19 1.02E-04 5.69 4.97 
peptide transporter activity 9.17 1.04E-04 50.00 5.46 
ribonucleotide binding 8.98 1.26E-04 5.63 4.93 
amide transmembrane transporter 
activity 
8.61 1.82E-04 44.44 4.99 
cytokine receptor activity 8.60 1.85E-04 15.79 4.89 
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protein dimerization activity 8.59 1.86E-04 6.13 4.56 
guanyl nucleotide binding 8.52 2.00E-04 8.24 5.03 
guanyl ribonucleotide binding 8.52 2.00E-04 8.24 5.03 
transporter activity 8.40 2.25E-04 6.05 4.22 
active transmembrane transporter 
activity 
8.30 2.48E-04 9.23 4.36 
GTP binding 8.25 2.61E-04 8.27 5.14 
organic anion transmembrane 
transporter activity 
8.11 3.00E-04 11.76 3.41 
secondary active transmembrane 
transporter activity 
8.11 3.02E-04 11.11 3.83 
transmembrane transporter 
activity 
8.07 3.14E-04 6.35 4.18 
single-stranded RNA binding 8.01 3.31E-04 22.22 5.32 
adenylyltransferase activity 7.97 3.47E-04 27.78 6.25 
substrate-specific transmembrane 
transporter activity 
7.78 4.18E-04 6.42 4.21 
carboxylic acid transmembrane 
transporter activity 
7.55 5.26E-04 12.66 3.39 
substrate-specific transporter 
activity 
7.55 5.26E-04 6.14 4.18 
carbohydrate binding 7.52 5.43E-04 8.65 4.29 
organic acid transmembrane 
transporter activity 
7.45 5.82E-04 12.50 3.39 
identical protein binding 7.10 8.26E-04 5.88 4.91 
amino acid transmembrane 
transporter activity 
7.08 8.38E-04 14.29 3.43 
CCR5 chemokine receptor binding 7.06 8.60E-04 50.00 5.67 
oligopeptide transmembrane 
transporter activity 
7.06 8.60E-04 50.00 5.73 
basic amino acid transmembrane 
transporter activity 
7.06 8.60E-04 50.00 3.02 
chloride transmembrane 
transporter activity 
6.85 1.06E-03 13.79 4.29 
hydrolase activity 6.74 1.18E-03 5.00 5.14 
phospholipase activator activity 6.53 1.46E-03 42.86 6.21 
IgG binding 6.53 1.46E-03 42.86 3.53 
glycosaminoglycan binding 6.50 1.51E-03 9.84 5.33 
drug transporter activity 6.40 1.66E-03 26.67 3.54 
hydrolase activity, acting on acid 
anhydrides 
6.38 1.70E-03 6.27 5.25 
inorganic anion transmembrane 
transporter activity 
6.35 1.75E-03 11.69 4.20 
cell adhesion molecule binding 6.22 1.98E-03 14.00 4.25 
heparin binding 6.19 2.04E-03 10.64 5.68 
immunoglobulin binding 6.14 2.15E-03 25.00 3.51 
nucleotide binding 6.12 2.20E-03 4.96 4.84 
nucleoside phosphate binding 6.12 2.20E-03 4.96 4.84 
protein tyrosine kinase activity 6.11 2.21E-03 10.53 4.18 
ion transmembrane transporter 
activity 
6.08 2.28E-03 6.10 4.04 
deaminase activity 5.90 2.74E-03 23.53 5.21 
cysteine-type endopeptidase 
activity 
5.85 2.89E-03 15.00 5.80 
lipase activator activity 5.70 3.33E-03 33.33 6.21 
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protease binding 5.67 3.45E-03 12.73 5.81 
small molecule binding 5.62 3.63E-03 4.79 4.85 
double-stranded RNA adenosine 
deaminase activity 
5.57 3.80E-03 66.67 5.56 
CCR10 chemokine receptor binding 5.57 3.80E-03 66.67 6.75 
lipoteichoic acid binding 5.57 3.80E-03 66.67 4.58 
lipopeptide binding 5.57 3.80E-03 66.67 3.50 
MHC class I receptor activity 5.57 3.80E-03 66.67 4.21 
superoxide-generating NADPH 
oxidase activity 
5.57 3.80E-03 66.67 4.12 
arginine transmembrane 
transporter activity 
5.57 3.80E-03 66.67 3.14 
oligopeptide-transporting ATPase 
activity 
5.57 3.80E-03 66.67 7.19 
peptide-transporting ATPase 
activity 
5.57 3.80E-03 66.67 7.19 
catalytic activity 5.46 4.25E-03 4.30 4.88 
antiporter activity 5.37 4.68E-03 16.13 3.90 
transferase activity, transferring 
pentosyl groups 
5.09 6.16E-03 15.15 5.58 
drug transmembrane transporter 
activity 
5.08 6.20E-03 27.27 3.17 
voltage-gated chloride channel 
activity 
5.08 6.20E-03 27.27 4.96 
ion binding 4.93 7.21E-03 4.27 4.81 
monocarboxylic acid 
transmembrane transporter 
activity 
4.92 7.29E-03 18.18 3.42 
molybdopterin cofactor binding 4.90 7.42E-03 50.00 3.93 
IgE binding 4.90 7.42E-03 50.00 3.53 
3'-5'-exodeoxyribonuclease activity 4.90 7.42E-03 50.00 7.66 
CARD domain binding 4.90 7.42E-03 50.00 5.26 
manganese ion transmembrane 
transporter activity 
4.90 7.42E-03 50.00 5.31 
gamma-aminobutyric acid:sodium 
symporter activity 
4.90 7.42E-03 50.00 3.62 
molecular_function 4.85 7.85E-03 3.77 4.73 
hydrolase activity, acting on 
carbon-nitrogen (but not peptide) 
bonds, in cyclic amidines 
4.76 8.58E-03 17.39 4.25 
transition metal ion 
transmembrane transporter 
activity 
4.76 8.58E-03 17.39 5.67 
symporter activity 4.75 8.69E-03 9.88 3.57 
phosphotyrosine binding 4.59 1.02E-02 23.08 4.65 
NAD+ ADP-ribosyltransferase 
activity 
4.59 1.02E-02 23.08 5.55 
protein complex binding 4.45 1.17E-02 5.55 4.60 
iron ion transmembrane 
transporter activity 
4.42 1.21E-02 40.00 6.04 
gamma-aminobutyric acid 
transmembrane transporter 
activity 
4.42 1.21E-02 40.00 3.62 
voltage-gated anion channel 
activity 
4.37 1.26E-02 21.43 4.96 
transferase activity, transferring 
phosphorus-containing groups 
4.23 1.45E-02 5.34 4.61 
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ATP binding 4.23 1.46E-02 4.99 4.90 
non-membrane spanning protein 
tyrosine kinase activity 
4.19 1.52E-02 14.81 4.29 
phosphatidylinositol-3,4-
bisphosphate binding 
4.18 1.54E-02 20.00 3.61 
protein kinase activity 4.10 1.66E-02 5.82 4.28 
receptor antagonist activity 4.04 1.77E-02 33.33 7.26 
immunoglobulin receptor activity 4.04 1.77E-02 33.33 3.09 
semaphorin receptor activity 4.04 1.77E-02 33.33 4.18 
metalloenzyme inhibitor activity 4.04 1.77E-02 33.33 3.77 
metalloendopeptidase inhibitor 
activity 
4.04 1.77E-02 33.33 3.77 
adenyl nucleotide binding 4.01 1.82E-02 4.90 4.97 
chemoattractant activity 4.00 1.84E-02 18.75 5.26 
sulfur compound binding 3.95 1.92E-02 7.69 5.68 
oxidoreductase activity, acting on 
paired donors, with incorporation 
or reduction of molecular oxygen, 
NAD(P)H as one donor, and 
incorporation of one atom of 
oxygen 
3.94 1.94E-02 13.79 4.74 
SNARE binding 3.89 2.04E-02 11.36 4.78 
transmembrane receptor protein 
tyrosine kinase activity 
3.89 2.04E-02 11.36 4.14 
adenyl ribonucleotide binding 3.86 2.12E-02 4.88 4.90 
UDP-N-acetylmuramate 
dehydrogenase activity 
3.72 2.42E-02 28.57 3.93 
low-density lipoprotein receptor 
activity 
3.72 2.42E-02 28.57 5.65 
proteasome binding 3.72 2.42E-02 28.57 4.67 
bicarbonate transmembrane 
transporter activity 
3.72 2.42E-02 28.57 3.50 
sodium:amino acid symporter 
activity 
3.72 2.42E-02 28.57 3.62 
protein heterodimerization activity 3.70 2.47E-02 5.81 4.13 
enzyme inhibitor activity 3.69 2.51E-02 6.33 4.56 
calcium ion binding 3.68 2.53E-02 5.53 4.16 
chloride channel activity 3.63 2.64E-02 10.64 4.53 
ubiquitin protein ligase binding 3.62 2.69E-02 7.63 3.68 
small conjugating protein ligase 
binding 
3.62 2.69E-02 7.63 3.68 
GTPase activity 3.62 2.69E-02 7.63 5.78 
kinase activity 3.61 2.70E-02 5.30 4.27 
protein self-association 3.61 2.70E-02 12.50 5.97 
peptidase regulator activity 3.58 2.79E-02 6.74 4.96 
beta-amyloid binding 3.53 2.94E-02 15.79 5.22 
protein phosphorylated amino acid 
binding 
3.53 2.94E-02 15.79 4.65 
cysteine-type peptidase activity 3.52 2.95E-02 7.50 5.45 
adenosine deaminase activity 3.46 3.15E-02 25.00 5.56 
complement binding 3.46 3.15E-02 25.00 5.04 
receptor inhibitor activity 3.46 3.15E-02 25.00 7.26 
exodeoxyribonuclease activity, 
producing 5'-phosphomonoesters 
3.46 3.15E-02 25.00 7.66 
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exodeoxyribonuclease activity 3.46 3.15E-02 25.00 7.66 
platelet-derived growth factor 
receptor binding 
3.46 3.15E-02 25.00 3.53 
metalloenzyme regulator activity 3.46 3.15E-02 25.00 3.77 
enzyme binding 3.44 3.20E-02 4.82 4.56 
monooxygenase activity 3.42 3.26E-02 7.77 4.14 
scavenger receptor activity 3.41 3.30E-02 11.76 5.94 
extracellular ligand-gated ion 
channel activity 
3.40 3.35E-02 10.00 3.61 
epidermal growth factor receptor 
binding 
3.39 3.37E-02 15.00 3.06 
ADP binding 3.39 3.37E-02 15.00 6.62 
exonuclease activity, active with 
either ribo- or deoxyribonucleic 
acids and producing 5'-
phosphomonoesters 
3.39 3.37E-02 15.00 7.10 
threonine-type endopeptidase 
activity 
3.39 3.37E-02 15.00 7.30 
threonine-type peptidase activity 3.39 3.37E-02 15.00 7.30 
anion channel activity 3.32 3.60E-02 9.80 4.53 
phosphotransferase activity, 
alcohol group as acceptor 
3.27 3.80E-02 5.26 4.28 
oxidoreductase activity, acting on 
NAD(P)H, oxygen as acceptor 
3.23 3.95E-02 22.22 4.12 
N,N-dimethylaniline 
monooxygenase activity 
3.23 3.95E-02 22.22 3.83 
protein binding, bridging 3.18 4.16E-02 9.43 4.71 
phosphoprotein binding 3.18 4.16E-02 9.43 4.09 
transmembrane receptor protein 
kinase activity 
3.18 4.16E-02 9.43 4.14 
iron ion binding 3.16 4.26E-02 6.51 4.39 
tumor necrosis factor receptor 
binding 
3.14 4.32E-02 13.64 5.68 
SNAP receptor activity 3.14 4.32E-02 13.64 6.18 
syntaxin binding 3.14 4.32E-02 10.81 4.10 
cytokine binding 3.11 4.45E-02 9.26 4.51 
ribonuclease activity 3.11 4.45E-02 9.26 4.58 
endopeptidase regulator activity 3.10 4.51E-02 6.67 5.15 
BH domain binding 3.03 4.82E-02 20.00 3.50 
D1 dopamine receptor binding 3.03 4.82E-02 20.00 3.96 
nucleoside diphosphate kinase 
activity 
3.03 4.82E-02 20.00 4.89 
macrolide binding 3.03 4.82E-02 20.00 3.51 
FK506 binding 3.03 4.82E-02 20.00 3.51 
neurotrophin receptor binding 3.03 4.82E-02 20.00 3.25 
insulin-like growth factor receptor 
binding 
3.03 4.82E-02 20.00 5.12 
cation:amino acid symporter 
activity 
3.03 4.82E-02 20.00 3.62 
pattern recognition receptor 
activity 
3.03 4.82E-02 20.00 3.96 
signaling pattern recognition 
receptor activity 
3.03 4.82E-02 20.00 3.96 
nucleotidyltransferase activity 3.03 4.83E-02 7.61 6.20 
steroid hydroxylase activity 3.03 4.84E-02 13.04 5.45 
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8.2.1.4 Table 4.4.1c: Significantly enriched cellular components by Partek 
Genomic Suite. Gene ontology clustering was performed on the genes 
differentially regulated by fold change or 1.4 or greater in the antibody in 
comparison to isotype treated cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group  
O4- vs. IgM- 
score 
plasma membrane part 35.19 5.20E-16 8.38 4.41 
extracellular region part 23.22 8.25E-11 6.39 5.06 
external side of plasma membrane 22.19 2.31E-10 15.17 4.76 
extracellular space 21.60 4.14E-10 8.30 4.99 
side of membrane 19.71 2.75E-09 13.21 4.70 
cell surface 17.99 1.54E-08 10.66 4.58 
MHC protein complex 16.94 4.40E-08 29.73 5.31 
cytoplasm 15.49 1.87E-07 5.33 4.73 
receptor complex 13.15 1.95E-06 11.73 4.44 
vesicle 12.09 5.60E-06 5.67 5.10 
MHC class I protein complex 10.78 2.08E-05 28.00 5.63 
intracellular 10.15 3.92E-05 6.86 5.06 
NLRP1 inflammasome complex 9.97 4.67E-05 100.00 5.71 
AIM2 inflammasome complex 9.97 4.67E-05 100.00 6.85 
TAP complex 9.97 4.67E-05 100.00 7.54 
membrane-bounded vesicle 9.96 4.75E-05 5.48 5.02 
extracellular vesicular exosome 9.40 8.23E-05 5.76 5.14 
extracellular organelle 9.38 8.45E-05 5.75 5.14 
extracellular membrane-bounded 
organelle 
9.38 8.45E-05 5.75 5.14 
integral component of plasma 
membrane 
9.38 8.46E-05 8.94 3.87 
blood microparticle 8.93 1.33E-04 13.75 5.62 
I-kappaB/NF-kappaB complex 8.61 1.82E-04 75.00 4.71 
NLRP3 inflammasome complex 8.61 1.82E-04 75.00 6.85 
symbiont-containing vacuole 
membrane 
8.61 1.82E-04 75.00 6.44 
late endosome 8.27 2.55E-04 12.79 5.26 
endosome 7.91 3.66E-04 7.90 5.16 
host cell part 7.72 4.42E-04 60.00 6.44 
other organism part 7.72 4.42E-04 60.00 6.44 
spermatoproteasome complex 7.72 4.42E-04 60.00 7.30 
membrane 7.72 4.43E-04 4.41 4.42 
integrin complex 7.43 5.92E-04 25.00 3.86 
MHC class II protein complex 7.33 6.57E-04 33.33 4.75 
lamellipodium 7.25 7.09E-04 12.20 3.70 
vacuolar part 7.23 7.24E-04 9.32 5.13 
extracellular region 7.06 8.59E-04 6.18 5.01 
basal part of cell 7.06 8.60E-04 50.00 5.43 
immunological synapse 6.96 9.47E-04 22.73 4.95 
vacuolar membrane 6.92 9.92E-04 9.40 5.23 
lysosomal membrane 6.67 1.27E-03 9.56 5.17 
lysosome 6.56 1.42E-03 8.72 4.25 
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lytic vacuole 6.50 1.51E-03 8.67 4.25 
cytosol 6.42 1.63E-03 5.62 4.59 
vacuole 6.32 1.79E-03 8.25 4.46 
stress fiber 6.26 1.92E-03 16.22 4.95 
actin filament bundle 5.98 2.53E-03 15.38 4.95 
perinuclear region of cytoplasm 5.81 3.00E-03 6.65 4.99 
membrane region 5.78 3.09E-03 5.79 4.11 
actomyosin 5.59 3.72E-03 14.29 4.95 
MHC class I peptide loading 
complex 
5.57 3.80E-03 66.67 6.94 
plasma membrane region 5.41 4.46E-03 6.75 3.92 
organelle membrane 5.11 6.05E-03 4.95 4.71 
IPAF inflammasome complex 4.90 7.42E-03 50.00 6.60 
ripoptosome 4.90 7.42E-03 50.00 4.31 
NADPH oxidase complex 4.90 7.42E-03 50.00 4.12 
external encapsulating structure 
part 
4.90 7.42E-03 50.00 4.73 
cytoplasmic vesicle 4.85 7.86E-03 5.66 5.04 
cell 4.68 9.31E-03 6.96 4.37 
microvillus membrane 4.59 1.02E-02 23.08 4.69 
apical part of cell 4.58 1.02E-02 10.45 5.64 
SNARE complex 4.46 1.16E-02 16.00 5.36 
lipopolysaccharide receptor 
complex 
4.42 1.21E-02 40.00 4.71 
proteasome activator complex 4.42 1.21E-02 40.00 6.99 
cell body 4.37 1.26E-02 6.23 4.11 
cytoplasmic part 4.30 1.36E-02 4.13 4.72 
membrane part 4.28 1.39E-02 4.09 4.47 
chloride channel complex 4.19 1.52E-02 14.81 4.92 
cell projection 4.11 1.63E-02 5.02 4.13 
basolateral plasma membrane 4.05 1.74E-02 7.81 3.97 
bounding membrane of organelle 4.01 1.82E-02 4.96 4.53 
multivesicular body 4.00 1.84E-02 18.75 5.22 
early endosome 3.96 1.90E-02 8.60 5.52 
proteasome complex 3.94 1.94E-02 13.79 7.00 
apical plasma membrane 3.71 2.46E-02 6.67 3.81 
endosome membrane 3.63 2.66E-02 7.30 4.76 
proteasome core complex 3.53 2.94E-02 15.79 7.30 
recycling endosome 3.47 3.10E-02 10.20 5.28 
cytoplasmic vesicle membrane 3.46 3.16E-02 6.83 4.85 
late endosome membrane 3.41 3.30E-02 11.76 5.39 
organelle envelope lumen 3.40 3.35E-02 10.00 4.88 
organelle envelope 3.34 3.55E-02 8.14 4.23 
envelope 3.34 3.55E-02 8.14 4.23 
plasma membrane 3.28 3.76E-02 4.20 4.33 
membrane raft 3.22 3.99E-02 6.38 4.61 
endosomal part 3.14 4.35E-02 6.71 4.76 
membrane-enclosed lumen 3.11 4.45E-02 5.98 4.70 
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endoplasmic reticulum lumen 3.11 4.45E-02 9.26 5.03 
secretory granule membrane 3.06 4.70E-02 10.53 4.13 
filopodium 3.06 4.70E-02 10.53 4.38 
acrosomal membrane 3.03 4.82E-02 20.00 3.54 
podosome 3.03 4.82E-02 20.00 5.98 
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8.2.2 Gene ontology clustering of cultures treated with serum alone 
 
8.2.2.1 Table 4.4.2a: Enriched biological processes by Partek Genomic Suite. 
Gene ontology clustering was performed on the genes differentially 
regulated by fold change of 1.4 or greater in the serum treated cultures in 
comparison to control cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group 
C+ vs C- 
score 
response to external stimulus 75.67 1.38E-33 15.83 4.44 
single-organism process 67.09 7.31E-30 8.17 4.17 
response to external biotic 
stimulus 
66.77 1.00E-29 19.81 4.36 
response to biotic stimulus 63.36 3.05E-28 19.05 4.36 
response to stress 62.87 4.95E-28 12.57 4.29 
positive regulation of biological 
process 
54.45 2.26E-24 10.09 4.25 
response to organic substance 53.13 8.45E-24 12.02 4.31 
single-organism cellular process 53.04 9.27E-24 8.4 4.22 
defense response 52.92 1.04E-23 18.16 4.75 
response to lipopolysaccharide 51.94 2.77E-23 24.42 4.53 
response to molecule of bacterial 
origin 
51.23 5.62E-23 23.79 4.52 
immune system process 51.19 5.89E-23 15.34 4.48 
response to cytokine 51.19 5.90E-23 20.83 4.72 
positive regulation of response to 
stimulus 
49.57 2.97E-22 13.84 4.16 
positive regulation of cellular 
process 
48.24 1.12E-21 10.16 4.25 
cellular response to chemical 
stimulus 
47.31 2.85E-21 12.86 4.48 
response to lipid 44.77 3.59E-20 15.24 4.30 
regulation of response to 
stimulus 
41.36 1.09E-18 10.73 4.22 
response to oxygen-containing 
compound 
41.03 1.52E-18 12.78 4.32 
regulation of cell communication 39.36 8.09E-18 11 4.18 
regulation of signaling 38.72 1.53E-17 10.96 4.17 
regulation of immune system 
process 
38.18 2.63E-17 14.84 4.24 
cellular response to organic 
substance 
37.14 7.40E-17 12.84 4.47 
response to wounding 36.67 1.19E-16 18.23 4.97 
response to organic cyclic 
compound 
36.48 1.44E-16 14.04 4.21 
positive regulation of signal 
transduction 
36.41 1.54E-16 13.79 4.11 
multi-organism process 36.32 1.69E-16 15.66 4.21 
regulation of multicellular 
organismal process 
36.19 1.92E-16 10.89 4.21 
positive regulation of cell 
communication 
34.81 7.63E-16 13.33 4.13 
positive regulation of signaling 34.81 7.63E-16 13.33 4.13 
negative regulation of biological 
process 
33.26 3.60E-15 9.39 4.13 
single-organism developmental 
process 
33.04 4.50E-15 9.06 4.32 
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developmental process 32.76 5.90E-15 8.9 4.32 
positive regulation of 
intracellular signal transduction 
32.5 7.66E-15 15.21 4.07 
positive regulation of immune 
system process 
32.32 9.17E-15 16.89 4.31 
cell chemotaxis 32.17 1.07E-14 30.93 4.93 
regulation of signal transduction 31.99 1.28E-14 10.83 4.14 
immune response 31.3 2.54E-14 16.54 4.67 
cellular response to cytokine 
stimulus 
30.54 5.44E-14 19.01 4.76 
negative regulation of cellular 
process 
30.3 6.95E-14 9.44 4.10 
response to other organism 30.03 9.12E-14 17.57 4.24 
inflammatory response 29.26 1.96E-13 20.57 5.34 
response to drug 29.22 2.04E-13 16.14 4.48 
aging 28.54 4.04E-13 20.92 4.67 
regulation of intracellular signal 
transduction 
28.39 4.68E-13 12.31 4.09 
taxis 28.31 5.09E-13 23.08 4.98 
chemotaxis 28.31 5.09E-13 23.08 4.98 
regulation of cell proliferation 28.15 5.96E-13 11.74 4.33 
regulation of response to 
external stimulus 
28.13 6.10E-13 16.08 4.28 
regulation of developmental 
process 
27.97 7.12E-13 10.74 4.28 
response to virus 27.56 1.08E-12 24.26 4.22 
cellular response to 
lipopolysaccharide 
27.53 1.11E-12 25.62 4.66 
positive regulation of transport 26.83 2.23E-12 14.5 4.30 
cellular response to molecule of 
bacterial origin 
26.59 2.83E-12 24.8 4.66 
organ development 26.26 3.94E-12 11.58 4.26 
leukocyte chemotaxis 26.08 4.72E-12 32.39 4.70 
response to nitrogen compound 26.04 4.92E-12 12.85 4.12 
response to endogenous stimulus 25.8 6.24E-12 11.27 4.12 
positive regulation of 
developmental process 
25.79 6.28E-12 13.11 4.09 
regulation of response to stress 24.84 1.63E-11 13.38 4.22 
anatomical structure 
development 
24.74 1.79E-11 9.35 4.30 
regulation of localization 24.7 1.87E-11 10.47 4.26 
response to organonitrogen 
compound 
24.58 2.12E-11 12.88 4.17 
cellular response to biotic 
stimulus 
24.23 3.00E-11 22.79 4.66 
leukocyte migration 24.01 3.72E-11 25.47 4.57 
response to alcohol 23.78 4.69E-11 15.79 4.64 
response to stimulus 23.74 4.89E-11 7.49 4.35 
response to hormone 23.69 5.14E-11 12.42 4.21 
regulation of locomotion 23.68 5.21E-11 14.22 4.38 
response to extracellular 
stimulus 
23.65 5.35E-11 15.92 4.57 
response to steroid hormone 23.49 6.30E-11 14.69 4.32 
cellular response to oxygen-
containing compound 
23.39 6.93E-11 13.16 4.45 
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regulation of leukocyte migration 23.32 7.47E-11 27.59 4.13 
response to abiotic stimulus 23.22 8.22E-11 11.8 4.38 
regulation of cytokine production 22.94 1.09E-10 15.81 4.21 
biological_process 22.84 1.21E-10 6.37 4.16 
positive regulation of locomotion 22.6 1.53E-10 17.52 4.28 
regulation of programmed cell 
death 
22.33 2.01E-10 11.19 4.21 
regulation of apoptotic process 22.23 2.21E-10 11.22 4.20 
regulation of cell death 22.04 2.67E-10 10.95 4.27 
response to interferon-gamma 22.01 2.77E-10 36.96 4.98 
regulation of biological quality 21.95 2.93E-10 9.49 4.30 
cellular response to lipid 21.86 3.21E-10 16.6 4.60 
regulation of multicellular 
organismal development 
21.57 4.29E-10 10.7 4.22 
regulation of phosphorus 
metabolic process 
21.27 5.80E-10 10.53 4.14 
positive regulation of response to 
external stimulus 
21.25 5.91E-10 20.39 4.28 
regulation of cell motility 21.15 6.55E-10 14.1 4.34 
response to nutrient levels 21.04 7.30E-10 15.54 4.67 
positive regulation of leukocyte 
migration 
20.92 8.21E-10 29.41 4.19 
myeloid leukocyte migration 20.91 8.30E-10 32.73 4.48 
regulation of phosphate 
metabolic process 
20.76 9.63E-10 10.47 4.16 
regulation of cell migration 20.69 1.03E-09 14.21 4.32 
response to tumor necrosis factor 20.66 1.07E-09 26.51 4.93 
positive regulation of cell 
motility 
20.49 1.26E-09 17.19 4.23 
cellular developmental process 20.21 1.67E-09 9.34 4.29 
negative regulation of viral 
process 
20.13 1.81E-09 35.56 3.97 
positive regulation of cell 
migration 
19.62 3.01E-09 16.97 4.17 
positive regulation of cellular 
component movement 
19.59 3.11E-09 16.67 4.23 
response to interleukin-1 19.54 3.26E-09 27.4 5.28 
regulation of transport 19.39 3.80E-09 10.67 4.21 
regulation of cellular component 
movement 
19.23 4.44E-09 13.27 4.32 
regulation of I-kappaB kinase/NF-
kappaB signaling 
19.21 4.53E-09 20.29 3.78 
regulation of chemotaxis 18.74 7.25E-09 23.23 4.44 
single-organism transport 18.65 7.91E-09 9.27 4.22 
cellular process 18.65 7.95E-09 6.63 4.20 
defense response to other 
organism 
18.61 8.27E-09 16.37 4.13 
regulation of ERK1 and ERK2 
cascade 
18.23 1.21E-08 21.19 4.19 
positive regulation of chemotaxis 18.05 1.45E-08 25.32 4.43 
negative regulation of multi-
organism process 
17.96 1.59E-08 26.39 4.01 
granulocyte chemotaxis 17.93 1.64E-08 35.9 5.01 
regulation of anatomical 
structure morphogenesis 
17.83 1.81E-08 12.27 4.34 
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positive regulation of behavior 17.72 2.01E-08 22.92 4.32 
granulocyte migration 17.55 2.39E-08 35 5.01 
establishment of localization 17.53 2.45E-08 8.65 4.25 
regulation of molecular function 17.45 2.65E-08 9.39 4.22 
cell differentiation 17.44 2.66E-08 9.89 4.23 
regulation of defense response 17.37 2.85E-08 15.18 4.17 
negative regulation of response 
to stimulus 
17.17 3.48E-08 11.08 4.31 
negative regulation of 
programmed cell death 
17.13 3.65E-08 12.61 4.41 
response to interferon-beta 16.83 4.89E-08 66.67 4.34 
regulation of cellular localization 16.75 5.30E-08 11.33 4.13 
regulation of leukocyte 
chemotaxis 
16.57 6.39E-08 28.57 4.23 
negative regulation of cell death 16.53 6.63E-08 12.11 4.50 
regulation of lymphocyte 
migration 
16.36 7.89E-08 42.31 4.78 
biological adhesion 16.22 9.03E-08 12.39 4.19 
cellular response to interleukin-1 16.04 1.08E-07 29.41 5.20 
negative regulation of apoptotic 
process 
16.01 1.11E-07 12.41 4.39 
single-organism metabolic 
process 
15.92 1.23E-07 8.19 4.14 
positive regulation of I-kappaB 
kinase/NF-kappaB signaling 
15.83 1.34E-07 20.75 3.77 
positive regulation of cell 
differentiation 
15.81 1.36E-07 12.44 4.07 
cell migration 15.71 1.50E-07 12.63 4.51 
positive regulation of 
multicellular organismal process 
15.58 1.72E-07 12.35 4.07 
immune effector process 15.52 1.82E-07 15.57 4.21 
regulation of vasculature 
development 
15.52 1.82E-07 17.65 4.45 
cellular response to interferon-
gamma 
15.44 1.97E-07 39.29 5.05 
metabolic process 15.43 1.99E-07 7.18 4.18 
response to peptide 15.41 2.03E-07 13.94 4.29 
cell adhesion 15.41 2.03E-07 12.18 4.16 
positive regulation of metabolic 
process 
15.38 2.09E-07 8.81 4.36 
eosinophil chemotaxis 15.34 2.18E-07 70 5.48 
regulation of behavior 15.33 2.21E-07 17.93 4.28 
negative regulation of viral 
genome replication 
15.29 2.29E-07 43.48 3.91 
defense response to virus 15.28 2.30E-07 22.62 3.88 
regulation of natural killer cell 
chemotaxis 
15.22 2.46E-07 85.71 5.65 
regulation of phosphorylation 14.99 3.08E-07 10.41 4.09 
positive regulation of leukocyte 
chemotaxis 
14.95 3.22E-07 29.17 4.25 
transport 14.89 3.41E-07 8.43 4.26 
positive regulation of ion 
transport 
14.8 3.73E-07 19.01 4.64 
response to progesterone 14.75 3.95E-07 30.95 3.93 
regulation of angiogenesis 14.71 4.08E-07 17.86 4.57 
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regulation of catalytic activity 14.56 4.77E-07 9.56 4.31 
regulation of immune effector 
process 
14.55 4.78E-07 15.79 4.36 
biological regulation 14.48 5.15E-07 6.75 4.26 
eosinophil migration 14.38 5.69E-07 63.64 5.48 
positive regulation of cytokine 
production 
14.33 5.97E-07 16.67 4.02 
regulation of protein metabolic 
process 
14.31 6.09E-07 9.14 4.12 
locomotion 14.17 6.99E-07 11.38 4.56 
regulation of symbiosis, 
encompassing mutualism through 
parasitism 
14.14 7.21E-07 21.11 4.06 
cellular response to tumor 
necrosis factor 
14.09 7.61E-07 24.24 5.04 
positive regulation of molecular 
function 
13.97 8.54E-07 10.28 4.00 
response to nutrient 13.96 8.63E-07 15.68 4.73 
cellular response to interferon-
beta 
13.88 9.34E-07 75 4.17 
response to estrogen 13.88 9.42E-07 15.31 4.29 
regulation of lymphocyte 
chemotaxis 
13.78 1.03E-06 50 5.19 
positive regulation of phosphorus 
metabolic process 
13.78 1.04E-06 10.95 4.07 
positive regulation of phosphate 
metabolic process 
13.78 1.04E-06 10.95 4.07 
response to organophosphorus 13.73 1.09E-06 18.49 4.19 
cell communication 13.67 1.16E-06 12.89 3.87 
positive regulation of protein 
metabolic process 
13.66 1.16E-06 10.49 4.10 
regulation of viral process 13.66 1.17E-06 23.53 3.97 
negative regulation of cell 
proliferation 
13.65 1.19E-06 12.11 4.08 
positive regulation of ERK1 and 
ERK2 cascade 
13.52 1.34E-06 21.18 3.99 
regulation of metabolic process 13.49 1.39E-06 7.51 4.26 
single-multicellular organism 
process 
13.4 1.51E-06 8.46 4.10 
positive regulation of cellular 
protein metabolic process 
13.34 1.61E-06 10.75 4.09 
regulation of primary metabolic 
process 
13.34 1.61E-06 7.67 4.25 
positive regulation of MAPK 
cascade 
13.31 1.67E-06 13.93 3.86 
wound healing 13.27 1.72E-06 21.79 4.20 
response to mechanical stimulus 13.25 1.76E-06 16.56 4.40 
response to ethanol 13.21 1.84E-06 17.42 5.27 
regulation of cellular metabolic 
process 
13.21 1.84E-06 7.66 4.24 
organonitrogen compound 
metabolic process 
13.17 1.90E-06 9.6 4.44 
response to decreased oxygen 
levels 
13.13 1.99E-06 14.04 4.27 
small molecule metabolic process 13.06 2.13E-06 9.07 4.19 
response to peptide hormone 13.04 2.18E-06 13.38 4.31 
cellular response to organic 
cyclic compound 
12.95 2.37E-06 14.16 4.77 
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multicellular organismal process 12.91 2.46E-06 8.36 4.08 
regulation of cellular component 
organization 
12.87 2.59E-06 9.18 4.19 
lymphocyte chemotaxis 12.83 2.67E-06 53.85 5.53 
cellular component movement 12.7 3.06E-06 10.37 4.24 
regulation of multi-organism 
process 
12.65 3.20E-06 15.66 3.98 
response to hypoxia 12.57 3.46E-06 13.91 4.20 
regulation of cell differentiation 12.56 3.50E-06 9.49 4.22 
cell motility 12.55 3.53E-06 11.36 4.51 
cellular response to lipoprotein 
particle stimulus 
12.52 3.66E-06 83.33 5.60 
response to ionizing radiation 12.49 3.77E-06 18.35 5.15 
cellular response to external 
stimulus 
12.41 4.09E-06 15.82 4.11 
positive chemotaxis 12.4 4.14E-06 37.5 4.71 
negative regulation of cell 
communication 
12.39 4.15E-06 10.5 4.24 
cell proliferation 12.32 4.48E-06 12.1 3.96 
positive regulation of calcium ion 
transport 
12.3 4.53E-06 25.49 4.97 
response to oxygen levels 12.24 4.83E-06 13.11 4.22 
regulation of biological process 12.15 5.27E-06 6.7 4.26 
positive regulation of cell 
proliferation 
12.05 5.87E-06 10.63 4.30 
secretion 12.03 5.99E-06 12.5 4.17 
response to vitamin 12 6.13E-06 19.15 4.71 
regulation of innate immune 
response 
11.85 7.16E-06 18.95 4.41 
response to radiation 11.82 7.32E-06 12.87 4.57 
response to purine-containing 
compound 
11.82 7.37E-06 16.54 4.19 
negative regulation of signaling 11.8 7.52E-06 10.36 4.21 
positive regulation of 
phosphorylation 
11.77 7.72E-06 10.82 3.89 
regulation of immune response 11.77 7.72E-06 12.23 4.24 
neutrophil migration 11.74 8.00E-06 31.25 4.67 
neutrophil chemotaxis 11.74 8.00E-06 31.25 4.67 
regulation of viral genome 
replication 
11.74 8.00E-06 31.25 3.91 
negative regulation of viral 
transcription 
11.71 8.20E-06 40 4.49 
cellular amide metabolic process 11.69 8.34E-06 18.75 4.65 
regulation of secretion 11.63 8.93E-06 11.45 3.74 
response to ketone 11.57 9.44E-06 15.86 4.09 
innate immune response 11.57 9.44E-06 15.86 4.55 
positive regulation of protein 
modification process 
11.54 9.74E-06 10.73 4.06 
regulation of protein 
modification process 
11.52 9.93E-06 9.69 4.03 
cellular response to nitrogen 
compound 
11.51 9.99E-06 12.37 4.27 
NIK/NF-kappaB signaling 11.41 1.11E-05 100 4.26 
positive regulation of catalytic 
activity 
11.32 1.21E-05 10.32 4.06 
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lipopolysaccharide-mediated 
signaling pathway 
11.28 1.26E-05 38.1 4.50 
positive regulation of cellular 
metabolic process 
11.27 1.28E-05 8.38 4.27 
anion transport 11.27 1.28E-05 12.89 4.13 
cellular response to 
organonitrogen compound 
11.26 1.28E-05 12.54 4.32 
regulation of MAPK cascade 11.26 1.29E-05 11.6 4.00 
monocyte chemotaxis 11.23 1.32E-05 54.55 3.85 
organic acid biosynthetic process 11.22 1.34E-05 14.21 4.39 
carboxylic acid biosynthetic 
process 
11.22 1.34E-05 14.21 4.39 
leukocyte cell-cell adhesion 11.13 1.46E-05 29.41 4.42 
regulation of tumor necrosis 
factor production 
11.03 1.62E-05 21.54 4.34 
response to inorganic substance 11.03 1.63E-05 11.28 5.09 
regulation of protein 
phosphorylation 
10.96 1.73E-05 10.08 4.06 
negative regulation of neuron 
apoptotic process 
10.96 1.73E-05 17.82 4.15 
regulation of cAMP metabolic 
process 
10.94 1.77E-05 20.27 4.90 
regulation of ion transport 10.88 1.89E-05 12.32 4.55 
organic substance metabolic 
process 
10.88 1.89E-05 6.97 4.16 
regulation of cellular protein 
metabolic process 
10.85 1.95E-05 9.04 4.08 
regulation of cellular process 10.83 1.98E-05 6.69 4.26 
positive regulation of 
programmed cell death 
10.67 2.31E-05 12.36 3.88 
cellular response to stimulus 10.66 2.34E-05 7.09 4.37 
regulation of myeloid leukocyte 
differentiation 
10.66 2.34E-05 20.9 4.23 
regeneration 10.61 2.46E-05 16.26 4.29 
positive regulation of 
macromolecule metabolic 
process 
10.61 2.47E-05 8.38 4.28 
antigen processing and 
presentation 
10.61 2.47E-05 19.74 4.45 
positive regulation of 
angiogenesis 
10.6 2.49E-05 18.82 4.74 
ensheathment of neurons 10.59 2.51E-05 22.03 5.04 
axon ensheathment 10.59 2.51E-05 22.03 5.04 
response to interferon-alpha 10.59 2.52E-05 50 4.46 
positive regulation of gliogenesis 10.58 2.55E-05 27.78 4.01 
regulation of cell adhesion 10.56 2.59E-05 13.46 4.32 
central nervous system 
myelination 
10.38 3.10E-05 62.5 4.70 
axon ensheathment in central 
nervous system 
10.38 3.10E-05 62.5 4.70 
rhythmic process 10.37 3.12E-05 13.57 3.87 
response to cAMP 10.35 3.21E-05 17.71 4.32 
negative regulation of signal 
transduction 
10.33 3.27E-05 10.15 4.17 
regulation of cell shape 10.31 3.32E-05 20.29 4.78 
response to glucocorticoid 10.29 3.39E-05 14.04 4.89 
cellular response to endogenous 10.27 3.45E-05 10.25 4.22 
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stimulus 
negative regulation of neuron 
death 
10.26 3.51E-05 16.38 4.29 
regulation of gliogenesis 10.22 3.65E-05 21.31 3.98 
regulation of neuron apoptotic 
process 
10.2 3.71E-05 14.97 4.17 
regulation of cellular response to 
stress 
10.19 3.75E-05 12.4 4.36 
regulation of mononuclear cell 
proliferation 
10.16 3.86E-05 15.33 4.38 
positive regulation of protein 
phosphorylation 
10.16 3.87E-05 10.89 4.07 
intracellular signal transduction 10.1 4.10E-05 9.25 4.35 
positive regulation of apoptotic 
process 
10.09 4.13E-05 12.18 3.91 
gland development 10.07 4.23E-05 17.35 3.66 
positive regulation of lipid 
transport 
10.06 4.27E-05 26.32 3.47 
positive regulation of tumor 
necrosis factor production 
10.03 4.42E-05 29.03 4.02 
chronic inflammatory response 10.02 4.45E-05 46.15 5.28 
response to lipoprotein particle 10.02 4.45E-05 46.15 5.34 
regulation of purine nucleotide 
metabolic process 
10 4.53E-05 11.82 4.51 
cytokine-mediated signaling 
pathway 
9.91 4.97E-05 15.5 4.75 
cellular response to stress 9.89 5.04E-05 9.46 4.16 
positive regulation of natural 
killer cell chemotaxis 
9.84 5.31E-05 80 5.94 
membrane to membrane docking 9.84 5.31E-05 80 5.08 
ISG15-protein conjugation 9.84 5.31E-05 80 4.55 
antigen processing and 
presentation of endogenous 
peptide antigen 
9.84 5.31E-05 80 4.45 
response to metal ion 9.84 5.35E-05 12.35 5.23 
one-carbon metabolic process 9.82 5.43E-05 32 3.49 
regulation of granulocyte 
chemotaxis 
9.82 5.43E-05 32 3.73 
cellular modified amino acid 
metabolic process 
9.8 5.56E-05 15.38 4.44 
regulation of nucleotide 
metabolic process 
9.79 5.58E-05 11.71 4.51 
regulation of calcium ion 
transport 
9.78 5.68E-05 15.83 4.59 
positive regulation of defense 
response 
9.78 5.68E-05 15.83 4.47 
response to growth hormone 9.76 5.77E-05 36.84 4.54 
negative regulation of 
developmental process 
9.76 5.79E-05 10.39 3.94 
regulation of leukocyte 
proliferation 
9.73 5.96E-05 14.89 4.38 
cell death 9.68 6.27E-05 11.38 4.54 
positive regulation of immune 
effector process 
9.66 6.38E-05 15.7 4.45 
response to bacterium 9.65 6.42E-05 14.11 4.65 
regulation of mononuclear cell 
migration 
9.62 6.64E-05 55.56 4.87 
positive regulation of antigen 
processing and presentation 
9.62 6.64E-05 55.56 3.39 
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positive regulation of transferase 
activity 
9.59 6.81E-05 12.03 4.10 
positive regulation of cell death 9.59 6.85E-05 11.59 3.88 
myelination 9.59 6.85E-05 21.43 5.18 
acute inflammatory response 9.59 6.85E-05 21.43 5.43 
regulation of cytokine-mediated 
signaling pathway 
9.58 6.89E-05 25 4.65 
response to corticosteroid 9.55 7.09E-05 13.44 4.89 
positive regulation of 
neurogenesis 
9.55 7.14E-05 16.67 4.06 
positive regulation of secretion 9.54 7.16E-05 12.73 3.85 
peptide metabolic process 9.52 7.37E-05 20 4.96 
purine nucleobase metabolic 
process 
9.51 7.41E-05 42.86 4.42 
drug metabolic process 9.5 7.45E-05 30.77 3.37 
regulation of leukocyte 
differentiation 
9.48 7.62E-05 14.29 4.19 
cellular response to peptide 9.47 7.73E-05 15.04 4.33 
regulation of inflammatory 
response 
9.46 7.77E-05 13.94 4.23 
positive regulation of immune 
response 
9.43 8.05E-05 12.86 4.39 
cellular component organization 9.42 8.14E-05 7.51 4.22 
positive regulation of leukocyte 
differentiation 
9.39 8.37E-05 17.86 4.41 
response to protozoan 9.38 8.44E-05 35 3.89 
regulation of astrocyte 
differentiation 
9.38 8.44E-05 35 3.69 
regulation of cyclic nucleotide 
metabolic process 
9.32 8.93E-05 17.02 4.75 
negative regulation of molecular 
function 
9.3 9.10E-05 9.94 4.21 
response to temperature stimulus 9.3 9.16E-05 15.79 4.63 
regulation of transferase activity 9.24 9.66E-05 10.48 4.14 
death 9.23 9.80E-05 11.14 4.54 
ion transport 9.22 9.86E-05 9.41 4.25 
regulation of neuron death 9.18 1.03E-04 13.69 4.28 
homeostatic process 9.16 1.05E-04 9.15 4.54 
regulation of lymphocyte 
proliferation 
9.15 1.06E-04 14.71 4.41 
response to estradiol 9.1 1.12E-04 15.08 4.46 
regulation of leukocyte apoptotic 
process 
9.05 1.17E-04 20.34 4.80 
lymphocyte migration 9.03 1.20E-04 33.33 5.53 
developmental growth 9.02 1.22E-04 14.19 4.25 
regulation of metal ion transport 9.01 1.22E-04 13.26 4.65 
primary metabolic process 9.01 1.22E-04 6.88 4.17 
positive regulation of myeloid 
leukocyte differentiation 
8.98 1.26E-04 25.71 4.37 
negative regulation of cellular 
metabolic process 
8.98 1.26E-04 8.52 4.16 
negative regulation by host of 
viral transcription 
8.98 1.26E-04 50 3.98 
regulation of antigen processing 
and presentation 
8.98 1.26E-04 50 3.39 
positive regulation of cellular 8.97 1.27E-04 10.13 4.23 
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component organization 
regulation of establishment of 
protein localization 
8.97 1.27E-04 11.5 3.94 
small molecule biosynthetic 
process 
8.96 1.29E-04 11.79 4.37 
regulation of kinase activity 8.94 1.32E-04 10.5 4.12 
apoptotic signaling pathway 8.91 1.35E-04 13.45 4.56 
regulation of interleukin-6 
production 
8.87 1.40E-04 18.84 3.92 
negative regulation of metabolic 
process 
8.87 1.40E-04 8.35 4.19 
negative regulation of locomotion 8.82 1.47E-04 14 5.02 
positive regulation of kinase 
activity 
8.82 1.48E-04 11.86 4.07 
cellular metabolic process 8.8 1.50E-04 6.87 4.10 
positive regulation of 
macrophage chemotaxis 
8.79 1.52E-04 66.67 4.67 
response to low-density 
lipoprotein particle 
8.79 1.52E-04 66.67 4.63 
antigen processing and 
presentation of endogenous 
antigen 
8.79 1.52E-04 66.67 4.45 
ovulation cycle process 8.71 1.65E-04 16.85 3.85 
adrenal gland development 8.69 1.68E-04 31.82 3.19 
regulation of growth 8.68 1.70E-04 10.55 3.81 
negative regulation of response 
to external stimulus 
8.68 1.70E-04 14.62 4.55 
protein kinase B signaling 8.65 1.75E-04 27.59 4.29 
protein trimerization 8.65 1.75E-04 27.59 3.94 
regulation of viral transcription 8.65 1.75E-04 27.59 4.49 
carboxylic acid transport 8.65 1.76E-04 14.18 3.99 
defense response to protozoan 8.63 1.79E-04 37.5 3.93 
cellular response to extracellular 
stimulus 
8.57 1.89E-04 16 4.07 
regulation of nervous system 
development 
8.55 1.93E-04 10.24 4.39 
negative regulation of 
lymphocyte chemotaxis 
8.55 1.93E-04 100 4.93 
negative regulation of 
lymphocyte migration 
8.55 1.93E-04 100 4.93 
response to type I interferon 8.55 1.93E-04 100 5.76 
cellular response to low-density 
lipoprotein particle stimulus 
8.55 1.93E-04 100 4.83 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class I 
8.55 1.93E-04 100 4.72 
organic acid transport 8.55 1.94E-04 14.08 3.99 
regulation of response to 
cytokine stimulus 
8.52 1.99E-04 22.22 4.65 
regulation of neurogenesis 8.52 2.00E-04 10.47 4.38 
regulation of cell activation 8.49 2.05E-04 11.35 4.29 
chemical homeostasis 8.46 2.11E-04 9.73 4.52 
reproductive process 8.46 2.11E-04 9.08 4.10 
organic acid metabolic process 8.46 2.12E-04 9.41 4.28 
programmed cell death 8.45 2.14E-04 11.19 4.55 
regulation of intracellular 8.4 2.24E-04 11.74 4.59 
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transport 
regulation of lipid biosynthetic 
process 
8.34 2.39E-04 15.69 3.63 
negative regulation of 
phosphorus metabolic process 
8.26 2.58E-04 11.81 4.24 
negative regulation of phosphate 
metabolic process 
8.26 2.58E-04 11.81 4.24 
organonitrogen compound 
biosynthetic process 
8.26 2.58E-04 10.84 4.20 
integrin-mediated signaling 
pathway 
8.25 2.61E-04 20 4.17 
single-organism biosynthetic 
process 
8.25 2.62E-04 9.16 4.16 
regulation of cAMP biosynthetic 
process 
8.24 2.63E-04 18.75 4.51 
response to chemical 8.23 2.65E-04 7.1 4.42 
regulation of protein kinase B 
signaling 
8.23 2.67E-04 16.87 4.15 
regulation of protein kinase 
activity 
8.2 2.76E-04 10.4 4.05 
regulation of cell morphogenesis 8.19 2.77E-04 11.76 4.67 
cellular component organization 
or biogenesis 
8.14 2.90E-04 7.34 4.22 
regulation of lipid metabolic 
process 
8.14 2.91E-04 12.78 3.74 
glial cell differentiation 8.14 2.91E-04 21.28 4.74 
positive regulation of protein 
kinase activity 
8.05 3.18E-04 11.67 3.95 
carboxylic acid metabolic process 8.01 3.31E-04 9.44 4.25 
cellular amino acid biosynthetic 
process 
8.01 3.33E-04 17.33 4.49 
positive regulation of NF-kappaB 
transcription factor activity 
8.01 3.33E-04 17.33 3.86 
epithelial cell differentiation 8 3.34E-04 12.2 4.40 
regulation of adaptive immune 
response 
8 3.36E-04 15.24 4.11 
lung development 7.97 3.45E-04 15.79 4.44 
organic anion transport 7.95 3.53E-04 12.37 4.10 
negative regulation of adenylate 
cyclase activity 
7.93 3.61E-04 41.67 4.90 
positive regulation of toll-like 
receptor signaling pathway 
7.93 3.61E-04 41.67 4.12 
response to fatty acid 7.92 3.63E-04 19.3 3.45 
positive regulation of protein 
kinase B signaling 
7.92 3.63E-04 19.3 4.20 
regulation of nucleocytoplasmic 
transport 
7.91 3.68E-04 14.17 4.04 
acute-phase response 7.91 3.68E-04 25 5.40 
negative regulation of cyclic 
nucleotide biosynthetic process 
7.89 3.75E-04 33.33 4.65 
negative regulation of cAMP 
biosynthetic process 
7.89 3.75E-04 33.33 4.65 
growth 7.86 3.85E-04 11.37 4.11 
regulation of T cell proliferation 7.86 3.87E-04 15.63 4.34 
endocytosis 7.82 4.00E-04 12.5 4.15 
positive regulation of 
phagocytosis 
7.81 4.06E-04 28 4.76 
regulation of multicellular 
organism growth 
7.76 4.24E-04 18.97 4.03 
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regulation of JAK-STAT cascade 7.76 4.24E-04 18.97 3.80 
MAPK cascade 7.74 4.34E-04 15.46 4.27 
regulation of protein 
serine/threonine kinase activity 
7.72 4.45E-04 11.43 3.91 
apoptotic mitochondrial changes 7.68 4.62E-04 24.24 5.21 
regulation of wound healing 7.66 4.72E-04 17.65 4.07 
negative regulation of cell 
adhesion 
7.66 4.72E-04 17.65 4.73 
transmembrane receptor protein 
tyrosine kinase signaling pathway 
7.62 4.90E-04 12.57 4.09 
intrinsic apoptotic signaling 
pathway in response to DNA 
damage 
7.61 4.94E-04 20 4.53 
response to gamma radiation 7.61 4.94E-04 20 5.98 
cellular chemical homeostasis 7.59 5.06E-04 10.56 4.40 
gamma-aminobutyric acid 
signaling pathway 
7.56 5.21E-04 31.58 5.30 
positive regulation of lymphocyte 
migration 
7.56 5.21E-04 31.58 5.09 
negative regulation of cyclic 
nucleotide metabolic process 
7.56 5.21E-04 31.58 4.65 
negative regulation of cAMP 
metabolic process 
7.56 5.21E-04 31.58 4.65 
temperature homeostasis 7.55 5.28E-04 26.92 4.35 
regulation of NF-kappaB import 
into nucleus 
7.55 5.28E-04 26.92 3.65 
regulation of toll-like receptor 
signaling pathway 
7.55 5.28E-04 26.92 4.27 
regulation of macromolecule 
metabolic process 
7.54 5.29E-04 7.12 4.23 
multicellular organismal 
homeostasis 
7.5 5.51E-04 21.43 4.54 
negative regulation of cyclase 
activity 
7.49 5.58E-04 38.46 4.90 
positive regulation of 
mononuclear cell proliferation 
7.49 5.59E-04 15.73 4.64 
regulation of cyclic nucleotide 
biosynthetic process 
7.49 5.61E-04 16.46 4.35 
regulation of endocrine process 7.46 5.74E-04 23.53 3.25 
multicellular organismal 
reproductive process 
7.46 5.74E-04 10.11 3.98 
positive regulation of 
inflammatory response 
7.46 5.75E-04 18.33 4.69 
enzyme linked receptor protein 
signaling pathway 
7.44 5.85E-04 10.95 3.97 
regulation of body fluid levels 7.44 5.85E-04 13.29 3.83 
cellular response to peptide 
hormone stimulus 
7.44 5.88E-04 14.05 4.34 
cell-cell signaling 7.43 5.94E-04 11.94 3.83 
positive regulation of adaptive 
immune response 
7.39 6.20E-04 17.14 4.29 
regulation of protein transport 7.35 6.39E-04 11.03 3.96 
regulation of macrophage 
chemotaxis 
7.35 6.46E-04 50 4.67 
response to lipoteichoic acid 7.35 6.46E-04 50 4.76 
cellular response to lipoteichoic 
acid 
7.35 6.46E-04 50 4.76 
regulation of endothelial cell 
chemotaxis 
7.35 6.46E-04 50 4.50 
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regulation of cellular senescence 7.35 6.46E-04 50 3.55 
positive regulation of 
intracellular transport 
7.34 6.47E-04 13.93 4.75 
digestive tract development 7.32 6.62E-04 20.93 3.92 
regulation of leukocyte mediated 
cytotoxicity 
7.32 6.65E-04 18.03 4.39 
behavior 7.31 6.72E-04 10.11 4.24 
secretion by tissue 7.29 6.85E-04 19.23 3.45 
oxoacid metabolic process 7.25 7.08E-04 9.09 4.26 
response to ATP 7.25 7.09E-04 30 4.15 
negative regulation of purine 
nucleotide biosynthetic process 
7.25 7.09E-04 30 4.65 
negative regulation of nucleotide 
biosynthetic process 
7.25 7.09E-04 30 4.65 
negative regulation of amine 
transport 
7.25 7.09E-04 30 4.60 
toll-like receptor signaling 
pathway 
7.25 7.09E-04 30 4.63 
positive regulation of growth 7.25 7.09E-04 13.43 3.82 
positive regulation of sequence-
specific DNA binding 
transcription factor activity 
7.25 7.09E-04 13.43 3.80 
positive regulation of protein 
transport 
7.22 7.33E-04 12.74 3.91 
regulation of dendritic cell 
antigen processing and 
presentation 
7.21 7.39E-04 75 3.12 
positive regulation of dendritic 
cell antigen processing and 
presentation 
7.21 7.39E-04 75 3.12 
positive regulation of RIG-I 
signaling pathway 
7.21 7.39E-04 75 2.90 
chronic inflammatory response to 
antigenic stimulus 
7.21 7.39E-04 75 5.40 
protection from natural killer cell 
mediated cytotoxicity 
7.21 7.39E-04 75 4.19 
regulation of cellular response to 
growth factor stimulus 
7.2 7.48E-04 14.71 3.83 
regulation of lipid transport 7.17 7.67E-04 17.74 3.85 
myeloid leukocyte activation 7.17 7.67E-04 17.74 4.14 
negative regulation of cell 
migration 
7.16 7.81E-04 13.71 5.02 
regulation of protein localization 7.15 7.86E-04 10.2 3.96 
positive regulation of leukocyte 
proliferation 
7.15 7.86E-04 15.22 4.64 
positive regulation of cytokine 
secretion 
7.13 8.01E-04 18.87 3.65 
learning or memory 7.1 8.24E-04 12.93 3.94 
purinergic receptor signaling 
pathway 
7.1 8.27E-04 35.71 4.35 
glial cell migration 7.1 8.27E-04 35.71 3.95 
negative regulation of lyase 
activity 
7.1 8.27E-04 35.71 4.90 
positive regulation of epithelial 
cell proliferation 
7.09 8.30E-04 14.56 4.34 
regulation of myeloid cell 
differentiation 
7.07 8.52E-04 14.04 4.21 
cognition 7.06 8.61E-04 12.58 3.89 
positive regulation of protein 7.06 8.61E-04 12.58 4.03 
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serine/threonine kinase activity 
activation of innate immune 
response 
7.06 8.63E-04 22.22 4.32 
monocarboxylic acid metabolic 
process 
7.05 8.65E-04 10.82 3.94 
ossification 7.04 8.78E-04 15.05 3.63 
signaling 7.03 8.81E-04 11.26 3.81 
single organism signaling 7.03 8.81E-04 11.26 3.81 
regulation of cell-cell adhesion 7.03 8.82E-04 17.46 4.43 
secretion by cell 7.02 8.96E-04 11.42 4.52 
regulation of purine nucleotide 
biosynthetic process 
7 9.08E-04 15.66 4.35 
regulation of nucleotide 
biosynthetic process 
7 9.08E-04 15.66 4.35 
regulation of nitrogen compound 
metabolic process 
7 9.10E-04 7.31 4.27 
negative regulation of cell 
differentiation 
7 9.14E-04 10.03 3.97 
positive regulation of peptidyl-
tyrosine phosphorylation 
6.99 9.20E-04 14.42 3.96 
regulation of hormone levels 6.98 9.32E-04 12.5 4.19 
positive regulation of epithelial 
cell migration 
6.97 9.37E-04 20 3.90 
signal transduction by 
phosphorylation 
6.97 9.38E-04 13.91 4.20 
endothelial cell development 6.97 9.44E-04 28.57 4.16 
negative regulation of 
chemotaxis 
6.97 9.44E-04 28.57 4.94 
negative regulation of purine 
nucleotide metabolic process 
6.97 9.44E-04 28.57 4.65 
regulation of neuron 
differentiation 
6.95 9.61E-04 10.39 4.42 
regulation of JNK cascade 6.93 9.78E-04 14.89 4.28 
response to toxic substance 6.9 1.00E-03 13.04 4.88 
positive regulation of innate 
immune response 
6.9 1.01E-03 17.19 4.21 
regulation of protein secretion 6.88 1.03E-03 13.79 3.73 
negative regulation of 
neurogenesis 
6.87 1.03E-03 16.22 3.86 
lactation 6.86 1.05E-03 21.62 3.74 
regulation of phagocytosis 6.86 1.05E-03 21.62 4.91 
regulation of osteoclast 
differentiation 
6.86 1.05E-03 21.62 4.15 
regulation of adenylate cyclase 
activity 
6.83 1.08E-03 24.14 4.37 
response to increased oxygen 
levels 
6.83 1.08E-03 24.14 4.48 
response to hyperoxia 6.83 1.08E-03 24.14 4.48 
positive regulation of cell-cell 
adhesion 
6.83 1.08E-03 24.14 4.28 
body fluid secretion 6.83 1.08E-03 18.18 3.45 
positive regulation of 
homeostatic process 
6.83 1.08E-03 18.18 5.22 
positive regulation of cell 
activation 
6.82 1.09E-03 12.35 4.73 
cellular response to hormone 
stimulus 
6.82 1.09E-03 10.66 4.54 
positive regulation of lymphocyte 6.82 1.09E-03 12.95 4.70 
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activation 
defense response to bacterium 6.82 1.09E-03 12.95 4.42 
organic hydroxy compound 
metabolic process 
6.81 1.10E-03 10.93 3.76 
heat generation 6.8 1.11E-03 44.44 4.24 
cellular response to ethanol 6.8 1.11E-03 44.44 7.07 
positive regulation of astrocyte 
differentiation 
6.8 1.11E-03 44.44 3.53 
regulation of interferon-alpha 
production 
6.8 1.11E-03 44.44 3.76 
single organism cell adhesion 6.8 1.11E-03 12.07 4.17 
negative regulation of cell 
motility 
6.79 1.12E-03 13.28 5.02 
regulation of cell killing 6.76 1.15E-03 16.92 4.39 
execution phase of apoptosis 6.74 1.18E-03 33.33 4.86 
modulation by host of viral 
transcription 
6.74 1.18E-03 33.33 3.98 
modulation of transcription in 
other organism involved in 
symbiotic interaction 
6.74 1.18E-03 33.33 3.98 
modulation by host of symbiont 
transcription 
6.74 1.18E-03 33.33 3.98 
nitrogen compound metabolic 
process 
6.71 1.22E-03 7.19 4.14 
negative regulation of secretion 6.71 1.22E-03 13.18 3.86 
regulation of T cell apoptotic 
process 
6.7 1.23E-03 27.27 5.08 
response to insulin 6.69 1.24E-03 12.5 3.98 
response to acid 6.69 1.24E-03 10.45 4.13 
negative regulation of leukocyte 
apoptotic process 
6.68 1.26E-03 21.05 4.75 
positive regulation of cell 
development 
6.65 1.29E-03 12.77 4.07 
positive regulation of hydrolase 
activity 
6.65 1.30E-03 10.55 4.00 
cation homeostasis 6.63 1.32E-03 10.19 4.43 
pattern recognition receptor 
signaling pathway 
6.62 1.33E-03 23.33 4.38 
positive regulation of T cell 
activation 
6.62 1.34E-03 14.43 4.58 
cell activation 6.58 1.39E-03 10.26 4.23 
single-organism behavior 6.55 1.43E-03 10.61 4.08 
regulation of cell cycle 6.55 1.43E-03 9.35 3.86 
alpha-amino acid biosynthetic 
process 
6.54 1.44E-03 17.54 4.46 
positive regulation of endocytosis 6.54 1.44E-03 17.54 4.80 
negative regulation of cellular 
component movement 
6.54 1.45E-03 12.98 5.02 
amino acid transport 6.52 1.48E-03 15.58 3.98 
regulation of steroid metabolic 
process 
6.51 1.49E-03 16.42 3.54 
regulation of protein localization 
to nucleus 
6.5 1.50E-03 13.76 4.09 
regulation of pH 6.5 1.50E-03 20.51 4.00 
antigen processing and 
presentation of peptide antigen 
6.49 1.52E-03 18.75 3.81 
positive regulation of leukocyte 
activation 
6.46 1.56E-03 12.26 4.77 
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positive regulation of lymphocyte 
proliferation 
6.45 1.58E-03 14.77 4.70 
modification by host of symbiont 
morphology or physiology 
6.44 1.59E-03 26.09 4.11 
regulation of extrinsic apoptotic 
signaling pathway via death 
domain receptors 
6.44 1.59E-03 26.09 5.25 
regulation of leukocyte mediated 
immunity 
6.42 1.62E-03 13.22 4.30 
regulation of extrinsic apoptotic 
signaling pathway 
6.42 1.63E-03 14.14 4.45 
semaphorin-plexin signaling 
pathway 
6.41 1.64E-03 31.25 5.77 
positive regulation of protein 
secretion 
6.4 1.66E-03 15.38 3.75 
regulation of nucleobase-
containing compound metabolic 
process 
6.36 1.72E-03 7.24 4.26 
positive regulation of lipid 
metabolic process 
6.35 1.76E-03 14.61 3.67 
negative regulation of catalytic 
activity 
6.34 1.76E-03 9.59 4.37 
T cell migration 6.34 1.76E-03 40 5.37 
regulation of macrophage 
cytokine production 
6.34 1.76E-03 40 3.32 
DNA replication initiation 6.34 1.76E-03 40 2.99 
positive regulation of 
prostaglandin secretion 
6.34 1.76E-03 40 3.66 
purinergic nucleotide receptor 
signaling pathway 
6.34 1.76E-03 40 3.67 
defense response to Gram-
positive bacterium 
6.34 1.77E-03 18.37 4.28 
negative regulation of platelet 
aggregation 
6.34 1.77E-03 60 3.92 
negative regulation of 
neurotrophin TRK receptor 
signaling pathway 
6.34 1.77E-03 60 3.46 
response to iron(III) ion 6.34 1.77E-03 60 4.09 
T cell chemotaxis 6.34 1.77E-03 60 4.93 
positive regulation of cell-cell 
adhesion mediated by integrin 
6.34 1.77E-03 60 4.67 
regulation of keratinocyte 
migration 
6.34 1.77E-03 60 3.68 
positive regulation of 
keratinocyte migration 
6.34 1.77E-03 60 3.68 
radial glial cell differentiation 6.34 1.77E-03 60 4.82 
positive regulation of endothelial 
cell chemotaxis 
6.34 1.77E-03 60 5.02 
toll-like receptor 4 signaling 
pathway 
6.34 1.77E-03 60 5.22 
modification of morphology or 
physiology of other organism 
involved in symbiotic interaction 
6.33 1.79E-03 20 3.88 
positive regulation of myeloid 
cell differentiation 
6.27 1.89E-03 16.95 4.40 
regulation of sequence-specific 
DNA binding transcription factor 
activity 
6.26 1.90E-03 10.82 3.83 
organ regeneration 6.26 1.91E-03 15.94 4.31 
positive regulation of adaptive 
immune response based on 
somatic recombination of 
6.26 1.91E-03 15.94 4.33 
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immune receptors built from 
immunoglobulin superfamily 
domains 
regulation of adaptive immune 
response based on somatic 
recombination of immune 
receptors built from 
immunoglobulin superfamily 
domains 
6.22 1.98E-03 13.86 4.07 
regulation of excitatory 
postsynaptic membrane potential 
6.22 1.99E-03 21.88 3.82 
response to cold 6.22 1.99E-03 21.88 4.75 
innate immune response-
activating signal transduction 
6.22 1.99E-03 21.88 4.38 
positive regulation of 
transmembrane transport 
6.21 2.02E-03 25 4.29 
positive regulation of production 
of molecular mediator of immune 
response 
6.21 2.02E-03 25 3.76 
negative regulation of nucleotide 
metabolic process 
6.21 2.02E-03 25 4.65 
neutral amino acid transport 6.21 2.02E-03 25 3.98 
negative regulation of 
angiogenesis 
6.19 2.05E-03 18 4.30 
cellular response to 
glucocorticoid stimulus 
6.19 2.05E-03 18 5.46 
regulation of epithelial cell 
migration 
6.18 2.07E-03 15 4.13 
regulation of T cell activation 6.16 2.10E-03 11.95 4.33 
regulation of nitric oxide 
biosynthetic process 
6.16 2.11E-03 19.51 5.35 
regulation of chemokine 
production 
6.16 2.11E-03 19.51 3.73 
memory 6.14 2.15E-03 15.71 4.64 
fat cell differentiation 6.14 2.15E-03 15.71 3.55 
activation of immune response 6.14 2.15E-03 13.27 4.85 
regulation of protein import into 
nucleus 
6.13 2.18E-03 13.73 4.01 
angiogenesis 6.13 2.19E-03 12.5 4.33 
cellular cation homeostasis 6.12 2.21E-03 10.42 4.41 
regulation of leukocyte 
activation 
6.12 2.21E-03 10.42 4.40 
regulation of necrotic cell death 6.11 2.21E-03 29.41 4.89 
positive regulation of neutrophil 
migration 
6.11 2.21E-03 29.41 3.00 
positive regulation of type I 
interferon production 
6.11 2.21E-03 29.41 3.76 
biosynthetic process 6.07 2.31E-03 7.27 4.04 
cellular response to 
corticosteroid stimulus 
6.05 2.36E-03 17.65 5.46 
regulation of transcription factor 
import into nucleus 
6.05 2.36E-03 17.65 3.67 
positive regulation of endothelial 
cell proliferation 
6.05 2.36E-03 17.65 4.61 
negative regulation of behavior 6.03 2.41E-03 21.21 4.71 
regulation of cytokine 
biosynthetic process 
6.03 2.41E-03 15.49 4.07 
interspecies interaction between 
organisms 
6.03 2.41E-03 15.49 4.18 
regulation of MAP kinase activity 6.02 2.43E-03 11.8 3.79 
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regulation of cell development 6.01 2.47E-03 9.03 4.31 
regulation of neurological system 
process 
6 2.48E-03 19.05 3.76 
regulation of glial cell 
differentiation 
6 2.48E-03 19.05 3.61 
regulation of lymphocyte 
apoptotic process 
6 2.48E-03 19.05 4.92 
modification of morphology or 
physiology of other organism 
6 2.48E-03 19.05 3.88 
regulation of T cell mediated 
cytotoxicity 
6 2.48E-03 19.05 4.01 
interaction with symbiont 5.98 2.53E-03 24 4.11 
cell projection organization 5.97 2.55E-03 9.31 4.55 
nitrogen compound transport 5.95 2.60E-03 10.31 4.55 
ion homeostasis 5.95 2.61E-03 9.68 4.41 
regulation of spindle organization 5.93 2.65E-03 36.36 4.61 
regulation of necroptotic process 5.93 2.65E-03 36.36 5.12 
regulation of triglyceride 
biosynthetic process 
5.93 2.65E-03 36.36 4.22 
macrophage chemotaxis 5.93 2.65E-03 36.36 4.60 
negative regulation of amino acid 
transport 
5.93 2.65E-03 36.36 5.27 
regulation of prostaglandin 
secretion 
5.93 2.65E-03 36.36 3.66 
regulation of lymphocyte 
activation 
5.93 2.65E-03 10.71 4.48 
phosphorylation 5.93 2.67E-03 9 4.06 
positive regulation of leukocyte 
mediated immunity 
5.92 2.70E-03 15.28 4.54 
regulation of hemostasis 5.91 2.71E-03 17.31 4.17 
regulation of blood coagulation 5.91 2.71E-03 17.31 4.17 
response to oxidative stress 5.9 2.73E-03 10.4 4.64 
positive regulation of gene 
expression 
5.9 2.73E-03 8.14 4.27 
regulation of system process 5.9 2.74E-03 10.03 3.73 
negative regulation of transport 5.9 2.74E-03 10.27 3.98 
regulation of fibroblast 
proliferation 
5.89 2.76E-03 16.13 3.74 
positive regulation of cell cycle 5.86 2.84E-03 14.46 3.72 
hormone metabolic process 5.86 2.86E-03 13.33 4.11 
antigen processing and 
presentation of peptide antigen 
via MHC class I 
5.85 2.88E-03 20.59 4.02 
protein secretion 5.85 2.89E-03 18.6 4.66 
positive regulation of osteoclast 
differentiation 
5.84 2.92E-03 27.78 4.30 
cellular homeostasis 5.79 3.06E-03 9.35 4.42 
phosphate-containing compound 
metabolic process 
5.78 3.08E-03 7.74 4.19 
regulation of lipid storage 5.77 3.13E-03 23.08 4.77 
positive regulation of chemokine 
production 
5.77 3.13E-03 23.08 3.81 
response to copper ion 5.77 3.13E-03 23.08 4.86 
monocarboxylic acid biosynthetic 
process 
5.77 3.13E-03 13.21 4.29 
single organism reproductive 
process 
5.74 3.21E-03 8.56 4.10 
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positive regulation of JNK 
cascade 
5.7 3.36E-03 18.18 3.63 
cellular response to interferon-
alpha 
5.69 3.38E-03 50 4.17 
T-helper 1 type immune response 5.69 3.38E-03 50 4.73 
astrocyte cell migration 5.69 3.38E-03 50 4.25 
cellular extravasation 5.69 3.38E-03 50 4.82 
regulation of calcidiol 1-
monooxygenase activity 
5.69 3.38E-03 50 3.52 
regulation of viral-induced 
cytoplasmic pattern recognition 
receptor signaling pathway 
5.69 3.38E-03 50 2.90 
regulation of RIG-I signaling 
pathway 
5.69 3.38E-03 50 2.90 
fever generation 5.69 3.38E-03 50 4.74 
lipid metabolic process 5.68 3.43E-03 8.36 4.09 
negative regulation of immune 
system process 
5.67 3.43E-03 11.45 4.20 
regulation of catabolic process 5.66 3.47E-03 8.97 4.38 
response to hydrogen peroxide 5.66 3.48E-03 13.54 5.40 
negative regulation of cell 
development 
5.66 3.48E-03 13.54 3.87 
regulation of homeostatic process 5.65 3.53E-03 10.48 4.35 
regulation of coagulation 5.65 3.53E-03 16.67 4.17 
monovalent inorganic cation 
homeostasis 
5.65 3.53E-03 16.67 3.83 
positive regulation of leukocyte 
mediated cytotoxicity 
5.65 3.53E-03 16.67 4.49 
establishment of localization in 
cell 
5.59 3.72E-03 8.06 4.23 
positive regulation of hormone 
secretion 
5.59 3.74E-03 14.67 3.95 
cellular ion homeostasis 5.59 3.75E-03 10.04 4.41 
regulation of neutrophil 
migration 
5.58 3.77E-03 26.32 3.00 
positive regulation of 
phosphatidylinositol 3-kinase 
activity 
5.58 3.77E-03 26.32 3.68 
response to interleukin-6 5.58 3.77E-03 26.32 6.81 
placenta blood vessel 
development 
5.58 3.77E-03 26.32 3.69 
estrous cycle phase 5.58 3.79E-03 33.33 3.81 
positive regulation of calcium ion 
import 
5.58 3.79E-03 33.33 4.48 
negative regulation of osteoclast 
differentiation 
5.58 3.79E-03 33.33 3.57 
phosphorus metabolic process 5.57 3.81E-03 7.65 4.16 
regulation of hydrolase activity 5.57 3.81E-03 8.64 4.43 
regulation of catecholamine 
secretion 
5.57 3.83E-03 22.22 3.96 
cellular response to fatty acid 5.57 3.83E-03 22.22 3.53 
spleen development 5.57 3.83E-03 22.22 4.72 
regulation of type I interferon 
production 
5.57 3.83E-03 22.22 3.77 
response to reactive oxygen 
species 
5.53 3.96E-03 12.12 4.98 
regulation of peptidyl-tyrosine 
phosphorylation 
5.52 3.99E-03 11.81 3.99 
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negative regulation of G-protein 
coupled receptor protein 
signaling pathway 
5.51 4.04E-03 19.44 4.83 
regulation of postsynaptic 
membrane potential 
5.51 4.04E-03 19.44 3.82 
positive regulation of interleukin-
6 production 
5.51 4.04E-03 19.44 3.81 
positive regulation of nitrogen 
compound metabolic process 
5.49 4.13E-03 7.89 4.34 
cellular response to alcohol 5.49 4.15E-03 14.47 5.65 
leukocyte activation 5.48 4.17E-03 10.08 4.20 
cellular response to insulin 
stimulus 
5.47 4.21E-03 13.79 3.91 
myeloid leukocyte differentiation 5.39 4.54E-03 16.07 4.09 
regulation of T cell mediated 
immunity 
5.39 4.54E-03 16.07 3.83 
regulation of cytokine secretion 5.38 4.59E-03 14.29 3.58 
regulation of cyclase activity 5.35 4.74E-03 18.92 4.37 
positive regulation of 
developmental growth 
5.35 4.74E-03 18.92 4.52 
cytokine secretion 5.34 4.79E-03 25 5.38 
positive regulation of lipid kinase 
activity 
5.34 4.79E-03 25 3.68 
regulation of fibroblast growth 
factor receptor signaling pathway 
5.34 4.79E-03 25 4.31 
cellular hormone metabolic 
process 
5.31 4.92E-03 14.93 4.50 
negative regulation of catabolic 
process 
5.28 5.08E-03 14.1 4.66 
positive regulation of cytokine 
biosynthetic process 
5.28 5.11E-03 17.02 4.29 
positive regulation of T cell 
mediated immunity 
5.28 5.11E-03 17.02 3.91 
protein oligomerization 5.27 5.13E-03 9.6 4.16 
regulation of norepinephrine 
secretion 
5.25 5.23E-03 30.77 3.17 
release of cytochrome c from 
mitochondria 
5.25 5.23E-03 30.77 5.53 
cellular response to interleukin-6 5.25 5.23E-03 30.77 6.56 
regulation of interleukin-6 
biosynthetic process 
5.25 5.23E-03 30.77 3.46 
JAK-STAT cascade 5.25 5.23E-03 30.77 4.22 
fatty acid metabolic process 5.23 5.33E-03 10.61 4.08 
organic substance transport 5.21 5.47E-03 7.73 4.23 
regulation of G-protein coupled 
receptor protein signaling 
pathway 
5.21 5.48E-03 14.71 5.48 
tissue regeneration 5.2 5.53E-03 18.42 4.40 
cellular modified amino acid 
biosynthetic process 
5.2 5.53E-03 18.42 4.32 
positive regulation of T cell 
mediated cytotoxicity 
5.2 5.53E-03 18.42 4.13 
liver development 5.19 5.55E-03 13.33 4.78 
cellular response to steroid 
hormone stimulus 
5.19 5.55E-03 13.33 5.47 
positive regulation of reactive 
oxygen species metabolic process 
5.19 5.56E-03 20.69 3.63 
cellular monovalent inorganic 
cation homeostasis 
5.19 5.56E-03 20.69 4.05 
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positive regulation of nitric oxide 
biosynthetic process 
5.19 5.56E-03 20.69 5.32 
nucleobase metabolic process 5.19 5.56E-03 20.69 4.42 
adenylate cyclase-modulating G-
protein coupled receptor 
signaling pathway 
5.19 5.60E-03 13.92 4.20 
cellular response to nutrient 
levels 
5.19 5.60E-03 13.92 4.48 
regulation of stress-activated 
MAPK cascade 
5.19 5.60E-03 12.39 4.28 
regulation of hormone secretion 5.18 5.64E-03 11.41 3.76 
G-protein coupled purinergic 
receptor signaling pathway 
5.17 5.67E-03 42.86 5.32 
negative regulation of homotypic 
cell-cell adhesion 
5.17 5.67E-03 42.86 3.92 
protein K6-linked ubiquitination 5.17 5.67E-03 42.86 2.57 
positive regulation of 
corticosteroid hormone secretion 
5.17 5.67E-03 42.86 3.35 
interleukin-1 beta production 5.17 5.67E-03 42.86 3.33 
interleukin-1 production 5.17 5.67E-03 42.86 3.33 
negative regulation of leukocyte 
chemotaxis 
5.17 5.67E-03 42.86 4.93 
cellular response to ATP 5.17 5.67E-03 42.86 5.27 
regulation of cell-cell adhesion 
mediated by integrin 
5.17 5.67E-03 42.86 4.67 
positive regulation of 
macrophage cytokine production 
5.17 5.67E-03 42.86 3.07 
regulation of vitamin D 
biosynthetic process 
5.17 5.67E-03 42.86 3.52 
positive regulation of triglyceride 
biosynthetic process 
5.17 5.67E-03 42.86 3.20 
negative regulation of glutamate 
secretion 
5.17 5.67E-03 42.86 4.68 
positive regulation of interferon-
alpha production 
5.17 5.67E-03 42.86 3.68 
regulation of reactive oxygen 
species metabolic process 
5.16 5.76E-03 15.52 4.26 
positive regulation of cell killing 5.16 5.76E-03 15.52 4.49 
cellular response to drug 5.14 5.83E-03 16.67 4.95 
apoptotic process 5.13 5.92E-03 9.81 4.53 
regulation of platelet activation 5.12 6.00E-03 23.81 3.65 
negative regulation of innate 
immune response 
5.12 6.00E-03 23.81 4.68 
negative regulation of protein 
metabolic process 
5.12 6.00E-03 9.17 4.03 
regulation of stress-activated 
protein kinase signaling cascade 
5.11 6.05E-03 12.28 4.28 
negative regulation of 
macromolecule metabolic 
process 
5.1 6.08E-03 7.63 4.03 
neuron differentiation 5.1 6.10E-03 10.86 4.12 
regulation of lyase activity 5.05 6.41E-03 17.95 4.37 
cellular response to mechanical 
stimulus 
5.04 6.46E-03 15.25 4.17 
regulation of anion transport 5.04 6.46E-03 15.25 4.65 
positive regulation of T cell 
proliferation 
5.04 6.46E-03 15.25 4.76 
organic substance biosynthetic 
process 
5.04 6.48E-03 7.11 4.00 
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negative regulation of nitrogen 
compound metabolic process 
5.02 6.58E-03 8.04 4.09 
regulation of interleukin-1 
production 
5.02 6.62E-03 20 3.86 
chondrocyte differentiation 5.02 6.62E-03 20 3.44 
positive regulation of lymphocyte 
mediated immunity 
5 6.74E-03 14.29 4.33 
inorganic anion transport 5 6.74E-03 14.29 4.23 
regulation of endocytosis 4.97 6.91E-03 12.5 4.81 
establishment of endothelial 
barrier 
4.96 6.98E-03 28.57 4.32 
negative regulation of systemic 
arterial blood pressure 
4.96 6.98E-03 28.57 4.69 
regulation of membrane protein 
ectodomain proteolysis 
4.96 6.98E-03 28.57 4.18 
regulation of cell aging 4.96 6.98E-03 28.57 3.55 
negative regulation of 
endothelial cell apoptotic 
process 
4.96 6.98E-03 28.57 5.58 
regulation of viral entry into host 
cell 
4.96 6.98E-03 28.57 4.26 
positive regulation of fatty acid 
transport 
4.96 6.98E-03 28.57 3.66 
positive regulation of icosanoid 
secretion 
4.96 6.98E-03 28.57 3.66 
regulation of peptide transport 4.96 7.05E-03 12.07 3.95 
intrinsic apoptotic signaling 
pathway 
4.93 7.22E-03 12.9 4.69 
single organismal cell-cell 
adhesion 
4.92 7.33E-03 11.11 4.13 
positive regulation of 
phosphatidylinositol 3-kinase 
signaling 
4.91 7.39E-03 17.5 4.06 
regulation of tyrosine 
phosphorylation of STAT protein 
4.91 7.39E-03 17.5 4.21 
cell aging 4.91 7.39E-03 17.5 4.31 
cyclic-nucleotide-mediated 
signaling 
4.91 7.40E-03 22.73 4.36 
positive regulation of ion 
transmembrane transport 
4.91 7.40E-03 22.73 4.49 
regulation of phosphatidylinositol 
3-kinase activity 
4.91 7.40E-03 22.73 3.68 
negative regulation of myeloid 
leukocyte differentiation 
4.91 7.40E-03 22.73 3.36 
negative regulation of 
intracellular signal transduction 
4.9 7.46E-03 10.29 3.90 
positive regulation of organelle 
organization 
4.9 7.46E-03 10.29 3.95 
branching morphogenesis of an 
epithelial tube 
4.9 7.48E-03 12.38 4.85 
positive regulation of cAMP 
metabolic process 
4.89 7.50E-03 16 5.32 
multi-organism reproductive 
process 
4.88 7.59E-03 11.63 3.90 
kidney development 4.88 7.59E-03 11.97 4.06 
cellular response to oxidative 
stress 
4.88 7.59E-03 11.97 5.35 
nerve development 4.85 7.82E-03 19.35 4.08 
negative regulation of cytokine 
production 
4.85 7.85E-03 12.77 3.98 
negative regulation of 4.84 7.87E-03 10.24 4.18 
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phosphorylation 
cellular biosynthetic process 4.83 7.95E-03 7.09 4.02 
heart development 4.83 8.01E-03 11.27 4.93 
positive regulation of cyclic 
nucleotide metabolic process 
4.82 8.05E-03 14.75 4.97 
epithelial cell development 4.8 8.21E-03 13.89 3.79 
female pregnancy 4.8 8.21E-03 13.89 3.91 
regulation of apoptotic signaling 
pathway 
4.8 8.23E-03 9.91 4.22 
single-organism nuclear import 4.77 8.45E-03 15.69 3.95 
regulation of amine transport 4.77 8.45E-03 15.69 4.23 
protein import into nucleus 4.77 8.45E-03 15.69 3.95 
positive regulation of cell division 4.77 8.45E-03 15.69 3.91 
positive regulation of fibroblast 
proliferation 
4.77 8.48E-03 17.07 3.34 
regulation of neurotrophin TRK 
receptor signaling pathway 
4.75 8.68E-03 37.5 3.46 
purine nucleobase biosynthetic 
process 
4.75 8.68E-03 37.5 3.87 
negative regulation of 
necroptotic process 
4.75 8.68E-03 37.5 5.78 
regulation of cellular 
extravasation 
4.75 8.68E-03 37.5 5.15 
regulation of cholesterol storage 4.75 8.68E-03 37.5 3.65 
diterpenoid biosynthetic process 4.75 8.68E-03 37.5 4.51 
retinoic acid biosynthetic process 4.75 8.68E-03 37.5 4.51 
regulation of vitamin metabolic 
process 
4.75 8.68E-03 37.5 3.52 
regulation of immature T cell 
proliferation 
4.75 8.68E-03 37.5 3.86 
mammary gland involution 4.75 8.68E-03 37.5 3.75 
luteinization 4.75 8.68E-03 37.5 4.38 
cellular response to iron ion 4.75 8.68E-03 37.5 4.35 
negative regulation of JAK-STAT 
cascade 
4.75 8.68E-03 37.5 2.53 
positive regulation of interleukin-
2 biosynthetic process 
4.75 8.68E-03 37.5 4.01 
mitotic metaphase plate 
congression 
4.75 8.68E-03 37.5 3.78 
maintenance of fidelity involved 
in DNA-dependent DNA 
replication 
4.75 8.68E-03 37.5 2.99 
serine transport 4.75 8.68E-03 37.5 3.43 
rRNA transcription 4.75 8.68E-03 37.5 4.73 
cellular response to growth 
hormone stimulus 
4.75 8.68E-03 37.5 5.25 
regulation of mitotic spindle 
organization 
4.75 8.68E-03 37.5 4.04 
negative regulation of natural 
killer cell mediated immunity 
4.75 8.68E-03 37.5 4.19 
negative regulation of natural 
killer cell mediated cytotoxicity 
4.75 8.68E-03 37.5 4.19 
negative regulation of cellular 
biosynthetic process 
4.74 8.70E-03 7.91 4.04 
positive regulation of cytosolic 
calcium ion concentration 
4.74 8.74E-03 12.15 3.66 
regulation of mitotic cell cycle 4.74 8.76E-03 10.14 3.71 
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developmental process involved 
in reproduction 
4.73 8.80E-03 9.15 4.35 
regulation of interferon-gamma 
production 
4.72 8.94E-03 14.52 4.26 
regulation of fatty acid 
biosynthetic process 
4.71 9.01E-03 21.74 3.46 
positive regulation of protein 
tyrosine kinase activity 
4.71 9.01E-03 21.74 3.79 
positive regulation of glial cell 
differentiation 
4.71 9.01E-03 21.74 3.44 
mammary gland development 4.71 9.01E-03 21.74 4.12 
regulation of intracellular pH 4.71 9.01E-03 21.74 4.37 
regulation of homotypic cell-cell 
adhesion 
4.7 9.09E-03 26.67 4.65 
response to glucagon 4.7 9.09E-03 26.67 4.87 
positive regulation of cytokine-
mediated signaling pathway 
4.7 9.09E-03 26.67 4.46 
positive regulation of lipid 
storage 
4.7 9.09E-03 26.67 5.52 
regulation of glial cell 
proliferation 
4.7 9.09E-03 26.67 3.64 
cytokine metabolic process 4.7 9.09E-03 26.67 4.51 
collagen catabolic process 4.7 9.09E-03 26.67 2.62 
adenylate cyclase-activating G-
protein coupled receptor 
signaling pathway 
4.69 9.16E-03 18.75 4.03 
cyclic nucleotide metabolic 
process 
4.69 9.16E-03 18.75 4.03 
positive regulation of endothelial 
cell migration 
4.69 9.16E-03 18.75 4.01 
purine-containing compound 
biosynthetic process 
4.68 9.25E-03 12.5 3.91 
cell maturation 4.68 9.25E-03 12.5 4.50 
regulation of biosynthetic process 4.68 9.28E-03 6.96 4.20 
morphogenesis of a branching 
epithelium 
4.66 9.43E-03 11.67 4.67 
nuclear import 4.66 9.50E-03 15.38 3.95 
cytokine production 4.66 9.50E-03 15.38 3.96 
positive regulation of stress-
activated MAPK cascade 
4.66 9.50E-03 15.38 3.63 
regulation of steroid biosynthetic 
process 
4.66 9.50E-03 15.38 3.40 
regulation of cellular 
biosynthetic process 
4.65 9.60E-03 6.97 4.19 
alcohol metabolic process 4.65 9.60E-03 10.59 3.96 
establishment of blood-nerve 
barrier 
4.64 9.65E-03 66.67 3.85 
positive regulation of 
somatostatin secretion 
4.64 9.65E-03 66.67 2.77 
embryonic placenta 
morphogenesis 
4.64 9.65E-03 66.67 4.74 
positive regulation of monocyte 
differentiation 
4.64 9.65E-03 66.67 3.61 
positive regulation of MDA-5 
signaling pathway 
4.64 9.65E-03 66.67 2.97 
central nervous system myelin 
maintenance 
4.64 9.65E-03 66.67 5.64 
negative regulation of gamma-
aminobutyric acid secretion 
4.64 9.65E-03 66.67 5.37 
negative regulation of pro-B cell 4.64 9.65E-03 66.67 3.77 
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differentiation 
negative regulation of inner ear 
receptor cell differentiation 
4.64 9.65E-03 66.67 3.77 
forebrain radial glial cell 
differentiation 
4.64 9.65E-03 66.67 3.77 
auditory receptor cell fate 
determination 
4.64 9.65E-03 66.67 3.77 
negative regulation of 
mechanoreceptor differentiation 
4.64 9.65E-03 66.67 3.77 
positive regulation of cell aging 4.64 9.65E-03 66.67 3.24 
response to linoleic acid 4.64 9.65E-03 66.67 3.74 
virion attachment to host cell 4.64 9.65E-03 66.67 5.57 
adhesion of symbiont to host 4.64 9.65E-03 66.67 5.57 
adhesion of symbiont to host cell 4.64 9.65E-03 66.67 5.57 
receptor-mediated virion 
attachment to host cell 
4.64 9.65E-03 66.67 5.57 
NLS-bearing protein import into 
nucleus 
4.64 9.65E-03 66.67 4.30 
creatinine metabolic process 4.64 9.65E-03 66.67 4.28 
cellular lactam metabolic process 4.64 9.65E-03 66.67 4.28 
positive regulation of receptor 
binding 
4.64 9.65E-03 66.67 3.03 
negative regulation of 
transcription from RNA 
polymerase III promoter 
4.64 9.65E-03 66.67 4.54 
nucleotide-binding domain, 
leucine rich repeat containing 
receptor signaling pathway 
4.64 9.65E-03 66.67 4.52 
nucleotide-binding 
oligomerization domain 
containing signaling pathway 
4.64 9.65E-03 66.67 4.52 
nucleotide-binding 
oligomerization domain 
containing 2 signaling pathway 
4.64 9.65E-03 66.67 4.52 
anterior/posterior axon guidance 4.64 9.65E-03 66.67 4.39 
G-protein coupled purinergic 
nucleotide receptor signaling 
pathway 
4.64 9.65E-03 66.67 4.44 
RNA import into mitochondrion 4.64 9.65E-03 66.67 4.95 
rRNA import into mitochondrion 4.64 9.65E-03 66.67 4.95 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class Ib 
4.64 9.65E-03 66.67 3.66 
succinate transport 4.64 9.65E-03 66.67 4.51 
citrate transport 4.64 9.65E-03 66.67 4.51 
succinate transmembrane 
transport 
4.64 9.65E-03 66.67 4.51 
intracellular transport of viral 
protein in host cell 
4.64 9.65E-03 66.67 4.48 
symbiont intracellular protein 
transport in host 
4.64 9.65E-03 66.67 4.48 
intracellular protein transport in 
other organism involved in 
symbiotic interaction 
4.64 9.65E-03 66.67 4.48 
extracellular transport 4.64 9.65E-03 66.67 4.48 
positive regulation of extrinsic 
apoptotic signaling pathway 
4.64 9.68E-03 16.67 3.98 
tissue remodeling 4.61 9.91E-03 14.29 4.41 
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response to amino acid 4.59 1.01E-02 11.57 4.43 
multi-multicellular organism 
process 
4.59 1.02E-02 11.93 3.64 
regulation of GTPase activity 4.58 1.03E-02 10.33 4.31 
regulation of cellular catabolic 
process 
4.57 1.03E-02 8.71 4.54 
regulation of intracellular protein 
transport 
4.57 1.03E-02 10.96 4.03 
negative regulation of 
nucleobase-containing compound 
metabolic process 
4.56 1.04E-02 7.91 4.04 
cellular metal ion homeostasis 4.56 1.05E-02 9.7 4.39 
terpenoid metabolic process 4.54 1.06E-02 15.09 3.60 
positive regulation of protein 
import into nucleus 
4.54 1.06E-02 15.09 4.07 
positive regulation of stress-
activated protein kinase signaling 
cascade 
4.54 1.06E-02 15.09 3.63 
activation of protein kinase 
activity 
4.54 1.06E-02 11.19 3.88 
response to dexamethasone 4.54 1.07E-02 18.18 4.67 
substantia nigra development 4.54 1.07E-02 18.18 5.59 
regulation of developmental 
growth 
4.52 1.08E-02 12.24 4.18 
behavioral defense response 4.52 1.09E-02 20.83 3.36 
regulation of tyrosine 
phosphorylation of Stat3 protein 
4.52 1.09E-02 20.83 3.58 
fatty acid biosynthetic process 4.52 1.09E-02 13.33 4.37 
positive regulation of JAK-STAT 
cascade 
4.51 1.10E-02 16.28 4.54 
negative regulation of neuron 
differentiation 
4.51 1.10E-02 16.28 3.88 
cellular response to DNA damage 
stimulus 
4.49 1.12E-02 8.98 3.91 
morphogenesis of an epithelium 4.48 1.13E-02 9.91 4.54 
hematopoietic or lymphoid organ 
development 
4.48 1.14E-02 11.11 4.49 
G-protein coupled receptor 
signaling pathway, coupled to 
cyclic nucleotide second 
messenger 
4.47 1.14E-02 12.64 4.20 
negative regulation of defense 
response 
4.47 1.14E-02 12.64 3.93 
regulation of GTP catabolic 
process 
4.47 1.14E-02 10.22 4.31 
ERK1 and ERK2 cascade 4.46 1.16E-02 25 4.02 
positive regulation of response to 
cytokine stimulus 
4.46 1.16E-02 25 4.46 
intrinsic apoptotic signaling 
pathway in response to DNA 
damage by p53 class mediator 
4.46 1.16E-02 25 3.81 
positive regulation of neutrophil 
chemotaxis 
4.46 1.16E-02 25 2.78 
regulation of macrophage derived 
foam cell differentiation 
4.46 1.16E-02 25 3.81 
regulation of cellular response to 
oxidative stress 
4.46 1.16E-02 25 5.24 
regulation of peptidyl-threonine 
phosphorylation 
4.46 1.16E-02 25 5.86 
regulation of cAMP-mediated 4.46 1.16E-02 25 5.49 
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signaling 
response to food 4.46 1.16E-02 25 4.11 
peripheral nervous system 
development 
4.46 1.16E-02 25 3.84 
regulation of glutamate secretion 4.46 1.16E-02 25 5.27 
morphogenesis of a branching 
structure 
4.46 1.16E-02 11.38 4.67 
regulation of lymphocyte 
mediated immunity 
4.45 1.17E-02 12.12 4.10 
positive regulation of cell 
adhesion 
4.44 1.17E-02 11.71 3.95 
cellular response to hydrogen 
peroxide 
4.43 1.19E-02 14.81 5.52 
positive regulation of peptide 
secretion 
4.43 1.19E-02 14.81 4.35 
cellular amino acid metabolic 
process 
4.42 1.21E-02 9.36 4.50 
positive regulation of purine 
nucleotide metabolic process 
4.42 1.21E-02 13.85 4.97 
positive regulation of nucleotide 
metabolic process 
4.42 1.21E-02 13.85 4.97 
response to zinc ion 4.4 1.23E-02 17.65 5.57 
regulation of cytokine production 
involved in immune response 
4.4 1.23E-02 17.65 3.71 
negative regulation of protein 
transport 
4.39 1.24E-02 12.5 3.73 
response to starvation 4.39 1.24E-02 12.5 3.87 
regulation of platelet aggregation 4.38 1.25E-02 33.33 3.92 
necroptotic process 4.38 1.25E-02 33.33 5.36 
positive regulation of steroid 
hormone secretion 
4.38 1.25E-02 33.33 3.35 
negative regulation of NF-kappaB 
import into nucleus 
4.38 1.25E-02 33.33 3.54 
positive regulation of myeloid 
leukocyte cytokine production 
involved in immune response 
4.38 1.25E-02 33.33 3.07 
positive regulation of glial cell 
proliferation 
4.38 1.25E-02 33.33 3.92 
negative regulation of astrocyte 
differentiation 
4.38 1.25E-02 33.33 3.90 
regulation of carbohydrate 
metabolic process 
4.37 1.26E-02 12 3.77 
regulation of membrane 
potential 
4.36 1.27E-02 10.11 4.13 
negative regulation of 
multicellular organismal process 
4.36 1.28E-02 9.22 3.63 
cellular lipid metabolic process 4.36 1.28E-02 8.25 4.03 
positive regulation of calcium ion 
transport into cytosol 
4.35 1.29E-02 20 5.69 
brown fat cell differentiation 4.35 1.29E-02 20 3.78 
regulation of sensory perception 
of pain 
4.35 1.29E-02 20 3.43 
regulation of sensory perception 4.35 1.29E-02 20 3.43 
termination of G-protein coupled 
receptor signaling pathway 
4.35 1.29E-02 20 4.84 
negative regulation of 
lymphocyte apoptotic process 
4.35 1.29E-02 20 5.24 
regulation of cellular pH 4.35 1.29E-02 20 4.37 
negative regulation of gliogenesis 4.35 1.29E-02 20 3.69 
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positive regulation of protein 
complex assembly 
4.34 1.30E-02 12.99 3.66 
steroid metabolic process 4.33 1.32E-02 10.67 4.06 
response to osmotic stress 4.33 1.32E-02 14.55 4.38 
membrane depolarization 4.32 1.33E-02 13.64 3.67 
amine metabolic process 4.32 1.33E-02 13.64 4.43 
response to amine 4.27 1.40E-02 15.56 4.69 
regulation of organic acid 
transport 
4.27 1.40E-02 15.56 4.62 
protein complex assembly 4.26 1.41E-02 7.97 4.02 
cofactor metabolic process 4.26 1.41E-02 10 3.83 
anatomical structure 
morphogenesis 
4.26 1.41E-02 7.58 4.40 
negative regulation of kinase 
activity 
4.26 1.42E-02 11.11 4.01 
positive regulation of tyrosine 
phosphorylation of STAT protein 
4.26 1.42E-02 17.14 4.51 
glial cell development 4.26 1.42E-02 17.14 5.37 
L-amino acid transport 4.26 1.42E-02 17.14 3.75 
positive regulation of 
nucleobase-containing compound 
metabolic process 
4.24 1.44E-02 7.55 4.19 
regulation of triglyceride 
metabolic process 
4.24 1.45E-02 23.53 4.22 
positive regulation of interleukin-
1 beta production 
4.24 1.45E-02 23.53 3.17 
regulation of T cell migration 4.24 1.45E-02 23.53 4.20 
regulation of response to 
oxidative stress 
4.24 1.45E-02 23.53 5.24 
positive regulation of cytokine 
production involved in immune 
response 
4.24 1.45E-02 23.53 2.88 
prostanoid metabolic process 4.24 1.45E-02 23.53 3.70 
prostaglandin metabolic process 4.24 1.45E-02 23.53 3.70 
regulation of icosanoid secretion 4.24 1.45E-02 23.53 3.66 
negative regulation of protein 
kinase activity 
4.24 1.45E-02 11.4 4.06 
regulation of peptide secretion 4.24 1.45E-02 11.4 4.00 
positive regulation of MAP kinase 
activity 
4.24 1.45E-02 11.4 3.83 
cellular nitrogen compound 
metabolic process 
4.23 1.45E-02 6.87 4.06 
negative regulation of sequence-
specific DNA binding 
transcription factor activity 
4.23 1.45E-02 12.22 4.06 
negative regulation of 
biosynthetic process 
4.23 1.45E-02 7.7 4.04 
negative regulation of cell 
activation 
4.22 1.46E-02 11.76 3.53 
coenzyme metabolic process 4.21 1.48E-02 10.53 3.79 
termination of signal 
transduction 
4.18 1.53E-02 19.23 4.84 
positive regulation of 
multicellular organism growth 
4.18 1.53E-02 19.23 3.25 
response to vitamin D 4.18 1.53E-02 19.23 4.11 
regulation of interleukin-1 beta 
production 
4.18 1.53E-02 19.23 3.44 
regulation of lipid kinase activity 4.18 1.53E-02 19.23 3.68 
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negative regulation of ERK1 and 
ERK2 cascade 
4.18 1.53E-02 19.23 4.02 
inflammatory response to 
antigenic stimulus 
4.18 1.53E-02 19.23 5.53 
cellular response to acid 4.17 1.55E-02 10.71 3.86 
response to transition metal 
nanoparticle 
4.15 1.57E-02 12.09 5.28 
regulation of bone mineralization 4.15 1.57E-02 15.22 3.22 
signal transduction by p53 class 
mediator 
4.15 1.57E-02 15.22 4.16 
negative regulation of myeloid 
cell differentiation 
4.15 1.57E-02 15.22 3.59 
ethanolamine-containing 
compound metabolic process 
4.12 1.62E-02 16.67 4.23 
regulation of smooth muscle cell 
migration 
4.12 1.62E-02 16.67 4.36 
response to dsRNA 4.12 1.62E-02 16.67 4.04 
cellular divalent inorganic cation 
homeostasis 
4.11 1.64E-02 9.84 4.01 
protein metabolic process 4.11 1.64E-02 6.85 4.16 
cellular response to metal ion 4.09 1.67E-02 12.5 4.19 
regulation of nucleotide 
catabolic process 
4.07 1.70E-02 9.66 4.23 
regulation of purine nucleotide 
catabolic process 
4.07 1.70E-02 9.66 4.23 
divalent inorganic cation 
homeostasis 
4.07 1.70E-02 9.66 3.97 
programmed necrotic cell death 4.07 1.71E-02 30 5.36 
regulation of corticosteroid 
hormone secretion 
4.07 1.71E-02 30 3.35 
positive regulation of circadian 
rhythm 
4.07 1.71E-02 30 3.38 
positive regulation of 
macrophage differentiation 
4.07 1.71E-02 30 4.45 
positive regulation of monocyte 
chemotaxis 
4.07 1.71E-02 30 6.62 
positive regulation of fever 
generation 
4.07 1.71E-02 30 4.87 
positive regulation of 
macrophage derived foam cell 
differentiation 
4.07 1.71E-02 30 3.90 
serine family amino acid 
biosynthetic process 
4.07 1.71E-02 30 3.89 
regulation of transcription from 
RNA polymerase III promoter 
4.07 1.71E-02 30 3.93 
myelin maintenance 4.07 1.71E-02 30 4.80 
negative regulation of 
catecholamine secretion 
4.07 1.71E-02 30 4.51 
negative regulation of 
oligodendrocyte differentiation 
4.07 1.71E-02 30 4.10 
astrocyte differentiation 4.07 1.71E-02 30 5.62 
negative regulation of cellular 
response to oxidative stress 
4.07 1.71E-02 30 6.02 
negative regulation of response 
to oxidative stress 
4.07 1.71E-02 30 6.02 
negative regulation of viral entry 
into host cell 
4.07 1.71E-02 30 4.55 
negative regulation of membrane 
potential 
4.07 1.71E-02 30 4.37 
oligopeptide transport 4.07 1.71E-02 30 4.63 
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negative regulation of protein 
serine/threonine kinase activity 
4.05 1.75E-02 13.04 3.67 
polyol metabolic process 4.04 1.76E-02 14.89 3.82 
regulation of phosphatidylinositol 
3-kinase signaling 
4.04 1.76E-02 14.89 4.06 
positive regulation of lipid 
biosynthetic process 
4.04 1.76E-02 14.89 3.70 
protein import into nucleus, 
translocation 
4.03 1.78E-02 22.22 4.02 
regulation of vascular endothelial 
growth factor production 
4.03 1.78E-02 22.22 5.30 
positive regulation of interleukin-
1 production 
4.03 1.78E-02 22.22 3.17 
macrophage activation 4.03 1.78E-02 22.22 3.45 
positive regulation of granulocyte 
chemotaxis 
4.03 1.78E-02 22.22 2.78 
regulation of neutrophil 
chemotaxis 
4.03 1.78E-02 22.22 2.78 
decidualization 4.03 1.78E-02 22.22 4.45 
negative regulation of organic 
acid transport 
4.03 1.78E-02 22.22 5.27 
regulation of glycolytic process 4.03 1.78E-02 22.22 5.04 
positive regulation of Notch 
signaling pathway 
4.03 1.78E-02 22.22 4.34 
positive regulation of interleukin-
8 production 
4.03 1.78E-02 22.22 4.93 
multicellular organismal 
catabolic process 
4.03 1.78E-02 22.22 2.62 
positive regulation of axon 
extension 
4.03 1.78E-02 22.22 4.22 
intrinsic apoptotic signaling 
pathway by p53 class mediator 
4.02 1.79E-02 18.52 3.97 
positive regulation of organic 
acid transport 
4.02 1.79E-02 18.52 4.33 
regulation of endothelial cell 
migration 
4.02 1.79E-02 13.79 4.14 
amide transport 4.02 1.79E-02 13.79 4.59 
positive regulation of 
biosynthetic process 
4.02 1.80E-02 7.39 4.31 
choline metabolic process 3.99 1.86E-02 50 4.16 
regulation of monocyte 
chemotactic protein-1 production 
3.99 1.86E-02 50 2.83 
positive regulation of circadian 
sleep/wake cycle, non-REM sleep 
3.99 1.86E-02 50 3.60 
regulation of apoptotic cell 
clearance 
3.99 1.86E-02 50 5.33 
response to macrophage colony-
stimulating factor 
3.99 1.86E-02 50 4.43 
cellular response to macrophage 
colony-stimulating factor 
stimulus 
3.99 1.86E-02 50 4.43 
regulation of chemokine-
mediated signaling pathway 
3.99 1.86E-02 50 5.73 
negative regulation of 
chemokine-mediated signaling 
pathway 
3.99 1.86E-02 50 5.73 
regulation of interleukin-10 
secretion 
3.99 1.86E-02 50 3.97 
mammary duct terminal end bud 
growth 
3.99 1.86E-02 50 5.59 
hydrogen sulfide metabolic 
process 
3.99 1.86E-02 50 3.14 
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positive regulation of integrin 
activation 
3.99 1.86E-02 50 3.59 
9-cis-retinoic acid biosynthetic 
process 
3.99 1.86E-02 50 3.94 
9-cis-retinoic acid metabolic 
process 
3.99 1.86E-02 50 3.94 
regulation of MDA-5 signaling 
pathway 
3.99 1.86E-02 50 2.97 
locomotion involved in 
locomotory behavior 
3.99 1.86E-02 50 4.33 
negative regulation of 
epinephrine secretion 
3.99 1.86E-02 50 5.24 
positive regulation of cortisol 
secretion 
3.99 1.86E-02 50 3.86 
creatine metabolic process 3.99 1.86E-02 50 5.11 
glutamate biosynthetic process 3.99 1.86E-02 50 5.19 
response to triglyceride 3.99 1.86E-02 50 4.30 
regulation of pro-B cell 
differentiation 
3.99 1.86E-02 50 3.77 
regulation of forebrain neuron 
differentiation 
3.99 1.86E-02 50 3.77 
renal interstitial cell 
development 
3.99 1.86E-02 50 2.63 
metanephric nephron tubule 
morphogenesis 
3.99 1.86E-02 50 3.77 
macropinocytosis 3.99 1.86E-02 50 3.88 
cellular response to cell-matrix 
adhesion 
3.99 1.86E-02 50 2.44 
replication fork processing 3.99 1.86E-02 50 2.54 
regulation of hyaluronan 
biosynthetic process 
3.99 1.86E-02 50 2.96 
D-amino acid transport 3.99 1.86E-02 50 3.67 
antigen processing and 
presentation of peptide antigen 
via MHC class Ib 
3.99 1.86E-02 50 3.66 
phagosome acidification 3.99 1.86E-02 50 6.05 
tricarboxylic acid transport 3.99 1.86E-02 50 4.51 
JAK-STAT cascade involved in 
growth hormone signaling 
pathway 
3.99 1.86E-02 50 5.85 
negative regulation of membrane 
protein ectodomain proteolysis 
3.99 1.86E-02 50 4.64 
developmental maturation 3.97 1.88E-02 11.02 4.46 
carbohydrate homeostasis 3.97 1.88E-02 11.02 4.62 
glucose homeostasis 3.97 1.88E-02 11.02 4.62 
negative regulation of cell 
projection organization 
3.96 1.91E-02 12.86 4.85 
receptor-mediated endocytosis 3.96 1.91E-02 12.86 3.67 
isoprenoid metabolic process 3.96 1.91E-02 12.86 3.71 
regulation of endothelial cell 
proliferation 
3.96 1.91E-02 12.86 4.61 
adaptive immune response based 
on somatic recombination of 
immune receptors built from 
immunoglobulin superfamily 
domains 
3.93 1.96E-02 14.58 4.44 
positive regulation of smooth 
muscle cell proliferation 
3.93 1.96E-02 14.58 4.12 
regulation of extent of cell 3.93 1.96E-02 14.58 4.22 
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growth 
cellular glucose homeostasis 3.93 1.96E-02 14.58 4.49 
regulation of binding 3.93 1.96E-02 10.19 3.97 
multicellular organismal response 
to stress 
3.93 1.97E-02 13.56 3.75 
tissue development 3.92 1.99E-02 8.47 4.33 
organic cyclic compound 
metabolic process 
3.91 2.00E-02 6.78 4.03 
regulation of nucleoside 
metabolic process 
3.89 2.05E-02 9.48 4.23 
regulation of ossification 3.89 2.05E-02 10.61 3.56 
myeloid cell differentiation 3.88 2.07E-02 11.22 3.94 
response to iron ion 3.88 2.07E-02 17.86 4.63 
positive regulation of mitosis 3.88 2.07E-02 17.86 3.65 
adaptive immune response 3.87 2.08E-02 12.68 4.55 
regulation of protein tyrosine 
kinase activity 
3.87 2.08E-02 15.79 4.15 
retinoid metabolic process 3.87 2.08E-02 15.79 3.85 
regulation of epidermis 
development 
3.87 2.08E-02 15.79 3.67 
immune response-activating 
signal transduction 
3.86 2.12E-02 12.05 4.61 
regulation of epithelial cell 
proliferation 
3.85 2.13E-02 9.73 4.26 
tissue morphogenesis 3.85 2.14E-02 9.09 4.46 
cAMP metabolic process 3.84 2.15E-02 21.05 4.05 
response to X-ray 3.84 2.15E-02 21.05 3.95 
neuron recognition 3.84 2.15E-02 21.05 4.42 
regulation of calcium ion import 3.84 2.15E-02 21.05 4.48 
lipid storage 3.84 2.15E-02 21.05 3.36 
cranial nerve development 3.84 2.15E-02 21.05 4.10 
regulation of biomineral tissue 
development 
3.83 2.18E-02 14.29 3.22 
coagulation 3.83 2.18E-02 14.29 4.80 
blood coagulation 3.83 2.18E-02 14.29 4.80 
regulation of DNA metabolic 
process 
3.82 2.20E-02 9.55 3.81 
response to alkaloid 3.81 2.21E-02 11.11 4.93 
cAMP biosynthetic process 3.8 2.25E-02 27.27 4.67 
nucleobase biosynthetic process 3.8 2.25E-02 27.27 3.87 
microglial cell activation 3.8 2.25E-02 27.27 3.40 
regulation of fever generation 3.8 2.25E-02 27.27 4.87 
nitric oxide mediated signal 
transduction 
3.8 2.25E-02 27.27 3.75 
positive regulation of peptidyl-
threonine phosphorylation 
3.8 2.25E-02 27.27 6.15 
terpenoid biosynthetic process 3.8 2.25E-02 27.27 4.51 
peptide catabolic process 3.8 2.25E-02 27.27 5.14 
cytokine biosynthetic process 3.8 2.25E-02 27.27 4.43 
organ growth 3.8 2.25E-02 27.27 4.13 
negative regulation of protein 
phosphorylation 
3.78 2.28E-02 9.83 3.90 
DNA replication 3.78 2.28E-02 11.9 3.25 
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metal ion homeostasis 3.76 2.32E-02 8.83 4.52 
regulation of neuronal synaptic 
plasticity 
3.75 2.34E-02 15.38 4.06 
negative regulation of 
nucleocytoplasmic transport 
3.75 2.34E-02 15.38 3.63 
positive regulation of 
nucleocytoplasmic transport 
3.75 2.36E-02 13.11 4.07 
signal transduction in absence of 
ligand 
3.73 2.39E-02 17.24 5.44 
extrinsic apoptotic signaling 
pathway in absence of ligand 
3.73 2.39E-02 17.24 5.44 
lung alveolus development 3.73 2.39E-02 17.24 4.09 
catabolic process 3.73 2.40E-02 7.26 4.15 
regulation of vesicle-mediated 
transport 
3.73 2.41E-02 9.45 4.60 
peptide transport 3.73 2.41E-02 14 4.83 
hemostasis 3.73 2.41E-02 14 4.80 
negative regulation of leukocyte 
differentiation 
3.73 2.41E-02 14 3.28 
chloride transport 3.73 2.41E-02 14 4.23 
negative regulation of 
transferase activity 
3.71 2.44E-02 10.37 4.01 
cellular response to reactive 
oxygen species 
3.71 2.45E-02 12.33 5.95 
response to heat 3.71 2.45E-02 12.33 4.34 
protein heterooligomerization 3.71 2.46E-02 11.76 4.27 
ovulation 3.66 2.57E-02 20 3.62 
positive regulation of tyrosine 
phosphorylation of Stat3 protein 
3.66 2.57E-02 20 3.87 
positive regulation of epidermis 
development 
3.66 2.57E-02 20 3.50 
negative regulation of axon 
extension 
3.66 2.57E-02 20 4.29 
negative regulation of glial cell 
differentiation 
3.66 2.57E-02 20 3.63 
axon development 3.66 2.57E-02 20 5.55 
developmental growth involved 
in morphogenesis 
3.66 2.58E-02 12.9 4.15 
regulation of production of 
molecular mediator of immune 
response 
3.66 2.58E-02 12.9 4.12 
long-chain fatty acid metabolic 
process 
3.64 2.63E-02 15 3.49 
regulation of alcohol biosynthetic 
process 
3.64 2.63E-02 15 3.60 
response to antibiotic 3.64 2.63E-02 15 5.26 
regulation of interleukin-8 
production 
3.64 2.63E-02 15 4.82 
regulation of axon extension 3.64 2.63E-02 15 4.09 
positive regulation of lymphocyte 
differentiation 
3.63 2.66E-02 13.73 4.52 
positive regulation of peptide 
hormone secretion 
3.63 2.66E-02 13.73 4.44 
negative regulation of 
axonogenesis 
3.6 2.74E-02 16.67 4.36 
response to exogenous dsRNA 3.6 2.74E-02 16.67 4.36 
positive regulation of apoptotic 
signaling pathway 
3.56 2.84E-02 11.49 3.63 
alpha-amino acid metabolic 3.55 2.86E-02 9.93 4.47 
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process 
positive regulation of fatty acid 
biosynthetic process 
3.55 2.87E-02 25 3.97 
activation of NF-kappaB-inducing 
kinase activity 
3.55 2.87E-02 25 4.76 
midgut development 3.55 2.87E-02 25 4.44 
glutamine family amino acid 
biosynthetic process 
3.55 2.87E-02 25 5.47 
negative regulation of necrotic 
cell death 
3.55 2.87E-02 25 5.78 
necrotic cell death 3.55 2.87E-02 25 5.36 
positive regulation of interleukin-
1 secretion 
3.55 2.87E-02 25 3.06 
positive regulation of interleukin-
1 beta secretion 
3.55 2.87E-02 25 3.06 
positive regulation of nitric-oxide 
synthase biosynthetic process 
3.55 2.87E-02 25 5.22 
positive regulation of heat 
generation 
3.55 2.87E-02 25 4.87 
positive regulation of cAMP-
mediated signaling 
3.55 2.87E-02 25 6.59 
phosphatidylinositol 3-kinase 
signaling 
3.55 2.87E-02 25 4.10 
labyrinthine layer blood vessel 
development 
3.55 2.87E-02 25 2.89 
response to L-ascorbic acid 3.55 2.87E-02 25 5.57 
metaphase plate congression 3.55 2.87E-02 25 3.78 
negative regulation of leukocyte 
mediated cytotoxicity 
3.55 2.87E-02 25 4.19 
negative regulation of cell killing 3.55 2.87E-02 25 4.19 
cytosolic calcium ion homeostasis 3.55 2.88E-02 10.4 3.66 
positive regulation of protein 
ubiquitination 
3.53 2.93E-02 13.46 4.62 
activation of cysteine-type 
endopeptidase activity involved 
in apoptotic process 
3.53 2.93E-02 13.46 3.92 
cellular response to carbohydrate 
stimulus 
3.53 2.93E-02 13.46 4.57 
positive regulation of 
carbohydrate metabolic process 
3.53 2.93E-02 14.63 3.82 
negative regulation of NF-kappaB 
transcription factor activity 
3.53 2.93E-02 14.63 4.00 
positive regulation of DNA 
metabolic process 
3.52 2.96E-02 11 3.95 
single-organism membrane 
organization 
3.52 2.96E-02 9.38 4.55 
adenylate cyclase-inhibiting 
dopamine receptor signaling 
pathway 
3.51 2.97E-02 40 5.83 
astrocyte activation 3.51 2.97E-02 40 3.27 
diaphragm development 3.51 2.97E-02 40 5.94 
negative regulation of protein 
export from nucleus 
3.51 2.97E-02 40 4.14 
regulation of short-term neuronal 
synaptic plasticity 
3.51 2.97E-02 40 3.56 
positive regulation of histone H3-
K9 methylation 
3.51 2.97E-02 40 2.91 
complement activation, 
alternative pathway 
3.51 2.97E-02 40 4.80 
regulation of interleukin-1 alpha 
production 
3.51 2.97E-02 40 4.36 
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regulation of somatostatin 
secretion 
3.51 2.97E-02 40 2.77 
positive regulation of cellular 
extravasation 
3.51 2.97E-02 40 6.15 
response to high density 
lipoprotein particle 
3.51 2.97E-02 40 6.76 
maternal process involved in 
parturition 
3.51 2.97E-02 40 5.23 
positive regulation of cholesterol 
storage 
3.51 2.97E-02 40 3.97 
copper ion transmembrane 
transport 
3.51 2.97E-02 40 6.09 
hydrogen peroxide biosynthetic 
process 
3.51 2.97E-02 40 6.61 
positive regulation of 
transcription from RNA 
polymerase I promoter 
3.51 2.97E-02 40 3.53 
Schwann cell differentiation 3.51 2.97E-02 40 4.56 
post-embryonic hemopoiesis 3.51 2.97E-02 40 3.77 
positive regulation of interleukin-
6 biosynthetic process 
3.51 2.97E-02 40 3.40 
skeletal muscle acetylcholine-
gated channel clustering 
3.51 2.97E-02 40 4.43 
regulation of epinephrine 
secretion 
3.51 2.97E-02 40 5.24 
positive regulation of 
glucocorticoid secretion 
3.51 2.97E-02 40 3.86 
regulation of cortisol secretion 3.51 2.97E-02 40 3.86 
regulation of inner ear receptor 
cell differentiation 
3.51 2.97E-02 40 3.77 
regulation of mechanoreceptor 
differentiation 
3.51 2.97E-02 40 3.77 
comma-shaped body 
morphogenesis 
3.51 2.97E-02 40 3.77 
metanephric tubule 
morphogenesis 
3.51 2.97E-02 40 3.77 
negative regulation of glycolytic 
process 
3.51 2.97E-02 40 5.30 
positive regulation of immature T 
cell proliferation 
3.51 2.97E-02 40 4.43 
type I interferon biosynthetic 
process 
3.51 2.97E-02 40 5.05 
SMAD protein import into nucleus 3.51 2.97E-02 40 3.77 
negative regulation of 
lamellipodium organization 
3.51 2.97E-02 40 5.12 
positive regulation of myelination 3.51 2.97E-02 40 5.38 
cytoplasmic pattern recognition 
receptor signaling pathway 
3.51 2.97E-02 40 4.52 
glycine biosynthetic process 3.51 2.97E-02 40 4.56 
lactate transport 3.51 2.97E-02 40 5.08 
lactate transmembrane transport 3.51 2.97E-02 40 5.08 
plasma membrane lactate 
transport 
3.51 2.97E-02 40 5.08 
growth hormone receptor 
signaling pathway 
3.51 2.97E-02 40 4.93 
bud elongation involved in lung 
branching 
3.51 2.97E-02 40 3.95 
positive regulation of steroid 
metabolic process 
3.5 3.03E-02 19.05 3.10 
alpha-beta T cell differentiation 3.5 3.03E-02 19.05 4.82 
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regulation of oligodendrocyte 
differentiation 
3.5 3.03E-02 19.05 3.84 
positive regulation of cellular 
component biogenesis 
3.5 3.03E-02 19.05 3.95 
positive regulation of nervous 
system development 
3.5 3.03E-02 19.05 3.95 
positive regulation of synapse 
assembly 
3.5 3.03E-02 19.05 3.95 
G2 DNA damage checkpoint 3.5 3.03E-02 19.05 3.05 
negative regulation of 
transcription factor import into 
nucleus 
3.5 3.03E-02 19.05 3.37 
osteoclast differentiation 3.5 3.03E-02 19.05 4.45 
response to immobilization stress 3.5 3.03E-02 19.05 5.17 
regulation of fatty acid transport 3.5 3.03E-02 19.05 3.66 
positive regulation of alpha-beta 
T cell differentiation 
3.5 3.03E-02 19.05 4.87 
regulation of cell growth 3.49 3.04E-02 9.09 3.52 
cell cycle process 3.49 3.04E-02 8 3.73 
cation transport 3.49 3.04E-02 8 4.28 
extrinsic apoptotic signaling 
pathway 
3.49 3.06E-02 12.5 4.84 
protein import 3.48 3.08E-02 11.84 3.75 
regulation of smooth muscle cell 
proliferation 
3.48 3.08E-02 11.84 3.90 
protein activation cascade 3.47 3.11E-02 16.13 5.77 
positive regulation of actin 
filament polymerization 
3.47 3.11E-02 16.13 4.26 
response to amphetamine 3.47 3.11E-02 16.13 4.56 
T cell proliferation 3.47 3.11E-02 16.13 4.20 
positive regulation of GTPase 
activity 
3.46 3.15E-02 10.89 4.02 
membrane organization 3.45 3.16E-02 9.05 4.62 
negative regulation of protein 
modification process 
3.45 3.18E-02 8.94 3.82 
negative regulation of cellular 
response to growth factor 
stimulus 
3.44 3.21E-02 13.21 3.57 
fatty acid derivative metabolic 
process 
3.44 3.21E-02 13.21 3.51 
icosanoid metabolic process 3.44 3.21E-02 13.21 3.51 
calcium ion homeostasis 3.43 3.24E-02 9.28 3.99 
regulation of morphogenesis of a 
branching structure 
3.42 3.26E-02 14.29 3.78 
cellular response to cAMP 3.42 3.26E-02 14.29 5.59 
positive regulation of DNA 
replication 
3.42 3.26E-02 14.29 3.93 
cellular response to glucose 
stimulus 
3.42 3.26E-02 14.29 4.83 
regulation of cell projection 
organization 
3.42 3.29E-02 8.71 4.85 
cellular response to abiotic 
stimulus 
3.4 3.33E-02 9.74 4.20 
leukocyte differentiation 3.4 3.34E-02 9.39 4.17 
macromolecule glycosylation 3.38 3.40E-02 10.43 4.20 
protein glycosylation 3.38 3.40E-02 10.43 4.20 
vesicle-mediated transport 3.38 3.40E-02 7.93 4.33 
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protein processing 3.38 3.40E-02 7.93 4.19 
response to activity 3.35 3.51E-02 12.96 5.43 
hormone transport 3.35 3.51E-02 12.96 4.13 
negative regulation of immune 
effector process 
3.35 3.51E-02 12.96 4.70 
regulation of phospholipase 
activity 
3.35 3.52E-02 15.63 4.78 
placenta development 3.35 3.52E-02 15.63 4.22 
regulation of calcium-mediated 
signaling 
3.35 3.52E-02 15.63 2.99 
glutathione metabolic process 3.35 3.52E-02 15.63 5.28 
regulation of interleukin-2 
production 
3.35 3.52E-02 15.63 4.30 
cyclic purine nucleotide 
metabolic process 
3.34 3.54E-02 18.18 4.06 
cyclic nucleotide biosynthetic 
process 
3.34 3.54E-02 18.18 4.06 
response to vitamin A 3.34 3.54E-02 18.18 3.56 
negative regulation of cell-
substrate adhesion 
3.34 3.54E-02 18.18 4.62 
regulation of endothelial cell 
apoptotic process 
3.34 3.54E-02 18.18 5.58 
apoptotic cell clearance 3.33 3.57E-02 23.08 3.57 
myeloid dendritic cell activation 3.33 3.57E-02 23.08 4.30 
I-kappaB kinase/NF-kappaB 
signaling 
3.33 3.57E-02 23.08 4.66 
positive regulation of release of 
cytochrome c from mitochondria 
3.33 3.57E-02 23.08 2.85 
regulation of steroid hormone 
secretion 
3.33 3.57E-02 23.08 3.35 
regulation of interleukin-1 beta 
secretion 
3.33 3.57E-02 23.08 3.06 
negative regulation of leukocyte 
migration 
3.33 3.57E-02 23.08 4.93 
positive regulation of cell 
adhesion mediated by integrin 
3.33 3.57E-02 23.08 4.67 
negative regulation of T cell 
apoptotic process 
3.33 3.57E-02 23.08 5.76 
positive regulation of triglyceride 
metabolic process 
3.33 3.57E-02 23.08 3.20 
regulation of interleukin-2 
biosynthetic process 
3.33 3.57E-02 23.08 4.01 
establishment of chromosome 
localization 
3.33 3.57E-02 23.08 3.78 
positive regulation of sterol 
transport 
3.33 3.57E-02 23.08 3.35 
positive regulation of cholesterol 
transport 
3.33 3.57E-02 23.08 3.35 
regulation of potassium ion 
transport 
3.32 3.61E-02 13.95 4.28 
regulation of protein complex 
disassembly 
3.32 3.61E-02 13.95 4.97 
cellular response to fibroblast 
growth factor stimulus 
3.32 3.61E-02 13.95 5.35 
positive regulation of protein 
polymerization 
3.32 3.61E-02 13.95 4.12 
cellular component 
morphogenesis 
3.32 3.62E-02 8.33 4.16 
purine nucleotide biosynthetic 
process 
3.29 3.72E-02 10.99 4.05 
response to carbohydrate 3.29 3.74E-02 9.79 4.55 
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cellular calcium ion homeostasis 3.27 3.81E-02 9.24 4.03 
peptidyl-tyrosine phosphorylation 3.26 3.83E-02 11.39 4.54 
plasma membrane organization 3.26 3.83E-02 12.73 4.61 
stem cell differentiation 3.26 3.83E-02 12.73 3.80 
regulation of DNA binding 3.26 3.83E-02 12.73 3.82 
positive regulation of cellular 
biosynthetic process 
3.25 3.87E-02 7.16 4.31 
central nervous system neuron 
differentiation 
3.25 3.88E-02 11.94 4.12 
brain development 3.24 3.93E-02 9.36 4.53 
positive regulation of lipase 
activity 
3.23 3.96E-02 15.15 4.09 
acid secretion 3.23 3.96E-02 15.15 3.54 
positive regulation of histone 
modification 
3.23 3.96E-02 15.15 3.51 
positive regulation of multi-
organism process 
3.23 3.96E-02 15.15 3.11 
negative regulation of MAP kinase 
activity 
3.22 3.98E-02 13.64 3.59 
diterpenoid metabolic process 3.22 3.98E-02 13.64 3.85 
positive regulation of T cell 
differentiation 
3.22 3.98E-02 13.64 4.47 
cellular response to hexose 
stimulus 
3.22 3.98E-02 13.64 4.83 
insulin secretion 3.2 4.09E-02 17.39 4.98 
behavioral fear response 3.2 4.09E-02 17.39 3.36 
positive regulation of calcium-
mediated signaling 
3.2 4.09E-02 17.39 3.15 
positive regulation of smooth 
muscle cell migration 
3.2 4.09E-02 17.39 3.95 
antigen processing and 
presentation of exogenous 
antigen 
3.2 4.09E-02 17.39 3.87 
regulation of interferon-beta 
production 
3.2 4.09E-02 17.39 3.50 
regulation of natural killer cell 
mediated immunity 
3.2 4.09E-02 17.39 4.34 
regulation of natural killer cell 
mediated cytotoxicity 
3.2 4.09E-02 17.39 4.34 
neurological system process 3.19 4.11E-02 7.81 4.21 
system development 3.19 4.12E-02 8.06 4.06 
activation of cysteine-type 
endopeptidase activity 
3.18 4.17E-02 12.5 3.92 
unsaturated fatty acid metabolic 
process 
3.18 4.17E-02 12.5 3.51 
monocarboxylic acid transport 3.17 4.18E-02 11.76 4.26 
lipid biosynthetic process 3.16 4.23E-02 8.49 4.26 
neuron projection development 3.16 4.26E-02 10.08 5.09 
negative regulation of apoptotic 
signaling pathway 
3.16 4.26E-02 10.08 4.53 
extracellular matrix organization 3.15 4.27E-02 10.38 4.36 
adenosine receptor signaling 
pathway 
3.15 4.29E-02 33.33 5.07 
response to oleic acid 3.15 4.29E-02 33.33 4.49 
skeletal muscle organ 
development 
3.15 4.29E-02 33.33 5.94 
cellular response to glucagon 
stimulus 
3.15 4.29E-02 33.33 6.19 
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cleavage furrow formation 3.15 4.29E-02 33.33 4.27 
positive regulation of natural 
killer cell differentiation 
3.15 4.29E-02 33.33 4.80 
amino-acid betaine biosynthetic 
process 
3.15 4.29E-02 33.33 3.63 
regulation of protein activation 
cascade 
3.15 4.29E-02 33.33 7.17 
regulation of complement 
activation 
3.15 4.29E-02 33.33 7.17 
cerebellar granule cell 
differentiation 
3.15 4.29E-02 33.33 4.89 
regulation of glial cell apoptotic 
process 
3.15 4.29E-02 33.33 5.08 
negative regulation of glial cell 
apoptotic process 
3.15 4.29E-02 33.33 5.08 
cellular response to 
hydroperoxide 
3.15 4.29E-02 33.33 4.86 
nucleoside diphosphate 
phosphorylation 
3.15 4.29E-02 33.33 2.80 
regulation of monocyte 
differentiation 
3.15 4.29E-02 33.33 3.61 
short-term memory 3.15 4.29E-02 33.33 3.55 
post-embryonic organ 
development 
3.15 4.29E-02 33.33 3.77 
NADPH oxidation 3.15 4.29E-02 33.33 3.46 
cytoplasm organization 3.15 4.29E-02 33.33 3.19 
positive regulation of potassium 
ion transmembrane transporter 
activity 
3.15 4.29E-02 33.33 4.71 
receptor guanylyl cyclase 
signaling pathway 
3.15 4.29E-02 33.33 2.81 
neuron fate determination 3.15 4.29E-02 33.33 3.77 
S-shaped body morphogenesis 3.15 4.29E-02 33.33 3.77 
heterochromatin assembly 3.15 4.29E-02 33.33 3.24 
mitotic G2 DNA damage 
checkpoint 
3.15 4.29E-02 33.33 2.94 
negative regulation of intrinsic 
apoptotic signaling pathway in 
response to oxidative stress 
3.15 4.29E-02 33.33 6.47 
response to ozone 3.15 4.29E-02 33.33 3.63 
ectopic germ cell programmed 
cell death 
3.15 4.29E-02 33.33 3.63 
regulation of T-helper 1 cell 
differentiation 
3.15 4.29E-02 33.33 4.51 
positive regulation of chemokine 
secretion 
3.15 4.29E-02 33.33 3.70 
positive regulation of 
corticotropin secretion 
3.15 4.29E-02 33.33 3.69 
negative regulation of peptidyl-
threonine phosphorylation 
3.15 4.29E-02 33.33 5.06 
mesenchymal-epithelial cell 
signaling 
3.15 4.29E-02 33.33 3.75 
cellular response to zinc ion 3.15 4.29E-02 33.33 4.01 
negative regulation of 
macroautophagy 
3.15 4.29E-02 33.33 5.99 
negative regulation of 
norepinephrine secretion 
3.15 4.29E-02 33.33 3.25 
cellular response to granulocyte 
macrophage colony-stimulating 
factor stimulus 
3.15 4.29E-02 33.33 3.48 
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response to granulocyte 
macrophage colony-stimulating 
factor 
3.15 4.29E-02 33.33 3.48 
rRNA transport 3.15 4.29E-02 33.33 4.95 
antigen processing and 
presentation via MHC class Ib 
3.15 4.29E-02 33.33 3.66 
positive regulation of necrotic 
cell death 
3.15 4.29E-02 33.33 3.55 
L-serine metabolic process 3.15 4.29E-02 33.33 4.56 
negative regulation of Ras 
GTPase activity 
3.15 4.29E-02 33.33 3.95 
oligopeptide transmembrane 
transport 
3.15 4.29E-02 33.33 4.48 
cellular response to exogenous 
dsRNA 
3.15 4.29E-02 33.33 3.39 
organic substance catabolic 
process 
3.14 4.33E-02 7.15 4.23 
nucleobase-containing small 
molecule metabolic process 
3.14 4.33E-02 7.85 4.30 
protein maturation 3.14 4.34E-02 7.78 4.19 
negative regulation of growth 3.14 4.34E-02 9.59 3.75 
inositol phosphate metabolic 
process 
3.13 4.35E-02 21.43 3.81 
ovulation cycle 3.13 4.35E-02 21.43 4.34 
mechanoreceptor differentiation 3.13 4.35E-02 21.43 3.39 
positive regulation vascular 
endothelial growth factor 
production 
3.13 4.35E-02 21.43 4.84 
negative regulation of I-kappaB 
kinase/NF-kappaB signaling 
3.13 4.35E-02 21.43 4.16 
regulation of macrophage 
differentiation 
3.13 4.35E-02 21.43 4.45 
positive regulation of NF-kappaB 
import into nucleus 
3.13 4.35E-02 21.43 3.19 
regulation of monocyte 
chemotaxis 
3.13 4.35E-02 21.43 6.62 
regulation of heat generation 3.13 4.35E-02 21.43 4.87 
protein homotrimerization 3.13 4.35E-02 21.43 5.41 
hexose catabolic process 3.13 4.35E-02 21.43 3.33 
transepithelial transport 3.13 4.35E-02 21.43 4.65 
regulation of catecholamine 
metabolic process 
3.13 4.35E-02 21.43 4.23 
negative regulation of GTPase 
activity 
3.13 4.35E-02 21.43 4.72 
intracellular pH reduction 3.13 4.35E-02 21.43 5.23 
regulation of JUN kinase activity 3.13 4.38E-02 13.33 4.70 
response to fibroblast growth 
factor 
3.13 4.38E-02 13.33 5.35 
pyridine-containing compound 
metabolic process 
3.13 4.38E-02 13.33 4.24 
cellular response to 
monosaccharide stimulus 
3.13 4.38E-02 13.33 4.83 
peptidyl-tyrosine modification 3.13 4.39E-02 11.11 4.54 
positive regulation of cysteine-
type endopeptidase activity 
involved in apoptotic process 
3.13 4.39E-02 11.11 4.17 
adenylate cyclase-inhibiting G-
protein coupled receptor 
signaling pathway 
3.12 4.43E-02 14.71 5.22 
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positive regulation of interferon-
gamma production 
3.12 4.43E-02 14.71 4.34 
positive regulation of alpha-beta 
T cell activation 
3.12 4.43E-02 14.71 4.63 
regulation of Notch signaling 
pathway 
3.12 4.43E-02 14.71 4.18 
stem cell proliferation 3.12 4.43E-02 14.71 4.77 
negative regulation of leukocyte 
activation 
3.1 4.49E-02 10.64 3.76 
positive regulation of 
endopeptidase activity 
3.1 4.49E-02 10.64 4.15 
positive regulation of cell cycle 
process 
3.1 4.49E-02 10 3.89 
cellular response to inorganic 
substance 
3.1 4.52E-02 10.28 4.27 
extracellular structure 
organization 
3.1 4.52E-02 10.28 4.36 
cell recognition 3.1 4.52E-02 12.28 4.03 
regulation of fat cell 
differentiation 
3.1 4.52E-02 12.28 4.67 
regulation of neuron projection 
development 
3.09 4.54E-02 8.91 4.62 
learning 3.06 4.69E-02 10.98 3.57 
negative regulation of cell-cell 
adhesion 
3.06 4.69E-02 16.67 4.68 
positive regulation of acute 
inflammatory response 
3.06 4.69E-02 16.67 5.46 
positive regulation of Ras protein 
signal transduction 
3.06 4.69E-02 16.67 4.17 
ERBB signaling pathway 3.06 4.69E-02 16.67 3.92 
pituitary gland development 3.06 4.69E-02 16.67 3.59 
response to monosaccharide 3.05 4.74E-02 9.92 4.82 
negative regulation of cellular 
protein metabolic process 
3.05 4.76E-02 8.18 3.91 
regulation of cellular 
carbohydrate metabolic process 
3.04 4.77E-02 10.53 3.94 
leukocyte homeostasis 3.04 4.80E-02 13.04 4.73 
regulation of neural precursor 
cell proliferation 
3.04 4.80E-02 13.04 4.03 
DNA metabolic process 3.03 4.81E-02 7.86 3.48 
regulation of anatomical 
structure size 
3.03 4.85E-02 9.26 4.10 
negative regulation of RNA 
biosynthetic process 
3.02 4.90E-02 7.42 4.00 
cellular amine metabolic process 3.02 4.90E-02 12.07 4.29 
cellular biogenic amine 
metabolic process 
3.02 4.90E-02 12.07 4.29 
positive regulation of JUN kinase 
activity 
3.01 4.93E-02 14.29 4.69 
regulation of cellular response to 
insulin stimulus 
3.01 4.93E-02 14.29 3.34 
purine-containing compound 
metabolic process 
3 4.96E-02 8.08 4.36 
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8.2.2.2 Significantly altered biological processes by Panther  
 
 
Figure 4.4.2a: Significantly altered biological processes. Panther analysis of 
differentially expressed gene list in serum alone treated cultures compared to control. 
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8.2.2.3 Table 4.4.2b: Enriched molecular function by Partek Genomic Suite. 
Gene ontology clustering was performed on the genes differentially 
regulated by fold change of 1.4 or greater in the serum treated cultures in 
comparison to control cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group 
C+ vs C-
score 
chemokine receptor binding 33.97 1.76E-15 52.63 5.38 
chemokine activity 33.05 4.45E-15 58.06 5.32 
cytokine receptor binding 24.98 1.42E-11 21.21 4.80 
binding 24.53 2.23E-11 6.95 4.21 
protein binding 24.06 3.54E-11 7.90 4.16 
CCR chemokine receptor binding 19.88 2.32E-09 62.50 5.08 
receptor binding 19.31 4.11E-09 10.49 4.14 
identical protein binding 17.95 1.60E-08 10.85 4.01 
G-protein coupled receptor binding 15.64 1.62E-07 16.57 4.78 
cytokine activity 14.82 3.68E-07 18.46 4.95 
CCR5 chemokine receptor binding 12.52 3.66E-06 83.33 5.20 
CCR1 chemokine receptor binding 11.41 1.11E-05 100.00 5.94 
2'-5'-oligoadenylate synthetase 
activity 
11.41 1.11E-05 100.00 3.55 
carbohydrate derivative binding 10.77 2.11E-05 8.31 4.32 
protein homodimerization activity 10.41 3.02E-05 10.58 4.05 
catalytic activity 9.89 5.09E-05 7.07 4.22 
CXCR3 chemokine receptor binding 9.84 5.31E-05 80.00 5.68 
glycosaminoglycan binding 9.55 7.15E-05 15.57 4.68 
anion transmembrane transporter 
activity 
9.37 8.55E-05 13.56 4.46 
ion binding 9.03 1.20E-04 7.03 4.29 
chemoattractant activity 8.63 1.79E-04 37.50 4.10 
protein dimerization activity 8.61 1.82E-04 8.89 4.02 
anion binding 8.55 1.93E-04 7.74 4.25 
TAP binding 8.55 1.93E-04 100.00 4.72 
TAP1 binding 8.55 1.93E-04 100.00 4.72 
TAP2 binding 8.55 1.93E-04 100.00 4.72 
low-density lipoprotein receptor 
activity 
7.99 3.38E-04 57.14 4.40 
CXCR chemokine receptor binding 7.99 3.38E-04 57.14 5.68 
double-stranded RNA binding 7.96 3.49E-04 20.83 3.51 
secondary active transmembrane 
transporter activity 
7.84 3.95E-04 14.53 4.48 
peptide binding 7.75 4.32E-04 12.96 3.98 
amide binding 7.50 5.53E-04 12.73 3.98 
carboxylic acid transmembrane 
transporter activity 
7.49 5.61E-04 16.46 4.14 
organic acid transmembrane 
transporter activity 
7.36 6.35E-04 16.25 4.14 
metalloenzyme regulator activity 7.35 6.46E-04 50.00 3.87 
organic anion transmembrane 
transporter activity 
7.20 7.48E-04 14.71 4.18 
collagen binding 7.06 8.63E-04 22.22 3.12 
carbohydrate binding 6.94 9.68E-04 11.54 4.25 
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purinergic nucleotide receptor 
activity 
6.74 1.18E-03 33.33 3.43 
nucleotide receptor activity 6.74 1.18E-03 33.33 3.43 
nucleoside binding 6.53 1.45E-03 7.82 4.21 
hyaluronic acid binding 6.41 1.64E-03 31.25 4.44 
CCR2 chemokine receptor binding 6.34 1.77E-03 60.00 6.57 
ribonucleoside binding 6.33 1.79E-03 7.78 4.19 
symporter activity 6.07 2.30E-03 14.81 5.08 
nucleotidyltransferase activity 6.04 2.38E-03 14.13 4.06 
transferase activity, transferring 
pentosyl groups 
6.03 2.41E-03 21.21 4.59 
anion:cation symporter activity 6.03 2.41E-03 21.21 5.19 
purine ribonucleoside binding 6.02 2.42E-03 7.72 4.20 
purine nucleoside binding 5.98 2.54E-03 7.71 4.20 
retinal binding 5.93 2.65E-03 36.36 4.01 
lipoprotein particle receptor 
activity 
5.93 2.65E-03 36.36 4.40 
transition metal ion binding 5.88 2.78E-03 7.96 4.31 
heparin binding 5.85 2.88E-03 13.83 4.63 
adenylyltransferase activity 5.84 2.92E-03 27.78 4.08 
transferase activity, transferring 
phosphorus-containing groups 
5.81 3.00E-03 8.48 4.07 
cargo receptor activity 5.70 3.36E-03 18.18 4.38 
adenyl ribonucleotide binding 5.70 3.36E-03 7.88 4.05 
adenyl nucleotide binding 5.69 3.37E-03 7.87 4.06 
intermediate filament binding 5.69 3.38E-03 50.00 3.59 
metalloenzyme inhibitor activity 5.69 3.38E-03 50.00 4.41 
metalloendopeptidase inhibitor 
activity 
5.69 3.38E-03 50.00 4.41 
sulfur compound binding 5.68 3.40E-03 12.31 4.73 
purinergic receptor activity 5.58 3.77E-03 26.32 3.43 
interleukin-1 receptor binding 5.58 3.79E-03 33.33 5.06 
protease binding 5.52 4.01E-03 16.36 5.39 
purine nucleotide binding 5.51 4.06E-03 7.57 4.20 
purine ribonucleotide binding 5.50 4.09E-03 7.58 4.20 
transferase activity 5.47 4.22E-03 7.54 4.12 
active transmembrane transporter 
activity 
5.41 4.47E-03 10.77 4.47 
amino acid transmembrane 
transporter activity 
5.39 4.54E-03 16.07 4.07 
peptide antigen binding 5.35 4.74E-03 18.92 3.85 
phosphoric diester hydrolase 
activity 
5.27 5.12E-03 15.79 4.07 
ribonucleotide binding 5.23 5.36E-03 7.50 4.20 
growth factor binding 5.19 5.55E-03 13.33 3.73 
L-amino acid transmembrane 
transporter activity 
5.19 5.56E-03 20.69 3.92 
hydroxymethyl-, formyl- and 
related transferase activity 
5.17 5.67E-03 42.86 4.99 
phospholipase activator activity 5.17 5.67E-03 42.86 4.30 
polypeptide N-
acetylgalactosaminyltransferase 
activity 
5.17 5.67E-03 42.86 4.31 
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oligopeptide transporter activity 5.17 5.67E-03 42.86 4.63 
ATP binding 5.10 6.08E-03 7.75 4.07 
transferase activity, transferring 
glycosyl groups 
5.10 6.10E-03 10.86 4.27 
purine ribonucleoside triphosphate 
binding 
5.09 6.14E-03 7.50 4.22 
drug binding 5.02 6.62E-03 13.04 3.74 
small molecule binding 4.98 6.86E-03 7.13 4.28 
MHC protein binding 4.96 6.98E-03 28.57 3.79 
cell adhesion molecule binding 4.89 7.50E-03 16.00 3.91 
neuropeptide binding 4.75 8.68E-03 37.50 4.61 
G-protein coupled nucleotide 
receptor activity 
4.75 8.68E-03 37.50 3.78 
G-protein coupled purinergic 
nucleotide receptor activity 
4.75 8.68E-03 37.50 3.78 
peptide transporter activity 4.75 8.68E-03 37.50 4.63 
purine nucleobase binding 4.64 9.65E-03 66.67 4.71 
CCR10 chemokine receptor binding 4.64 9.65E-03 66.67 2.57 
calcium-dependent protein kinase 
activity 
4.64 9.65E-03 66.67 2.56 
calcium-dependent protein kinase 
C activity 
4.64 9.65E-03 66.67 2.56 
calcium-dependent protein 
serine/threonine kinase activity 
4.64 9.65E-03 66.67 2.56 
oleic acid binding 4.64 9.65E-03 66.67 3.20 
oxidoreductase activity, acting on 
the CH-OH group of donors, 
quinone or similar compound as 
acceptor 
4.64 9.65E-03 66.67 6.52 
nuclear localization sequence 
binding 
4.64 9.65E-03 66.67 4.14 
citrate transmembrane transporter 
activity 
4.64 9.65E-03 66.67 4.51 
succinate transmembrane 
transporter activity 
4.64 9.65E-03 66.67 4.51 
oligopeptide-transporting ATPase 
activity 
4.64 9.65E-03 66.67 4.48 
peptide-transporting ATPase 
activity 
4.64 9.65E-03 66.67 4.48 
MHC class Ib protein binding 4.64 9.65E-03 66.67 4.48 
enzyme inhibitor activity 4.56 1.05E-02 9.70 4.29 
cytokine binding 4.43 1.19E-02 14.81 3.61 
solute:cation symporter activity 4.43 1.19E-02 14.81 5.36 
transmembrane receptor protein 
tyrosine kinase activity 
4.39 1.24E-02 15.91 4.36 
adenylate cyclase binding 4.38 1.25E-02 33.33 5.25 
lipase activator activity 4.38 1.25E-02 33.33 4.30 
MHC class I protein binding 4.38 1.25E-02 33.33 4.19 
amide transmembrane transporter 
activity 
4.38 1.25E-02 33.33 3.95 
inorganic anion transmembrane 
transporter activity 
4.34 1.30E-02 12.99 5.10 
pyridoxal phosphate binding 4.26 1.42E-02 17.14 3.88 
acetylgalactosaminyltransferase 
activity 
4.24 1.45E-02 23.53 4.02 
fibronectin binding 4.24 1.45E-02 23.53 3.36 
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cofactor binding 4.24 1.45E-02 9.68 4.57 
kinase inhibitor activity 4.18 1.53E-02 19.23 3.53 
cytokine receptor activity 4.12 1.62E-02 14.04 4.02 
protein heterodimerization activity 4.11 1.64E-02 8.72 3.63 
oxidoreductase activity, acting on 
paired donors, with incorporation 
or reduction of molecular oxygen 
4.10 1.66E-02 10.39 3.97 
UDP-galactosyltransferase activity 4.03 1.78E-02 22.22 3.93 
protein phosphatase inhibitor 
activity 
4.03 1.78E-02 22.22 3.16 
single-stranded RNA binding 4.02 1.79E-02 18.52 4.12 
iron ion binding 3.99 1.85E-02 10.06 4.44 
nucleobase binding 3.99 1.86E-02 50.00 4.71 
immunoglobulin receptor binding 3.99 1.86E-02 50.00 5.27 
5'-deoxyribose-5-phosphate lyase 
activity 
3.99 1.86E-02 50.00 3.24 
3'-5'-exodeoxyribonuclease activity 3.99 1.86E-02 50.00 4.45 
CARD domain binding 3.99 1.86E-02 50.00 4.33 
tricarboxylic acid transmembrane 
transporter activity 
3.99 1.86E-02 50.00 4.51 
secondary active monocarboxylate 
transmembrane transporter 
activity 
3.99 1.86E-02 50.00 5.08 
tumor necrosis factor-activated 
receptor activity 
3.99 1.86E-02 50.00 4.55 
transporter activity 3.87 2.09E-02 7.50 4.32 
DNA-directed DNA polymerase 
activity 
3.84 2.15E-02 21.05 3.69 
phosphatase inhibitor activity 3.84 2.15E-02 21.05 3.16 
neutral amino acid transmembrane 
transporter activity 
3.84 2.15E-02 21.05 3.70 
phosphatidylinositol phospholipase 
C activity 
3.80 2.25E-02 27.27 4.39 
low-density lipoprotein particle 
binding 
3.80 2.25E-02 27.27 3.72 
signal sequence binding 3.80 2.25E-02 27.27 3.49 
protein complex binding 3.76 2.32E-02 7.87 3.83 
vitamin binding 3.73 2.41E-02 14.00 4.36 
small GTPase binding 3.68 2.51E-02 10.91 4.63 
cadherin binding 3.66 2.57E-02 20.00 3.51 
threonine-type endopeptidase 
activity 
3.66 2.57E-02 20.00 5.08 
threonine-type peptidase activity 3.66 2.57E-02 20.00 5.08 
substrate-specific transporter 
activity 
3.65 2.60E-02 7.60 4.35 
metalloendopeptidase activity 3.63 2.65E-02 12.16 3.97 
hydrolase activity 3.58 2.78E-02 6.86 4.27 
phospholipase C activity 3.55 2.87E-02 25.00 4.39 
snRNA binding 3.55 2.87E-02 25.00 4.40 
nucleotide binding 3.53 2.92E-02 6.89 4.23 
nucleoside phosphate binding 3.53 2.92E-02 6.89 4.23 
opsonin binding 3.51 2.97E-02 40.00 4.62 
cAMP response element binding 3.51 2.97E-02 40.00 2.83 
sphingosine-1-phosphate receptor 3.51 2.97E-02 40.00 5.71 
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activity 
C4-dicarboxylate transmembrane 
transporter activity 
3.51 2.97E-02 40.00 4.51 
iron ion transmembrane 
transporter activity 
3.51 2.97E-02 40.00 6.51 
death receptor activity 3.51 2.97E-02 40.00 4.55 
organic acid:sodium symporter 
activity 
3.50 3.03E-02 19.05 5.50 
antiporter activity 3.47 3.11E-02 16.13 3.49 
regulatory region nucleic acid 
binding 
3.47 3.12E-02 8.59 4.11 
regulatory region DNA binding 3.47 3.12E-02 8.59 4.11 
transmembrane receptor protein 
kinase activity 
3.44 3.21E-02 13.21 4.36 
kinase activity 3.40 3.34E-02 7.77 4.12 
lipid binding 3.38 3.41E-02 8.10 4.29 
retinoid binding 3.34 3.54E-02 18.18 4.01 
DNA polymerase activity 3.34 3.54E-02 18.18 3.69 
NF-kappaB binding 3.34 3.54E-02 18.18 4.34 
monocarboxylic acid 
transmembrane transporter 
activity 
3.34 3.54E-02 18.18 4.80 
calmodulin binding 3.33 3.57E-02 11.54 4.01 
Ras GTPase binding 3.33 3.57E-02 10.68 4.51 
GABA receptor binding 3.33 3.57E-02 23.08 4.90 
carboxylic acid binding 3.30 3.67E-02 9.62 4.36 
phosphotransferase activity, 
alcohol group as acceptor 
3.22 4.01E-02 7.79 4.14 
organic acid binding 3.21 4.04E-02 9.49 4.36 
protein kinase inhibitor activity 3.20 4.09E-02 17.39 3.80 
steroid hydroxylase activity 3.20 4.09E-02 17.39 3.37 
RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding transcription factor 
activity 
3.19 4.10E-02 11.25 3.59 
transcription regulatory region DNA 
binding 
3.18 4.18E-02 8.42 4.07 
metallopeptidase activity 3.16 4.26E-02 10.08 4.00 
calcium- and calmodulin-
responsive adenylate cyclase 
activity 
3.15 4.29E-02 33.33 5.57 
receptor antagonist activity 3.15 4.29E-02 33.33 6.90 
GTP-Rho binding 3.15 4.29E-02 33.33 4.36 
axon guidance receptor activity 3.15 4.29E-02 33.33 6.24 
N-methyl-D-aspartate selective 
glutamate receptor activity 
3.15 4.29E-02 33.33 5.43 
glucose binding 3.15 4.29E-02 33.33 3.39 
3',5'-cyclic-GMP phosphodiesterase 
activity 
3.15 4.29E-02 33.33 3.25 
cation:chloride symporter activity 3.15 4.29E-02 33.33 4.88 
sodium:dicarboxylate symporter 
activity 
3.15 4.29E-02 33.33 4.51 
oligopeptide transmembrane 
transporter activity 
3.15 4.29E-02 33.33 4.48 
enzyme binding 3.15 4.30E-02 7.17 4.34 
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glutamate receptor activity 3.13 4.35E-02 21.43 4.59 
sequence-specific DNA binding RNA 
polymerase II transcription factor 
activity 
3.13 4.36E-02 8.96 4.19 
transmembrane transporter 
activity 
3.12 4.41E-02 7.43 4.31 
scavenger receptor activity 3.12 4.43E-02 14.71 5.19 
calcium ion binding 3.11 4.45E-02 7.83 4.34 
UDP-glycosyltransferase activity 3.10 4.50E-02 11.59 4.12 
hydrolase activity, acting on acid 
anhydrides 
3.09 4.54E-02 7.65 4.21 
nucleoside-triphosphatase activity 3.06 4.69E-02 7.73 4.16 
GTPase binding 3.05 4.74E-02 9.92 4.63 
chloride transmembrane 
transporter activity 
3.02 4.90E-02 12.07 5.14 
solute:sodium symporter activity 3.01 4.93E-02 14.29 5.45 
zinc ion binding 3.01 4.94E-02 7.29 4.04 
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8.2.2.4 Table 4.4.2c: Cellular components by Partek Genomic Suite. Gene 
ontology clustering was performed on the genes differentially regulated by 
fold change of 1.4 or greater in the serum treated cultures in comparison to 
control cultures.  
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group 
C+ vs C- 
score 
extracellular region part 32.34 9.02E-15 9.93 4.55 
extracellular space 30.40 6.29E-14 12.78 4.60 
cytoplasm 22.74 1.33E-10 8.46 4.14 
receptor complex 15.89 1.26E-07 16.76 4.66 
vesicle 15.03 2.96E-07 8.69 4.69 
plasma membrane part 13.99 8.43E-07 9.13 4.39 
membrane-bounded vesicle 13.47 1.41E-06 8.58 4.72 
extracellular vesicular exosome 11.86 7.07E-06 8.85 4.80 
extracellular organelle 11.82 7.34E-06 8.84 4.80 
extracellular membrane-bounded 
organelle 
11.82 7.34E-06 8.84 4.80 
cell surface 10.91 1.83E-05 11.91 4.16 
intracellular part 9.66 6.41E-05 6.43 4.10 
myelin sheath 8.63 1.79E-04 37.50 5.23 
AIM2 inflammasome complex 8.55 1.93E-04 100.00 4.32 
TAP complex 8.55 1.93E-04 100.00 4.72 
membrane-bounded organelle 8.55 1.93E-04 6.62 4.19 
membrane raft 8.42 2.19E-04 12.77 4.66 
extracellular region 8.19 2.77E-04 9.27 4.01 
organelle 7.71 4.47E-04 6.49 4.18 
blood microparticle 7.36 6.35E-04 16.25 6.04 
cellular_component 7.25 7.13E-04 6.00 4.16 
I-kappaB/NF-kappaB complex 7.21 7.39E-04 75.00 4.90 
NLRP3 inflammasome complex 7.21 7.39E-04 75.00 4.32 
symbiont-containing vacuole 
membrane 
7.21 7.39E-04 75.00 3.69 
cell pole 6.80 1.11E-03 44.44 3.60 
MCM complex 6.80 1.11E-03 44.44 2.65 
basolateral plasma membrane 6.79 1.12E-03 13.28 4.31 
side of membrane 6.67 1.26E-03 11.32 4.23 
external side of plasma membrane 6.51 1.48E-03 11.80 4.26 
host cell part 6.34 1.77E-03 60.00 3.69 
other organism part 6.34 1.77E-03 60.00 3.69 
spermatoproteasome complex 6.34 1.77E-03 60.00 5.65 
perinuclear region of cytoplasm 6.26 1.91E-03 9.70 4.17 
neuron part 5.79 3.06E-03 8.25 4.21 
basal plasma membrane 5.77 3.13E-03 23.08 3.89 
cell projection 5.63 3.59E-03 7.98 4.26 
cytoplasmic part 5.48 4.17E-03 6.56 4.15 
plasma membrane region 5.48 4.19E-03 9.65 4.04 
leading edge membrane 5.28 5.08E-03 14.10 5.04 
membrane region 5.28 5.08E-03 8.29 4.06 
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cell tip 5.17 5.67E-03 42.86 3.62 
intracellular membrane-bounded 
organelle 
4.87 7.70E-03 6.42 4.08 
BRCA1-BARD1 complex 4.64 9.65E-03 66.67 2.69 
NLRP1 inflammasome complex 4.64 9.65E-03 66.67 3.30 
astrocyte projection 4.64 9.65E-03 66.67 3.73 
MHC class I peptide loading 
complex 
4.64 9.65E-03 66.67 4.45 
extracellular matrix 4.63 9.72E-03 10.05 4.15 
dendrite 4.44 1.17E-02 9.73 4.53 
ruffle 4.33 1.32E-02 14.55 3.39 
intracellular organelle 4.30 1.36E-02 6.29 4.08 
proteinaceous extracellular matrix 4.26 1.42E-02 11.11 4.08 
neuron projection membrane 4.18 1.53E-02 19.23 5.52 
integral component of plasma 
membrane 
4.14 1.59E-02 9.35 4.72 
podosome 4.07 1.71E-02 30.00 4.53 
cytoplasmic vesicle 4.01 1.82E-02 7.96 4.52 
IPAF inflammasome complex 3.99 1.86E-02 50.00 4.55 
ripoptosome 3.99 1.86E-02 50.00 3.77 
intracellular 3.94 1.94E-02 7.81 4.51 
cell body 3.92 1.98E-02 8.72 4.46 
filopodium 3.87 2.08E-02 15.79 4.29 
proteasome core complex 3.84 2.15E-02 21.05 5.08 
collagen 3.73 2.41E-02 14.00 2.78 
integrin complex 3.66 2.57E-02 20.00 4.05 
replication fork 3.66 2.57E-02 20.00 3.33 
DNA polymerase complex 3.55 2.87E-02 25.00 3.72 
lipopolysaccharide receptor 
complex 
3.51 2.97E-02 40.00 5.66 
glial cell projection 3.51 2.97E-02 40.00 3.73 
proteasome activator complex 3.51 2.97E-02 40.00 4.62 
synaptic membrane 3.45 3.17E-02 9.80 4.37 
nucleus 3.40 3.32E-02 6.49 3.98 
neuron projection 3.40 3.34E-02 7.77 4.39 
synapse part 3.36 3.47E-02 8.50 4.07 
cytosol 3.35 3.52E-02 7.30 4.10 
microvillus membrane 3.33 3.57E-02 23.08 4.25 
perikaryon 3.18 4.17E-02 12.50 4.88 
basal part of cell 3.15 4.29E-02 33.33 4.75 
nucleotide-excision repair complex 3.15 4.29E-02 33.33 3.37 
cell-cell junction 3.14 4.31E-02 8.64 3.91 
organelle membrane 3.13 4.39E-02 6.91 4.50 
cell part 3.01 4.93E-02 5.98 4.15 
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8.2.3 Gene ontology clustering of cultures treated with O4 antibody in the 
presence of serum 
 
8.2.3.1 Table 4.4.3a: Significantly enriched biological processes by Partek 
Genomic Suite. Gene ontology clustering was performed on the genes 
differentially regulated by fold change of 1.4 or greater in the mAb O4 and 
serum treated cultures in comparison to serum only cultures. 
Function 
Enrichment 
Score 
Enrichment 
p-value 
% genes present 
in group 
O4+ vs C+ 
score 
regulation of toll-like receptor 
signaling pathway 
13.09 2.07E-06 11.54 4.66 
central nervous system myelin 
maintenance 
12.78 2.81E-06 66.67 5.96 
ensheathment of neurons 10.58 2.53E-05 5.08 5.13 
axon ensheathment 10.58 2.53E-05 5.08 5.13 
myelin maintenance 10.08 4.19E-05 20.00 5.96 
positive regulation of toll-like 
receptor signaling pathway 
9.70 6.14E-05 16.67 4.78 
oligodendrocyte development 9.10 1.11E-04 12.50 4.26 
glial cell development 7.51 5.46E-04 5.71 4.26 
epidermal cell differentiation 6.84 1.07E-03 4.08 6.12 
plasma membrane organization 6.61 1.35E-03 3.64 5.96 
myelination 6.57 1.40E-03 3.57 5.43 
sphingolipid metabolic process 5.92 2.69E-03 2.56 7.24 
propionate metabolic process 5.81 3.01E-03 33.33 4.41 
N-terminal protein lipidation 5.81 3.01E-03 33.33 6.86 
negative regulation of 
lamellipodium assembly 
5.81 3.01E-03 33.33 7.15 
developmental process 5.68 3.42E-03 0.27 5.78 
short-chain fatty acid catabolic 
process 
5.52 4.01E-03 25.00 4.41 
regulation of toll-like receptor 2 
signaling pathway 
5.52 4.01E-03 25.00 4.41 
cellular response to progesterone 
stimulus 
5.52 4.01E-03 25.00 4.41 
galactolipid metabolic process 5.52 4.01E-03 25.00 6.72 
paranodal junction assembly 5.52 4.01E-03 25.00 6.72 
galactosylceramide metabolic 
process 
5.52 4.01E-03 25.00 6.72 
membrane lipid metabolic process 5.41 4.47E-03 1.98 7.24 
negative regulation of toll-like 
receptor 4 signaling pathway 
5.30 5.01E-03 20.00 4.41 
positive regulation of myelination 5.30 5.01E-03 20.00 4.14 
negative regulation of 
lamellipodium organization 
5.30 5.01E-03 20.00 7.15 
positive regulation of immune 
system process 
5.19 5.55E-03 0.80 4.66 
calcium-independent cell-cell 
adhesion 
5.11 6.01E-03 16.67 4.54 
negative regulation of 
lipopolysaccharide-mediated 
signaling pathway 
5.11 6.01E-03 16.67 4.41 
cellular response to 
lipopolysaccharide 
5.06 6.35E-03 1.65 4.26 
cellular response to molecule of 
bacterial origin 
5.00 6.76E-03 1.60 4.26 
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peripheral nervous system myelin 
maintenance 
4.96 7.01E-03 14.29 7.77 
tolerance induction 4.96 7.01E-03 14.29 4.41 
negative regulation of type I 
interferon production 
4.96 7.01E-03 14.29 4.41 
positive regulation of neurological 
system process 
4.96 7.01E-03 14.29 4.14 
cellular response to biotic stimulus 4.83 7.96E-03 1.47 4.26 
cellular response to interferon-
beta 
4.83 8.00E-03 12.50 4.41 
central nervous system myelination 4.83 8.00E-03 12.50 4.14 
axon ensheathment in central 
nervous system 
4.83 8.00E-03 12.50 4.14 
glycosylceramide metabolic 
process 
4.83 8.00E-03 12.50 6.72 
cell adhesion 4.77 8.49E-03 0.69 5.83 
biological adhesion 4.76 8.54E-03 0.69 5.83 
short-chain fatty acid metabolic 
process 
4.61 1.00E-02 10.00 4.41 
glycosphingolipid biosynthetic 
process 
4.61 1.00E-02 10.00 6.72 
positive regulation of 
oligodendrocyte differentiation 
4.61 1.00E-02 10.00 4.37 
positive regulation of humoral 
immune response 
4.51 1.10E-02 9.09 4.41 
regulation of toll-like receptor 4 
signaling pathway 
4.51 1.10E-02 9.09 4.41 
keratinization 4.51 1.10E-02 9.09 4.47 
response to interferon-beta 4.42 1.20E-02 8.33 4.41 
N-terminal protein amino acid 
modification 
4.42 1.20E-02 8.33 6.86 
regulation of multicellular 
organismal process 
4.37 1.27E-02 0.33 4.96 
peptidyl-cysteine modification 4.34 1.30E-02 7.69 6.86 
cellular lipid metabolic process 4.34 1.30E-02 0.59 6.30 
regulation of lipopolysaccharide-
mediated signaling pathway 
4.27 1.40E-02 7.14 4.41 
negative regulation of toll-like 
receptor signaling pathway 
4.27 1.40E-02 7.14 4.41 
negative regulation of GTPase 
activity 
4.27 1.40E-02 7.14 7.15 
cellular developmental process 4.21 1.48E-02 0.32 5.50 
regulation of hair cycle 4.20 1.50E-02 6.67 7.77 
negative regulation of microtubule 
depolymerization 
4.20 1.50E-02 6.67 6.86 
single-organism membrane 
organization 
4.17 1.54E-02 1.04 5.96 
negative regulation of response to 
biotic stimulus 
4.14 1.60E-02 6.25 4.41 
semaphorin-plexin signaling 
pathway 
4.14 1.60E-02 6.25 7.15 
fatty acid metabolic process 4.12 1.63E-02 1.01 6.09 
regulation of lamellipodium 
assembly 
4.08 1.69E-02 5.88 7.15 
epithelial cell differentiation 4.05 1.74E-02 0.98 6.12 
regulation of microtubule 
depolymerization 
4.02 1.79E-02 5.56 6.86 
positive regulation of interleukin-8 
production 
4.02 1.79E-02 5.56 4.11 
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single organism reproductive 
process 
3.92 1.99E-02 0.50 4.35 
regulation of humoral immune 
response 
3.92 1.99E-02 5.00 4.41 
protein palmitoylation 3.92 1.99E-02 5.00 6.86 
regulation of myelination 3.92 1.99E-02 5.00 4.14 
oligodendrocyte differentiation 3.92 1.99E-02 5.00 4.14 
membrane organization 3.91 2.01E-02 0.90 5.96 
positive regulation of response to 
biotic stimulus 
3.87 2.09E-02 4.76 4.41 
negative regulation of innate 
immune response 
3.87 2.09E-02 4.76 4.41 
negative regulation of microtubule 
polymerization or 
depolymerization 
3.87 2.09E-02 4.76 6.86 
peptide cross-linking 3.87 2.09E-02 4.76 4.47 
regulation of oligodendrocyte 
differentiation 
3.87 2.09E-02 4.76 4.37 
regulation of lamellipodium 
organization 
3.82 2.19E-02 4.55 7.15 
regulation of immune system 
process 
3.81 2.21E-02 0.48 4.66 
positive regulation of glial cell 
differentiation 
3.78 2.29E-02 4.35 4.37 
positive chemotaxis 3.74 2.38E-02 4.17 7.15 
ceramide biosynthetic process 3.70 2.48E-02 4.00 6.72 
glycosphingolipid metabolic 
process 
3.70 2.48E-02 4.00 6.72 
positive regulation of cellular 
process 
3.70 2.48E-02 0.24 4.94 
negative regulation of protein 
depolymerization 
3.66 2.58E-02 3.85 6.86 
regulation of type I interferon 
production 
3.62 2.68E-02 3.70 4.41 
axon cargo transport 3.62 2.68E-02 3.70 6.72 
response to lipopolysaccharide 3.62 2.68E-02 0.78 4.26 
cellular response to lipid 3.61 2.70E-02 0.77 4.26 
lipid metabolic process 3.61 2.70E-02 0.45 6.30 
cellular response to interferon-
gamma 
3.58 2.78E-02 3.57 4.41 
negative regulation of protein 
complex disassembly 
3.58 2.78E-02 3.57 6.86 
positive regulation of reactive 
oxygen species metabolic process 
3.55 2.87E-02 3.45 4.41 
positive regulation of nitric oxide 
biosynthetic process 
3.55 2.87E-02 3.45 4.11 
glycolipid biosynthetic process 3.55 2.87E-02 3.45 6.72 
monocarboxylic acid metabolic 
process 
3.55 2.88E-02 0.75 6.09 
microtubule-based process 3.55 2.88E-02 0.75 6.79 
response to molecule of bacterial 
origin 
3.54 2.90E-02 0.74 4.26 
lipid biosynthetic process 3.53 2.94E-02 0.74 7.24 
reproductive process 3.48 3.08E-02 0.43 4.35 
anatomical structure development 3.47 3.12E-02 0.27 5.46 
positive regulation of multi-
organism process 
3.42 3.26E-02 3.03 4.41 
substantia nigra development 3.42 3.26E-02 3.03 7.51 
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keratinocyte differentiation 3.42 3.26E-02 3.03 4.47 
cell-cell junction assembly 3.42 3.26E-02 3.03 6.72 
negative regulation of cellular 
component organization 
3.41 3.30E-02 0.69 7.01 
sphingolipid biosynthetic process 3.36 3.46E-02 2.86 6.72 
positive regulation of gliogenesis 3.34 3.56E-02 2.78 4.37 
embryo implantation 3.28 3.75E-02 2.63 4.41 
regulation of protein 
depolymerization 
3.28 3.75E-02 2.63 6.86 
regulation of cytokine production 3.28 3.76E-02 0.65 4.26 
regulation of microtubule 
polymerization or 
depolymerization 
3.26 3.85E-02 2.56 6.86 
regulation of interleukin-8 
production 
3.23 3.94E-02 2.50 4.11 
negative regulation of NF-kappaB 
transcription factor activity 
3.21 4.04E-02 2.44 4.41 
regulation of nitric oxide 
biosynthetic process 
3.21 4.04E-02 2.44 4.11 
response to progesterone 3.19 4.14E-02 2.38 4.41 
regulation of neurological system 
process 
3.19 4.14E-02 2.38 4.14 
regulation of glial cell 
differentiation 
3.19 4.14E-02 2.38 4.37 
single-organism developmental 
process 
3.18 4.18E-02 0.22 5.26 
cellular response to ketone 3.16 4.23E-02 2.33 4.41 
regulation of protein complex 
disassembly 
3.16 4.23E-02 2.33 6.86 
positive regulation of biological 
process 
3.15 4.27E-02 0.22 4.94 
response to interferon-gamma 3.10 4.52E-02 2.17 4.41 
glial cell differentiation 3.08 4.62E-02 2.13 4.14 
glycolipid metabolic process 3.08 4.62E-02 2.13 6.72 
regulation of nitrogen compound 
metabolic process 
3.04 4.78E-02 0.24 4.84 
protein lipidation 3.03 4.81E-02 2.04 6.86 
ceramide metabolic process 3.03 4.81E-02 2.04 6.72 
 
 
 
 
